



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 129818

TO: Terra Gibbs
Location: rem/2d10
Art Unit: 1635
Thursday, August 12, 2004

2C18

Case Serial Number: 10/033742

From: Barb O'Bryen
Location: Biotech-Chem Library
Remsen 1A69
Phone: 571-272-2518

BOB

barbara.obryen@uspto.gov

Search Notes

Note:

EST database had no hits that matched your limitations. Consequently, there is no results set from the EST database in this packet.

THIS PAGE BLANK (USPTO)

O'Bryen, Barbara

From: Gibbs, Terra
Sent: Thursday, August 05, 2004 6:01 PM
To: O'Bryen, Barbara
Subject: Sequence search request...

Hi Barbara,

I have another request for a score over length search:

I need a length limited nucleotide sequence search nucleobases 361-425 of SEQ ID NO:3 in USSN 10/033,742, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched .

Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
571-272-0758

THIS PAGE BLANK (USPTO)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:34:29 ; Search time 0.001 Seconds

(without alignments)
164,450 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65

Sequence: 1 ttcttggaatggaatgcac.....gtctgggtgaggttcac 65

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 103 seqs, 1265 residues

Total number of hits satisfying chosen parameters: 206

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : rncdb:*

Listing first 103 summaries

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,

and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.8	30.5	23	1	US-09-071-353-12
2	19.8	30.5	23	1	US-09-426-126-12
3	14	21.5	18	1	US-08-525-654A-138
4	12.8	19.7	17	1	US-08-281-940-29
5	12.8	19.7	17	1	US-08-710-134-29
6	12.8	19.7	17	1	US-08-485-885-29
7	12.8	19.7	17	1	US-08-866-108A-2464
8	12.8	19.7	17	1	US-08-866-108A-2465
9	11.4	17.5	15	1	US-08-146-886-22
10	11.4	17.5	15	1	US-08-440-787A-139
11	11.4	17.5	15	1	US-09-109-613-22
12	11.4	17.5	15	1	US-08-730-635-5
13	11.4	17.5	15	1	US-08-730-635-9
14	10.8	16.6	14	1	US-08-242-664-25
15	10.8	16.6	14	1	US-08-484-138-25
16	10.8	16.6	14	1	US-09-580-923-29
17	10.8	16.6	14	1	US-09-580-923-30
18	10.8	16.6	14	1	PCT-US95-06379-25
19	10.4	16.0	12	1	US-08-004-800-9
20	10.4	16.0	12	1	US-08-004-800-10
21	10.4	16.0	12	1	US-08-004-800-11
22	10.4	16.0	12	1	US-08-004-800-12
23	10.4	16.0	12	1	US-08-115-497-14
24	10.4	16.0	12	1	US-08-115-497-15
25	10.4	16.0	12	1	US-08-413-813-9
26	10.4	16.0	12	1	US-08-413-813-9
27	10.4	16.0	12	1	US-08-413-813-10
28	10.4	16.0	12	1	US-08-413-813-28
29	10.4	16.0	12	1	US-08-413-813-29
30	10.4	16.0	12	1	US-08-413-813-31
31	10.4	16.0	12	1	US-08-466-670-14
32	10.4	16.0	12	1	US-08-466-670-15
33	10.4	16.0	12	1	US-08-466-670-17

34	10.4	16.0	12	1	US-08-467-346-9	Sequence 9, Appli
35	10.4	16.0	12	1	US-08-467-346-10	Sequence 10, Appl
36	10.4	16.0	12	1	US-08-467-346-28	Sequence 28, Appl
37	10.4	16.0	12	1	US-08-467-346-29	Sequence 29, Appl
38	10.4	16.0	12	1	US-08-467-346-31	Sequence 31, Appl
39	10.4	16.0	12	1	US-08-822-586-50	Sequence 50, Appl
40	10.4	16.0	12	1	PCT-US92-02480A-9	Sequence 9, Appli
41	10.4	16.0	12	1	PCT-US92-02480A-10	Sequence 10, Appl
42	10.4	16.0	12	1	PCT-US92-02480A-11	Sequence 11, Appl
43	10.4	16.0	12	1	PCT-US92-02480A-12	Sequence 12, Appl
44	10.4	16.0	12	1	PCT-US92-02480A-13	Sequence 13, Appl
45	10.4	16.0	13	1	US-08-284-746-14	Sequence 14, Appl
46	10.4	16.0	13	1	US-09-446-301A-45	Sequence 45, Appl
47	10.4	16.0	13	1	US-09-099-932-16	Sequence 36, Appl
48	10	15.4	12	1	US-09-862-844-6	Sequence 6, Appli
49	10	15.4	12	1	US-09-862-844-8	Sequence 8, Appli
50	9.4	14.5	11	1	US-08-152-955-3	Sequence 3, Appli
51	9.4	14.5	11	1	PCT-US93-05668-3	Sequence 3, Appli
52	9.4	14.5	12	1	US-08-115-497-12	Sequence 12, Appl
53	9.4	14.5	12	1	US-08-115-497-13	Sequence 13, Appl
54	9.4	14.5	12	1	US-08-031-147A-53	Sequence 53, Appl
55	9.4	14.5	12	1	US-08-413-813-38	Sequence 38, Appl
56	9.4	14.5	12	1	US-08-413-813-39	Sequence 39, Appl
57	9.4	14.5	12	1	US-08-466-670-12	Sequence 12, Appl
58	9.4	14.5	12	1	US-08-466-670-13	Sequence 13, Appl
59	9.4	14.5	12	1	US-08-494-301A-12	Sequence 12, Appl
60	9.4	14.5	12	1	US-08-467-346-38	Sequence 38, Appl
61	9.4	14.5	12	1	US-08-467-346-39	Sequence 39, Appl
62	9.4	14.5	12	1	US-08-403-888A-41	Sequence 41, Appl
63	9.4	14.5	12	1	US-08-403-888A-57	Sequence 57, Appl
64	9.4	14.5	12	1	US-08-403-888A-113	Sequence 113, App
65	9.4	14.5	12	1	US-08-819-867-5	Sequence 5, Appli
66	9.4	14.5	12	1	US-08-819-867-33	Sequence 33, Appl
67	9.4	14.5	12	1	US-08-819-867-35	Sequence 35, Appl
68	9.4	14.5	12	1	US-08-679-493A-64	Sequence 64, Appl
69	9.4	14.5	12	1	US-09-378-535-5	Sequence 5, Appli
70	9.4	14.5	12	1	US-09-378-535-33	Sequence 33, Appl
71	9.4	14.5	12	1	US-09-378-535-15	Sequence 15, Appl
72	9.4	14.5	12	1	PCT-US94-02471-53	Sequence 53, Appl
73	9	13.8	9	1	US-08-462-115B-34	Sequence 34, Appl
74	9	13.8	9	1	US-08-472-802C-32	Sequence 32, Appl
75	9	13.8	9	1	US-09-057-351-32	Sequence 32, Appl
76	9	13.8	10	1	US-08-330-123A-10	Sequence 10, Appl
77	9	13.8	10	1	US-08-482-115B-10	Sequence 10, Appl
78	9	13.8	10	1	US-08-650-678A-10	Sequence 10, Appl
79	9	13.8	10	1	US-08-485-778-41	Sequence 41, Appl
80	9	13.8	10	1	US-08-472-802C-11	Sequence 11, Appl
81	9	13.8	10	1	US-08-388-353-513	Sequence 513, App
82	9	13.8	10	1	US-08-388-353-514	Sequence 514, App
83	9	13.8	10	1	US-08-388-353-547	Sequence 547, App
84	9	13.8	10	1	US-08-388-353-548	Sequence 548, App
85	9	13.8	10	1	US-08-520-550A-41	Sequence 41, Appl
86	9	13.8	10	1	US-08-488-551B-514	Sequence 514, App
87	9	13.8	10	1	US-08-488-551B-515	Sequence 515, App
88	9	13.8	10	1	US-08-488-551B-547	Sequence 547, App
89	9	13.8	10	1	US-08-488-551B-548	Sequence 548, App
90	9	13.8	10	1	US-08-488-551B-831	Sequence 831, App
91	9	13.8	10	1	US-08-488-551B-832	Sequence 832, App
92	9	13.8	10	1	US-08-998-443-10	Sequence 10, Appl
93	9	13.8	10	1	US-09-060-523-10	Sequence 10, Appl
94	9	13.8	10	1	US-09-580-517-10	Sequence 10, Appl
95	9	13.8	10	1	US-09-057-351-10	Sequence 10, Appl
96	9	13.8	11	1	PCT-US96-09430-21	Sequence 21, Appl
97	9	13.8	12	1	US-08-117-91-19	Sequence 19, Appl
98	9	13.8	12	1	US-08-271-364A-19	Sequence 19, Appl
99	9	13.8	12	1	US-08-222-715B-19	Sequence 19, Appl
100	9	13.8	12	1	US-09-281-418-58	Sequence 58, Appl
101	9	13.8	12	1	PCT-US96-09430-16	Sequence 16, Appl
102	9	13.8	12	1	PCT-US96-09430-17	Sequence 17, Appl
103	9	13.8	12	1	PCT-US96-09430-18	Sequence 18, Appl

ALIGNMENTS

Issued - Patents - NA

RESULT 1
US-09-071-353-12/c
Sequence 12, Application US/09071353
Patent No. 6057426
GENERAL INFORMATION:
APPLICANT: Lesslauer, Werner
APPLICANT: Utans-Schneitz, Ulrike
TITLE OF INVENTION: NEW CHEROKINE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: N.J.
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071.353
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 97107135.2
FILING DATE: 30-APR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Kreisler, Lewis J
REGISTRATION NUMBER: 38522
REFERENCE/DOCKET NUMBER: 13235
TELEPHONE: (973) 235-4387
TELEFAX: (973) 235-2363
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-09-071-353-12

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.1;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGGACATGACC 26
Db 23 CTGGATGGAATTGGACACAGCC 1

RESULT 2
US-09-426-326-12/c
Sequence 12, Application US/09426326
Patent No. 6537794
GENERAL INFORMATION:
APPLICANT: Lesslauer, Werner
APPLICANT: Utans-Schneitz, Ulrike
TITLE OF INVENTION: NEW CHEROKINE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: N.J.
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/426.326
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/071.353
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kreisler, Lewis J
REGISTRATION NUMBER: 38522
REFERENCE/DOCKET NUMBER: 13235
TELECOMMUNICATION INFORMATION:
TELEPHONE: (973) 235-4387
TELEFAX: (973) 235-2363
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-09-426-326-12

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.1;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGGACATGACC 26
Db 23 CTGGATGGAATTGGACACAGCC 1

RESULT 3
US-08-525-654A-138/c
Sequence 138, Application US/08525654A
Patent No. 5736356
GENERAL INFORMATION:
APPLICANT: SANO, KOICHIRO
APPLICANT: KIMAZAWA, YOSHIYUKI
APPLICANT: YASUDA, HISASHI
APPLICANT: SEGUCHI, KATSUYA
APPLICANT: MOTOKI, MASAO
TITLE OF INVENTION: TRANSGLUAMINASE ORIGINATED FROM
NUMBER OF SEQUENCES: 150
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/525.654A
FILING DATE: 28-SEP-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6/8283
FILING DATE: 28-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7/3876
FILING DATE: 13-JAN-1995

ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-760-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 138:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-525-654A-138

Query Match 21.5%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.3;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAAC 43
Db 16 GAACAGAAAGAAC 3

RESULT 4
US-08-281-940-29
Sequence 29, Application US/08281940
Patent No. 5589330
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: METHOD FOR MULTIPLE ALLELE-SPECIFIC
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: DARBY & DARBY P.C.
STREET: 805 THIRD AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/281,940
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: LUDWIG, S. PETER
REGISTRATION NUMBER: 25351
REFERENCE/DOCKET NUMBER: 0372/09696
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212/527-7700
TELEFAX: 212/753-6237
TELEX: 236687
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapien
IMMEDIATE SOURCE:
CLONE: Q493XM
US-08-281-940-29

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGAACAGAAAGAA 41
Db 2 CTAAGAACAGAAATGAA 17

RESULT 5
US-08-710-134-29
Sequence 29, Application US/08710134
Patent No. 5834181
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA
ZIP: 01701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/710,134
FILING DATE: 13-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: IG5-8.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 508-872-8400
TELEFAX: 508-872-5415
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotides"
US-08-710-134-29

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGAACAGAAAGAA 41
Db 2 CTAAGAACAGAAATGAA 17

RESULT 6
US-08-485-885-29
Sequence 29, Application US/08485885
Patent No. 5849483
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA

```
ZIP: 01701
; COMPUTER READABLE FORM.
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,885
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 508-872-8400
; TELEFAX: 508-872-5415
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Oligonucleotides"
US-08-485-885-29

Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      26 CTAAGACGAAAGAA 41
DB      2 CTAAGACGAAATGAA 17

RESULT 7
US-09-866-108A-2464
; Sequence 2464, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
```

```
NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A60MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2464

Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      4 CTGGATGGAATTGGA 19
DB      2 CTGGATGGAATTGGA 17

RESULT 8
US-09-866-108A-2465
; Sequence 2465, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; SOFTWARE: A60MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2465
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2465

Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      4 CTGGATGGAATTGGA 19
DB      1 CTGGATGGAATTGGA 16
```

RESULT 9
US-08-146-886-22
Sequence 22, Application US/08146886
Patent No. 5639603
GENERAL INFORMATION:
APPLICANT: Dower, William J.
APPLICANT: Barrett, Ronald W.
APPLICANT: Gallop, Mark A.
APPLICANT: Needels, Michael C.
TITLE OF INVENTION: Method of Synthesizing Diverse
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: One Market Plaza, Stewart Tower, Suite 2000
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/146,886
FILING DATE: 02-NOV-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/946,239
FILING DATE: 16-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/762,522
FILING DATE: 18-SEP-1991
ATTORNEY/AGENT INFORMATION:
NAME: No. 5639603v1e1, Vernon A.
REGISTRATION NUMBER: 32,483
REFERENCE/DOCKET NUMBER: 11509-121/1007.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-326-2400
TELEFAX: 415-326-2422
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-146-886-22

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TTGGAATGGAATG 17
DB 2 TGGAAATGGAATG 14

RESULT 10
US-08-440-787A-139/C
Sequence 139, Application US/08440787A
Patent No. 5770434
GENERAL INFORMATION:
APPLICANT: Huse, William D.
TITLE OF INVENTION: Soluble Peptides Having Constrained,
TITLE OF INVENTION: Secondary Conformation in Solution and Method of Making
NUMBER OF SEQUENCES: 174
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell & Flores LLP
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego

STATE: California
COUNTRY: USA
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/440,787A
FILING DATE: 15-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/978,893
FILING DATE: 10-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: 31,815
REFERENCE/DOCKET NUMBER: P-IX 1586
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 139:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: misc.feature
LOCATION: 13..14
OTHER INFORMATION: /note= "N = X (used in Table VI),
OTHER INFORMATION: which represents an equal mixture of all four
US-08-440-787A-139

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 TTCTGGAATGGAAT 16
DB 15 TTNNTGGAATGGAAT 1

RESULT 11
US-09-109-613-22
Sequence 22, Application US/09109613
Patent No. 6165778
GENERAL INFORMATION:
APPLICANT: Dower, William J.
APPLICANT: Barrett, Ronald W.
APPLICANT: Gallop, Mark A.
APPLICANT: Needels, Michael C.
TITLE OF INVENTION: Method of Synthesizing Diverse
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: One Market Plaza, Stewart Tower, Suite 2000
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/109,613
FILING DATE:
CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/146,886
FILING DATE: 02-NOV-1993
APPLICATION NUMBER: US 07/946,239
FILING DATE: 16-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/762,522
FILING DATE: 18-SEP-1991
ATTORNEY/AGENT INFORMATION:
NAME: NO. 6165778v1el, Vernon A.
REGISTRATION NUMBER: 32,483
REFERENCE/DOCKET NUMBER: 11509-121/1007.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-326-2400
TELEFAX: 415-326-2422
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-09-109-613-22

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TCGAATGGAATG 17
Db 2 TCGAATGGAATG 14

RESULT 12
US-08-730-635-5/c
Sequence 5, Application US/08730635
Patent No. 6514693
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
TITLE OF INVENTION: a Repeat Sequence in a Nucleic Acid Molecule
Patent No. 6514693
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESS: HOMSON & HOMSON
STREET: 321 No. 65146931sttown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
US-08-730-635-5

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TCGAATGGAATG 17
Db 13 TCGAATGGAATG 1

RESULT 13
US-08-730-635-9
Sequence 9, Application US/08730635
Patent No. 6514693
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
TITLE OF INVENTION: a Repeat Sequence in a Nucleic Acid Molecule
Patent No. 6514693
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESS: HOMSON & HOMSON
STREET: 321 No. 65146931sttown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-730-635-9

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TCGAATGGAATG 17
Db 3 TCGAATGGAATG 15

RESULT 14
US-08-242-664-25
Sequence 25, Application US/08242664
Patent No. 5571937
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Weil, Roger
TITLE OF INVENTION: Complementary DNA and Toxins

NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/242,664
FILING DATE: May 12, 1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-664-0525
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-242-664-25

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAGAAATGAA 14

RESULT 15
US-08-484-138-25
Sequence 25, Application US/08484138
Patent No. 5652350
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Wei, Roger
TITLE OF INVENTION: Complementary DNA and Toxins
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44MB
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,138
FILING DATE: June 7, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-z/JPW/MJG
TELECOMMUNICATION INFORMATION:

TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-484-138-25

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAGAAATGAA 14

RESULT 16
US-09-580-923-29
Sequence 29, Application US/09580923
Patent No. 6319672
GENERAL INFORMATION:
APPLICANT: Crouzet, Joel
APPLICANT: Scherman, Daniel
APPLICANT: Wils, Pierre
APPLICANT: Cameron, Beatrice
APPLICANT: Blanche, Francis
TITLE OF INVENTION: IMMOBILIZED OLIGONUCLEOTIDE
FILE REFERENCE: 03804.0138-01
CURRENT APPLICATION NUMBER: US/09/580,923
CURRENT FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: 08/860,038
PRIOR FILING DATE: 1997-06-09
PRIOR APPLICATION NUMBER: PCT/FR95/01468
PRIOR FILING DATE: 1995-11-08
NUMBER OF SEQ ID NOS: 36
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 29
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
US-09-580-923-29

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAGAAATGAA 14

RESULT 17
US-09-580-923-30/c
Sequence 30, Application US/09580923
Patent No. 6319672
GENERAL INFORMATION:
APPLICANT: Crouzet, Joel
APPLICANT: Scherman, Daniel
APPLICANT: Wils, Pierre
APPLICANT: Cameron, Beatrice
APPLICANT: Blanche, Francis
TITLE OF INVENTION: IMMobilized OLIGONUCLEOTIDE
FILE REFERENCE: 03804.0138-01
CURRENT APPLICATION NUMBER: US/09/580,923

```
/ CURRENT FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: 08/860,038
/ PRIOR FILING DATE: 1997-06-09
/ PRIOR APPLICATION NUMBER: PCT/FR95/01468
/ PRIOR FILING DATE: 1995-11-08
/ NUMBER OF SEQ ID NOS: 36
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 30
/ LENGTH: 14
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence:
US-09-580-923-30
```

```
Query Match      16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      28 AAGAACAGAAAGAA 41
      ||||| |||||
Db      14 AAGAAAAAAGAA 1
```

```
RESULT 18
PCT-US95-06379-25
/ Sequence 25, Application PC/TUS9506379
/ GENERAL INFORMATION:
/ APPLICANT: Matanabe, Kyoichi A.
/ APPLICANT: Ren, Wu-Yun
/ APPLICANT: Weil, Roger
/ TITLE OF INVENTION: Complementary DNA and Toxins
/ NUMBER OF SEQUENCES: 43
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Cooper & Dunham LLP
/ STREET: 1185 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: U.S.A.
/ ZIP: 10036
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch 1.44MB
/ COMPUTER: IBM PC
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.24
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US95/06379
/ FILING DATE: May 13, 1994
/ CLASSIFICATION:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: White, John P.
/ REGISTRATION NUMBER: 28,678
/ REFERENCE/DOCKET NUMBER: 44683-PCT
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212-278-0400
/ TELEFAX: 212-391-0526
/ INFORMATION FOR SEQ ID NO: 25:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 14 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
PCT-US95-06379-25
```

```
Query Match      16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      28 AAGAACAGAAAGAA 41
      ||||| |||||
Db      1 AAGAAAAAAGAA 14
```

```
RESULT 19
US-08-004-800-9
/ Sequence 9, Application US/08004800
/ Patent No. 5426180
/ GENERAL INFORMATION:
/ APPLICANT: Koel, Eric T.
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
/ NUMBER OF SEQUENCES: 23
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
```

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/004,800
/ FILING DATE: 19930111
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: McNulty, William E.
/ REGISTRATION NUMBER: 22,606
/ REFERENCE/DOCKET NUMBER: 8085ZY
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELEX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 9:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-004-800-9
```

```
Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      28 AAGAACAGAAAG 39
      ||||| |||||
Db      1 AAGAAAAAGAAAG 12
```

```
RESULT 20
US-08-004-800-10/c
/ Sequence 10, Application US/08004800
/ Patent No. 5426180
/ GENERAL INFORMATION:
/ APPLICANT: Koel, Eric T.
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
/ NUMBER OF SEQUENCES: 23
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
```

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852Y
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-10

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGAAAG 39
|||||
Db 12 AAGAAAGAAAG 1

RESULT 21
US-08-004-800-11
Sequence 11, Application US/08004800
Patent No. 5426180
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
TITLE OF INVENTION: OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852Y
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-11

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGAACGAAAG 39
|||||
Db 1 AAGAAAGAAAG 12

RESULT 22
US-08-004-800-12
Sequence 12, Application US/08004800
Patent No. 5426180
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
TITLE OF INVENTION: OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852Y
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-12

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGAAAG 39
|||||
Db 1 AAGAAAGAAAG 12

RESULT 23
US-08-115-497-14
Sequence 14, Application US/08115497
Patent No. 5514546
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City

```
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/115,497
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-115-497-14

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAAGAAG 39
DB      1 AAGAATAGAAG 12

RESULT 24
US-08-115-497-15
/ Sequence 15, Application US/08115497
/ Patent No. 5514546
/ GENERAL INFORMATION:
/ APPLICANT: KOOL, Eric T.
/ TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
/ TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/115,497
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
```

```
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-115-497-15

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAAGAAG 39
DB      1 AAGAATAGAAG 12

RESULT 25
US-08-115-497-17/C
/ Sequence 17, Application US/08115497
/ Patent No. 5514546
/ GENERAL INFORMATION:
/ APPLICANT: KOOL, Eric T.
/ TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
/ TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/115,497
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-115-497-17

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAAGAAG 39
DB      12 AAGAATAGAAG 1

RESULT 26
US-08-413-813-9
/ Sequence 9, Application US/08413813
/ Patent No. 5683874
/ GENERAL INFORMATION:
/ APPLICANT: KOOL, Eric T.
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
```

NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEX: 230 901 SANS UR
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-9

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 28 AAGACGGAAG 39
DB 1 AAGAAAGAAAG 12

RESULT 27
US-08-413-813-10/c
Sequence 10, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366

TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-10

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 28 AAGACGGAAG 39
DB 12 AAGAAAGAAAG 1

RESULT 28
US-08-413-813-28
Sequence 28, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-28

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 30 GAACGGAAGA 41
DB 1 GAAAGGAAGA 12

RESULT 29
US-08-413-813-29
Sequence 29, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.

```
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
/ NUMBER OF SEQUENCES: 44
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/413,813
/ FILING DATE:
/ CLASSIFICATION: 536
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8085ZYX
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELETYPE: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 29:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-413-813-29

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 1 AAAAAAGAAAGAA 12

RESULT 30
US-08-413-813-31/C
/ Sequence 31, Application US/08413813
/ Patent No. 5683874
/ GENERAL INFORMATION:
/ APPLICANT: Kool, Eric T.
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
/ NUMBER OF SEQUENCES: 44
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/413,813
/ FILING DATE:
/ CLASSIFICATION: 536
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8085ZYX
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
```

```
/ TELEFAX: (516) 742-4366
/ TELETYPE: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 31:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: circular
/
US-08-413-813-31

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 12 AAAAAAGAAAGAA 1

RESULT 31
US-08-466-670-14
/ Sequence 14, Application US/08466670
/ Patent No. 5808036
/ GENERAL INFORMATION:
/ APPLICANT: Kool, Eric T.
/ TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
/ PARALLEL AND ANTIPARALLEL BINDING DOMAINS
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/466,670
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/115,497
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELETYPE: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/
US-08-466-670-14

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAAGAAAG 39
Db 1 AAGAATGAAG 12
```

```
RESULT 32
US-08-466-670-15
; Sequence 15, Application US/08466670
; Patent No. 5808036
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
; TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,670
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/115,497
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8771
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4366
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-466-670-15

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      28 AGAAGCAGAAAG 39
Db      1 AAGAAGGAAAG 12

RESULT 33
US-08-466-670-17/c
; Sequence 17, Application US/08466670
; Patent No. 5808036
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
; TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/413,813
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
```

```
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-17

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy      28 AGAAGCAGAAAG 39
Db      12 AAGATGAAAG 1

RESULT 34
US-08-467-346-9
; Sequence 9, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
```

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-9

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGGAAG 39
DB 1 AAGAAAAAGAAAG 12

RESULT 35
US-08-467-346-10/c
Sequence 10, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-10

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGGAAG 39
DB 12 AAGAAAAAGAAAG 1

RESULT 36
US-08-467-346-28
Sequence 28, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-28

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGGAAGAA 41
DB 1 GAAGAAAAAGAA 12

RESULT 37
US-08-467-346-29
Sequence 29, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:

NAME: Digilio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-29

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGA 41
Db 1 GAAAGAAAGA 12

RESULT 38
US-08-467-346-31/c
Sequence 31, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
City: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digilio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: circular
US-08-467-346-31

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGA 41
Db 1 GAAAGAAAGA 12

Db 12 GAAAGAAAGA 1

RESULT 39
US-08-822-586-50
Sequence 50, Application US/08822586
Patent No. 6015890
GENERAL INFORMATION:
APPLICANT: WILLIAM R. JACOBS, JR., JAMES M. MUSSER AND
AMALIO TELENIT
TITLE OF INVENTION: AN EMBCAB OPERON OF MYCOBACTERIA AND
MUTANTS THEREOF
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: AMSTER, ROTHSTEIN & EBENSTEIN
STREET: 90 PARK AVENUE
City: NEW YORK
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 10016

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 INCH 1.44 MB STORAGE
MEDIUM TYPE: DISKETTE
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: MS-DOS
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/822,586
FILING DATE: MARCH 20, 1997
ATTORNEY/AGENT INFORMATION:
NAME: ELIZABETH A. BOGOSIAN
REGISTRATION NUMBER: 39,911
REFERENCE/DOCKET NUMBER: 96700/437
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 697-5995
TELEFAX: (212) 286-0854 or 286-0082
TELEX: TWX 710-581-4766
INFORMATION FOR SEQ ID NO: 50:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: NO
US-08-822-586-50

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 TGGACATAGCCC 27
Db 1 TGGGATAGCCC 12

RESULT 40
PCT-US92-02480A-9
Sequence 9, Application PC/TUS9202480A
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
City: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

```
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-9
```

```
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 28 AAGAACAGAAAG 39
Db 1 AAGAACAGAAAG 12
```

```
RESULT 41
PCT-US92-02480A-10/c
; Sequence 10, Application PC/TUS9202480A
; GENERAL INFORMATION:
; APPLICANT: KOOL, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/02480A
; FILING DATE: 19920326
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McNulty, William E.
; REGISTRATION NUMBER: 22,606
; REFERENCE/DOCKET NUMBER: 80852
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US92-02480A-10
```

```
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 28 AAGAACAGAAAG 39
Db 12 AAGAACAGAAAG 1
```

```
RESULT 42
PCT-US92-02480A-11
; Sequence 11, Application PC/TUS9202480A
; GENERAL INFORMATION:
; APPLICANT: KOOL, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/02480A
; FILING DATE: 19920326
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McNulty, William E.
; REGISTRATION NUMBER: 22,606
; REFERENCE/DOCKET NUMBER: 80852
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US92-02480A-11
```

```
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 28 AAGAACAGAAAG 39
Db 1 AAGAACAGAAAG 12
```

```
RESULT 43
PCT-US92-02480A-12
; Sequence 12, Application PC/TUS9202480A
; GENERAL INFORMATION:
; APPLICANT: KOOL, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-12

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 28 AAGAACGAAAG 39
Db 1 AAGAAUAGAAG 12

RESULT 44
PCT-US92-02480A-13/c
Sequence 13, Application PC/TUS9202480A
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
TITLE OF INVENTION: OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-13

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 28 AAGAACGAAAG 39

Db 12 AAGATAGAAAG 1

RESULT 45
US-08-284-746-14/c
Sequence 14, Application US/08284746
Patent No. 5525468
GENERAL INFORMATION:
APPLICANT: James A. McSwiggen
TITLE OF INVENTION: ASSAY FOR RIBOZYME TARGET SITE
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/284,746
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/883,849
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 197/070
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-284-746-14

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 10 TGAATTGACA 21
Db 13 TGAATCGACA 2

RESULT 46
US-09-446-301A-45/c
Sequence 45, Application US/09446301A
Patent No. 6506893
GENERAL INFORMATION:
APPLICANT: ELI SOLH, NEVINE
TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
FILE REFERENCE: 03715-0059
CURRENT APPLICATION NUMBER: US/09/446,301A
CURRENT FILING DATE: 1999-12-20
NUMBER OF SEQ ID NOS: 51
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 45
LENGTH: 13

```
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-446-301A-45
```

```
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      7 GAATGGAATTGG 18
        |||||
Db      13 GAATGAGTTGG 2
```

```
RESULT 47
US-09-099-932-36/c
Sequence 36, Application US/09099932
Patent No. 6570001
GENERAL INFORMATION:
APPLICANT: El Solh, Nevine
APPLICANT: Allignet, Jeanine
TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
FILE REFERENCE: 03495.0173-00000
CURRENT APPLICATION NUMBER: US/09/099,932
CURRENT FILING DATE: 1998-06-19
EARLIER APPLICATION NUMBER: 60/050,380
NUMBER OF SEQ ID NOS: 50
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 36
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-099-932-36
```

```
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      7 GAATGGAATTGG 18
        |||||
Db      13 GAATGAGTTGG 2
```

```
RESULT 48
US-09-862-844-6/c
Sequence 6, Application US/09862844
Patent No. 6583986
GENERAL INFORMATION:
APPLICANT: Cai, Hong
APPLICANT: Keller, Richard
APPLICANT: Werner, James
APPLICANT: Goodwin, Peter
TITLE OF INVENTION: RAPID HAPLOTYPEING BY SINGLE MOLECULE DETECTION
FILE REFERENCE: S-94,652
CURRENT APPLICATION NUMBER: US/09/862,844
CURRENT FILING DATE: 2001-05-21
SOFTWARE: Patentin version 3.0
SEQ ID NO 6
LENGTH: 12
TYPE: DNA
ORGANISM: PNA probe MLCy5P
US-09-862-844-6
```

```
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      23 AGCCCAAGAA 32
        |||||
Db      11 AGCCCAAGAA 2
```

```
RESULT 49
US-09-862-844-8/c
Sequence 8, Application US/09862844
Patent No. 6583986
GENERAL INFORMATION:
APPLICANT: Cai, Hong
APPLICANT: Keller, Richard
APPLICANT: Werner, James
APPLICANT: Goodwin, Peter
TITLE OF INVENTION: RAPID HAPLOTYPEING BY SINGLE MOLECULE DETECTION
FILE REFERENCE: S-94,652
CURRENT APPLICATION NUMBER: US/09/862,844
CURRENT FILING DATE: 2001-05-21
NUMBER OF SEQ ID NOS: 21
SOFTWARE: Patentin version 3.0
SEQ ID NO 8
LENGTH: 12
TYPE: DNA
ORGANISM: LNA probe MLCy5L
US-09-862-844-8
```

```
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      23 AGCCCAAGAA 32
        |||||
Db      11 AGCCCAAGAA 2
```

```
RESULT 50
US-08-152-955-3
Sequence 3, Application US/08152955
Patent No. 5474897
GENERAL INFORMATION:
APPLICANT: Weiss, Arthur
APPLICANT: Fraser, James
TITLE OF INVENTION: Screening Assay for the Identification
TITLE OF INVENTION: of Immunosuppressive Drugs
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSER: Townsend and Townsend
STREET: One Market Plaza, Stewart Tower, Suite 2000
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/152,955
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,639
FILING DATE: 15-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Heslin, James M.
REGISTRATION NUMBER: 29,541
REFERENCE/DOCKET NUMBER: 2307U-356
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-326-2400
TELEFAX: 415-326-2422
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
```

LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-152-955-3

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 44;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TGGAGGTTTCA 64
|||||
Db 1 TGGAGGTTTCA 11

RESULT 51
PCT-US93-05668-3
Sequence 3, Application PC/TUS9305668

GENERAL INFORMATION:

APPLICANT: Welles, Arthur
TITLE OF INVENTION: Screening Assay for the Identification
of Immunosuppressive Drugs
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fisher & Amzel
STREET: 1320 Harbor Bay Parkway, Suite 225
CITY: Alameda
STATE: California
COUNTRY: USA
ZIP: 94501

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/05668
FILING DATE: 19930611
CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,639
FILING DATE: 15-JUN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Fisher, Stanley P.

REGISTRATION NUMBER: 24,344

REFERENCE/DOCKET NUMBER: 91-143-1PCT

TELECOMMUNICATION INFORMATION:

TELEPHONE: 510-748-6868

TELEFAX: 510-748-6868

INFORMATION FOR SEQ ID NO: 3:

SEQUENCE CHARACTERISTICS:

LENGTH: 11 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

PCT-US93-05668-3

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 44;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TGGAGGTTTCA 64
|||||
Db 1 TGGAGGTTTCA 11

RESULT 52
US-08-115-497-12
Sequence 12, Application US/08115497
Patent No. 551546

GENERAL INFORMATION:
APPLICANT: Koel, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/115,497

FILING DATE:

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Digilio, Frank S.

REGISTRATION NUMBER: 31,346

REFERENCE/DOCKET NUMBER: 8771

TELECOMMUNICATION INFORMATION:

TELEPHONE: (516) 742-4343

TELEFAX: (516) 742-4366

TELEX: 230 901 SANS UR

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-115-497-12

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAG 39
|||||
Db 1 AAGACAGAG 12

RESULT 53

US-08-115-497-13

Sequence 13, Application US/08115497

Patent No. 551546

GENERAL INFORMATION:

APPLICANT: Koel, Eric T.

TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS

NUMBER OF SEQUENCES: 21

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Presser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: USA

ZIP: 11530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/115,497

FILING DATE:

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Digilio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-115-497-13

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 28 AAGAACAGAAAG 39
|||||
Db 1 AAGAAAANAAG 12

RESULT 54
US-08-031-147A-53
Sequence 53, Application US/08031147A
Patent No. 5514577
GENERAL INFORMATION:
APPLICANT: Draper et al.
TITLE OF INVENTION: Oligonucleotide Therapies for
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/031,147A
FILING DATE: March 12, 1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 485,297
FILING DATE: February 26, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 852,132
FILING DATE: April 28, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 954,185
FILING DATE: September 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-0469
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

ANTI-SENSE: yes
US-08-031-147A-53

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGAG 12

RESULT 55
US-08-413-813-38
Sequence 38, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digilio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-38

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 28 AAGAACAGAAAG 39
|||||
Db 1 AAGAAAANAAG 12

RESULT 56
US-08-413-813-39
Sequence 39, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City

```
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-39

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGAAAG 39
      |||||
      1 AAGAAANAAAG 12

RESULT 57
US-08-466-670-12
Sequence 12, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4366
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
```

```
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-13

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGAAAG 39
      |||||
      1 AAGAAANAAAG 12

RESULT 58
US-08-466-670-13
Sequence 13, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-13

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGAAAG 39
      |||||
      1 AAGAAANAAAG 12

RESULT 59
```

```
US-08-494-301A-12/c
; Sequence 12, Application US/08494301A
; Patent No. 5856461
; GENERAL INFORMATION:
; APPLICANT: Colote, Soudhir
; APPLICANT: Pirotzky, Eduardo
; TITLE OF INVENTION: Oligonucleotides to inhibit the
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lucas & Just
; STREET: 205 E. 42nd Street
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch,
; MEDIUM TYPE: 1.44 MB storage
; COMPUTER: IBM 486 Compatible
; OPERATING SYSTEM: MS-DOS 5.0
; SOFTWARE: WordPerfect 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/494,301A
; FILING DATE: 23-JUNE-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9413035.8
; FILING DATE: 29-JUNE-1994
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleotide
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: Yes
; US-08-494-301A-12

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      23 AGCCGAGAAC 33
Db      11 AGCCCAAAAC 1

RESULT 60
US-08-467-346-38
; Sequence 38, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8085ZYX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-346-39

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8085ZYX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-346-38

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGACGAAAG 39
Db      1 AAGANAGAAAG 12

RESULT 61
US-08-467-346-39
; Sequence 39, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8085ZYX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-346-39

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```


QY 28 AGACAGAAAG 39
|||||
Db 1 AAGAAAAMAAAG 12

RESULT 62
US-08-403-888A-41
Sequence 41, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
TITLE OF INVENTION: Sequence
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490 is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-888A-41

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 63
US-08-403-888A-57
Sequence 57, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
TITLE OF INVENTION: Sequence
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490 is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-888A-57

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 64
US-08-403-888A-113
Sequence 113, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
TITLE OF INVENTION: Sequence
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490 is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:

LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-8888-113

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
DB 2 TGGGGTTGGAG 12

RESULT 65

US-08-819-867-5
Sequence 5, Application US/08819867
Patent No. 6007989

GENERAL INFORMATION:

APPLICANT: Michael D. West
APPLICANT: Calvin B. Harley
APPLICANT: Scott L. Weinrich
APPLICANT: Catherine M. Strahl
APPLICANT: Michael J. McEachern
APPLICANT: Jerry Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth H. Blackburn
APPLICANT: Nam Woo Kim
APPLICANT: Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
TITLE OF INVENTION: CONDITIONS RELATED TO
TITLE OF INVENTION: TELOMERE LENGTH AND/OR
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/819,867
FILING DATE: March 14, 1997
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/153,051
FILING DATE: No. 6007989 September 12, 1993
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-819-867-5

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
DB 2 TGGGGTTGGAG 12

RESULT 66

US-08-819-867-33
Sequence 33, Application US/08819867
Patent No. 6007989

GENERAL INFORMATION:

APPLICANT: Michael D. West
APPLICANT: Calvin B. Harley
APPLICANT: Scott L. Weinrich
APPLICANT: Catherine M. Strahl
APPLICANT: Michael J. McEachern
APPLICANT: Jerry Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth H. Blackburn
APPLICANT: Nam Woo Kim
APPLICANT: Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
TITLE OF INVENTION: CONDITIONS RELATED TO
TITLE OF INVENTION: TELOMERE LENGTH AND/OR
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/819,867
FILING DATE: March 14, 1997
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/153,051
FILING DATE: No. 6007989 September 12, 1993
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-819-867-33

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGTTGAG 58
DB 2 TGGGTTGAG 12

RESULT 67

US-08-819-867-35
Sequence 35, Application US/08819867
Patent No. 6007989
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Calvin B. Harley
APPLICANT: Scott L. Weinrich
APPLICANT: Catherine M. Strahl
APPLICANT: Michael J. McEachern
APPLICANT: Jerry Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth H. Blackburn
APPLICANT: Nam Woo Kim
APPLICANT: Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
TITLE OF INVENTION: CONDITIONS RELATED TO
TITLE OF INVENTION: TELOMERE LENGTH AND/OR
TITLE OF INVENTION: TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/819,867
FILING DATE: March 14, 1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/153,051
FILING DATE: No. 6007989 September 12, 1993
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-819-867-35

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGTTGAG 58
DB 2 TGGGTTGAG 12

RESULT 68

US-08-679-493A-64/C
Sequence 64, Application US/08679493A
Patent No. 6303295
GENERAL INFORMATION:
APPLICANT: Taylor, Ethan W.
TITLE OF INVENTION: SELENOPROTEINS, CODING SEQUENCES AND METHODS
FILE REFERENCE: 55-95
CURRENT APPLICATION NUMBER: US/08/679,493A
CURRENT FILING DATE: 1996-07-12
PRIOR APPLICATION NUMBER: 60/001203
PRIOR FILING DATE: 1995-07-14
PRIOR APPLICATION NUMBER: 60/003,112
PRIOR FILING DATE: 1995-09-01
NUMBER OF SEQ ID NOS: 216
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 64
LENGTH: 12
TYPE: RNA
ORGANISM: Human immunodeficiency virus type 1
US-08-679-493A-64

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 TCTGAAATGGA 13
DB 12 TCTGAAATGGA 2

RESULT 69

US-09-378-535-5
Sequence 5, Application US/09378535
Patent No. 6551774
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Calvin B. Harley
APPLICANT: Scott L. Weinrich
APPLICANT: Catherine M. Strahl
APPLICANT: Michael J. McEachern
APPLICANT: Jerry Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth H. Blackburn
APPLICANT: Nam Woo Kim
APPLICANT: Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
TITLE OF INVENTION: CONDITIONS RELATED TO
TITLE OF INVENTION: TELOMERE LENGTH AND/OR
TITLE OF INVENTION: TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:

NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-378-535-5

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 70
US-09-378-535-33
Sequence 33, Application US/09378535
Patent No. 6551774
GENERAL INFORMATION:
APPLICANT: Michael D. West
Calvin B. Harley
Scott L. Weinrich
Catherine M. Strahl
Michael J. McEachern
Jerry Shay
Woodring E. Wright
Elizabeth H. Blackburn
Nam Woo Kim
Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
CONDITIONS RELATED TO
TELOMERE LENGTH AND/OR
TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-378-535-33

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 71
US-09-378-535-35
Sequence 35, Application US/09378535
Patent No. 6551774
GENERAL INFORMATION:
APPLICANT: Michael D. West
Calvin B. Harley
Scott L. Weinrich
Catherine M. Strahl
Michael J. McEachern
Jerry Shay
Woodring E. Wright
Elizabeth H. Blackburn
Nam Woo Kim
Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
CONDITIONS RELATED TO
TELOMERE LENGTH AND/OR
TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 35;
US-09-378-535-35

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 72
PCT-US94-02471-53
Sequence 53, Application PC/TUS9402471
GENERAL INFORMATION:
APPLICANT: Draper et al.
TITLE OF INVENTION: Oligonucleotide Therapies for
TITLE OF INVENTION: Modulating the Effects of Herpesviruses
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & Norris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2 PC-DOS
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02471
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 485,297
FILING DATE: February 26, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 852,132
FILING DATE: April 28, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 954,185
FILING DATE: September 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-0469
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: yes
PCT-US94-02471-53

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 73

US-08-482-115B-34/C
Sequence 34, Application US/08482115B
Patent No. 576679
GENERAL INFORMATION:

APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Assays for the RNA Component of Human
TITLE OF INVENTION: Telomerase
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,115B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000830US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-482-115B-34

Query Match 13.8%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||
Db 9 TGGGGTTGG 1

RESULT 74
US-08-472-802C-32/C
Sequence 32, Application US/08472802C
Patent No. 595680
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California

```
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,802C
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000820
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0300
TELEFAX: (415) 576-0200
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-472-802C-32

Query Match      13.8%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 TGGGGTTGG 56
DB      9 TGGGGTTGG 1

RESULT 75
US-09-057-351-32/C
; Sequence 32, Application US/09057351
; Patent No. 6548298
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: Mammalian Telomerase
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/057,351
; FILING DATE: 08-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; PRIOR APPLICATION DATA:
```

```
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,802
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000821US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-09-057-351-32
```

```
Query Match      13.8%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      48 TGGGGTTGG 56
DB      9 TGGGGTTGG 1
```

```
RESULT 76
US-08-330-123A-10/C
; Sequence 10, Application US/08330123A
; Patent No. 5583018
; GENERAL INFORMATION:
; APPLICANT: VILLEPONTEAU, Bryant
; APPLICANT: FENG, Junli
; APPLICANT: FUNK, Walter
; APPLICANT: ANDREWS, William H.
; TITLE OF INVENTION: HUMAN TELOMERASE
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourlie and Crew
; STREET: 379 Lytton Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: US
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/330,123A
; FILING DATE: 27-OCT-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 15389-000810
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 326-2400
; TELEFAX: (415) 326-2422
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

MOLECULE TYPE: DNA
US-08-330-123A-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
Db 9 TGGGGTTGG 1

RESULT 77
US-08-482-115B-10/C
Sequence 10, Application US/08482115B
Patent No. 5776679

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Assays for the RNA Component of Human
TITLE OF INVENTION: Telomerase
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,115B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000810US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-482-115B-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
Db 9 TGGGGTTGG 1

RESULT 78
US-08-660-678A-10/C

Sequence 10, Application US/08660678A
Patent No. 5837857

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/660,678A
FILING DATE: 05-JUN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000811US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-660-678A-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
Db 9 TGGGGTTGG 1

RESULT 79
US-08-485-778-41/C
Sequence 41, Application US/08485778
Patent No. 5876979

GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avilion, Ariel Athena
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Greider, Carol
APPLICANT: Marhuenda, Maria Antonia Blasco
TITLE OF INVENTION: RNA COMPONENT OF TELOMERASE
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Militia Drive

```

? CITY: Lexington
? STATE: MA
? COUNTRY: US
? ZIP: 02173
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC-DOS/MS-DOS
? SOFTWARE: PatentIn Release #1.0, Version #1.30
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/485,778
? FILING DATE: 07-JE-1995
? CLASSIFICATION: 435
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/387,524
? FILING DATE: 13-FEB-1995
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/330,123
? FILING DATE: 27-OCT-1994
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/272,102
? FILING DATE: 07-JUL-1994
? ATTORNEY/AGENT INFORMATION:
? NAME: Granahan, Patricia
? REGISTRATION NUMBER: 32,227
? REFERENCE/DOCKET NUMBER: CSHL94-05A4
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: 617-861-6240
? TELEFAX: 617-861-9540
? INFORMATION FOR SEQ ID NO: 41:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 10 base pairs
? TYPE: nucleic acid
? STRANDEDNESS: single
? TOPOLOGY: linear
?
US-08-485-778-41

Query Match      13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 TGGGGTTGG 56
      |||||
Db      9 TGGGGTTGG 1

RESULT 80
US-08-472-802C-11/C
? Sequence 11, Application US/08472802C
? Patent No. 5958680
? GENERAL INFORMATION:
? APPLICANT: Villeponteau, Bryant
? APPLICANT: Feng, Junli
? TITLE OF INVENTION: Mammalian Telomerase
? NUMBER OF SEQUENCES: 44
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Townsend and Townsend and Crew LLP
? STREET: Two Embarcadero Center, Eighth Floor
? CITY: San Francisco
? STATE: California
? COUNTRY: USA
? ZIP: 94111-3834
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC-DOS/MS-DOS
? SOFTWARE: PatentIn Release #1.0, Version #1.30
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/472,802C
? FILING DATE: 07-JUN-1995
? CLASSIFICATION: 514
? PRIOR APPLICATION DATA:
```

```

? APPLICATION NUMBER: US 08/272,102
? FILING DATE: 07-JUL-1994
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 08/330,123
? FILING DATE: 27-OCT-1994
? ATTORNEY/AGENT INFORMATION:
? NAME: Smith, William M.
? REGISTRATION NUMBER: 30,223
? REFERENCE/DOCKET NUMBER: 15389-000820
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (415) 576-0200
? TELEFAX: (415) 576-0300
? INFORMATION FOR SEQ ID NO: 11:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 10 base pairs
? TYPE: nucleic acid
? STRANDEDNESS: single
? TOPOLOGY: linear
? MOLECULE TYPE: RNA
?
US-08-472-802C-11

Query Match      13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 TGGGGTTGG 56
      |||||
Db      9 TGGGGTTGG 1

RESULT 81
US-08-388-353-513
? Sequence 513, Application US/08388353
? Patent No. 6010895
? GENERAL INFORMATION:
? APPLICANT: Deacon, Nicholas J.
? APPLICANT: Learmont, Jennifer C.
? APPLICANT: McPhee, Dale A.
? APPLICANT: Crowe, Suzanne
? APPLICANT: Cooper, David
? TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
? NUMBER OF SEQUENCES: 800
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Scully, Scott, Murphy & Presser
? STREET: 400 Garden City Plaza
? CITY: Garden City
? STATE: New York
? COUNTRY: United States
? ZIP: 11530
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC-DOS/MS-DOS
? SOFTWARE: PatentIn Release #1.0, Version #1.25
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/388,353
? FILING DATE: 14-FEB-1995
? CLASSIFICATION: 424
? ATTORNEY/AGENT INFORMATION:
? NAME: DiGiulio, Frank S.
? REGISTRATION NUMBER: 31,346
? REFERENCE/DOCKET NUMBER: 9606
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (516) 742-4343
? TELEFAX: (516) 742-4366
? TELEX: 230 901 SANS UR
? INFORMATION FOR SEQ ID NO: 513:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 10 base pairs
? TYPE: nucleic acid
? STRANDEDNESS: single
? TOPOLOGY: linear
? MOLECULE TYPE: DNA (genomic)
```


US-08-388-353-513

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 5 TGAATGGA 13
| | | | |
Db 2 TGAATGGA 10

RESULT 82

US-08-388-353-514
; Sequence 514, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 514:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-514

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 5 TGAATGGA 13
| | | | |
Db 1 TGAATGGA 9

RESULT 83

US-08-388-353-547
; Sequence 547, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.

APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR

INFORMATION FOR SEQ ID NO: 547:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-547

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 54 TGAAGTTT 62
| | | | |
Db 2 TGAAGTTT 10

RESULT 84

US-08-388-353-548
; Sequence 548, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995

CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: DIGIGLO, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 548:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-548

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 TGGAGCTT 62
Db 1 TGGAGCTT 9

RESULT 85
US-08-520-550A-41/C
Sequence 41, Application US/08520550A
Patent No. 6013468
GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avilion, Ariel A.
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Greider, Carol
APPLICANT: Marinenda, Maria A. B.
APPLICANT: Villeponteau, Bryant
TITLE OF INVENTION: RNA Component of Telomerase
NUMBER OF SEQUENCES: 47
CURRENT APPLICATION DATA:
CORRESPONDENCE ADDRESS:
ADDRESS: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Millia Drive
CITY: Lexington
STATE: MA
COUNTRY: US
ZIP: 02173
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/520,550A
FILING DATE: 29-AUG-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/387,524
FILING DATE: 13-FEB-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: CSH94-05A3B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540

INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-520-550A-41

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGTTGG 56
Db 9 TGGGTTGG 1

RESULT 86
US-08-488-551B-513
Sequence 513, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESS: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3664 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 513:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-513

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGGA 13

Db 2 TGGATGGA 10

RESULT 87
US-08-488-551B-514
; Sequence 514, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 96062
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 514:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-514

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGGA 13
Db 1 TGGATGGA 9

RESULT 88
US-08-488-551B-547
; Sequence 547, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1

NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 547:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-547

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 TGGAGTTT 62
Db 2 TGGAGTTT 10

RESULT 89
US-08-488-551B-548
; Sequence 548, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 548:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-548

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 TGGAGCTTT 62
|||||||
Db 1 TGGAGCTTT 9

RESULT 90
US-08-488-551B-831
Sequence 831, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95

FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 831:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-831

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGGA 13
|||||||
Db 2 TGGATGGA 10

RESULT 91
US-08-488-551B-832
Sequence 832, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 832:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA
US-08-488-551B-832

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGCA 13
Db 1 TGGATGCA 9

RESULT 92

US-08-998-443-10/c
Sequence 10, Application US/08998443
Patent No. 6034575
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,443
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/660,678
FILING DATE: 05-JUN-1996
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000811US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-998-443-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGTTGG 56
Db 9 TGGGTTGG 1

RESULT 93

US-09-060-523-10/c
Sequence 10, Application US/09060523
Patent No. 6258535

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/060,523
FILING DATE: 14-APR-1998
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/660,678
FILING DATE: 05-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000813US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-060-523-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGTTGG 56
Db 9 TGGGTTGG 1

RESULT 94
US-09-580-517-10/c
Sequence 10, Application US/09580517
Patent No. 6320039

GENERAL INFORMATION:
APPLICANT: VILLEPONTEAU, Bryant
APPLICANT: FENG, Junli
APPLICANT: FUNK, Walter
APPLICANT: ANDREWS, William H.

TITLE OF INVENTION: HUMAN TELOMERASE
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Khourie and Crew

STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/580,517
FILING DATE: 25-May-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/330,123
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000810
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-580-517-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||||
Db 9 TGGGGTTGG 1

RESULT 95
US-09-057-351-10/c
Sequence 10, Application US/09057351
Patent No. 6548298
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/057,351
FILING DATE: 08-APR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,802
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000821US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-057-351-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||||
Db 9 TGGGGTTGG 1

RESULT 96
PCT-US96-09430-21/c
Sequence 21, Application PC/TUS9609430
GENERAL INFORMATION:
APPLICANT: Glazer, Peter M.
TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: OncorPharm, Inc.
STREET: 200 Perry Parkway
CITY: Gaithersburg
STATE: Maryland
COUNTRY: US
ZIP: 20877
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09430
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/473,845
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Katra, Glenn E.
REGISTRATION NUMBER: 30,649
REFERENCE/DOCKET NUMBER: PA-0040
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-527-2058
TELEFAX: 301-208-6997
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO

PCT-US96-09430-21

Query Match 13.8%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 36 AAAGACCT 44
11 AAAGACCT 3

Db 11 AAAGACCT 3

RESULT 97
US-08-117-491-19/c
; Sequence 19, Application US/08117491
; Patent No. 5500363
; GENERAL INFORMATION:
; APPLICANT: Comb, Donald G.
; APPLICANT: Perlter, Francine
; APPLICANT: Kucera, Rebecca
; APPLICANT: Jack, William E.
; TITLE OF INVENTION: RECOMBINANT THERMOSTABLE DNA
; TITLE OF INVENTION: POLYMERS FROM ARCHAEABACTERIA
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: DAVID G. CONLIN, DIKE, BRONSTEIN, ROBERTS
; ADDRESSEE: 6 CUSHMAN
; STREET: 130 WATER STREET
; CITY: BOSTON
; STATE: MASSACHUSETTS
; COUNTRY: US
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,491
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/811,421
; FILING DATE: 12-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/686,340
; FILING DATE: 17-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/626,057
; FILING DATE: 11-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/513,994
; FILING DATE: 26-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Resnick, David S.
; REGISTRATION NUMBER: 34,235
; REFERENCE/DOCKET NUMBER: 39296C3FWC2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 523-3400
; TELEFAX: (617) 523-6440
; TELEX: 200291 SYR UR
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; US-08-117-491-19

Query Match 13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 37 AAGACCTT 45

Db 12 AAGACCTT 4

RESULT 98
US-08-271-364A-19/c
; Sequence 19, Application US/08271364A
; Patent No. 5756334
; GENERAL INFORMATION:
; APPLICANT: PERLER, FRANCINE B.
; APPLICANT: SOUTHWORTH, MAURICE W.
; TITLE OF INVENTION: RECOMBINANT THERMOSTABLE DNA POLYMERASE
; TITLE OF INVENTION: FROM ARCHAEABACTERIA
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: NEW ENGLAND BIOLABS, INC.
; STREET: 32 TOZER ROAD
; CITY: BEVERLY
; STATE: MASSACHUSETTS
; COUNTRY: US
; ZIP: 01915
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/271,364A
; FILING DATE: 06-JUL-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/811,421
; FILING DATE: 18-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/686,340
; FILING DATE: 17-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/626,057
; FILING DATE: 11-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/513,994
; FILING DATE: 26-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, GREGORY D.
; REGISTRATION NUMBER: 30901
; REFERENCE/DOCKET NUMBER: NEB-101.
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 927-5054
; TELEFAX: (508) 927-1705
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-271-364A-19

Query Match 13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 37 AAGACCTT 45
12 AAGACCTT 4

RESULT 99
US-08-222-715B-19/c
; Sequence 19, Application US/08222715B
; Patent No. 5834285
; GENERAL INFORMATION:
; APPLICANT: Comb, Donald G.

```

;
; APPLICANT: Perler, Francine
; APPLICANT: Kucera, Rebecca
; TITLE OF INVENTION: RECOMBINANT THERMOSTABLE DNA
; TITLE OF INVENTION: POLYMERASE FROM ARCHAEABACTERIA
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: GREGORY D. WILLIAMS, NEW ENGLAND BIOLABS,
; ADDRESSER: INC.
; STREET: 32 TOZER ROAD
; CITY: BEVERLY
; STATE: MASSACHUSETTS
; COUNTRY: US
; ZIP: 01915
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,715B
; FILING DATE: 04-APR-1994
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/167,238
; FILING DATE: 15-DEC-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/686,340
; FILING DATE: 17-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/626,057
; FILING DATE: 11-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/513,994
; FILING DATE: 26-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Gregory D.
; REGISTRATION NUMBER: 30901
; REFERENCE/DOCKET NUMBER: NEB-054C3FC2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (508) 927-5054
; TELEFAX: (508) 927-1705
;
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
;
; US-08-222-715B-19
;
; Query Match 13.8%; Score 9; DB 1; Length 12;
; Best Local Similarity 100.0%; Pred. No. 52;
; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 37 AAGAACCTT 45
; Db 12 AAGAACCTT 4
;
; RESULT 100
; US-09-281-418-58
; Sequence 58, Application US/09281418
; Patent No. 6287769
; GENERAL INFORMATION:
; APPLICANT: Inoue, Takakazu
; TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
; TITLE OF INVENTION: Method of Assaying Microorganisms, Method of Analyzing MI
; TITLE OF INVENTION: nisms and Method of Assaying Contaminant
; FILE REFERENCE: 9982-7
; CURRENT APPLICATION NUMBER: US/09/281,418
; CURRENT FILING DATE: 1999-03-30
; EARLIER APPLICATION NUMBER: JP/1998/87651

```

```

;
; EARLIER FILING DATE: 1998-03-31
; EARLIER APPLICATION NUMBER: JP/1999/69694
; EARLIER FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 216
; SEQ ID NO 58
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
;
; US-09-281-418-58
;
; Query Match 13.8%; Score 9; DB 1; Length 12;
; Best Local Similarity 100.0%; Pred. No. 52;
; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 12 GAATTGAC 20
; Db 2 GAATTGAC 10
;
; RESULT 101
; PCT-US96-09430-16/c
; Sequence 16, Application PC/TUS9609430
; GENERAL INFORMATION:
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Oncorphanm, Inc.
; STREET: 200 Perry Parkway
; CITY: Galthersburg
; STATE: Maryland
; COUNTRY: US
; ZIP: 20877
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/09430
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/473,845
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Katta, Glenn E.
; REGISTRATION NUMBER: 30,649
; REFERENCE/DOCKET NUMBER: PA-0040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-527-2058
; TELEFAX: 301-208-6997
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
;
; PCT-US96-09430-16
;
; Query Match 13.8%; Score 9; DB 1; Length 12;
; Best Local Similarity 100.0%; Pred. No. 52;
; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 36 AAGAACCT 44
; Db 12 AAGAACCT 4

```



```
RESULT 102
PCT-US96-09430-17/c
; Sequence 17, Application PC/TUS9609430
; GENERAL INFORMATION:
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OncorPharm, Inc.
; STREET: 200 Perry Parkway
; CITY: Gaithersburg
; STATE: Maryland
; COUNTRY: US
; ZIP: 20877
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/09430
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/473,845
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Karta, Glenn E.
; REGISTRATION NUMBER: 30,649
; REFERENCE/DOCKET NUMBER: PA-0040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-527-2058
; TELEFAX: 301-208-6997
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
;
PCT-US96-09430-17

Query Match          13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      36 AAAGAACT 44
      |||||
Db      12 AAAGAACT 4

RESULT 103
PCT-US96-09430-18/c
; Sequence 18, Application PC/TUS9609430
; GENERAL INFORMATION:
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OncorPharm, Inc.
; STREET: 200 Perry Parkway
; CITY: Gaithersburg
; STATE: Maryland
; COUNTRY: US
; ZIP: 20877
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
```

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/09430
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/473,845
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Karta, Glenn E.
; REGISTRATION NUMBER: 30,649
; REFERENCE/DOCKET NUMBER: PA-0040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-527-2058
; TELEFAX: 301-208-6997
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
;
PCT-US96-09430-18

Query Match          13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      36 AAAGAACT 44
      |||||
Db      12 AAAGAACT 4
```

Search completed: August 12, 2004, 15:34:29
Job time : 0.001 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:28:53 ; Search time 1 Seconds
(without alignments)
0.904 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65

Sequence: 1 ttcttcggaatggaatgcac.....gtcggggctcgaggttcac 65

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 534 seqs, 6954 residues

Total number of hits satisfying chosen parameters: 1068

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Database : ngs:*
Listing first 534 summaries

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	36.9	24	1	ADCO2407
2	20	30.8	20	1	AAD57273
3	20	30.8	20	1	AAD57274
4	20	30.8	20	1	AAD57275
5	20	30.8	20	1	AAD57275
6	19.8	30.5	21	1	AAV82678
7	15.8	24.3	21	1	AAF74520
8	14.4	22.2	18	1	AAI42340
9	14	21.5	18	1	AAQ99361
10	13.4	20.6	16	1	ABX75231
11	13.4	20.6	17	1	ABK02829
12	13.4	20.6	17	1	ABK02828
13	13	20.0	17	1	ABK02830
14	13	20.0	17	1	ABK03198
15	13	20.0	17	1	ABT39879
16	13	20.0	17	1	ADB40491
17	12.8	19.7	17	1	AAI60238
18	12.8	19.7	17	1	AAF06139
19	12.8	19.7	17	1	AAF06172
20	12.8	19.7	17	1	ABK03743
21	12.8	19.7	17	1	ABN02473
22	12.8	19.7	17	1	ABN02472
23	12.4	19.1	15	1	AAZ97663
24	12.4	19.1	15	1	AAZ97684
25	12	18.5	12	1	AB167380
26	12	18.5	12	1	AB148814
27	12	18.5	13	1	ABC19998
28	12	18.5	13	1	ABC19998
29	12	18.5	15	1	AAI41830
30	11.8	18.2	15	1	AAF51170
31	11.8	18.2	15	1	AAF51169
32	11.8	18.2	15	1	AAZ98678
33	11.8	18.2	15	1	AAI48106

34	11.4	17.5	13	1	AAZ99594	Immunostimulatory
35	11.4	17.5	13	1	ABF69510	Oligonucleotide SE
36	11.4	17.5	13	1	ABH44501	Oligonucleotide SE
37	11.4	17.5	13	1	ABF69511	Oligonucleotide SE
38	11.4	17.5	13	1	ABF07727	Oligonucleotide SE
39	11.4	17.5	13	1	ABC73222	Oligonucleotide SE
40	11.4	17.5	13	1	ABC73223	Oligonucleotide SE
41	11.4	17.5	13	1	ABF07726	Oligonucleotide SE
42	11.4	17.5	13	1	ABH57826	Oligonucleotide SE
43	11.4	17.5	13	1	ABH44500	Oligonucleotide SE
44	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
45	11.4	17.5	13	1	ABF78312	Angiogenesis inhib
46	11.4	17.5	13	1	ABL39046	Immunostimulatory
47	11.4	17.5	13	1	ACH03134	Immunostimulatory
48	11.4	17.5	13	1	ADB37096	Immunostimulatory
49	11.4	17.5	14	1	AAZ97685	HIV-1 protease gen
50	11.4	17.5	15	1	AAQ90131	69-mer oligonucleo
51	11.4	17.5	15	1	AAI86416	Human satellite II
52	11.4	17.5	15	1	ABX03968	Resistance gene te
53	11.4	17.5	15	1	AAZ96597	Primer SP14
54	11.4	17.5	15	1	ABN87928	Human GSR allele s
55	11.4	17.5	15	1	AAZ97335	Human CRXB1 gene
56	11.4	17.5	15	1	ABK54466	ASO primer #16 to
57	11.4	17.5	15	1	AB154483	Oligonucleotide pr
58	11	16.9	12	1	AB144216	Oligonucleotide pr
59	11	16.9	12	1	AB118186	Oligonucleotide pr
60	11	16.9	12	1	AB144217	Oligonucleotide pr
61	11	16.9	12	1	AB181139	Oligonucleotide pr
62	11	16.9	12	1	AB106790	Oligonucleotide pr
63	11	16.9	13	1	AAZ77962	Human tenascin bin
64	11	16.9	13	1	AAZ77963	Human tenascin bin
65	11	16.9	13	1	AAZ77961	Human tenascin bin
66	11	16.9	13	1	ABC91347	Oligonucleotide SE
67	11	16.9	13	1	ABC57026	Oligonucleotide SE
68	11	16.9	13	1	ABF02652	Oligonucleotide SE
69	11	16.9	13	1	ABH48359	Oligonucleotide SE
70	11	16.9	13	1	ABG91346	Oligonucleotide SE
71	11	16.9	13	1	ABG57027	Oligonucleotide SE
72	11	16.9	13	1	ABC01035	Oligonucleotide SE
73	11	16.9	13	1	ABH48358	Oligonucleotide SE
74	11	16.9	13	1	ABF02653	Oligonucleotide SE
75	11	16.9	13	1	AAZ56933	Oligonucleotide SE
76	10.8	16.6	14	1	AAZ56933	Oligonucleotide SE
77	10.8	16.6	14	1	AAZ56933	Oligonucleotide SE
78	10.8	16.6	14	1	AAZ56933	Oligonucleotide SE
79	10.8	16.6	14	1	AAZ56933	Oligonucleotide SE
80	10.6	16.3	13	1	ABF38003	Oligonucleotide SE
81	10.6	16.3	13	1	ABF38002	Oligonucleotide SE
82	10.6	16.3	13	1	AAQ22815	Random oligonucleo
83	10.4	16.0	12	1	AAQ22813	Random oligonucleo
84	10.4	16.0	12	1	AAQ21300	Circular oligonucleo
85	10.4	16.0	12	1	AAI42866	Single stranded ci
86	10.4	16.0	12	1	AAI42866	Single stranded ci
87	10.4	16.0	12	1	AAI42866	Single stranded ci
88	10.4	16.0	12	1	AAI42867	Single stranded ci
89	10.4	16.0	12	1	AB125498	Oligonucleotide pr
90	10.4	16.0	12	1	AB107008	Oligonucleotide pr
91	10.4	16.0	12	1	ABH89802	Oligonucleotide pr
92	10.4	16.0	12	1	ABH52262	Oligonucleotide pr
93	10.4	16.0	12	1	AB104542	Oligonucleotide pr
94	10.4	16.0	12	1	AB106919	Oligonucleotide pr
95	10.4	16.0	12	1	AB107431	Oligonucleotide pr
96	10.4	16.0	12	1	AB161725	Oligonucleotide pr
97	10.4	16.0	12	1	AB122655	Oligonucleotide pr
98	10.4	16.0	12	1	AB123553	Oligonucleotide pr
99	10.4	16.0	12	1	AB172830	Oligonucleotide pr
100	10.4	16.0	12	1	AB173289	Oligonucleotide pr
101	10.4	16.0	12	1	ABH94429	Oligonucleotide pr
102	10.4	16.0	12	1	AB128154	Oligonucleotide pr
103	10.4	16.0	12	1	ABH80462	Oligonucleotide pr
104	10.4	16.0	12	1	AB106918	Oligonucleotide pr
105	10.4	16.0	12	1	ABH84964	Oligonucleotide pr
106	10.4	16.0	12	1	AB109323	Oligonucleotide pr

C 107	10.4	16.0	12	1	AB124668	Oligonucleotide pr
C 108	10.4	16.0	12	1	AB157127	Oligonucleotide pr
C 109	10.4	16.0	12	1	ABH70112	Oligonucleotide pr
C 110	10.4	16.0	12	1	AB175408	Oligonucleotide pr
C 111	10.4	16.0	12	1	ABH76819	Oligonucleotide pr
C 112	10.4	16.0	12	1	AB108168	Oligonucleotide pr
C 113	10.4	16.0	12	1	AB111964	Oligonucleotide pr
C 114	10.4	16.0	12	1	AB111865	Oligonucleotide pr
C 115	10.4	16.0	12	1	AB138926	Oligonucleotide pr
C 116	10.4	16.0	12	1	ABH73791	Oligonucleotide pr
C 117	10.4	16.0	12	1	AB177010	Oligonucleotide pr
C 118	10.4	16.0	12	1	AB123551	Oligonucleotide pr
C 120	10.4	16.0	12	1	AB142492	Oligonucleotide pr
C 121	10.4	16.0	12	1	AB175632	Oligonucleotide pr
C 122	10.4	16.0	12	1	AB126119	Oligonucleotide pr
C 123	10.4	16.0	12	1	AB117994	Oligonucleotide pr
C 124	10.4	16.0	12	1	AB107453	Oligonucleotide pr
C 125	10.4	16.0	12	1	AB162010	Oligonucleotide pr
C 126	10.4	16.0	12	1	AB100155	Oligonucleotide pr
C 127	10.4	16.0	13	1	ABC95493	Oligonucleotide pr
C 128	10.4	16.0	13	1	ABC72046	Oligonucleotide pr
C 129	10.4	16.0	13	1	ABC11945	Oligonucleotide pr
C 130	10.4	16.0	13	1	ABC87797	Oligonucleotide pr
C 131	10.4	16.0	13	1	ABC89082	Oligonucleotide pr
C 132	10.4	16.0	13	1	ABF60882	Oligonucleotide pr
C 133	10.4	16.0	13	1	ABF09494	Oligonucleotide pr
C 134	10.4	16.0	13	1	ABH08614	Oligonucleotide pr
C 135	10.4	16.0	13	1	ABCI18620	Oligonucleotide pr
C 136	10.4	16.0	13	1	ABC95834	Oligonucleotide pr
C 137	10.4	16.0	13	1	ABC22672	Oligonucleotide pr
C 138	10.4	16.0	13	1	ABF53874	Oligonucleotide pr
C 139	10.4	16.0	13	1	ABC93477	Oligonucleotide pr
C 140	10.4	16.0	13	1	ABCI19966	Oligonucleotide pr
C 141	10.4	16.0	13	1	ABH45216	Oligonucleotide pr
C 142	10.4	16.0	13	1	ABR12720	Oligonucleotide pr
C 143	10.4	16.0	13	1	ABH18990	Oligonucleotide pr
C 144	10.4	16.0	13	1	ABF72258	Oligonucleotide pr
C 145	10.4	16.0	13	1	ABH64846	Oligonucleotide pr
C 146	10.4	16.0	13	1	ABH18991	Oligonucleotide pr
C 147	10.4	16.0	13	1	ABH61688	Oligonucleotide pr
C 148	10.4	16.0	13	1	ABH18991	Oligonucleotide pr
C 149	10.4	16.0	13	1	ABC95492	Oligonucleotide pr
C 150	10.4	16.0	13	1	ABC97700	Oligonucleotide pr
C 151	10.4	16.0	13	1	ABF35272	Oligonucleotide pr
C 152	10.4	16.0	13	1	ABH56067	Oligonucleotide pr
C 153	10.4	16.0	13	1	ABC69962	Oligonucleotide pr
C 154	10.4	16.0	13	1	ABC00654	Oligonucleotide pr
C 155	10.4	16.0	13	1	ABF44599	Oligonucleotide pr
C 156	10.4	16.0	13	1	ABF72259	Oligonucleotide pr
C 157	10.4	16.0	13	1	ABC93476	Oligonucleotide pr
C 158	10.4	16.0	13	1	ABC00655	Oligonucleotide pr
C 159	10.4	16.0	13	1	ABF15052	Oligonucleotide pr
C 160	10.4	16.0	13	1	ABF15053	Oligonucleotide pr
C 161	10.4	16.0	13	1	ABF53875	Oligonucleotide pr
C 162	10.4	16.0	13	1	ABH08607	Oligonucleotide pr
C 163	10.4	16.0	13	1	ABH56066	Oligonucleotide pr
C 164	10.4	16.0	13	1	ABC58355	Oligonucleotide pr
C 165	10.4	16.0	13	1	ABC72047	Oligonucleotide pr
C 166	10.4	16.0	13	1	ABC75859	Oligonucleotide pr
C 167	10.4	16.0	13	1	ABC11944	Oligonucleotide pr
C 168	10.4	16.0	13	1	ABC87801	Oligonucleotide pr
C 169	10.4	16.0	13	1	ABF60883	Oligonucleotide pr
C 170	10.4	16.0	13	1	ABC99009	Oligonucleotide pr
C 171	10.4	16.0	13	1	ABC89701	Oligonucleotide pr
C 172	10.4	16.0	13	1	ABF67787	Oligonucleotide pr
C 173	10.4	16.0	13	1	ABF51528	Oligonucleotide pr
C 174	10.4	16.0	13	1	ABC69963	Oligonucleotide pr
C 175	10.4	16.0	13	1	ABC22673	Oligonucleotide pr
C 176	10.4	16.0	13	1	ABC99008	Oligonucleotide pr
C 177	10.4	16.0	13	1	ABC87800	Oligonucleotide pr
C 178	10.4	16.0	13	1	ABC89083	Oligonucleotide pr
C 179	10.4	16.0	13	1	ABF67786	Oligonucleotide pr
C 180	10.4	16.0	13	1	ABH08615	Oligonucleotide pr
C 181	10.4	16.0	13	1	ABC18621	Oligonucleotide pr
C 182	10.4	16.0	13	1	ABF12721	Oligonucleotide pr
C 183	10.4	16.0	13	1	ABH7796	Oligonucleotide pr
C 184	10.4	16.0	13	1	ABF35273	Oligonucleotide pr
C 185	10.4	16.0	13	1	ABF44598	Oligonucleotide pr
C 186	10.4	16.0	13	1	ABC75858	Oligonucleotide pr
C 187	10.4	16.0	13	1	ABC45858	Oligonucleotide pr
C 188	10.4	16.0	13	1	ABF51689	Oligonucleotide pr
C 189	10.4	16.0	13	1	ABH08606	Oligonucleotide pr
C 190	10.4	16.0	13	1	ABH45217	Oligonucleotide pr
C 191	10.4	16.0	13	1	ABH64847	Oligonucleotide pr
C 192	10	15.4	10	1	AAQ79357	Sequence of lympho
C 193	10	15.4	10	1	AAV50176	Yeast tag for addi
C 194	10	15.4	10	1	AAZ77894	Human denaritic ce
C 195	10	15.4	10	1	AAZ82445	Metastatic breast
C 196	10	15.4	10	1	AA556570	Human macrophage g
C 197	10	15.4	10	1	AAH64133	Human ubilquitously
C 198	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 199	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 200	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 201	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 202	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 203	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 204	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 205	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 206	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 207	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 208	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 209	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 210	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 211	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 212	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 213	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 214	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 215	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 216	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 217	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 218	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 219	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 220	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 221	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 222	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 223	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 224	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 225	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 226	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 227	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 228	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 229	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 230	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 231	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 232	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 233	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 234	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 235	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 236	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 237	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 238	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 239	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 240	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 241	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 242	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 243	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 244	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 245	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 246	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 247	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 248	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 249	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 250	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 251	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 252	10	15.4	10	1	AAH64133	Yeast NORF gene SA

253	10	15.4	13	1	ABF78290	Oligonucleotide SE	C 326	10	15.4	13	1	ABC53077	Oligonucleotide SE
254	10	15.4	13	1	ABH09785	Oligonucleotide SE	C 327	10	15.4	13	1	ABC08543	Oligonucleotide SE
255	10	15.4	13	1	ABH14635	Oligonucleotide SE	C 328	10	15.4	13	1	ABF93014	Oligonucleotide SE
256	10	15.4	13	1	ABF35131	Oligonucleotide SE	C 329	10	15.4	13	1	ABH16776	Oligonucleotide SE
257	10	15.4	13	1	ABF68180	Oligonucleotide SE	C 330	10	15.4	13	1	ABC08542	Oligonucleotide SE
258	10	15.4	13	1	ABF72180	Oligonucleotide SE	C 331	10	15.4	13	1	ABC88550	Oligonucleotide SE
259	10	15.4	13	1	ABF78291	Oligonucleotide SE	C 332	10	15.4	13	1	ABF93358	Oligonucleotide SE
260	10	15.4	13	1	ABF78294	Oligonucleotide SE	C 333	10	15.4	13	1	ABF73194	Oligonucleotide SE
261	10	15.4	13	1	ABH12398	Oligonucleotide SE	C 334	10	15.4	13	1	ABH10858	Oligonucleotide SE
262	10	15.4	13	1	ABC18902	Oligonucleotide SE	C 335	10	15.4	13	1	ABF60991	Oligonucleotide SE
263	10	15.4	13	1	ABC18903	Oligonucleotide SE	C 336	10	15.4	13	1	ABC74004	Oligonucleotide SE
264	10	15.4	13	1	ABC69993	Oligonucleotide SE	C 337	10	15.4	13	1	ABF02806	Oligonucleotide SE
265	10	15.4	13	1	ABC53076	Oligonucleotide SE	C 338	10	15.4	13	1	ABF14905	Oligonucleotide SE
266	10	15.4	13	1	ABF14904	Oligonucleotide SE	C 339	10	15.4	13	1	ABC16840	Oligonucleotide SE
267	10	15.4	13	1	ABC16841	Oligonucleotide SE	C 340	10	15.4	13	1	ABH27161	Oligonucleotide SE
268	10	15.4	13	1	ABF29456	Oligonucleotide SE	C 341	10	15.4	13	1	ABH27162	Oligonucleotide SE
269	10	15.4	13	1	ABF78295	Oligonucleotide SE	C 342	10	15.4	13	1	ABF52056	Oligonucleotide SE
270	10	15.4	13	1	ABH28568	Oligonucleotide SE	C 343	10	15.4	13	1	ABE58187	Oligonucleotide SE
271	10	15.4	13	1	ABH09787	Oligonucleotide SE	C 344	9.8	15.1	13	1	AA019397	Partial PRSPTC-NFI
272	10	15.4	13	1	ABH41477	Oligonucleotide SE	C 345	9.8	15.1	13	1	ABF05600	Oligonucleotide SE
273	10	15.4	13	1	ABC88819	Oligonucleotide SE	C 346	9.8	15.1	13	1	ABC06574	Oligonucleotide SE
274	10	15.4	13	1	ABF35130	Oligonucleotide SE	C 347	9.8	15.1	13	1	ABC63815	Oligonucleotide SE
275	10	15.4	13	1	ABF68181	Oligonucleotide SE	C 348	9.8	15.1	13	1	ABF16688	Oligonucleotide SE
276	10	15.4	13	1	ABF72181	Oligonucleotide SE	C 349	9.8	15.1	13	1	ABF69512	Oligonucleotide SE
277	10	15.4	13	1	ABH28569	Oligonucleotide SE	C 350	9.8	15.1	13	1	ABF69513	Oligonucleotide SE
278	10	15.4	13	1	ABH66664	Oligonucleotide SE	C 351	9.8	15.1	13	1	ABH00238	Oligonucleotide SE
279	10	15.4	13	1	ABC08155	Oligonucleotide SE	C 352	9.8	15.1	13	1	ABC54295	Oligonucleotide SE
280	10	15.4	13	1	ABC08156	Oligonucleotide SE	C 353	9.8	15.1	13	1	ABF05602	Oligonucleotide SE
281	10	15.4	13	1	ABC88551	Oligonucleotide SE	C 354	9.8	15.1	13	1	ABC31788	Oligonucleotide SE
282	10	15.4	13	1	ABF14836	Oligonucleotide SE	C 355	9.8	15.1	13	1	ABC11500	Oligonucleotide SE
283	10	15.4	13	1	ABF39155	Oligonucleotide SE	C 356	9.8	15.1	13	1	ABC11501	Oligonucleotide SE
284	10	15.4	13	1	ABH36930	Oligonucleotide SE	C 357	9.8	15.1	13	1	ABC17879	Oligonucleotide SE
285	10	15.4	13	1	ABH59464	Oligonucleotide SE	C 358	9.8	15.1	13	1	ABH00234	Oligonucleotide SE
286	10	15.4	13	1	ABF21342	Oligonucleotide SE	C 359	9.8	15.1	13	1	ABF65172	Oligonucleotide SE
287	10	15.4	13	1	ABH27163	Oligonucleotide SE	C 360	9.8	15.1	13	1	ABH62562	Oligonucleotide SE
288	10	15.4	13	1	ABF52228	Oligonucleotide SE	C 361	9.8	15.1	13	1	ABC92815	Oligonucleotide SE
289	10	15.4	13	1	ABF60990	Oligonucleotide SE	C 362	9.8	15.1	13	1	ABC75155	Oligonucleotide SE
290	10	15.4	13	1	ABC68982	Oligonucleotide SE	C 363	9.8	15.1	13	1	ABC58518	Oligonucleotide SE
291	10	15.4	13	1	ABF02807	Oligonucleotide SE	C 364	9.8	15.1	13	1	ABC11401	Oligonucleotide SE
292	10	15.4	13	1	ABC68772	Oligonucleotide SE	C 365	9.8	15.1	13	1	ABF35262	Oligonucleotide SE
293	10	15.4	13	1	ABF18949	Oligonucleotide SE	C 366	9.8	15.1	13	1	ABF39902	Oligonucleotide SE
294	10	15.4	13	1	ABF24945	Oligonucleotide SE	C 367	9.8	15.1	13	1	ABH33027	Oligonucleotide SE
295	10	15.4	13	1	ABF73195	Oligonucleotide SE	C 368	9.8	15.1	13	1	ABH10963	Oligonucleotide SE
296	10	15.4	13	1	ABC69992	Oligonucleotide SE	C 369	9.8	15.1	13	1	ABH38624	Oligonucleotide SE
297	10	15.4	13	1	ABF18948	Oligonucleotide SE	C 370	9.8	15.1	13	1	ABH15566	Oligonucleotide SE
298	10	15.4	13	1	ABH16777	Oligonucleotide SE	C 371	9.8	15.1	13	1	ABH41660	Oligonucleotide SE
299	10	15.4	13	1	ABH42921	Oligonucleotide SE	C 372	9.8	15.1	13	1	ABH42926	Oligonucleotide SE
300	10	15.4	13	1	ABF14837	Oligonucleotide SE	C 373	9.8	15.1	13	1	ABH62128	Oligonucleotide SE
301	10	15.4	13	1	ABF21338	Oligonucleotide SE	C 374	9.8	15.1	13	1	ABF71135	Oligonucleotide SE
302	10	15.4	13	1	ABF21339	Oligonucleotide SE	C 375	9.8	15.1	13	1	ABC52081	Oligonucleotide SE
303	10	15.4	13	1	ABF35339	Oligonucleotide SE	C 376	9.8	15.1	13	1	ABF05603	Oligonucleotide SE
304	10	15.4	13	1	ABH36931	Oligonucleotide SE	C 377	9.8	15.1	13	1	ABC06244	Oligonucleotide SE
305	10	15.4	13	1	ABH42920	Oligonucleotide SE	C 378	9.8	15.1	13	1	ABF07731	Oligonucleotide SE
306	10	15.4	13	1	ABH66665	Oligonucleotide SE	C 379	9.8	15.1	13	1	ABC10826	Oligonucleotide SE
307	10	15.4	13	1	ABC08157	Oligonucleotide SE	C 380	9.8	15.1	13	1	ABC11400	Oligonucleotide SE
308	10	15.4	13	1	ABF21343	Oligonucleotide SE	C 381	9.8	15.1	13	1	ABF16686	Oligonucleotide SE
309	10	15.4	13	1	ABF24944	Oligonucleotide SE	C 382	9.8	15.1	13	1	ABF20476	Oligonucleotide SE
310	10	15.4	13	1	ABF52229	Oligonucleotide SE	C 383	9.8	15.1	13	1	ABF39903	Oligonucleotide SE
311	10	15.4	13	1	ABH10859	Oligonucleotide SE	C 384	9.8	15.1	13	1	ABF67880	Oligonucleotide SE
312	10	15.4	13	1	ABH12399	Oligonucleotide SE	C 385	9.8	15.1	13	1	ABF98316	Oligonucleotide SE
313	10	15.4	13	1	ABH41476	Oligonucleotide SE	C 386	9.8	15.1	13	1	ABF98317	Oligonucleotide SE
314	10	15.4	13	1	ABF14180	Oligonucleotide SE	C 387	9.8	15.1	13	1	ABH29613	Oligonucleotide SE
315	10	15.4	13	1	ABC66873	Oligonucleotide SE	C 388	9.8	15.1	13	1	ABH57829	Oligonucleotide SE
316	10	15.4	13	1	ABF39154	Oligonucleotide SE	C 389	9.8	15.1	13	1	ABH62563	Oligonucleotide SE
317	10	15.4	13	1	ABF93015	Oligonucleotide SE	C 390	9.8	15.1	13	1	ABC44907	Oligonucleotide SE
318	10	15.4	13	1	ABF52057	Oligonucleotide SE	C 391	9.8	15.1	13	1	ABC71134	Oligonucleotide SE
319	10	15.4	13	1	ABH14634	Oligonucleotide SE	C 392	9.8	15.1	13	1	ABC52080	Oligonucleotide SE
320	10	15.4	13	1	ABH59465	Oligonucleotide SE	C 393	9.8	15.1	13	1	ABF04649	Oligonucleotide SE
321	10	15.4	13	1	ABC68985	Oligonucleotide SE	C 394	9.8	15.1	13	1	ABF07729	Oligonucleotide SE
322	10	15.4	13	1	ABF29457	Oligonucleotide SE	C 395	9.8	15.1	13	1	ABC10827	Oligonucleotide SE
323	10	15.4	13	1	ABF96458	Oligonucleotide SE	C 396	9.8	15.1	13	1	ABC16849	Oligonucleotide SE
324	10	15.4	13	1	ABH27160	Oligonucleotide SE	C 397	9.8	15.1	13	1	ABF32796	Oligonucleotide SE
325	10	15.4	13	1	ABC74005	Oligonucleotide SE	C 398	9.8	15.1	13	1	ABF32797	Oligonucleotide SE

C 399	9.8	15.1	13	1	ABF47357	Oligonucleotide SE
C 400	9.8	15.1	13	1	ABF73592	Oligonucleotide SE
C 401	9.8	15.1	13	1	ABH3542	Oligonucleotide SE
C 402	9.8	15.1	13	1	ABF58451	Oligonucleotide SE
C 403	9.8	15.1	13	1	ABH34278	Oligonucleotide SE
C 404	9.8	15.1	13	1	ABF6466	Oligonucleotide SE
C 405	9.8	15.1	13	1	ABH16219	Oligonucleotide SE
C 406	9.8	15.1	13	1	ABH16219	Oligonucleotide SE
C 407	9.8	15.1	13	1	ABH16219	Oligonucleotide SE
C 408	9.8	15.1	13	1	ABH16219	Oligonucleotide SE
C 409	9.8	15.1	13	1	ABF33180	Oligonucleotide SE
C 410	9.8	15.1	13	1	ABF67881	Oligonucleotide SE
C 411	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 412	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 413	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 414	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 415	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 416	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 417	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 418	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 419	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 420	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 421	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 422	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 423	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 424	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 425	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 426	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 427	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 428	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 429	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 430	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 431	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 432	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 433	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 434	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 435	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 436	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 437	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 438	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 439	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 440	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 441	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 442	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 443	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 444	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 445	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 446	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 447	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 448	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 449	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 450	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 451	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 452	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 453	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 454	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 455	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 456	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 457	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 458	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 459	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 460	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 461	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 462	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 463	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 464	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 465	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 466	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 467	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 468	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 469	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 470	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 471	9.8	15.1	13	1	ABH04581	Oligonucleotide SE

ALIGNMENTS

RESULT 1
ADCC02407/c
ID ADCC02407 standard; DNA; 24 BP.
XX
AC ADCC02407;

```

XX 16-DEC-2003 (first entry)
DT
XX Human macrophage inhibitory protein-3-alpha (MIP-3-alpha) PCR primer #4.
DE
XX osteoarthritis; macrophage inhibitory protein-3-alpha; MIP-3-alpha;
KM CCR6 receptor; PCR, primer; human; ss.
XX
XX Homo sapiens.
OS
XX WO2003069348-A2.
PN
XX 21-AUG-2003.
PD
XX 14-FEB-2003; 2003WO-EP001506.
PF
XX 15-FEB-2002; 2002US-0357588P.
PR
XX (NOVS ) NOVARTIS AG.
PA (NOVS ) NOVARTIS PHARMA GMBH.
XX
XX Kumar CS, Labow MA, Latario BJ;
PI
XX WPI; 2003-671684/63.
DR
XX
XX Identifying compounds for diagnosing and treating osteoarthritis
PT utilizing reaction mixtures with chemokine macrophage inhibitory protein-
PT 3 alpha polypeptides and CCR6 receptors.
XX
XX Example 2; Page 62; 72pp; English.
PS
XX The invention comprises a method for identifying compounds that may be
CC used to treat osteoarthritis. The method involves contacting a reaction
CC mixture having a macrophage inhibitory protein-3-alpha (MIP-3-alpha) and
CC a CCR6 receptor with or without a test compound, detecting levels of
CC formation of the binding complex in the reaction mixture and comparing
CC the level of the binding complex formed in the presence and absence of
CC the test compound. A decrease indicates that the test compound may be
CC used to treat osteoarthritis. The method of the invention is useful for
CC identifying compounds that modulate MIP-3-alpha binding to its receptor,
CC and for treating, diagnosing and ameliorating osteoarthritis. The present
CC DNA sequence represents a PCR primer that was used to amplify the human
CC MIP-3-alpha gene.
XX
XX Sequence 24 BP; 1 A; 6 C; 5 G; 12 T; 0 U; 0 Other;
SQ
Query Match 36.9%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 17 GGACATAGCCCAAGACAGAAAGA 40
DB 24 GGACATAGCCCAAGACAGAAAGA 1
RESULT 2
AADS7273/C
ID AADS7273 standard; DNA; 20 BP.
XX
XX AAD57273;
AC
XX
XX 06-NOV-2003 (first entry)
DT
XX Human MIP3A DNA specific antisense oligo, ISIS 150687.
DE
XX
XX Macrophage inflammatory protein-3-alpha; MIP3A; antisense therapy;
XX liver and activation-regulated kinase; LARC; CC chemokine ligand 20;
XX small inducible cytokine subfamily A; SCYA20; inflammatory disorder;
XX CCL20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1;
XX human; phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.

```

```

XX Key Location/Qualifiers
FH modified_base 1..20
FT /+tag= a
FT /mod_base= OTHER
FT /note= "2'phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /+tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /+tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003057142-A2.
PN
XX 17-JUL-2003.
PD
XX
XX 17-DEC-2002; 2002WO-US040426.
PF
XX 28-DEC-2001; 2001US-00033742.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Karras JG, Condon TP;
PI
XX WPI; 2003-598310/56.
DR
XX
XX Novel oligonucleotide targeted to nucleic acids encoding macrophage
PT inflammatory protein-3-alpha and inhibiting expression of the protein,
PT useful for treating psoriasis.
XX
XX Claim 3; Page 104; 116pp; English.
PS
XX The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of macrophage inflammatory protein-3-alpha
CC (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
CC -Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
CC kinase (LARC), CC chemokine ligand 20 (CCL20). The invention is useful
CC for inhibiting the expression of MIP3A DNA in cells or tissues. It is
CC useful for treating an animal having a disease or condition associated
CC with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
CC syndrome or Crohn's disease. The antisense compound is utilized for
CC diagnostics, therapeutic, prophylaxis and as research reagents and kits.
CC It is also used in antisense therapy. The present sequence is an
CC antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
CC used to illustrate the method of the invention
XX
XX Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
SQ
Query Match 30.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TTTCGGAATGGAATTGAC 20
DB 20 TTTCGGAATGGAATTGAC 1
RESULT 3
AADS7274/C
ID AADS7274 standard; DNA; 20 BP.
XX
XX AAD57274;
AC
XX
XX 06-NOV-2003 (first entry)
DT
XX Human MIP3A DNA specific antisense oligo, ISIS 150688.
DE
XX
XX Macrophage inflammatory protein-3-alpha; MIP3A; antisense therapy;
XX liver and activation-regulated kinase; LARC; CC chemokine ligand 20;

```

KW	small inducible cytokine subfamily A; SCYA20; inflammatory disorder;
KM	CCL20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1;
XX	human; phosphorothioate backbone; antisense; ss.
OS	Homo sapiens.
XX	Synthetic.
FT	Key
FM	modified_base
FT	Location/Qualifiers
FT	1..20
FT	/+tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone; All cytidines are 5-
FT	methylcytidines"
FT	methyletydindes"
FT	1..5
FT	/+tag= b
FT	/mod_base= OTHER
FT	/note= "2'methoxyethyl nucleotides"
FT	16..20
FT	/+tag= c
FT	/mod_base= OTHER
FT	/note= "2'methoxyethyl nucleotides"
XX	
XX	WO2003057142-A2.
PN	
PD	17-JUL-2003.
XX	
PF	17-DEC-2002; 2002WO-US040426.
XX	
PR	28-DEC-2001; 2001US-00033742.
XX	
PA	(ISIS-) ISIS PHARM INC.
PI	
XX	Karras JG, Condon TP;
DR	WPI; 2003-598310/56.
XX	
PT	Novel oligonucleotide targeted to nucleic acids encoding macrophage
PT	inflammatory protein-3-alpha and inhibiting expression of the protein,
XX	useful for treating psoriasis.
PS	Claim 3; Page 104; 116pp; English.
XX	
CC	The invention relates to antisense compounds, compositions and methods
CC	for modulating the expression of macrophage inflammatory protein-3-alpha
CC	(MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
CC	-Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
CC	kinase (IARC), CC chemokine ligand 20 (CCL20). The invention is useful
CC	for inhibiting the expression of MIP3A DNA in cells or tissues. It is
CC	useful for treating an animal having a disease or condition associated
CC	with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
CC	dysndrome or Crohn's disease. The antisense compound is utilized for
CC	diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC	It is also used in antisense therapy. The present sequence is an
CC	antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
CC	used to illustrate the method of the invention
SQ	Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
Query Match	30.8%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 7.5;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	11 GGAAATTGGACATAGCCCAAG 30
DB	20 GGAAATTGGACATAGCCCAAG 1
RESULT 4	
AAD57276/c	
ID	AAD57276 standard; DNA; 20 BP.
XX	
XX	AAD57276;

06-NOV-2003 (first entry)

Human MIP3A DNA specific antisense oligo, ISIS 150690.

Macrophage inflammatory protein-3-alpha; MIP3A; antisense therapy, liver and activation-regulated kinase; IARC; CC chemokine ligand 20; small inducible cytokine subfamily A; SCYA20; inflammatory disorder; CCL20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1; human; phosphorothioate backbone; antisense; ss.

Homo sapiens.
Synthetic.

Key	Location/Qualifiers
modified_base	1..20 /*tag= a /mod_base= OTHER /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
modified_base	1..5 /*tag= b /mod_base= OTHER /note= "2'methoxyethyl nucleotides" 16...20 /*tag= c /mod_base= OTHER /note= "2'methoxyethyl nucleotides"

WO2003057142-A2.

17-JUL-2003.

17-DEC-2002; 2002WO-US040426.

28-DEC-2001; 2001US-0003742.

(ISIS-) ISIS PHARM INC.

Karras JG, Condon TP;

WPI; 2003-598310/56.

Novel oligonucleotide targeted to nucleic acids encoding macrophage inflammatory protein-3-alpha and inhibiting expression of the protein, useful for treating psoriasis.

Claim 3; Page 104; 116pp; English.

The invention relates to antisense compounds, compositions and methods for modulating the expression of macrophage inflammatory protein-3-alpha (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys-Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated kinase (IARC), CC chemokine ligand 20 (CCL20). The invention is useful for inhibiting the expression of MIP3A DNA in cells or tissues. It is useful for treating an animal having a disease or condition associated with MIP3A such as inflammatory disorder, psoriasis, irritable bowel syndrome or Crohn's disease. The antisense compound is utilised for diagnostics, therapeutics, prophylaxis and as research reagents and kits. It is also used in antisense therapy. The present sequence is an antisense oligonucleotide targeted to human MIP3A DNA. This sequence is used to illustrate the method of the invention

Sequence 20 BP; 6 A; 9 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 30.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

46 GCTGGGGTTTGAGGTTTCAC 65
|||||
|||
20 GCTGGGGTTTGAGGTTTCAC 1


```

RESULT 5
AADS7275/c
ID AAD57275 standard; DNA; 20 BP.
XX
AC AAD57275;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human MIP3A DNA specific antisense oligo, ISIS 150689.
XX
KW Macrophage inflammatory protein-3-alpha; MIP3A; antisense therapy;
KW liver and activation-regulated kinase; IARC; CC chemokine ligand 20;
KW small inducible cytokine subfamily A; SCYA20; inflammatory disorder;
KW CCL20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1;
KW human; phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylycytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003057142-A2.
XX
XX 17-JUL-2003.
XX
XX 17-DEC-2002; 2002WO-US040426.
XX
XX 28-DEC-2001; 2001US-0003742.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Karres JG, Condon TP;
XX
XX WPI; 2003-598310/56.
XX
XX Novel oligonucleotide targeted to nucleic acids encoding macrophage
XX inflammatory protein-3-alpha and inhibiting expression of the protein,
XX useful for treating psoriasis.
XX
XX Claim 3; Page 104; 116pp; English.
XX
XX The invention relates to antisense compounds, compositions and methods
XX for modulating the expression of macrophage inflammatory protein-3-alpha
XX (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
XX -Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
XX kinase (IARC), CC chemokine ligand 20 (CCL20). The invention is useful
XX for inhibiting the expression of MIP3A DNA in cells or tissues. It is
XX useful for treating an animal having a disease or condition associated
XX with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
XX syndrome or Crohn's disease. The antisense compound is utilised for
XX diagnostics, therapeutics, prophylaxis and as research reagents and kits.
XX It is also used in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
XX used to illustrate the method of the invention
XX
XX Sequence 20 BP; 2 A; 4 C; 4 G; 10 T; 0 U; 0 Other;
XX
Query Match 30.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 27 CAGAAACAGAAAGACCTTG 46
Db 20 CAGAAACAGAAAGACCTTG 1

RESULT 6
AAV82678/c
ID AAV82678 standard; DNA; 23 BP.
XX
AC AAV82678;
XX
DT 16-FEB-1999 (first entry)
XX
DE Biotinylated probe used to detect ST38.2 cDNA.
XX
KW Rat; chemokine; ST38.2; chemotaxis; leucocyte-activating; inflammation;
KW immune response; brain injury; trauma; ischaemia;
KW autoimmune inflammation; multiple sclerosis; stroke;
KW rheumatoid arthritis; meningitis; encephalitis; probe; ss.
XX
OS Synthetic.
OS Rattus sp.
XX
XX WO9849309-A1.
XX
XX 05-NOV-1998.
XX
XX 23-APR-1998; 98WO-EP002405.
XX
XX 30-APR-1997; 97EP-00107135.
XX
XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX
XX Lesslauer W, Utansschneitz U;
XX
XX WPI; 1999-009430/01.
XX
XX New chemokine ST38.2 with chemotactic and leucocyte-activating properties
XX - used to treat inflammation and immune responses and to identify
XX specific modulators.
XX
XX Example 5; Page 31; 64pp; English.
XX
XX The present biotinylated probe was used to detect a ST38.2 cDNA fragment
XX in a semiquantitative RT-PCR assay. In the course of the invention.
XX ST38.2 is a novel rat chemokine designated ST38.2. The protein has
XX chemotactic and leucocyte-activating properties. ST38.2 is involved in
XX inflammation and immune responses, particularly inflammatory response to
XX brain injury (trauma, ischaemia or autoimmune inflammation) but also in
XX multiple sclerosis, stroke, rheumatoid arthritis and infections
XX (particularly meningitis and encephalitis)
XX
XX Sequence 23 BP; 4 A; 8 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 9.4;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 4 CTGGAAATGGAATTGGACATAGCC 26
Db 23 CTGGAAATGGAATTGGACATAGCC 1

RESULT 7
AAAF74520/c
ID AAF74520 standard; DNA; 21 BP.
XX
AC AAF74520;
XX
XX 09-MAY-2001 (first entry)
XX
XX Clone 16467945 PRO16 forward PCR primer SEQ ID NO:117.
XX

```

```

XX Human; PRO; cyrostatic; immunomodulatory; reproduction;
KW gene therapy; cell proliferation; differentiation disorder; cancer;
KW immune associated disorder; gestational disease; pre-clampsia;
KW PCR primer; sequencing primer; ss.
OS Homo sapiens.
PN W0200110902-A2.
XX
XX
PD 15-FEB-2001.
XX
XX 11-AUG-2000; 2000WO-US021857.
XX
XX 11-AUG-1999; 99US-0148433P.
XX 10-AUG-2000; 2000US-00635949.
XX
XX (CURA-) CUPAGEN CORP.
XX
XX Shimkets RA, Fernandes E;
DR WPI; 2001-147509/15.
XX
XX Nucleic acids encoding secreted polypeptides, designated PROX
PT polypeptides, useful for treating a syndrome associated with a PROX-
PT associated disorder, e.g. cancer.
XX
XX Example 15; Page 148; 166pp; English.
XX
XX The present invention describes isolated nucleic acids encoding secreted
CC polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC X is an integer from 1 to 17). PROX polypeptides have cyrostatic,
CC immunomodulatory and reproduction activities, and can be used in gene
CC therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC nucleic acids and antibodies are useful in the manufacture of a
CC medicament for treating a syndrome associated with a PROX-associated
CC disorder, e.g. a cell proliferation and/or differentiation disorder (e.g.
CC cancer or immune associated disorders) and a gestational disease (e.g.
CC pre-clampsia). They are also used for screening for a modulator of
CC activity or of latency or predisposition to a PROX-associated disorder.
CC AAF74432 to AAF74448 encode the specifically claimed human PROX
CC polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC sequence represents a primer used in an example from the present
CC invention
XX
SQ Sequence 21 BP; 8 A; 9 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 24.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 41;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 42 CCTTGTGGGGTTGGAGCT 60
Db 21 CCTTCTGGGGTTGTAGCT 3
XX
RESULT 8
AAL42340
ID AAL42340 standard; DNA; 18 BP.
XX
XX AAL42340;
XX
XX 28-JUN-2002 (first entry)
XX
XX Novel sand pear microsatellite DNA PCR primer 4.
XX
XX Sand pear; ss; PCR; primer; novel microsatellite DNA sequence;
XX
XX Pyrus plant discrimination.
XX
XX Pyrus pyrifolia.
XX
XX JP2002034597-A.
XX

```

```

PD 05-FEB-2002.
XX
XX 21-JUL-2000; 2000JP-00220339.
XX
XX 21-JUL-2000; 2000JP-00220339.
XX
XX (DOKU-) DOKURITSU GYOSEI HOJIN NOGYO SEIBUTSU SH.
XX
XX WPI; 2002-298819/34.
XX
XX A new microsatellite DNA derived from a Pyrus plant and discrimination of
PT Pyrus plants by using it.
XX
XX Claim 6; Page 6; 22pp; Japanese.
XX
XX The invention comprises a novel microsatellite DNA sequence derived from
CC Pyrus plants. The invention also comprises a method for discriminating
CC Pyrus plants - utilizing the novel Pyrus microsatellite DNA. The novel
CC microsatellite DNA sequence can be used in discriminating Pyrus plants.
CC The present DNA sequence represents a PCR primer specific for a novel
CC Pyrus pyrifolia (sand pear) microsatellite DNA sequence
XX
XX
SQ Sequence 18 BP; 11 A; 4 C; 3 G; 0 T; 0 U; 0 Other;
XX
Query Match 22.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 60;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 28 AAGACAGAGAAAGAAC 43
Db 2 AAGACACGACGAGAAC 17
XX
RESULT 9
AAQ9361/C
ID AAQ9361 standard; DNA; 18 BP.
XX
XX AAQ9361;
XX
XX 07-MAR-1996 (first entry)
XX
XX Japanese oyster transglutaminase cDNA PCR primer.
XX
XX Japanese oyster; transglutaminase; gelling agent; PCR primer yoghurt;
XX jelly; cheese; fish-paste; calcium ion activation; ss.
XX
XX Synthetic.
XX
XX W09520662-A1.
XX
XX 03-AUG-1995.
XX
XX 30-JAN-1995; 95WO-JP000117.
XX
XX 28-JAN-1994; 94JP-00008283.
XX 13-JAN-1995; 95JP-00003876.
XX
XX (AJIN ) AJINOMOTO CO INC.
XX
XX Sano K, Kumazawa Y, Yasueda H, Seguro K, Motoki M;
XX
XX WPI; 1995-275447/36.
XX
XX Transglutaminase derived from the Japanese oyster - is activated by
PT calcium ions and is a gelling agent for foodstuffs.
XX
XX Example 9; Page 105; 127pp; Japanese.
XX
XX AAQ9360 and AAQ9361 are a primer pair for the PCR amplification of
CC Japanese oyster transglutaminase (TGA) cDNA. TGA (when activated by
CC calcium ions) is a gelling agent, useful in the prodn. of foodstuffs,
CC e.g. yoghurt, jelly, cheese and fishpaste
XX

```

SQ Sequence 18 BP; 1 A; 3 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 21.5%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 30 GAACAGAAAGACC 43
|||
16 GAACAGAAAGACC 3

Db

RESULT 10
ABX75231
ID ABX75231 standard; DNA; 16 BP.
XX
AC ABX75231;
XX
DT 25-MAR-2003 (first entry)
XX
DE Human 216 gene allele specific oligonucleotide probe #47.
XX
KW Human; mouse; ss; probe; gene 216; antiasthmatic; antiinflammatory;
KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW gene therapy; respiratory disease; asthma; obesity;
KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
OS Homo sapiens.
XX
PN WO200283077-A2.
XX
PD 24-OCT-2002.
XX
PF 15-APR-2002; 2002WO-US012063.
XX
PR 13-APR-2001; 2001US-00834597.
XX
PR 13-APR-2001; 2001WO-US012245.
XX
PA (SCHE) SCHERING CORP.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
DR WPI; 2003-092960/08.
XX
PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT syndrome.
XX
PS Example 10; Page 166; 650pp; English.
XX
CC This invention relates to a novel isolated nucleic acid, gene 216,
CC identified from human chromosome 20p13-p12. The invention also discloses
CC regions of the 216 gene that contain single nucleotide polymorphisms
CC (SNP's) which may be used as markers for disease susceptibility or
CC severity. The nucleotides of the invention may have antiasthmatic,
CC antiinflammatory or anorectic activities and may be used in gene therapy.
CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
CC preventing or treating a disorder, such as respiratory diseases (e.g.
CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
CC disease or adult respiratory distress syndrome), obesity, or inflammatory
CC bowel syndrome. The nucleic acids are also useful for identifying
CC increased susceptibility of a subject to the disorders mentioned. The
CC nucleic acids can also be used as primers and templates for the
CC recombinant production of disorder-associated peptides or polypeptides,
CC for chromosome and gene mapping, or for tissue distribution studies. The
CC present sequence represents a gene 216 specific oligonucleotide probe
CC used in the scope of the invention
XX
SQ Sequence 16 BP; 1 A; 1 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 20.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 78;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGGTTGGAGT 60
|||
2 GCTGGGGTTGGGGT 16

Db

RESULT 11
ABK02829/c
ID ABK02829 standard; RNA; 17 BP.
XX
AC ABK02829;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 Hammerhead ribozyme #128.
XX
KW Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNasezyme; inozyme; G-cleaver; ambezyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
XX
PR 28-FEB-2000; 2000US-0185516P.
XX
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (BLAT/) BLATT L.
XX
PA (MCSW/) MCSWIGGEN J.
XX
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mewiggen J, Chowrira BM;
XX
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 30; Page 142; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNasezyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a RN motif) or
CC an ambezyme (cleaving RNA with an NGM triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more

therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is a hammerhead ribozyme of the invention

Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 20.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 83;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACGAGAA 38
Db 15 GCCCAAGAACGAGAA 1

RESULT 12

ABK02828/C
ID ABK02828 standard; RNA; 17 BP.

AC ABK02828;

DT 12-MAR-2002 (first entry)

DE Human CD20 Hammerhead ribozyme #127.

Human, ss; antisense therapy; cytosolic; antiinflammatory; haemostatic; cerebroprotective; nootropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrotrophic accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; Parkinson's disease; ataxia; Huntington's disease; Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.
OS Synthetic.

PN WO200159103-A2.

PD 16-AUG-2001.

PF 09-FEB-2001; 2001WO-US004273.

PR 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGEN J.

PA (CHOW/) CHOWRIRA B M.

PI Blatt L, Mcswigen J, Chowrira BM;

XX WPI; 2001-607195/69.

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.

PS Claim 30; Page 142; 200pp; English.

The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with an RNA molecule with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, lymphocytic lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is a hammerhead ribozyme of the invention

Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 20.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 83;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACGAGAA 38
Db 16 GCCCAAGAACGAGAA 2

RESULT 13

ABK02830/C
ID ABK02830 standard; RNA; 17 BP.

AC ABK02830;

DT 12-MAR-2002 (first entry)

DE Human CD20 Hammerhead ribozyme #129.

Human, ss; antisense therapy; cytosolic; antiinflammatory; haemostatic; cerebroprotective; nootropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrotrophic accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;

KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 OS Homo sapiens.
 OS Synthetic.
 PN MO200159103-A2.
 PD 16-AUG-2001.
 PF 09-FEB-2001; 2001MO-US004273.
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSM/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 PI Blatt L, Mcswiggen J, Chowrira BM;
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 PS Claim 30; Page 142; 200pp; English.
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOCO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOCO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOCO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOCO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 1 A; 3 C; 4 G; 0 T; 9 U; 0 Other;
 Query Match 20 0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 24 GCCCAGACAGCA 36
 |||||
 Db 13 GCCCAGACAGCA 1

RESULT 14
 ABK03198/C
 ID ABK03198 standard; RNA; 17 BP.
 XX
 AC ABK03198;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Inozyme #149.
 DE
 XX Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
 KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KM muscular; CD20; neurite growth inhibitor gene; NOCO; hammerhead ribozyme;
 KM DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN MO200159103-A2.
 PD 16-AUG-2001.
 PF 09-FEB-2001; 2001MO-US004273.
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSM/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 PI Blatt L, Mcswiggen J, Chowrira BM;
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 PS Claim 30; Page 148; 200pp; English.
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the

CC presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an Inozyme of the invention

SQ Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAGAGACAGA 36
 |||||
 Db 14 GCCCAGAGACAGA 2

RESULT 15

ABT39879
 ID ABT39879 standard; DNA; 17 BP.

AC ABT39879;

DT 12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEQ ID No 5516.

KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrenia; protein chip; gene therapy; tumour suppression;
 KM human fukutin; ds.

OS Homo sapiens.

PN WO2003025175-A2.

PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004208.

PR 17-SEP-2001; 2001FR-00011978.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-313353/30.

PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumours and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

PS Disclosure; Page 678; 720pp; French.

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids, and
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention

SQ Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TCGAATTGGACAT 22
 |||||
 Db 5 TCGAATTGGACAT 17

RESULT 16

ADB40491
 ID ADB40491 standard; DNA; 17 BP.

AC ADB40491;

DT 18-DEC-2003 (revised)

DT 04-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #814.

KM Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KM primer; probe; tumour suppression; tumour reversion; apoptosis;
 KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KM diagnosis.

OS Homo sapiens.

PN WO2003040369-A2.

PD 15-MAY-2003.

PF 17-SEP-2002; 2002WO-IB004219.

PR 17-SEP-2001; 2001FR-00011981.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-441574/41.

PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumours and viral infection, also related
 PT polypeptide and antibodies.

PS Disclosure; Page 127; 771pp; French.

CC The invention relates to the isolation of 637 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80 % identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.

SO Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TGGATTGACAT 22
 |||||
 DB 5 TGGATTGACAT 17

RESULT 17

AA60238
 ID AAT60238 standard; DNA; 17 BP.

AC AAT60238;

DT 19-OCT-1997 (first entry)

DE ASO Q493XM representing known cystic fibrosis mutation.

XX Multiplex allele-specific diagnostic assay; MASDA;

KM allele-specific oligonucleotide; ASO; polymorphism; genetic disease;

KW diagnosis; cystic fibrosis; ss.

OS Synthetic.

PN WO9710366-A2.

PD 20-MAR-1997.

PF 13-SEP-1996; 96WO-US014842.

PR 15-SEP-1995; 95US-0003788P.

PA (GEN2) GENZYME CORP.

PI Shuber AP;

DR WPI; 1997-202258/18.

PT Identifying genetic alterations or target sequences in nucleic acid
 PT samples - useful for detecting genetic alterations associated with a
 PT disease, e.g. cystic fibrosis and sickle cell anaemia.

PS Example 2; Page 40; 855p; English.

XX Allele-specific oligonucleotides (ASOs) (AAT60210-41) representing known
 CC cystic fibrosis mutations, and corresponding ASOs (AAT60242-70)
 CC representing wild-type sequences, are examples of ASOs that can be used
 CC in a multiplex allele-specific diagnostic assay (MASDA) that has the
 CC capacity to analyse over 500 samples of a large number of mutations (over
 CC 100) in a single assay. Target DNA is immobilised to a solid support and
 CC interrogated in combinatorial fashion with a mixture of mutation-specific
 CC ASOs in solution. The ASOs(s) corresponding to the specific mutation(s)
 CC present in the sample is hybrid-selected from the pool, and the
 CC mutation(s) is identified. MASDA can be used to detect genetic
 CC alterations associated with genetic disorders, to identify genetic
 CC polymorphisms, to determine the molecular basis of genetic diseases, or
 CC for high-resolution identification of disease-causing microorganisms

SO Sequence 17 BP; 10 A; 2 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGAACAGAAAGAA 41
 |||||
 DB 2 CTAAGAACAGAAATGAA 17

RESULT 18

AA602139/C

ID AAF02139 standard; DNA; 17 BP.

AC AAF02139;

DT 16-FEB-2001 (first entry)

DE Hammerhead ribozyme substrate #434.

KM Ribozyme; erythropoietin; granulocyte colony stimulating factor;

KW interferon alpha; ss.

OS Homo sapiens.

PN WO200061729-A2.

PD 19-OCT-2000.

PF 11-APR-2000; 2000WO-US009721.

PR 12-APR-1999; 99US-0129390P.

PA (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Zwick M, Pavco P, Meswigen J;

DR WPI; 2000-647423/62.

PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.

PS Claim 37; Page 65; 164pp; English.

XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha

SO Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTCGGGTTGAGGTTT 62
 |||||
 DB 17 CTCGGGTTGAGGTTT 2

RESULT 19

AA606172/C

ID AAF06172 standard; DNA; 17 BP.

AC AAF06172;

DT 16-FEB-2001 (first entry)

DE Hammerhead ribozyme substrate #2969.

KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;

```

XX      interferon alpha; ss.
OS      Homo sapiens.
XX      WO200061729-A2.
XX      19-OCT-2000.
XX      11-APR-2000; 2000MO-US009721.
XX      12-APR-1999; 99US-0129390P.
XX      (RIBO-) RIBOZYME PHARM INC.
XX      Blatt L, Zwick M, Pavco P, Mcswigen J;
XX      WPI; 2000-647423/62.
XX      MPI; 2000-647423/62.
XX      Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX      useful for producing e.g. granulocyte colony stimulating factor protein,
XX      interferon alpha and erythropoietin.
XX      Claim 42; Page 124; 164pp; English.
XX      The present invention relates to enzymatic and antisense nucleic acid
XX      molecules that act as inhibitors of the expression of repressor genes
XX      encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX      factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
XX      Inhibition of the repressors removes prevents inhibition (and
XX      consequently increases expression of) genes involved in the production of
XX      erythropoietin, granulocyte colony stimulating factor protein and
XX      interferon alpha
XX      Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
XX      Query Match      19.7%; Score 12.8; DB 1; Length 17;
XX      Best Local Similarity 87.5%; Pred. No. 1e+02;
XX      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy      10 TGGAAATTGGACATGAC 25
Db      17 TGGAGTTGGACACAGC 2
XX      RESULT 20
XX      ABR03743
XX      ID ABR03743 standard; RNA; 17 BP.
XX      AC ABR03743;
XX      12-MAR-2002 (first entry)
XX      Human CD20 Ambrzyme #92.
XX      Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX      cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX      muscular; CD20; neurite growth inhibitor gene; NOGO, hammerhead ribozyme;
XX      DNAzyme; inozyme; G-cleaver; ambrzyme; zinzyme; lymphoma; leukaemia;
XX      B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX      MCL; immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX      inflammatory arthropathy; immune thrombocytopenia; stroke; dementia;
XX      cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX      chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX      Parkinson's disease; ataxia; Huntington's disease;
XX      Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX      Homo sapiens.
XX      Synthetic.
XX      WO200159103-A2.
XX      16-AUG-2001.

```

```

XX      09-FEB-2001; 2001MO-US004273.
XX      11-FEB-2000; 2000US-0181797P.
XX      28-FEB-2000; 2000US-0185516P.
XX      06-MAR-2000; 2000US-0187128P.
XX      (RIBO-) RIBOZYME PHARM INC.
XX      (BLAT/) BLATT L.
XX      (MCSW/) MCSWIGGEN J.
XX      (CHOW/) CHOWRIRA B W.
XX      Blatt L, Mcswigen J, Chowrira BW;
XX      WPI; 2001-607195/69.
XX      MPI; 2001-607195/69.
XX      Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX      constructs, which down regulate expression of a CD20 gene or neurite
XX      growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX      central nervous system injury.
XX      Claim 30; Page 168; 200pp; English.
XX      The invention relates to a nucleic acid molecule which down regulates
XX      expression of a CD20 gene and a nucleic acid molecule which down
XX      regulates expression of a neurite growth inhibitor gene (NOGO). The
XX      nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX      DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX      possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX      an ambrzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX      with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX      of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX      Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX      the cell and treat a patient having a condition associated with the level
XX      of CD20. The treatment may further comprise the use of one or more
XX      therapies. In particular, the CD20 targeting nucleic acid may be used to
XX      treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX      Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX      leukaemia, HIV (human immunodeficiency virus) associated NHL, lymphocytic
XX      lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX      immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
XX      targeting nucleic acid is used to cleave RNA of the NOGO gene in the
XX      presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX      nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX      cell and treat a patient having a condition associated with the level of
XX      NOGO. The treatment may further comprise the use of one or more
XX      therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX      treat central nervous system (CNS) injury and cerebrovascular accident
XX      (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX      chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX      Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX      disease, muscular dystrophy, and/or other neurodegenerative disease
XX      states which respond to the modulation of NOGO expression. The present
XX      sequence is an ambrzyme molecule of the invention
XX      Sequence 17 BP; 9 A; 2 C; 5 G; 0 T; 1 U; 0 Other;
XX      Query Match      19.7%; Score 12.8; DB 1; Length 17;
XX      Best Local Similarity 87.5%; Pred. No. 1e+02;
XX      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy      26 CCAAGAAACGAAGAA 41
Db      2 CCAAGAAAGAGAGAA 17
XX      RESULT 21
XX      ABR02473
XX      ID ABR02473 standard; DNA; 17 BP.
XX      AC ABR02473;
XX      29-MAY-2002 (first entry)

```



```
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2465.
DE
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 2465; 21app; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 2 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 19.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. NO. 1e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 4 CTGGATTGCAATTGGA 19
```

```
Db ||||| ||||| |||||
1 CTGGATTGCACTTGA 16
RESULT 22
ABN02472
ID ABN02472 standard; DNA; 17 BP.
XX
XX ABN02472;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2464.
DE
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 2464; 21app; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
```

CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGAATGGAATTGGA 19
Db 2 CTGGAATGGAATTGGA 17

RESULT 23

AAZ97663
ID AAZ97663 standard; DNA; 15 BP.

AC AAZ97663;

DT 15-SEP-2003 (revised)

DT 26-APR-2000 (first entry)

DE HIV-1 protease gene probe SEQ ID NO:153.

KW Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.

OS Human immunodeficiency virus 1.

XX WO9967428-A2.

XX 29-DEC-1999.

PF 22-JUN-1999; 99WO-EP004317.

PR 24-JUN-1998; 98EP-00870143.

PA (INNO-) INNOGENETICS NV.

XX Stuyver L;

DR WPI; 2000-147219/13.

PT Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.

PS Claim 3; Page 35; 76pp; English.

XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC assays. The probes are able to discriminate between wild type and mutated
CC drug resistance sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)

SQ Sequence 15 BP; 2 A; 0 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGAGGTTT 62
Db 1 GGAGTTGAGGTTT 14

RESULT 24

AAZ97684
ID AAZ97684 standard; DNA; 15 BP.

AC AAZ97684;

DT 15-SEP-2003 (revised)

DT 26-APR-2000 (first entry)

DE HIV-1 protease gene probe SEQ ID NO:174.

KW Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.

OS Human immunodeficiency virus 1.

XX WO9967428-A2.

XX 29-DEC-1999.

PF 22-JUN-1999; 99WO-EP004317.

PR 24-JUN-1998; 98EP-00870143.

PA (INNO-) INNOGENETICS NV.

XX Stuyver L;

DR WPI; 2000-147219/13.

PT Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.

PS Claim 3; Page 36; 76pp; English.

XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC assays. The probes are able to discriminate between wild type and mutated
CC drug resistance sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)

SQ Sequence 15 BP; 2 A; 0 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGAGGTTT 62
Db 1 GGAGTTGAGGTTT 14

RESULT 25

```

AB167380
ID AB167380 standard; DNA; 12 BP.
XX
AC AB167380;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367353 for detecting SNP TSC0056294.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 367353; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 8 AATGGAATTGGA 19
DB 1 AATGGAATTGGA 12
XX
RESULT 26
AB148814/c
ID AB148814 standard; DNA; 12 BP.
XX
AC AB148814;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 348787 for detecting SNP TSC0045748.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 348787; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 50 GCGTTGAGAGTT 61
DB 12 GCGTTGAGAGTT 1
XX
RESULT 27
ABCI9998
ID ABCI9998 standard; DNA; 13 BP.
XX
AC ABCI9998;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 20015 for detecting SNP TSC0004117.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 20015; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. The
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 18.5%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGG 59
Db 2 TGGGGTTGGAGG 13
RESULT 28
ABC19999/c
ID ABC19999 standard; DNA; 13 BP.
XX
XX ABC19999;
AC
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 20016 for detecting SNP TSC0004117.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
FN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 20016; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. The
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 18.5%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGG 59
Db 12 TGGGGTTGGAGG 1
RESULT 29
AAL41830/c
ID AAL41830 standard; DNA; 15 BP.
XX
XX AAL41830;
AC
XX 25-APR-2002 (first entry)
DT
XX
XX Human GCNT1 allele specific primer SEQ ID NO: 15.
DE
XX Human; glucosaminyl (N-acetyl) transferase 1, core 2; GCNT1; cancer;
KW gene therapy; haplotype; chromosome 9q13; SNP; primer; cytostatic;
KW single nucleotide polymorphism; ss.
XX
OS Homo sapiens.
XX
XX WO200204470-A2.
FN
XX
XX 17-JAN-2002.
PD
XX
XX 06-JUL-2001; 2001WO-US021451.
PF
XX
XX 06-JUL-2000; 2000US-0216281P.
PR
XX (GENA-) GENMAISSANCE PHARM INC.
PA
XX Duda A, Finkel K, Koshy B;
PI
XX WPI; 2002-171696/22.
DR
XX
XX Genetic variants of glucosaminyl (N-acetyl) transferase 1, core 2 gene
PT useful in studying expression and function of the protein, and for
PT screening drugs to treat diseases e.g. cancer.
XX
XX Claim 16; Page 13; 72pp; English.
PS
XX
XX The present invention provides the gene, protein and cDNA sequences of
CC the human glucosaminyl (N-acetyl) transferase 1, core 1 (GCNT1). Also
CC identified are single nucleotide polymorphisms (SNPs) located within the
CC sequences. The sequences can be used in the treatment of GCNT1 related
CC diseases, including cancer. The present sequence is an allele specific
CC primer for the GCNT1 gene, which is located on chromosome 9q13
XX
SQ Sequence 15 BP; 3 A; 7 C; 2 G; 2 T; 0 U; 1 Other;
Query Match 18.5%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 39 GAACCTTGCTGGGG 52
Db 15 GRAGCTTGCTGGGG 2

```

RESULT 30
AAFS1170
ID AAF51170 standard; DNA; 15 BP.
XX
XX AAF51170;
AC
DE 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #2130.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiant; virocidic; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000MO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX Wraight CJ, Werther GA, Edmondson SR;
PI WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 74; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 18.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 35 GAAAGAACCTTGCTG 49
DB 1 GAAAGGCGCTTGCTG 15

```

```

XX
XX AAF51169;
AC
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #2129.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiant; virocidic; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000MO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX Wraight CJ, Werther GA, Edmondson SR;
PI WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 74; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 3 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 18.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 34 AGAAGAACCTTGCT 48
DB 1 AGAAGGCGCTTGCT 15

```

```

RESULT 31
AAFS1169
ID AAF51169 standard; DNA; 15 BP.

```

```

RESULT 32
AAS98678/c
ID AAS98678 standard; DNA; 15 BP.
XX
XX AAS98678;
AC
XX 26-MAR-2002 (first entry)
DT

```

XX Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #44.
 DE
 XX
 KW Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
 KW cytostatic; gene therapy; malignant histiocytosis; isogene;
 KW myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;
 KW genotype; human; allele specific oligonucleotide; ASO; probe; ss.
 OS
 XX Homo sapiens.
 XX
 PN WO200179225-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 12-APR-2001; 2001WO-US012044.
 XX
 PR 12-APR-2000; 2000US-0196411P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Chew A, Choi JY, Koshy B;
 XX
 DR WPI; 2002-075058/10.
 XX
 PT Novel polymorphic variants of colony stimulating factor 1 receptor useful
 PT in studying expression and function of the protein, useful for screening
 PT candidate drugs to treat diseases e.g. inflammatory disorders.
 XX
 PS Claim 15; Page 15; 164pp; English.
 XX
 CC The invention describes a novel isolated polynucleotide (I) comprising a
 CC sequence which is a polymorphic variant (PV) of a reference sequence for
 CC colony stimulating factor 1 receptor (CSF1R) gene, found on the
 CC polypeptide are useful for improving the discovery and development of
 CC drugs for treating diseases associated with CSF1R activity, e.g.,
 CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders
 CC and the haplotypes can be used to validate CSF1R as a candidate target
 CC for treating a specific condition or disease predicted to be associated
 CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also
 CC be used in developing diagnostic tests and therapeutic treatments. (I) is
 CC useful in studying the expression and function of CSF1R, and in
 CC expressing CSF1R protein for use in screening for candidate drugs to
 CC treat diseases related to CSF1R activity and in studying the effect of
 CC the variation on the biological activity of CSF1R as well as on the
 CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
 CC useful in a variety of diagnostic and prognostic formats and therapeutic
 CC methods. A transgenic animal is useful in studying expression of the
 CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs
 CC targeted against CSF1R protein, and for testing the efficacy of
 CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
 CC are useful as probes and primers, and for assaying a polymorphism in the
 CC target region. Without requiring any a priori knowledge of the phenotypic
 CC effect of any particular CSF1R or haplotype the invention provides a
 CC method for identifying lead compounds that are more likely to show
 CC efficacy in clinical trials. This sequence is an allele specific
 CC oligonucleotide probe used for detecting CSF1R gene polymorphisms,
 CC described in the method of the invention
 CC
 SO Sequence 15 BP; 1 A; 4 C; 4 G; 5 T; 0 U; 1 Other;
 QY
 Query Match 18.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 17 GGACATAGCCCAAGA 31
 15 GGGCATATGCCAAGA 1
 RESULT 33
 AAL48106
 ID AAL48106 standard; DNA; 15 BP.
 XX

AC AAL48106;
 XX
 DT 27-SEP-2002 (first entry)
 XX
 DE Human neuropeptide Y allele specific primer SEQ ID NO: 30.
 XX
 KW Human; neuropeptide Y; NPY; isogene; SNP; atherosclerosis; obesity;
 KW psychological disorder; single nucleotide polymorphism; alcoholism;
 KW antiarteriosclerotic; anorectic; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200251857-A1.
 XX
 PD 04-JUL-2002.
 XX
 PF 21-DEC-2000; 2000WO-US034758.
 XX
 PR 21-DEC-2000; 2000WO-US034758.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Chew A, Denton RR, Lanz EM, Nandabalan K, Stephens JC;
 XX
 DR WPI; 2002-566671/60.
 XX
 PT New genetic variants of the human Neuropeptide Y (NPY) gene useful for
 PT treating disorders affected by abnormal expression or function of NPY
 PT isogene e.g., atherosclerosis or obesity.
 XX
 PS Claim 11; Page 17; 80pp; English.
 XX
 CC The present invention provides the human neuropeptide Y (NPY) gene and
 CC single nucleotide polymorphisms (SNPs) identified therein. The sequence
 CC can be used in the treatment of disorders associated with NPY, including
 CC atherosclerosis, obesity, psychological disorders and alcoholism. The
 CC present sequence is an allele specific primer used to isolate the human
 CC NPY coding sequence
 CC
 SO Sequence 15 BP; 1 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 QY
 Query Match 18.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 47 CTGGGCTTGGAGGTT 61
 1 CTGGGCGCGGAGGTT 15
 RESULT 34
 AAF99594
 ID AAF99594 standard; DNA; 13 BP.
 XX
 AC AAF99594;
 XX
 DT 12-JUN-2001 (first entry)
 XX
 DE Immunostimulatory nucleic acid #710.
 XX
 KW Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
 KW immunostimulatory; tumour; viral infection; bacterial infection;
 KW fungal infection; parasitic infection; cancer; asthma;
 KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
 XX
 OS Synthetic.
 XX
 PN WO200122972-A2.
 XX
 PD 05-APR-2001.
 XX
 PF 25-SEP-2000; 2000WO-US026383.
 XX

```

PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA) UNIV IOWA RES FOUND.
XX (COLE-) COLEY PHARM GMBH.
XX
PI Krieg AM, Schetter C, Volmer J;
XX WPI; 2001-273485/28.
XX
XX Vaccinating against tumors, infectious diseases, allergies and asthma
XX using immunostimulatory Py-rich and TG nucleic acids.
XX
XX Claim 101; Page 54; 338pp; English.
XX
XX The present invention relates to a method for stimulating an immune
XX response. The method comprises administering an immunostimulatory nucleic
XX acid to a non-rodent subject in sufficient quantity to stimulate an
XX immune response. The present sequence is one such immunostimulatory
XX nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
XX (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
XX against tumor antigens, viral antigens (e.g. herpesviridae, retroviridae
XX and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
XX haemophilus, campylobacter, clostridium, Escherichia coli and/or
XX staphylococcus), fungal antigens and/or parasitic antigens. The method is
XX also useful for preventing cancer, asthma, infectious disease, allergy or
XX immune deficiency. The present sequence can also be used to redirect a
XX Th2 to a Th1 immune response and to activate immune cells. Note: the
XX present sequence may have a phosphorothioate backbone
XX
SQ Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
Db 1 GGGGTTGGGAGTT 13
XX
RESULT 35
ABF69510
ID ABF69510 standard; DNA; 13 BP.
XX
AC ABF69510;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 169507 for detecting SNP TSC0042344.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is

```

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 169507; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
Db 1 GGAGTTGGAGGTT 13
XX
RESULT 36
ABH44501/c
ID ABH44501 standard; DNA; 13 BP.
XX
XX ABH44501;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 244478 for detecting SNP TSC0059689.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 244478; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989 and ABI00010-ABI82073
XX

```

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 3 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACAGAAAGA 40
Db 13 AAGAAAGAAAGA 1

RESULT 37
ABF69511/c
ID ABF69511 standard; DNA; 13 BP.

AC ABF69511;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 169508 for detecting SNP TSC0042344.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

FR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 169508; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGTTTGAGAGTT 61
|||

Db 13 GGAGTTTGAGAGTT 1

RESULT 38
ABF07727/c
ID ABF07727 standard; DNA; 13 BP.

AC ABF07727;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 107724 for detecting SNP TSC0026974.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

FR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PS Claim 1; SEQ ID NO 107724; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGTTTGAGAGTT 61
Db 13 GGGTTTGAGAGTT 1

RESULT 39
ABC73222

ID ABC73222 standard; DNA; 13 BP.

AC ABC73222;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 73239 for detecting SNP TSC0018875.


```

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 73239; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 46 GCTGGGGTTGGAG 58
Db 1 GGTGGGGTTGGAG 13
XX
RESULT 40
ABC73223/C
ID ABC73223 standard; DNA; 13 BP.
XX
AC ABC73223;
XX
DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 73240 for detecting SNP TSC0018875.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS Claim 1; SEQ ID NO 73239; 29pp + Sequence Listing; German.

```

```

XX
XX (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 73240; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 46 GCTGGGGTTGGAG 58
Db 13 GGTGGGGTTGGAG 1
XX
RESULT 41
ABF07726
ID ABF07726 standard; DNA; 13 BP.
XX
AC ABF07726;
XX
DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 107723 for detecting SNP TSC0026974.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 107723; 29pp + Sequence Listing; German.

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGTTGGAGGTT 61
DB 1 GGGTTGGAGGTT 13

RESULT 42

ABH57826
ID ABH57826 standard; DNA; 13 BP.

XX ABH57826;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 257803 for detecting SNP TSC062709.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS
XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT Claim 1; SEQ ID NO 257803; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GGGTTGGAGGTT 62
DB 1 GGGTTGGAGGTT 13

RESULT 43

ABH44500
ID ABH44500 standard; DNA; 13 BP.

XX ABH44500;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 244477 for detecting SNP TSC059689.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS
XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT Claim 1; SEQ ID NO 244477; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 10 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAAAGAAAGA 40
DB 1 AAGAAAGAAAGA 13

RESULT 44

ABH57827/c

ID	ABH57827	standard; DNA; 13 BP.
XX		
AC	ABH57827;	
XX		
DT	22-FEB-2002	(first entry)
XX		
DE	Oligonucleotide SEQ ID NO 257804	for detecting SNP TSC0062709.
XX		
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KX	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX		
OS	Homo sapiens.	
PN	WO200177384-A2.	
XX		
PD	18-OCT-2001.	
XX		
PF	06-APR-2001; 2001WO-IB000713.	
XX		
PR	07-APR-2000; 2000DE-01019173.	
XX		
PA	(EPIG-) EPIGENOMICS AG.	
XX		
PI	Olek A, Piepenbrock C, Berlin K;	
XX		
DR	WPI; 2001-657177/75.	
XX		
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
XX	methylation status.	
PS	Claim 1; SEQ ID NO 257804; 29pp + Sequence Listing; German.	
XX		
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC00010	
CC	-ABC99989, ABH00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX		
XX	Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;	
SO		
	Query Match	17.5%; Score 11.4; DB 1; Length 13;
	Best Local Similarity	92.3%; Pred. No. 1.4e+02;
	Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	50 GGGTTGGAGGTTT 62	
DB	13 GGGTTGGAGATT 1	
RESULT 45		
ABST78312		
ID	ABST78312	standard; DNA; 13 BP.
AC	ABST78312;	
XX		
DT	13-DEC-2002	(first entry)
XX		
DE	Angiogenesis inhibitory oligonucleotide #796.	
XX		
KM	Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;	
KW	tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;	
KX	diabetic retinopathy; retinopathy of prematurity; macular degeneration;	
KX	corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;	
KW	rubeosis; Osler-Weber Syndrome; myocardial angiogenesis;	

KW	plaque neovascularization; telangiectasia; haemophilic joint;
KW	angiodiroma; wound granulation; intestinal adhesion; atherosclerosis;
KW	sceleroderma; hypertrophic scar.
XX	
OS	Synthetic.
XX	
PN	WO200253141-A2.
XX	
PD	11-JUL-2002.
XX	
PF	14-DEC-2001; 2001WO-US048458.
XX	
PR	14-DEC-2000; 2000US-0255534P.
XX	
PA	(COLE-) COLEY PHARM GROUP INC.
PI	Bratzler RL;
XX	
DR	WPI; 2002-566690/60.
XX	
PT	Inhibiting angiogenesis in a subject, involves administering at least one
PR	antiangiogenic nucleic acid molecule to the subject.
XX	
PS	Claim 2; Page 33; 276pp; English.
XX	
CC	The invention relates to inhibiting angiogenesis in a subject, comprising
CC	administering at least one antiangiogenic nucleic acid molecule. Also
CC	included is a kit comprising a first container housing the antiangiogenic
CC	nucleic acids, and instructions for administering them to a subject
CC	having a condition characterized by unwanted angiogenesis. The method is
CC	useful for inhibiting angiogenesis associated with solid tumour growth,
CC	tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC	diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC	corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC	rubeosis, Osler-Weber Syndrome, myocardial angiogenesis, plaque
CC	neovascularisation, telangiectasia, haemophilic joints, angiodiroma,
CC	wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC	hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC	acid of the invention
XX	
SQ	Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
XX	
QY	49 GGGGTTGGAGCTT 61
DB	1 GGGGTTGGAGCTT 13
XX	
RESULT 46	
ABL39046	
ID	ABL39046 standard; DNA; 13 BP.
XX	
AC	ABL39046;
XX	
DT	16-APR-2002 (first entry)
XX	
DE	Immunostimulatory nucleic acid SEQ ID NO: 450.
XX	
KW	Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW	angiogenesis; metastasis; cytostatic; phosphorothioate backbone; ss.
XX	
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	1. .13
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "phosphorothioate backbone"
XX	
PN	WO200197843-A2.

XX 27-DEC-2001.
 PD
 XX
 XX 22-JUN-2001; 2001WO-US020154.
 PF
 XX 22-JUN-2000; 2000US-0213346P.
 PR
 XX (IOWA) UNIV IOWA RES FOUND.
 PA
 XX
 PI Weiner G, Hartmann G;
 XX
 XX WPI; 2002-154611/20.
 DR
 XX
 XX Treating or preventing cancer, such as basal cell carcinoma, comprises
 PT administering immunostimulatory nucleic acids that induce expression of
 PT cell surface antigens and antibodies to a subject having or at risk of
 PT developing cancer.
 XX
 XX Disclosure; Page 209, 312pp; English.
 XX
 XX The present invention relates to methods for treating or preventing
 CC cancer, involving administering to a subject having or at risk of
 CC developing cancer immunostimulatory nucleic acids that induce expression
 CC of cell surface antigens and antibodies. The methods are useful for
 CC treating or preventing cancer such as basal cell carcinoma, bladder
 CC cancer, bone cancer, brain and central nervous system (CNS) cancer,
 CC breast cancer, cervical cancer, colon and rectum cancer, connective
 CC tissue cancer, esophageal cancer, eye cancer, kidney cancer, larynx
 CC cancer, leukemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
 CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
 CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
 CC cancer, stomach cancer, testicular cancer, and uterine cancer. The
 CC present sequence is an immunostimulatory oligonucleotide described in the
 CC exemplification of the invention
 XX
 SQ Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 17.5%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 49 GGGGTTGGAGGTT 61
 |||||
 1 GGGGTTGGGGTT 13
 DB
 RESULT 47
 ACH03134
 ID ACH03134 standard; DNA; 13 BP.
 XX
 AC ACH03134;
 XX
 DT 25-SEP-2003 (first entry)
 XX
 DE Immunostimulatory nucleic acid #769.
 XX
 KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
 KW anticancer; gene therapy; vaccine; non-allergic inflammatory disease;
 KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
 KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
 XX
 OS Synthetic.
 XX
 PN US2003050268-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 29-MAR-2002; 2002US-00112653.
 XX
 PR 29-MAR-2001; 2001US-0279642P.
 XX
 PA (KRIE/) KRIEG A M.
 PA (BERG/) BERG D J.

XX Krieg AM, Berg DJ;
 PI
 XX WPI; 2003-521815/49.
 DR
 XX
 XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
 PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
 PT disease by administering an immunostimulatory nucleic acid.
 XX
 XX Disclosure; Page 29; 229pp; English.
 XX
 XX The invention describes a method of treating non-allergic inflammatory
 CC disease comprising administering to a subject having or at risk of
 CC developing a non-allergic inflammatory disease an immunostimulatory
 CC nucleic acid for prevention or treatment of the disease. The method is
 CC useful for treating non-allergic inflammatory diseases, such as
 CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
 CC This sequence represents an immunostimulatory nucleic acid
 XX
 SQ Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 17.5%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 49 GGGGTTGGAGGTT 61
 |||||
 1 GGGGTTGGGGTT 13
 DB
 RESULT 48
 ADB37096
 ID ADB37096 standard; DNA; 13 BP.
 XX
 AC ADB37096;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Immunostimulatory nucleic acid #710.
 XX
 KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
 KW hypo-responsive subject; immunostimulatory.
 XX
 OS Synthetic.
 XX
 PN US2003087848-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 02-FEB-2001; 2001US-00776479.
 XX
 PR 03-FEB-2000; 2000US-0179991P.
 XX
 PA (BRAT/) BRATZLER R L.
 PA (PETE/) PETERSEN D M.
 PA (FOUR/) FOURN Y.
 PI Bratzler RL, Petersen DM, Fourn Y;
 XX
 XX WPI; 2003-657977/62.
 DR
 XX Treating and/or preventing allergy or asthma using an immunostimulatory
 PT nucleic acid alone or in combination with an asthma/allergy medicament.
 XX
 PS Disclosure; Page 16; 221pp; English.
 XX
 CC The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The method and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.

```

XX Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
SQ
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGGTTGGAGGTT 61
Db 1 GGGGTTGGAGGTT 13

RESULT 49
AA297685
ID AA297685 standard; DNA; 14 BP.
XX
AC AA297685;
XX
DT 15-SEP-2003 (revised)
DT 26-APR-2000 (first entry)
XX
DE HIV-1 protease gene probe SEQ ID NO:175.
XX
KM Human immunodeficiency virus; HIV; protease; probe; detection;
KM drug selected mutation; hybridisation; genotyping; infection;
KM drug resistance; 88.
XX
OS Human immunodeficiency virus 1.
XX
PN WO967428-A2.
XX
PD 29-DEC-1999.
XX
PF 22-JUN-1999; 99MO-EP004317.
XX
PR 24-JUN-1998; 98EP-00870143.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L;
XX
DR WPI; 2000-147219/13.
XX
PT Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.
XX
PS Claim 3; Page 36; 76pp; English.
XX
CC The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AA297517 to AA297997 represent specifically claimed probes for use
CC in the assay, and AA297479 to AA297501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AA297502 to AA297515, and
CC AA298004 to AA298007 represent PCR primers for the HIV protease gene, the
CC and AA297516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC drug resistance. The method may also be used for HIV protease genotyping
CC assays. The probes are able to discriminate between wild type and mutated
CC protease sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)
XX
SQ Sequence 14 BP; 2 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 17.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTGGAGGTTT 62

```

```

Db 1 GAGTTGAGGTTT 13

RESULT 50
AAQ90131
ID AAQ90131 standard; DNA; 15 BP.
XX
AC AAQ90131;
XX
DT 09-JAN-1996 (first entry)
XX
DE 69-mer oligonucleotide ST08 PCR primer SPI4.
XX
KM Opioid peptide dynorphin B; molecular synthesis; antigenic epitope; ST08;
KM monoclonal antibody D32.39; PCR primer SPI4; 88.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /label= biotinylated
XX
PN WO9512608-A1.
XX
PD 11-MAY-1995.
XX
PF 02-NOV-1994; 94MO-US012347.
XX
PR 02-NOV-1993; 93US-00146886.
XX
PR 02-NOV-1993; 93US-00149675.
XX
PA (AFFY-) AFFYMAX TECHNOLOGIES NV.
XX
PI Sugarman JH, Rava RP, Kedari H, Dower WJ, Barrett RW, Gallop MA,
PI Needels MC;
XX
DR WPI; 1995-185735/24.
XX
PT Apparatus and methods for synthesis of diverse molecules - for generating
PT and screening molecular libraries which contain tagged individual
PT molecules.
XX
PS Example 1; Page 129; 201pp; English.
XX
CC AAQ90130 and AAQ90131 are a pair of primers for the PCR amplification of
CC AAQ90129, the 69-mer oligonucleotide ST08. ST08 was synthesised in
CC parallel with the epitope AAR8484 reactive with the anti-dynorphin B
CC monoclonal antibody D32.39, on 10 micron diameter beads to demonstrate a
CC new molecular synthesis method
XX
SQ Sequence 15 BP; 5 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGAGTGAATTG 17
Db 2 TGGAGTGAAGTG 14

RESULT 51
AAT86416/c
ID AAT86416 standard; DNA; 15 BP.
XX
AC AAT86416;
XX
DT 28-JUN-1998 (first entry)
XX
DE Human satellite II and III centromere repeat peptide nucleic acid probe.
XX

```

```

KM Peptide nucleic acid; PNA: hybridisation probe; polyamide backbone;
KM tandem repeat sequence; quantitation; human satellite; centromere; ss.
XX Synthetic.
OS
FH Key Location/Qualifiers
FT modified_base 1..15
FT /tag= b
FT /note= "This sequence is a peptide nucleic acid, i.e. it
FT contains a polyamide backbone instead of a deoxyribose
FT backbone"
FT repeat_unit 1..5
FT /tag= a
FT /rpt_type= TANDEM
XX WO9714026-A2.
XX 17-APR-1997.
XX PD
XX PF 10-OCT-1996; 96WO-CA000676.
XX PR 12-OCT-1995; 95US-0005590P.
XX PR 28-NOV-1995; 95US-0007616P.
XX XX
XX PA (LANS/) LANSDORP P.
XX PI Lamsdorp P;
XX DR WPI; 1997-236021/21.
XX XX
XX PT Detection of multiple copies of repeat sequences in telomeres - useful
XX for determining replicative potential of cells.
XX BS
XX CC Disclosure; Page 9; 38pp; English.
XX CC This is a peptide nucleic acid (PNA) probe which is used for detecting
XX and optionally quantitating the length of multiple copies of a centromere
XX repeat sequence common to human satellites II and III. The probe is
XX suitable for use in a new method for detecting and optionally
XX quantitating multiple copies of a repeat sequence. For use in the method,
XX the probe is labelled, preferably with a fluorescent molecule, and the
XX length of the repeat region can be determined based on the intensity of
XX the label signal
XX
XX SQ Sequence 15 BP; 3 A; 6 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 17.5%; Score 11.4; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 1.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 5 TGGATGCGATTTG 17
XX |||||
XX 13 TGGATGCGATTTG 1
XX Db
XX
XX RESULT 52
XX ABX03968
XX ID ABX03968 standard; DNA; 15 BP.
XX XX
XX AC ABX03968;
XX XX
XX DT 09-JAN-2003 (first entry)
XX XX
XX DE Resistance gene tetQ DNA fragment.
XX XX
XX KM Detection; probe; diagnosis; oral disease; parodontitis; carries; therapy;
XX polymorphism; virulence factor; antibiotic resistance gene; prognosis;
XX oral infection; detection; pathogen; coronary heart disease;
XX diabetic symptom; ss.
XX Unidentified.
XX OS
XX PN DE20110013-U1.

```

```

XX XX
XX PD 18-OCT-2001.
XX XX
XX PE 13-MAR-2001; 2001DE-02010013.
XX PR 13-MAR-2001; 2001DE-01012348.
XX PR 13-MAR-2001; 2001DE-02010013.
XX XX
XX PA (ROET/) ROETGER A.
XX DR WPI; 2001-657777/76.
XX XX
XX PT Oligonucleotide array, useful for diagnosing oral diseases, particularly
XX parodontitis, carries human or microbial reference sequences.
XX XX
XX PS Claim 10; Page 25; 58pp; German.
XX XX
XX CC This invention describes a novel nucleotide carrier with probes used for
XX diagnosis of oral diseases, particularly parodontitis, but also carries,
XX especially to identify genetic predisposition (as indicated by
XX polymorphisms) to disease and to identify causative microorganisms or
XX their associated virulence factors and antibiotic resistance genes, e.g.
XX for selection of therapy and for prognosis. They are also useful for
XX research into oral infections. The carriers allow simultaneous detection
XX of both host and pathogen parameters, providing quickly and simply an
XX individual's parodontitis profile, including detection of pathogens that
XX are associated with increased risk of coronary heart diseases and/or
XX aggravation of diabetic symptoms, and of opportunistic pathogens.
XX CC ABX03870-ABX04044 represent DNA fragments used to illustrate the method
XX of the invention
XX
XX SQ Sequence 15 BP; 4 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 17.5%; Score 11.4; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 1.5e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 3 TCTGGATGCGAT 15
XX |||||
XX Db 2 TCTGGATGCGAT 14
XX
XX RESULT 53
XX AAF26597
XX ID AAF26597 standard; DNA; 15 BP.
XX XX
XX AC AAF26597;
XX XX
XX DT 28-MAR-2001 (first entry)
XX XX
XX DE Primer SPI4.
XX XX
XX KM Synthesis; tagged chemical library; ss.
XX OS Unidentified.
XX XX
XX PN US6165778-A.
XX PD 26-DEC-2000.
XX XX
XX PE 02-JUL-1998; 98US-00109613.
XX XX
XX PR 02-NOV-1993; 93US-00146886.
XX PR 02-NOV-1993; 93US-00149675.
XX PR 01-MAY-1995; 95US-00432312.
XX XX
XX PA (AFFY-) AFFYMAX TECHNOLOGIES NV.
XX XX
XX PI Kedar H;
XX XX
XX DR WPI; 2001-090483/10.
XX XX
XX PT Reaction vessel agitator for synthesizing collections of diverse

```

PT molecules such as tagged chemical libraries, has non-concentric shafts
 PT which rotates reaction vessel holding brackets relatively.
 XX
 PS Example 1; Col 100; 111pp; English.
 XX
 CC The present invention relate to non-concentric shafts mounted inside
 CC housings are rotatably held by the brackets attached to reaction vessels.
 CC A vortexing motor is attached to the top bracket and transmission
 CC supplies rotational force to the shaft end connected to the bottom
 CC bracket which causes rotation of the lower bracket relative to top
 CC bracket thereby agitating contents of reaction vessels. The invention is
 CC used for synthesizing very large collections of diverse molecules such as
 CC tagged chemical libraries
 XX
 SQ Sequence 15 BP; 5 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 17.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 5 TGGAAATGGAATTG 17
 Db 2 TGGAAATGGAAGTG 14
 XX
 RESULT 54
 ABN87928/c
 ID ABN87928 standard; DNA; 15 BP.
 AC ABN87928;
 XX
 DT 12-AUG-2002 (first entry)
 XX
 DE Human GSR allele specific oligonucleotide primer SEQ ID NO:47.
 XX
 KM Human; glutathione reductase; GSR; enzyme; haemolytic anaemia; SNP;
 KM gene therapy; anti anaemic; polymorphic; single nucleotide polymorphism;
 KM primer; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 14
 FT /*tag= a
 FT /note= "polymorphic base"
 FT
 PN WO200242320-A2.
 PD 30-MAY-2002.
 XX
 PF 13-NOV-2001; 2001WO-US046473.
 XX
 PR 10-NOV-2000; 2000US-0247202P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bieglecki KM, Sanchis A, Sausker EA, Sun X;
 DR WPI; 2002-471719/50.
 XX
 PT New genetic variants of Glutathione reductase isogenes, useful for
 PT improving efficiency and reliability in drug development for treating
 PT hemolytic anemia.
 XX
 PS Claim 14; Page 14; 137pp; English.
 XX
 CC The present invention describes genetic variants of the human glutathione
 CC reductase (GSR) gene (1). (1) has anti anaemic activity and can be used in
 CC gene therapy. (1) can be used in screening for drugs targeting (1) that
 CC are useful for treating haemolytic anaemia. Methods from the present
 CC invention can be used for improving the efficiency and reliability of
 CC several steps in the discovery and development of drugs for treating
 CC diseases associated with GSR activity; for haplotyping, which is also

CC used by the pharmaceutical research scientist to validate GSR as a
 CC candidate target for treating a specific condition or disease predicted
 CC to be associated with GSR activity, e.g. haemolytic anaemia, and in the
 CC design of clinical trials for treating a specific condition of disease
 CC associated with GSR activity; and for screening compounds targeting GSR.
 CC (1) is useful in studying the expression and function of GSR, and in
 CC expressing GSR protein for use in screening for candidate drugs to treat
 CC diseases related to GSR activity. (1) is also useful in studying the
 CC effect of the variation on the biological activity of GSR as well as on
 CC the binding affinity of candidate drugs targeting GSR for the treatment
 CC of haemolytic anaemia. The present sequence represents an allele specific
 CC oligonucleotide (ASO) primer for the human GSR gene, which is given in
 CC the exemplification of the present invention. N.B. The polymorphic base
 CC (showing a single nucleotide polymorphism) in the ASO primer is shown
 CC using an IUPAC ambiguity code (as given in the present invention)
 XX
 SQ Sequence 15 BP; 1 A; 4 C; 2 G; 7 T; 0 U; 1 Other;
 XX
 Query Match 17.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 32 ACAGAAAGAACCTTG 46
 Db 15 AAGAAAGAACCATG 1
 XX
 RESULT 55
 AAS97335/c
 ID AAS97335 standard; DNA; 15 BP.
 AC AAS97335;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CRYBB1 gene ASO PCR primer #18.
 XX
 KM Human; crystallin beta B1; CRYBB1; chromosome 22q12.1; ophthalmological;
 KM cataract; allele specific oligonucleotide; ASO; ss; haplotype;
 KM genotyping; transgenic animal; PCR primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200185998-A1.
 PD 15-NOV-2001.
 XX
 PF 07-MAY-2001; 2001WO-US014715.
 XX
 PR 05-MAY-2000; 2000US-0202253P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Choi JY, Kazemi A, Kliehm SE, Koshy B, Rounds E;
 DR WPI; 2002-062253/08.
 XX
 PT Novel polymorphic variants of crystallin, beta B1 useful in studying
 PT expression and function of the protein, useful for screening candidate
 PT drugs to treat diseases e.g. cataract.
 XX
 PS Claim 15; Page 12; 94pp; English.
 XX
 CC The invention relates to an isolated polynucleotide comprising a sequence
 CC which is a polymorphic variant of a reference sequence for crystallin,
 CC beta B1 (CRYBB1, located on chromosome 22q12.1) gene or their fragment,
 CC where the polymorphic variant comprises a CRYBB1 isogene defined by a
 CC haplotype from haplotypes 1-16 as given in the specification. Also
 CC included are a transgenic non-human animal transformed or transfected
 CC with the polymorphic variant, a computer system for storing and analysing
 CC polymorphism data for CRYBB1 gene, a genome anthology for the CRYBB1 gene
 CC which comprises the defined CRYBB1 isogenes, methods of determining an
 CC individuals haplotype or genotype as well as methods of determining the

```
CC association of a particular haplotype with a disease or trait and a
CC composition comprising at least one genotyping oligonucleotide
CC (especially allele-specific oligonucleotides (ASO)) for detecting a
CC polymorphism in the CRYBB1. The isogenes or haplotypes are useful for
CC improving the efficiency and reliability of several steps in the
CC discovery and development of drugs for treating diseases associated with
CC CRYBB1 activity, e.g. cataract, and can also be used by the
CC pharmaceutical research scientist to validate CRYBB1 as a candidate
CC target for, and in design of clinical trials of candidate drugs for,
CC treating a specific condition drugs or disease predicted to be associated
CC with CRYBB1 activity. The ASOs are useful as probes and primers, and for
CC assaying a polymorphism in the target region. The present sequence is an
CC ASO PCR primer for CRYBB1
XX
SQ Sequence 15 BP; 2 A; 8 C; 3 G; 1 T; 0 U; 1 Other;

Query Match      17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGGTTGGAG 58
   |||||
DB 13 GCTGGGGCTGGAG 1

RESULT 56
ABK54466
ID ABK54466 standard; DNA; 15 BP.
AC ABK54466;
XX
XX
DT 05-JUN-2002 (first entry)
XX
XX
DE ASO primer #16 to detect human BMPR2 gene polymorphisms.
XX
XX
KW Human; single nucleotide polymorphism; SNP; BMPR2; chromosome 2q33-q34;
KW bone morphogenetic protein receptor type II; serine/threonine kinase;
KW haplotyping; genotyping; gene; primary pulmonary hypertension; PPH;
KW bone disorder; allele-specific oligonucleotide; ASO; primer; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200216398-A2.
XX
XX
PD 28-FEB-2002.
XX
XX
PF 27-AUG-2001; 2001WO-US026641.
XX
XX
PR 25-AUG-2000; 2000US-0228272P.
XX
XX
PA (GENA-) GENAISSANCE PHARM INC.
PA (LANZ/) LANZ E M.
XX
XX
PI Chew A, Klem SE, Messer C, Sanchis A;
XX
XX
DR WPI; 2002-280906/32.
XX
XX
PT Novel isolated polynucleotide which is a polymorphic variant of bone
PT morphogenetic protein receptor, type II (serine/threonine kinase) (BMPR2)
PT gene useful for expressing BMPR2 protein isoform used in drug screening.
XX
XX
PS Claim 16; Page 15; 98pp; English.
XX
XX
CC The present invention relates to novel single nucleotide polymorphisms
CC (SNPs) in the human bone morphogenetic protein receptor type II
CC (serine/threonine kinase) (BMPR2) gene located on chromosome 2q33-q34,
CC and methods for haplotyping and/or genotyping the BMPR2 gene. The methods
CC of the invention make use of allele-specific oligonucleotides (ASOs) as
CC probes and primers, and/or primer-extension oligonucleotides for
CC detecting the BMPR2 gene polymorphisms. The polynucleotides and screened
CC compounds are useful for the treatment of diseases associated with BMPR2
CC activity, such as primary pulmonary hypertension (PPH) and bone
CC disorders. ABK54451-ABK54466 represent ASO primers for detecting human
```

```
CC BMPR2 gene polymorphisms
XX
SQ Sequence 15 BP; 2 A; 1 C; 9 G; 2 T; 0 U; 1 Other;

Query Match      17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 45 TGCTGGGGTTGGAG 59
   |||||
DB 1 TGCAAGGGGTGGAG 15

RESULT 57
AB154483/c
ID AB154483 standard; DNA; 12 BP.
AC AB154483;
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide primer SEQ ID NO 354456 for detecting SNP TSC0008950.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPIC-) EPICGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 354456; 23pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

Query Match      16.9%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGAATGGAAT 15
   |||||
DB 12 TGGAATGGAAT 2
```



```

RESULT 58
ABI44216 standard; DNA; 12 BP.
XX ID
XX AC
XX AB144216;
XX DT
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 344189 for detecting SNP TSC0043433.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 344189; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 16.9%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTT 62
XX |||||||
XX 2 GTTGAGGTTT 12
XX
XX RESULT 59
XX AB18186/C
XX ID AB18186 standard; DNA; 12 BP.
XX
XX AC AB18186;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 318159 for detecting SNP TSC0028484.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 318159; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.9%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTT 62
XX |||||||
XX 12 GTTGAGGTTT 2
XX
XX RESULT 60
XX AB144217
XX ID AB144217 standard; DNA; 12 BP.
XX
XX AC AB144217;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 344190 for detecting SNP TSC0043433.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX

```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 344190; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 16.9%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTTT 62
DB 2 GTTGAGGTTT 12
RESULT 61
AB181139
ID AB181139 standard; DNA; 12 BP.
XX
AC AB181139;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 381112 for detecting SNP TSC0064177.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 381112; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 16.9%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5 TGGATGGAAT 15
DB 1 TGGATGGAAT 11
RESULT 62
AB106790
ID AB106790 standard; DNA; 12 BP.
XX
AC AB106790;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306763 for detecting SNP TSC0022165.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 306763; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 16.9%; Score 11; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 52 GTTGAGAGTTT 62
| | | | | | | | | |
Db 1 GTTGAGAGTTT 11

RESULT 63

AAK77962
ID AAK77962 standard; DNA; 13 BP.

AC AAX77962;

DT 16-AUG-1999 (first entry)

DE Human tenascin binding primer 38.

XX Tenascin; anti-angiogenesis; anti-vascular; anti-inflammatory;

KW cardiovascular; treatment; disease; degeneration; albinism; cancer;

KM psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;

XX diagnosis; human; primer; ss.

OS Synthetic.

XX Homo sapiens.

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
| | | | | | | | | |
Db 3 ACAGAAAGAAC 13

RESULT 64

AAK77943
ID AAK77943 standard; DNA; 13 BP.

AC AAX77943;

DT 16-AUG-1999 (first entry)

DE Human tenascin binding primer 19.

XX Tenascin; anti-angiogenesis; anti-vascular; anti-inflammatory;

KW cardiovascular; treatment; disease; degeneration; albinism; cancer;

KM psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;

XX diagnosis; human; primer; ss.

OS Synthetic.

XX Homo sapiens.

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
| | | | | | | | | |
Db 3 ACAGAAAGAAC 13

RESULT 65

AAK77981
ID AAK77981 standard; DNA; 13 BP.

AC AAX77981;

DT 16-AUG-1999 (first entry)

DE Human tenascin binding primer 19.

XX Tenascin; anti-angiogenesis; anti-vascular; anti-inflammatory;

KW cardiovascular; treatment; disease; degeneration; albinism; cancer;

KM psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;

XX diagnosis; human; primer; ss.

OS Synthetic.

XX Homo sapiens.

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

FT misc_difference 1. .3

```

AC  AAX77981;
XX
XX  16-AUG-1999 (first entry)
XX
DE  Human tenascin binding primer 57.
XX
XX  Tenascin; antipsoiastis; antivittiligo; anticancer; anti-inflammatory;
XX  cardiovascular; treatment; disease; depigmentation; albinism; cancer;
XX  psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;
XX  diagnosis; human; primer; ss.
XX
OS  Synthetic.
XX  Homo sapiens.
XX
XX  Key Location/Qualifiers
XX  misc_difference 1..2
XX  /tag= a
XX  /note= "nucleotides joined by phosphorothioate or
XX  phosphorodiester bonds"
XX  misc_difference 3..9
XX  /tag= b
XX  /note= "nucleotides modified with 2'-O-Methyl, and/or 2'-
XX  O-Propyl and/or 2'-Methoxyethoxy and or a peptide nucleic
XX  acid backbone"
XX  misc_difference 10..12
XX  /tag= c
XX  /note= "nucleotides modified with 2'-O-Methyl, and/or 2'-
XX  O-Propyl and/or 2'-Methoxyethoxy and or a peptide nucleic
XX  acid backbone"
XX
XX  DE19750702-A1.
XX
XX  27-MAY-1999.
XX
XX  15-NOV-1997; 97DE-01050702.
XX
XX  15-NOV-1997; 97DE-01050702.
XX
XX  15-NOV-1997; 97DE-01050702.
XX
XX  (HMRI ) HOECHST MARION ROUSSEL DEUT GMBH.
XX
XX  Peyman A, Uhlmann E, Weiser C;
XX
XX  WPI; 1999-314075/27.
XX
XX  Antisense oligonucleotides that bind to sequences encoding human tenascin
XX  for treating depigmentation, cancer, inflammation and cardiovascular
XX  disease.
XX
XX  Claim 22; Page 17; 18pp; German.
XX
XX  This invention describes novel oligonucleotides with up to 17 optionally
XX  modified nucleotides (m), or their salts which are capable of binding to
XX  a nucleic acid encoding an isoform of human tenascin, or a part of it.
XX  The oligonucleotides of the invention have antipsoiastis, antivittiligo,
XX  anticancer, anti-inflammatory and cardiovascular activity. The
XX  oligonucleotides are used to treat or prevent diseases associated with
XX  (over)expression of tenascin, particularly depigmentation (albinism,
XX  psoriasis or vitiligo), cancer or metastases, particularly melanoma,
XX  inflammation or cardiovascular disease (e.g. restenosis). A preferred
XX  application is treatment of vitiligo. The oligonucleotides may also be
XX  used for diagnosis of these diseases. AAX77925-X77981 represent the
XX  primers used in the method of the invention
XX
SQ  Sequence 13 BP; 7 A; 4 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
    |||||
    3 ACAGAAAGAAC 13

DB

```

```

RESULT 66
ID  ABC91347/C
XX  ABC91347 standard; DNA; 13 BP.
XX
XX  ABC91347;
XX
XX  21-FEB-2002 (first entry)
XX
DE  Oligonucleotide SEQ ID NO 91364 for detecting SNP TSC0022885.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-1B000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPITENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
XX  designed to detect single-nucleotide polymorphisms and cytosine
XX  methylation status.
XX
XX  Claim 1; SEQ ID NO 91364; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
XX  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX  and cytosine methylation status in chemically pretreated genomic DNA. The
XX  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX  range of diseases including immune system, gastrointestinal, respiratory,
XX  central nervous system, cardiovascular and metabolic disorders. The
XX  oligomers are also used for detecting cell type differentiation. ABC00010
XX  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI92073
XX  represent the oligomers described in the invention. NOTE: The sequence
XX  data for this patent did not form part of the printed specification, but
XX  was obtained in electronic format from WIPO at
XX  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 3 A; 9 C; 0 G; 0 T; 0 U; 1 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAGGT 60
    |||||
    13 TGGGGTTGGGGY 1

DB

RESULT 67
ID  ABC57026
XX  ABC57026 standard; DNA; 13 BP.
XX
XX  ABC57026;
XX
XX  21-FEB-2002 (first entry)
XX
DE  Oligonucleotide SEQ ID NO 57043 for detecting SNP TSC0015429.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

```

KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIC-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
XX	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 57043; 29bp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 1 Other;
	Query Match 16.9%; Score 11; DB 1; Length 13;
	Best Local Similarity 84.6%; Pred. No. 1.6e+02;
	Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0
QY	51 GGTGGAGGTTTC 63
DB	1 GGTTGAAGCTT 13
RESULT 68	
ABF02652	
ID	ABF02652 standard; DNA; 13 BP.
XX	
AC	ABF02652;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 102649 for detecting SNP TSC0025640.
XX	
KM	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
FN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 102649; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABH00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0

OY 48 TGGCGTTGAGCT 60
||| |||||:
DB 1 TGGAGTTGAGGY 13

RESULT 69
ABH48359/C
ID ABH48359 standard; DNA; 13 BP.
XX
AC ABH48359;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 248336 for detecting SNP TS0060682.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; se;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.

XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1; SEQ ID NO 248336; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 9 ATGGAATTGGA 19
DB 13 ATGGAATTGGA 3

RESULT 70

ABC91346
ID ABC91346 standard; DNA; 13 BP.

AC ABC91346;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 91363 for detecting SNP TSC0022885.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS
XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 91363; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 0 C; 9 G; 3 T; 0 U; 1 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGCTTGGAGCT 60
DB 1 TGGGCTTGGAGCT 13

RESULT 71

ABC57027/c
ID ABC57027 standard; DNA; 13 BP.

AC ABC57027;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 57044 for detecting SNP TSC0015429.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS
XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 57044; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;

Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 51 GGTGGAGCTTC 63
DB 13 GGTGGAGCTTC 1

RESULT 72

ABC01035/c
ID ABC01035 standard; DNA; 13 BP.

```

AC ABC01035;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 1026 for detecting SNP TSC0000336.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 1026; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAG 58
DB 12 TGGGGTTGGAG 2
RESULT 73
ABH48358
ID ABH48358 standard; DNA; 13 BP.
XX
XX ABH48358;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248335 for detecting SNP TSC0060682.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.

```

```

XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 248335; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 9 ATGGAATTGGA 19
DB 1 ATGGAATTGGA 11
RESULT 74
ABF02653/C
ID ABF02653 standard; DNA; 13 BP.
XX
XX ABF02653;
AC
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 102650 for detecting SNP TSC0025640.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 102650; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;
 Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 1.6e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 48 TGGGGTTGGAGCT 60
 ||| |||||
 13 TGGAGTTGGAGCY 1
 Db
 RESULT 75
 ID ABC01034 standard; DNA; 13 BP.
 AC ABC01034;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 1025 for detecting SNP TSC0000336.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 1025; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 48 TGGGGTTGGAG 58
 |||||
 2 TGGGGTTGGAG 12
 Db
 RESULT 76
 ID AAX56933 standard; DNA; 14 BP.
 AC AAX56933;
 XX
 DT 16-OCT-2003 (revised)
 DT 15-JUL-1999 (first entry)
 XX
 DE HIV-1 proviral DNA fragment 16.
 XX
 KW DNA-targeting conjugate; anticancer drug; viral DNA-cleaving agent;
 KW viral DNA-binding agent; solid support; primer; ss.
 XX
 OS Human immunodeficiency virus 1.
 XX
 PN WO9531434-A1.
 XX
 PD 23-NOV-1995.
 XX
 PF 12-MAY-1995; 95WO-US006379.
 XX
 PR 13-MAY-1994; 94US-00242664.
 XX
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 PA (ZMBI-) ZW BIOMEDICAL RES AG.
 XX
 PI Watanabe KA, Ren W, Weil R;
 XX
 DR WPI; 1996-010846/01.
 XX
 PT Derivatized solid supports and reagents for oligo:nucleotide synthesis -
 PT and new oligo:nucleotide phosphoramidate conjugates.
 XX
 PS Disclosure; Page 46; 68pp; English.
 XX
 CC This invention describes novel derivatised solid supports of formula S'-L
 CC -Z-CH₂CH₂-R, where: S' = a solid support; L = a bond or an (in)organic
 CC linker; Z = SO₂ or S-S; R = OH, an H-phosphonate, alkane phosphonate,
 CC phosphotriester, phosphite triester, phosphite diester, phosphorothioate,
 CC phosphorodithioate, phosphoramidate or phosphoramidite group, ORL, SRI, or an
 CC optionally substituted or modified nucleotide (N'), or an
 CC oligonucleotide of formula (N')₂GR₂; G = 1-200; R₁ = a protecting group;
 CC R₂ = an H-phosphonate, alkane phosphonate, phosphotriester, phosphite
 CC triester, phosphite diester, phosphorothioate, phosphotriester, phosphite
 CC phosphoramidate or phosphoramidite group, OH, ORL, SRI or
 CC OP(OCH₂CH₂CN)OCH₂CH₂CH₂CH₂ORL. Also mentioned are compounds of formula
 CC R₃CH₂CH₂CH₂CH₂R₄, where: R₃ = a protecting group; and R₄ = OH or an H-
 CC phosphonate, alkane phosphonate, phosphotriester, phosphite triester,
 CC phosphite diester, phosphorothioate, phosphorodithioate, phosphoramidate
 CC or phosphoramidite group. Also claimed are new phosphoramidates, a
 CC process for preparing an oligonucleotide 5'-phosphate, a process for
 CC preparing a solid support useful for preparation of an oligonucleotide 3'-
 CC -phosphate, a process for preparing an oligonucleotide 3'-phosphate and a
 CC process for preparing an oligonucleotide 3',5'-diphosphate. The
 CC oligonucleotide 3'- and/or 5'-phosphates may be used to prepare DNA-

CC targeting conjugates, e.g. with anticancer drugs or viral (e.g. HIV) DNA-
CC cleaving or -binding agents. The process for preparing oligonucleotide
CC 3',5'-diphosphates is simple and suitable for use in automatic DNA
CC synthesizers. This sequence represents a fragment of the HIV-1 provirus
CC genome, used to describe the method of the invention. (Updated on 16-OCT-
CC 2003 to standardise OS field)

XX
SQ Sequence 14 BP; 10 A; 0 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 77

AA259021
ID AA259021 standard; DNA; 14 BP.

XX
AC AA259021;

DT 11-APR-2000 (first entry)

XX
DE Triple helix forming target sequence from ori-gamma plasmids.

XX Antitumour; antiviral; antimicrobial; transfer vector; targeting system;
KM triplex; triple helix; antisense; ribozyme; gene therapy; blood factor;
KM hormone; tumour suppressor; antigenic peptide; vaccine; immunotherapy;
KM cancer; pCOR; ori; origin of replication; ss.

XX
OS Unidentified.

XX
PN WO949067-A1.

XX
PD 30-SEP-1999.

XX
PF 19-MAR-1999; 99WO-FR000643.

XX
PR 24-MAR-1998; 98FR-00003573.

XX
PR 18-MAY-1998; 98US-0085848P.

XX
PA (RHON) RHONE-POULENC RORER SA.

XX
PI Ciolina C, Scherman D, Wils P;

XX
DR WPI; 1999-57204/48.

XX
PT New nucleic acid transfer vector comprising double-stranded DNA linked to
PT oligonucleotide, used for gene therapy.

XX
PS Claim 13; Page 40; 72pp; French.

XX
CC The invention relates to a method of delivering a therapeutic double
CC stranded DNA to a target cell or tissue by administering the DNA in a
CC transfer vector. The vector comprises the double-stranded DNA molecule
CC and at least one oligonucleotide that is linked to a targeting system and
CC can form a triplex with a specific sequence within target cell or tissue.
CC This sequence represents an example of a target sequence able to form a
CC triple helix with the oligonucleotide. The sequence is found in the
CC gamma origin of replication of plasmids such as pCOR. The vector is used
CC to deliver therapeutic DNA (including antisense sequences or ribozymes)
CC for gene therapy, e.g. sequences that encode enzymes, blood factors,
CC hormones, tumour suppressors, also antigenic peptides for use as vaccines
CC or immunotherapeutic agents for control of microbial or viral infections,
CC or cancer

XX
SQ Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 78

AA21101
ID AA21101 standard; DNA; 14 BP.

XX
AC AA21101;

DT 20-MAR-2002 (first entry)

XX
DE Oligonucleotide corresponding to pXL3296 DNA sequence.

XX
KM ss; DNA purification; triple helix; plasmid purification;

XX
KM double purification.

XX
OS Synthetic.

XX
PN WO200192511-A2.

XX
PD 06-DEC-2001.

XX
PF 25-MAY-2001; 2001WO-US017122.

XX
PR 26-MAY-2000; 2000US-00580923.

XX
PA (AVENTIS PHARMA SA.

XX
PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;

XX
DR WPI; 2002-097772/13.

XX
PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and
PT other components, comprises passing the solution through a support
PT comprising a covalently coupled oligonucleotide able to form a triple
PT helix with the dsDNA.

XX
PS Claim 2; Page 23; 40pp; English.

XX
CC This invention comprises a method of purifying double-stranded DNA from a
CC solution containing the double-stranded DNA mixed with other components,
CC comprising passing the solution through a support comprising a covalently
CC coupled oligonucleotide capable of forming a triple helix with the double
CC -stranded DNA by hybridisation with a specific sequence present in the
CC double-stranded DNA. The method is useful for purifying double-stranded
CC DNA contained in a solution and mixed with other components. The new
CC method is a simple, rapid and effective method for DNA purification, and
CC makes it possible to obtain especially high purities with high yields.
CC The method enables DNA to be purified from complex mixtures comprising
CC other nucleic acids, proteins, endotoxins, nucleases and the like. The
CC supports may be readily recycled, and the DNAs obtained display improved
CC properties to pharmaceutical safety. Further, the method entails only one
CC step contrary to prior art. The present sequence represents an
CC oligonucleotide corresponding to a sequence contained within plasmid
CC pXL3296, that is capable of forming a triple helix for use in the DNA
CC double purification method of the invention

XX
SQ Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 79

AAS21102/c
ID AAS21102 standard; DNA; 14 BP.
XX
AC AAS21102;
XX
DT 20-MAR-2002 (first entry)
XX
DE Oligonucleotide used to prepare a DNA triplex affinity gel.
XX
XX ss; DNA purification; triple helix; plasmid purification;
KM homopyrimidine oligonucleotide.
XX
OS Synthetic.
XX
PN WO200192511-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US017122.
XX
PR 26-MAY-2000; 2000US-00580923.
XX
PA (AVERT) AVENTIS PHARMA SA.
XX
PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;
XX
DR WPI; 2002-097772/13.
XX
PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and
PT other components, comprises passing the solution through a support
PT comprising a covalently coupled oligonucleotide able to form a triple
PT helix with the dsDNA.
XX
PS Claim 1; Page 23; 40pp; English.
XX
CC This invention comprises a method of purifying double-stranded DNA from a
CC solution containing the double-stranded DNA mixed with other components,
CC comprising passing the solution through a support comprising a covalently
CC coupled oligonucleotide capable of forming a triple helix with the double
CC double-stranded DNA. The method is useful for purifying double-stranded
CC DNA contained in a solution and mixed with other components. The new
CC method is a simple, rapid and effective method for DNA purification, and
CC makes it possible to obtain especially high purities with high yields.
CC The method enables DNA to be purified from complex mixtures comprising
CC other nucleic acids, proteins, endotoxins, nucleases and the like. The
CC supports may be readily recycled, and the DNAs obtained display improved
CC properties to pharmaceutical safety. Further, the method entails only one
CC step contrary to prior art. The present sequence represents a homopyrimine
CC oligonucleotide used to purify the PCOR plasmid using an oligonucleotide
CC corresponding to a sequence present in the origin of replication (ori
CC gamma) of the plasmid
XX
SQ Sequence 14 BP; 0 A; 2 C; 0 G; 12 T; 0 U; 0 Other;
XX
Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 28 AAGAAACAGAAAGA 41
DB 14 AAGAAAAAAGAA 1
XX
RESULT 80
ID ABF38003/c
XX ABF38003 standard; DNA; 13 BP.
AC ABF38003;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 138000 for detecting SNP TSC0034524.
XX

XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 138000; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG93989, ABF00010-ABF93989, ABH00010-ABH93989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 16.3%; Score 10.6; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 53 TTGAGGTTTC 63
DB 11 TTGAGGTTT 1
XX
RESULT 81
ID ABF38002
XX ABF38002 standard; DNA; 13 BP.
AC ABF38002;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 137999 for detecting SNP TSC0034524.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

PR 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 137999; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
XX
Query Match 16.3%; Score 10.6; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 1.8e+02;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 53 TTGGAGGTTTC 63
DB 3 TTGGAGGTTT 13
XX
RESULT 82
AAQ22815/c
ID AAQ22815 standard; DNA; 12 BP.
XX
AC AAQ22815;
XX
DT 09-JUL-1992 (first entry)
XX
XX Random oligonucleotide #35.
XX
XX Diverse library; ss.
XX
OS Synthetic.
XX
XX WO9203461-A.
XX
XX 05-MAR-1992.
XX
XX 20-AUG-1991; 91WO-US005939.
XX
XX 24-AUG-1990; 90US-00573648.
XX
XX (IXSY-) IXSYS INC.
XX
XX Huse WD;
XX
XX WPI; 1992-096824/12.
XX
XX Synthesizing oligo-nucleotide(s) having random tuplets - by sequentially
PT coupling monomers on separate supports, mixing, dividing and repeating
PT the steps.
XX
XX Claim 24; Page 20; 34pp; English.
XX
XX The oligonucleotide was prep'd. using a new method for the synthesis of

CC oligos having random tuplets, starting from individual monomers. The
CC method comprises: (1) sequentially coupling monomers on separate supports
CC to form at least 2 different tuplets, the coupling being performed in
CC separate reaction vessels; (2) mixing the supports from the reaction
CC vessels; and (3) dividing the mixed supports into 2 or more separate reaction
CC vessels; and (4) repeating steps (1)-(3) one or more times in the
CC reaction vessel of (3), where the last step ends at step (2). The method
CC may also be used to prepare oligos having tuplets which are diverse but
CC which are biased towards a predetermined sequence. See also AAQ22781-
CC Q22822
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TGGATGGAATT 16
DB 12 TGGATGGAATT 1
XX
RESULT 83
AAQ22813/c
ID AAQ22813 standard; DNA; 12 BP.
XX
AC AAQ22813;
XX
DT 09-JUL-1992 (first entry)
XX
XX Random oligonucleotide #33.
XX
XX Diverse library; ss.
XX
OS Synthetic.
XX
XX WO9203461-A.
XX
XX 05-MAR-1992.
XX
XX 20-AUG-1991; 91WO-US005939.
XX
XX 24-AUG-1990; 90US-00573648.
XX
XX (IXSY-) IXSYS INC.
XX
XX Huse WD;
XX
XX WPI; 1992-096824/12.
XX
XX Synthesizing oligo-nucleotide(s) having random tuplets - by sequentially
PT coupling monomers on separate supports, mixing, dividing and repeating
PT the steps.
XX
XX Claim 24; Page 19; 34pp; English.
XX
XX The oligonucleotide was prep'd. using a new method for the synthesis of
CC oligos having random tuplets, starting from individual monomers. The
CC method comprises: (1) sequentially coupling monomers on separate supports
CC to form at least 2 different tuplets, the coupling being performed in
CC separate reaction vessels; (2) mixing the supports from the reaction
CC vessels; (3) dividing the mixed supports into 2 or more separate reaction
CC vessels; and (4) repeating steps (1)-(3) one or more times in the
CC reaction vessel of (3), where the last step ends at step (2). The method
CC may also be used to prepare oligos having tuplets which are diverse but
CC which are biased towards a predetermined sequence. See also AAQ22781-
CC Q22822
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TGGATGGAATT 16
 ||| ||| ||| |||
 Db 12 TGGGATGGAATT 1

RESULT 84
 AAQ91300
 ID AAQ91300 standard; DNA; 12 BP.
 XX
 AC AAQ91300;

DT 25-MAR-2003 (revised)
 DT 07-FEB-1996 (first entry)

DE Circular oligonucleotide end joining oligonucleotide.

KW Circular oligonucleotide; infection inhibitor; labelled probe;
 KW nuclease resistant; high selectivity; high affinity;
 KW gene expression inhibitor; end joining oligonucleotide; ss.

OS Synthetic.

PN US5426180-A.

PD 20-JUN-1995.

PF 11-JAN-1993; 93US-00004800.

PR 27-MAR-1991; 91US-00675843.

PR 26-MAR-1992; 92US-00859922.

PA (RESE) RESEARCH CORP TECHNOLOGIES INC.

PI Kool ET;

DR WPI; 1995-230952/30.

PT Prep. of single-stranded circular oligo:nucleotide cpds. - using a
 PT linear pre-circle and an end-joining oligo:nucleotide to form distinct
 PT binding domains.

PS Example 1; Fig 3; 43pp; English.

XX AAQ91300 is a circular oligonucleotide end joining oligo, used in the
 CC prep. of the circular oligos given in AAQ91296-98. Circular oligos can
 CC be used to inhibit viral infection and gene expression, or (when
 CC labelled) as probes for the detection of target sequences. Circular
 CC oligos are resistant to nucleases, and bind targets with higher
 CC selectivity and affinity than do linear oligos. (Updated on 25-MAR-2003
 CC to correct PF field.)

SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACGGAAG 39
 ||| ||| ||| |||
 Db 1 AAGAAAAGAAAG 12

RESULT 85
 AAT42866
 ID AAT42866 standard; DNA; 12 BP.
 XX
 AC AAT42866;

DT 10-JUN-1997 (first entry)

DE Single stranded circular oligonucleotide target sequence #2.

KW single stranded; circular; target sequence; parallel; detection;
 KW binding domain; anti-parallel; loop domain; complementarity; ss;
 KW synthesis; regulation; drug delivery; biosynthesis; tumour cell.

OS Synthetic.

PN WO9630384-A1.

PD 03-OCT-1996.

PF 21-MAR-1996; 96WO-US003757.

PR 30-MAR-1995; 95US-00413813.

PA (RESE) RESEARCH CORP TECHNOLOGIES INC.

PI Kool ET;

DR WPI; 1996-455262/45.

PT Single stranded circular oligo:nucleotide comprising parallel and or anti-
 PT -parallel binding domain - used to regulate biosynthesis of DNA, RNA or
 PT protein in targetted mammalian tumour cell in vivo.

PS Example 2; Fig 2A; 195pp; English.

XX The sequences given in AAT42860-80 represent single stranded (ss)
 CC circular oligonucleotides or their target sequences. The ss circular
 CC oligonucleotides comprise a parallel binding (P) domain, and/or an anti-
 CC parallel binding (AP) domain, and at least 1 loop domain. The P and AP
 CC domains have sufficient complementarity to bind detectably to 1 strand of
 CC a defined nucleic acid target. The P domain is capable of binding in a
 CC parallel manner to the target. The AP domain is capable of binding in an
 CC anti-parallel manner to the target and the ends of the P and AP domains
 CC are separated by the loop domains. The ss circular oligonucleotides can
 CC be used to regulate the synthesis of DNA, RNA or protein (pref. by DNA
 CC replication, DNA reverse transcription, RNA splicing, RNA
 CC polyadenylation, RNA translocation or protein translocation) by binding a
 CC target sequence in the template. They can also be used to deliver a drug
 CC to a specific cell type by administering a drug covalently bound to them
 CC (i.e. to regulate the biosynthesis of DNA, RNA or protein in a targetted
 CC mammalian tumour cell in vivo, without substantially altering the
 CC biosynthesis of the DNA). They can also be used to detect a target
 CC nucleic acid by detecting an oligonucleotide-target complex. The circular
 CC oligonucleotide can bind both single and double stranded target nucleic
 CC acids, and has enhanced stability, compared to linear forms. This
 CC sequence is specifically the target region for the ss circular
 CC oligonucleotide given in AAT42863-64

SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACGGAAG 39
 ||| ||| ||| |||
 Db 1 AAGAAAAGAAAG 12

RESULT 86
 AAT42896
 ID AAT42896 standard; RNA; 12 BP.
 XX
 AC AAT42896;

DT 10-JUN-1997 (first entry)

DE Single stranded circular oligonucleotide RNA target region.

XX single stranded; circular; target sequence; parallel; detection;
 KW binding domain; anti-parallel; loop domain; complementarity; ss;
 KW synthesis; regulation; drug delivery; biosynthesis; tumour cell.

XX 21-MAR-1996; 96WO-US003757.
 XX
 XX 30-MAR-1995; 95US-00413813.
 XX
 PA (RESE) RESEARCH CORP TECHNOLOGIES INC.
 XX
 PI Kool ET;
 XX
 DR WPI; 1996-455262/45.
 XX
 PT Single stranded circular oligo:nucleotide comprising parallel and or anti
 PT -parallel binding domain - used to regulate biosynthesis of DNA, RNA or
 PT protein in targetted mammalian tumour cell in vivo.
 XX
 PS Example 2; Fig 2B; 195pp; English.
 XX
 CC The sequences given in AAT42860-80 represent single stranded (ss)
 CC circular oligonucleotides or their target sequences. The ss circular
 CC oligonucleotides comprises a parallel binding (P) domain, and/or an anti-
 CC parallel binding (AP) domain, and at least 1 loop domain. The P and AP
 CC domains have sufficient complementarity to bind detectably to 1 strand of
 CC a defined nucleic acid target. The P domain is capable of binding in a
 CC parallel manner to the target. The AP domain is capable of binding in an
 CC anti-parallel manner to the target and the ends of the P and AP domains
 CC are separated by the loop domains. The ss circular oligonucleotides can
 CC be used to regulate the synthesis of DNA, RNA or protein (pref. by DNA
 CC replication, DNA reverse transcription, RNA splicing, RNA
 CC polyadenylation, RNA translocation or protein translocation) by binding a
 CC target sequence in the template. They can also be used to deliver a drug
 CC to a specific cell type by administering a drug covalently bound to them
 CC (i.e. to regulate the biosynthesis of DNA, RNA or protein in a targetted
 CC mammalian tumour cell in vivo, without substantially altering the
 CC biosynthesis of the DNA). They can also be used to detect a target
 CC nucleic acid by detecting an oligonucleotide-target complex. The circular
 CC oligonucleotide can bind both single and double stranded target nucleic
 CC acids, and has enhanced stability, compared to linear forms
 CC
 SQ Sequence 12 BP; 0 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 28 AAGACGAGAAG 39
 Db 12 AAGAAAAGAAG 1
 XX
 RESULT 89
 ID AB125498
 AC AB125498 standard; DNA; 12 BP.
 XX
 AC AB125498;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 325471 for detecting SNP TSC0032556.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 325471; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 8 AATGGAATTGGA 19
 Db 1 AATGGAATTGGA 12
 XX
 RESULT 90
 ID AB107008/C
 AC AB107008 standard; DNA; 12 BP.
 XX
 AC AB107008;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 306981 for detecting SNP TSC0022282.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 306981; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTTCTGGAATGG 12
Db 12 TTTTGGAAATGC 1

RESULT 91
ABH89802
ID ABH89802 standard; DNA; 12 BP.
AC ABH89802;
XX
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide primer SEQ ID NO 289795 for detecting SNP TSC0014096.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WPI; 2001-657177/75.
DR
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001MO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 289795; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 8 A; 0 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 AGAAGAGAAAGA 40
Db 1 AGAAGAGAAAGA 12

RESULT 92
AB152262/C
ID AB152262 standard; DNA; 12 BP.
XX
XX AB152262;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide primer SEQ ID NO 352235 for detecting SNP TSC0047750.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WPI; 2001-657177/75.
DR
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001MO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 352235; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 6 GGAATGAATTG 17
Db 12 GGAATGAATTG 1

RESULT 93
AB104542
ID AB104542 standard; DNA; 12 BP.

```

XX AC AB104542;
XX XX
DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 304515 for detecting SNP TSC0020975.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 304515; 29pp + Sequence listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 44 TTGCTGGGGTTG 55
XX ||| ||| ||| |||
XX 1 TTGGTGGGGTTG 12
XX
XX RESULT 94
XX AB106919/c
XX ID AB106919 standard; DNA; 12 BP.
XX AC AB106919;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 306892 for detecting SNP TSC0022229.
XX XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX

```

```

XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 306892; 29pp + Sequence listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 3 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 5 TGGAAATGGAATT 16
XX ||| ||| ||| |||
XX 12 TGGAAATGGAATT 1
XX
XX Db
XX
XX RESULT 95
XX AB107431
XX ID AB107431 standard; DNA; 12 BP.
XX AC AB107431;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 307404 for detecting SNP TSC0022484.
XX XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX

```


XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 307404; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT0073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTT 61
Db 1 GGGTTGAGGAT 12
XX
RESULT 96
ABT61725
ID ABT61725 standard; DNA; 12 BP.
XX
AC ABT61725;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 361698 for detecting SNP TSC0052780.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 361698; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT0073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGGTTGAGGTT 62
Db 1 GGGTTGAGGTT 12
XX
RESULT 97
ABT22625
ID ABT22625 standard; DNA; 12 BP.
XX
AC ABT22625;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 322598 for detecting SNP TSC0030953.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 322598; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT0073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGAGTTGAGAGT 60
 | | | | | | | | | |
 Db 1 GAGTTTGAGAGT 12

RESULT 98

ID AB123553
 ID AB123553 standard; DNA; 12 BP.

AC AB123553;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 323526 for detecting SNP TSC0031438.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 323526; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 12 BP; 0 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGAGTTTC 63
 | | | | | | | | | |
 Db 1 GTTGAGAGTTTC 12

RESULT 99

ID AB172830/c
 ID AB172830 standard; DNA; 12 BP.

AC AB172830;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 372803 for detecting SNP TSC0059648.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 372803; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GCTTGAGAGTTT 62
 | | | | | | | | | |
 Db 12 GCTTGAGAGTTT 1

RESULT 100

ID AB173289
 ID AB173289 standard; DNA; 12 BP.

AC AB173289;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 373262 for detecting SNP TSC0059932.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
PR (EPIC-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 373262; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TCGAATGGAATT 16
DB 1 TCGAATGTAATT 12
XX
RESULT 101
ABH94429
ID ABH94429 standard; DNA; 12 BP.
XX
XX ABH94429;
AC
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 294422 for detecting SNP TSC0016107.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 294422; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 50 GGGTTGGAGCTT 61
DB 1 GGGTGGAGCTT 12
XX
RESULT 102
AB128154
ID AB128154 standard; DNA; 12 BP.
XX
XX AB128154;
AC
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 328127 for detecting SNP TSC0034118.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 328127; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 50 GGGTTGAGGTT 61
Db 1 GGGTTGAGGTT 12

RESULT 103
ABH80482
ID ABH80482 standard; DNA; 12 BP.
XX
AC ABH80482;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 280475 for detecting SNP TSC0008681.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 280475; 29bp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 9 G; 2 T; 0 U; 0 Other;

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGGTTGAGG 59
Db 1 TGGGGTTGAGG 12
```

```
RESULT 104
AB106918/c
ID AB106918 standard; DNA; 12 BP.
XX
AC AB106918;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 306891 for detecting SNP TSC0022229.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 306891; 29bp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 TGAATGGAATT 16
Db 12 TGAATGGAATT 1

RESULT 105
ABH84964
ID ABH84964 standard; DNA; 12 BP.
XX
AC ABH84964;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 284957 for detecting SNP TSC0012071.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```

XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 284957; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 8 AATGGAATTGGA 19
XX |||||
XX 1 AATGGAATTGTA 12
XX
XX Db
XX
XX RESULT 106
XX ABI09323/C
XX ID ABI09323 standard; DNA; 12 BP.
XX
XX AC ABI09323;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 309296 for detecting SNP TSC0023469.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX OS
XX WO200177384-A2.
XX
XX PN 18-OCT-2001.
XX
XX PD 06-APR-2001; 2001WO-IB000713.
XX
XX PF 07-APR-2000; 2000DE-01019173.
XX
XX PR (EPIC-) EPIGENOMICS AG.
XX
XX PA
XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 309296; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 51 GGTGAGAGGTTT 62
XX |||||
XX 12 GGTGAGAGGTT 1
XX
XX Db
XX
XX RESULT 107
XX ABI24668
XX ID ABI24668 standard; DNA; 12 BP.
XX
XX AC ABI24668;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 324641 for detecting SNP TSC0032154.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX OS
XX WO200177384-A2.
XX
XX PN 18-OCT-2001.
XX
XX PD 06-APR-2001; 2001WO-IB000713.
XX
XX PF 07-APR-2000; 2000DE-01019173.
XX
XX PR (EPIC-) EPIGENOMICS AG.
XX
XX PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 324641; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTT 61
Db 1 GGGTTGAGGTT 12

RESULT 108
ABI57127/c
ID ABI57127 standard; DNA; 12 BP.

AC ABI57127;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 357100 for detecting SNP TSC0008265.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-1B000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 357100; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

SEQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 6 GGAATGGAATTG 17
Db 12 GGAATGGAATTG 1

RESULT 109
ABH70112/c
ID ABH70112 standard; DNA; 12 BP.

AC ABH70112;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 270089 for detecting SNP TSC0001994.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-1B000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 270089; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

SEQ Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTT 61
Db 12 GGGTTGAGGTT 1

RESULT 110
ABI75408

ID ABI75408 standard; DNA; 12 BP.

AC ABI75408;

```

XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 375381 for detecting SNP TSC0061225.
DE Oligonucleotide primer SEQ ID NO 375381 for detecting SNP TSC0061225.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX MPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 375381; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 48 TGGGGTTGGAGG 59
DB 1 TACGGTTGGAGG 12
XX
RESULT 111
ABH76819
ID ABH76819 standard; DNA; 12 BP.
XX
AC ABH76819;
XX
DT 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 276812 for detecting SNP TSC0004295.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS Homo sapiens.
XX WO200177384-A2.
XX

```

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX MPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 276812; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGGAGGTTT 62
DB 1 GGTGGAGGTTT 12
XX
RESULT 112
AB108168
ID AB108168 standard; DNA; 12 BP.
XX
AC AB108168;
XX
DT 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 308141 for detecting SNP TSC0022886.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX MPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT

```

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1, SEQ ID NO 308141; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 0 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGG 59
DB 1 TGGGGTTGGAGG 12
RESULT 113
AB11964/C
ID AB11964 standard; DNA; 12 BP.
XX
AC AB11964;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 311937 for detecting SNP TSC0024770.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 311937; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 5 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTTCGAGGTTT 62
DB 12 GGTTCGAGGTTT 1
RESULT 114
AB113865/C
ID AB113865 standard; DNA; 12 BP.
XX
AC AB113865;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 313838 for detecting SNP TSC0025998.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 313838; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGG 59
DB 1 TGGGGTTGGAGG 59

Db 12 TGGGTTTGAGG 1

RESULT 115

AB138926
ID AB138926 standard; DNA; 12 BP.

XX
AC AB138926;

XX
DT 22-FEB-2002 (first entry)

XX
DE Oligonucleotide primer SEQ ID NO 338899 for detecting SNP TSC0005508.

XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

XX
PA (EPIC-) EPIGENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;

XX
PI WPI; 2001-657177/75.

XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 338899; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 AGAACAAGAAAGA 40
Db 1 AGAAGAAAGAAAGA 12

RESULT 116

ABH73791/c
ID ABH73791 standard; DNA; 12 BP.

XX
AC ABH73791;

XX
DT 22-FEB-2002 (first entry)

XX
DE Oligonucleotide primer SEQ ID NO 273776 for detecting SNP TSC0003307.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

XX
PA (EPIC-) EPIGENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;

XX
PI WPI; 2001-657177/75.

XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 273776; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTGAGAGTTT 62
Db 12 GGTGGAAGTTT 1

RESULT 117

AB177010/c
ID AB177010 standard; DNA; 12 BP.

XX
AC AB177010;

XX
DT 22-FEB-2002 (first entry)

XX
DE Oligonucleotide primer SEQ ID NO 376983 for detecting SNP TSC0062083.

XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

```

XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 376983; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTTT 61
Db 12 GGGTAGGAGGTTT 1
XX
RESULT 118
AB123551
ID AB123551 standard; DNA; 12 BP.
XX
AC AB123551;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 323524 for detecting SNP TSC0031438.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 323524; 29pp + Sequence Listing; German.
XX

```

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 52 GTTGGAGGTTTC 63
Db 1 GTTGGGTGTTTC 12
XX
RESULT 119
AB142492/C
ID AB142492 standard; DNA; 12 BP.
XX
AC AB142492;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 342465 for detecting SNP TSC0042557.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 342465; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 51 GGTGGAGGTTT 62
 | |||||
 DB 12 GATTGAGGTTT 1
 |||||
 RESULT 120
 ABI75632/c
 ID ABI75632 standard; DNA; 12 BP.
 AC ABI75632;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 375605 for detecting SNP TSC0061350.
 XX
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 375605; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/publ/published_pct_sequences
 CC
 XX
 SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 51 GGTGGAGGTTT 62
 | |||||
 DB 12 GATTGAGGTTT 1
 |||||
 RESULT 121
 ABI26119/c
 ID ABI26119 standard; DNA; 12 BP.
 AC ABI26119;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 326092 for detecting SNP TSC0032896.
 XX
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 326092; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/publ/published_pct_sequences
 CC
 XX
 SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 50 GGGTTGAGGTTT 61
 |||||
 DB 12 GGTGGAGGTTT 1
 |||||
 RESULT 122
 ABI17994/c
 ID ABI17994 standard; DNA; 12 BP.
 AC ABI17994;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 317967 for detecting SNP TSC0028358.
 XX
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 317967; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

Seq Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 50 GGGTTGGAGGTT 61
DB 12 GGGTTGGAGGTT 1

RESULT 123
AB107453
ID AB107453 standard; DNA; 12 BP.
XX
XX AB107453;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 307426 for detecting SNP TSC0022492.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX

DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 307426; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

Seq Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 45 TGCTGGGGTGG 56
DB 1 TGATGGGGTGG 12

RESULT 124
AB162010
ID AB162010 standard; DNA; 12 BP.
XX
XX AB162010;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 361983 for detecting SNP TSC0052976.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 361983; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAGTT 16
 |||||
 Db 1 TGGAAAGGAGTT 12

RESULT 125

ABI00155 standard; DNA; 12 BP.

AC ABI00155;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 300128 for detecting SNP TSC0018874.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

PS Claim 1; SEQ ID NO 300128; 29pp + Sequence Listing; German.

XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGTTGGAGCT 60
 |||||
 Db 1 GGGTTGGAGCT 12

RESULT 126

ABC95493/C standard; DNA; 13 BP.

AC ABC95493;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 95510 for detecting SNP TSC023770.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

PS Claim 1; SEQ ID NO 95510; 29pp + Sequence Listing; German.

XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTGGAGGTTT 62
 |||||
 Db 13 GGTGGAGGTTT 2

RESULT 127

ABC72046 standard; DNA; 13 BP.

AC ABC72046;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 72063 for detecting SNP TSC0018626.
 DE
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

XX WO200177384-A2.
 PN
 XX

XX 18-OCT-2001.
 PD
 XX

XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX

XX 07-APR-2000; 2000DE-01019173.
 PR
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 72063; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the invention. NOTE: The sequence
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 2 A; 0 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGT 60
 |||||
 1 GGGGTTGGAGT 12

DB 1 GGGGTTGGAGT 12

RESULT 128

ABCI1945/C

ID ABCI1945 standard; DNA; 13 BP.

XX ABCI1945;
 AC
 XX

DT 20-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 11952 for detecting SNP TSC0002866.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX

XX WO200177384-A2.
 PN
 XX

PD 18-OCT-2001.
 PD

PF 06-APR-2001; 2001WO-IB000713.
 XX

PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 11952; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the invention. NOTE: The sequence
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGAAATGGAATT 16
 |||||
 12 TGGAAATGGAATT 1

DB 12 TGGAAATGGAATT 1

RESULT 129

ABC87797/C

ID ABC87797 standard; DNA; 13 BP.

XX ABC87797;
 AC
 XX

DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 87814 for detecting SNP TSC00022071.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX

XX WO200177384-A2.
 PN
 XX

PD 18-OCT-2001.
 PD

PF 06-APR-2001; 2001WO-IB000713.
 XX

PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

XX Claim 1; SEQ ID NO 87814; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 51 GGTTCGAGGTTT 62
Db 12 GGGTGGAGGTTT 1
XX
XX RESULT 130
XX ABC89082
XX ID ABC89082 standard; DNA; 13 BP.
XX
XX ABC89082;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 89099 for detecting SNP TSC0022367.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 89099; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1 TTCTCGAATGG 12
Db 2 TTTTGGAAATGG 13
XX
XX RESULT 131
XX ABF60882
XX ID ABF60882 standard; DNA; 13 BP.
XX
XX ABF60882;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 160879 for detecting SNP TSC0040514.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 160879; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 3 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TGGAAATGGAATT 16
Db 1 TAGAAATGGAATT 12

RESULT 132
ABF09494
ID ABF09494 standard; DNA; 13 BP.
XX
AC ABF09494;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 109491 for detecting SNP TSC0027394.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 109491; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTGGAGGTT 62
Db 1 GGTGGAGGATT 12
XX
RESULT 133
ABH08614
ID ABH08614 standard; DNA; 13 BP.
XX
AC ABH08614;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 208591 for detecting SNP TSC0050963.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 208591; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGATGGAATT 16
Db 2 TGGATGGAATT 13
XX
RESULT 134
ABC18620
ID ABC18620 standard; DNA; 13 BP.
XX
AC ABC18620;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 18627 for detecting SNP TSC0003928.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 18627, 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 44 TTGCTGGGGTTG 55
 Db 2 TTGCTGGGGTTG 13
 RESULT 135
 ABC19997/c
 ID ABC19997 standard; DNA; 13 BP.
 AC ABC19997;
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 20014 for detecting SNP TSC0004117.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 20014, 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 10 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 48 TGGCGTTGAGG 59
 Db 12 TGGCGTTGAGG 1
 RESULT 136
 ABC95834
 ID ABC95834 standard; DNA; 13 BP.
 AC ABC95834;
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 95851 for detecting SNP TSC0023842.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 95851, 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;

```
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1 TTTCTGGAATGG 12
        ||| |||||
DB      1 TTTTGGAAATGG 12

RESULT 137
ABC22672
ID      ABC22672 standard; DNA; 13 BP.
XX
AC      ABC22672;
XX
DT      20-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 22669 for detecting SNP TSC0004469.
XX
KM      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS      Homo sapiens.
XX
PI      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PS      (EPIG-) EPIGENOMICS AG.
PA      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX
DR      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 22689; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABF93989, ABF00010-ABF93989, ABH00010-ABH93989 and AB100010-AB182073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 9 A; 0 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      29 AGAAGAGAAAGA 40
        ||||| |||||
DB      1 AGAAGAGAAAGA 12

RESULT 138
ABF53874
ID      ABF53874 standard; DNA; 13 BP.
XX
```

```
AC      ABF53874;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 153871 for detecting SNP TSC0038903.
XX
KM      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS      Homo sapiens.
XX
PI      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PS      (EPIG-) EPIGENOMICS AG.
PA      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX
DR      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 153871; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABF93989, ABF00010-ABF93989, ABH00010-ABH93989 and AB100010-AB182073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTGGAGGT 60
        ||||| |||||
DB      1 GGGGTGGAGGT 12

RESULT 139
ABC93477/C
ID      ABC93477 standard; DNA; 13 BP.
XX
AC      ABC93477;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 93494 for detecting SNP TSC0023368.
XX
KM      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS      Homo sapiens.
XX
PI      WO200177384-A2.
XX
```

XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPiG-) EPIGENOMICS AG.
XX
PA Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
PS Claim 1; SEQ ID NO 93494; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 0 A; 5 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACGAGAG 39
|||
DB 12 AAGACGAGAG 1

RESULT 140

ABCI9996
ID ABCI9996 standard; DNA; 13 BP.

XX
AC ABCI9996;

XX
DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 20013 for detecting SNP TSC0004117.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX PD 06-APR-2001; 2001WO-IB000713.

XX PF 07-APR-2000; 2000DE-01019173.

XX (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
PS Claim 1; SEQ ID NO 20013; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 0 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGAGG 59
|||||
DB 2 TGGGGTTGAGG 13

RESULT 141

ABF09495/C
ID ABF09495 standard; DNA; 13 BP.

XX
AC ABF09495;

XX
DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 109492 for detecting SNP TSC0027394.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX PD 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 109492; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTGAGGCTTT 62
DB 13 GGTGAGGCTT 2

RESULT 142

ABH45216
ID ABH45216 standard; DNA; 13 BP.

AC ABH45216;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 245193 for detecting SNP TSC0059877.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 245193; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGTTGGAGG 59

DB 1 TGGGTTGGAGG 12

RESULT 143

ABF12720
ID ABF12720 standard; DNA; 13 BP.

AC ABF12720;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 112717 for detecting SNP TSC0028167.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 112717; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 10 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
DB 1 GAACAGAAAGAA 12

RESULT 144

ABH18990
ID ABH18990 standard; DNA; 13 BP.

AC ABH18990;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 218967 for detecting SNP TSC0053258.

```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 218967; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 TTTCTGGATGG 12
Db 1 TTTTGGATGG 12
XX
XX RESULT 145
XX ABF72258
XX ID ABF72258 standard; DNA; 13 BP.
XX AC ABF72258;
XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 172255 for detecting SNP TSC0042953.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS
XX PN WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX
```

```
PR 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 172255; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGCTTGGAGCT 60
Db 2 GGGCTTGGAGCT 13
XX
XX RESULT 146
XX ABH64846
XX ID ABH64846 standard; DNA; 13 BP.
XX AC ABH64846;
XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 264823 for detecting SNP TSC0064191.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX OS
XX PN WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 264823; 29pp + Sequence Listing; German.
```

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGT 60
|||
1 GGGGTGGAGAT 12

Db 1 GGGGTGGAGAT 12

RESULT 147
ABC61688
ID ABC61688 standard; DNA; 13 BP.
AC ABC61688;
XX
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 61705 for detecting SNP TSC0016408.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 61705; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 44 TTGCTGGGTTG 55
|||
2 TTGATGGGTTG 13

Db 2 TTGATGGGTTG 13

RESULT 148
ABH18991/c
ID ABH18991 standard; DNA; 13 BP.
AC ABH18991;
XX
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 218968 for detecting SNP TSC0053258.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 218968; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTGGATGG 12
|||
13 TTCTGGATGG 2

Db 13 TTCTGGATGG 2

RESULT 149

```

ABC95492
ID ABC95492 standard; DNA; 13 BP.
XX
AC ABC95492;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 95509 for detecting SNP TSC0023770.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 95509; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTCGAGGTTT 62
XX |||||
XX 1 GGTTCGAGGTTT 12
XX
RESULT 150
ABC9700
ID ABC9700 standard; DNA; 13 BP.
XX
AC ABC9700;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 89717 for detecting SNP TSC0022492.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 89717; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTCGAGGTTT 62
XX |||||
XX 1 GGTTCGAGGTTT 12
XX
RESULT 151
ABF35272
ID ABF35272 standard; DNA; 13 BP.
XX
AC ABF35272;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 135269 for detecting SNP TSC0033745.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 135269; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTTT 61
DB 1 GAGTTGAGGTTT 12
XX
XX RESULT 152
XX ABH56067/C
XX ID ABH56067 standard; DNA; 13 BP.
XX AC ABH56067;
XX
XX ABH56067;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 256044 for detecting SNP TSC0062390.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 256044; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTTT 61
DB 1 GAGTTGAGGTTT 12
XX
XX RESULT 153
XX ABC69962
XX ID ABC69962 standard; DNA; 13 BP.
XX AC ABC69962;
XX
XX ABC69962;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 69979 for detecting SNP TSC0018209.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 69979; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGAGGTTT 62
DB 12 GTTGGAGGTTT 1

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGAGGTTT 62
DB 12 GTTGGAGGTTT 1
XX
XX RESULT 153
XX ABC69962
XX ID ABC69962 standard; DNA; 13 BP.
XX AC ABC69962;
XX
XX ABC69962;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 69979 for detecting SNP TSC0018209.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 69979; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGAGGTTT 62
DB 12 GTTGGAGGTTT 1


```

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2 TTCTGGATGGA 13
   ||| |||||
   1 TTTCGAAATGGA 12
RESULT 154
ABC00654
ID ABC00654 standard; DNA; 13 BP.
AC ABC00654;
XX
XX 20-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 645 for detecting SNP TSC0000148.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 645; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 TTTCGGAATGG 12
   ||| |||||
   2 TTTCGGAATGG 13
RESULT 155
ABF44599/C
ID ABF44599 standard; DNA; 13 BP.
XX
XX ABF44599;
XX

```

```

DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 144596 for detecting SNP TSC0036362.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 144596; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTTGAGGTT 61
   ||| |||||
   13 GGGTTGAGGTT 2
RESULT 156
ABF72259/C
ID ABF72259 standard; DNA; 13 BP.
XX
XX ABF72259;
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 172256 for detecting SNP TSC0042953.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD

```

XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPiG-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 172256; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 49 GGGGTGGAGGT 60
 Db 12 GGGTTGGAGGT 1
 XX
 RESULT 157
 ABC93476
 ID ABC93476 standard; DNA; 13 BP.
 AC ABC93476;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 93493 for detecting SNP TSC0023368.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 93493; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 1 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 28 AAGAACGAAAG 39
 Db 2 AAGAACGAAAG 13
 XX
 RESULT 158
 ABC00655/C
 ID ABC00655 standard; DNA; 13 BP.
 AC ABC00655;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 646 for detecting SNP TSC0000148.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 646; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence

```
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

Query Match          16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTTCGGAATG 12
   |||||
Db 12 TTTCGGAATG 1

RESULT 159
ABF15052
ID ABF15052 standard; DNA; 13 BP.
XX
AC ABF15052;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 115049 for detecting SNP TSC0028823.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 115049; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 10 G; 3 T; 0 U; 0 Other;

Query Match          16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAGG 59
   |||||
Db 1 TGGGGTTGGAGG 12
```

```
RESULT 160
ABF15053/c
ID ABF15053 standard; DNA; 13 BP.
XX
AC ABF15053;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 115050 for detecting SNP TSC0028823.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 115050; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match          16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAGG 59
   |||||
Db 13 TGGGGTTGGAGG 2

RESULT 161
ABF53875/c
ID ABF53875 standard; DNA; 13 BP.
XX
AC ABF53875;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 153872 for detecting SNP TS0038903.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PE 07-APR-2000; 2000DE-01019173.
XX PR
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 153872; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGGTTGGAGGT 60
Db 13 GGGGTTGTAGGT 2
XX
RESULT 162
ABH08607/c
ID ABH08607 standard; DNA; 13 BP.
XX
AC ABH08607;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 208584 for detecting SNP TSC0050963.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR
XX

PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 208584; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGATGGAATTT 16
Db 12 TGGATGGAATTT 1
XX
RESULT 163
ABH56066
ID ABH56066 standard; DNA; 13 BP.
XX
AC ABH56066;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 256043 for detecting SNP TSC0062390.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 256043; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic

CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
CC	
CC	Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
CC	
CC	Query Match 16.0%; Score 10.4; DB 1; Length 13;
CC	Best Local Similarity 91.7%; Pred. No. 2e+02;
CC	Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0
CC	
CC	51 GGTGGAGGTT 62
CC	1
CC	2 GTTGGAGGTT 13
CC	
CC	RESULT 164
CC	ABC95835/C
CC	ABC95835 standard; DNA; 13 BP.
CC	
CC	ABC95835;
CC	
CC	21-FEB-2002 (first entry)
CC	
CC	Oligonucleotide SEQ ID NO 95852 for detecting SNP TSC0023842.
CC	
CC	SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
CC	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
CC	central nervous system; gastrointestinal; respiratory; immune; metabolic.
CC	
CC	Homo sapiens.
CC	
CC	MO200177384-A2.
CC	
CC	18-OCT-2001.
CC	
CC	06-APR-2001; 2001WO-1B000713.
CC	
CC	07-APR-2000; 2000DE-01019173.
CC	
CC	(EPIG-) EPIGENOMICS AG.
CC	
CC	Olek A, Piepenbrock C, Berlin K;
CC	
CC	WPI, 2001-657177/75.
CC	
CC	Set of oligonucleotides, useful for diagnosis and cell typing, is
CC	designed to detect single-nucleotide polymorphisms and cytosine
CC	methylation status.
CC	
CC	Claim 1; SEQ ID NO 95852; 29bp + Sequence Listing; German.
CC	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. The
CC	oligonucleotides are also used for detecting cell type differentiation. The
CC	-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
CC	
CC	Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;

Query Match	16.0%;	Score 10.4;	DB 1;	Length 13;
Best Local Similarity	91.7%;	Pred. No. 2e+02;		
Matches	11;	Conservative	0;	Mismatches 1;
				Indels 0;
				Gaps 0;
Qy	1	TTTCGTGAATGG	12	
	11			
Db	13	TTTGTGAATGG	2	
RESULT 165				
ID	ABC72047/C	standard; DNA; 13 BP.		
XX	AC	ABC72047;		
XX	DT	21-FEB-2002 (first entry)		
XX	DE	Oligonucleotide SEQ ID NO 72064 for detecting SNP TSC0018626.		
XX	XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;		
XX	KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;		
XX	XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.		
XX	OS	Homo sapiens.		
XX	PN	WO200177384-A2.		
XX	PD	18-OCT-2001.		
XX	PF	06-APR-2001; 2001WO-IB000713.		
XX	PR	07-APR-2000; 2000DE-01019173.		
XX	PA	(EP1G-) EP1GENOMICS AG.		
XX	PI	Olek A, Piepenbrock C, Berlin K;		
XX	DR	WPI; 2001-657177/75.		
PT	XX	Set of oligonucleotides, useful for diagnosis and cell typing, is		
PT	XX	designed to detect single-nucleotide polymorphisms and cytosine		
PT	XX	methylation status.		
PS	XX	Claim 1; SEQ ID NO 72064; 29pp + Sequence Listing; German.		
CC	XX	This invention describes novel oligonucleotide primers or peptide nucleic		
CC	XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)		
CC	XX	and cytosine methylation status in chemically pretreated genomic DNA. The		
CC	XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a		
CC	XX	range of diseases including immune system, gastrointestinal, respiratory,		
CC	XX	central nervous system, cardiovascular and metabolic disorders. The		
CC	XX	oligomers are also used for detecting cell type differentiation. ABC00010		
CC	XX	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and A3100010-AB182073		
CC	XX	represent the oligomers described in the invention. NOTES: The sequence		
CC	XX	data for this patent did not form part of the printed specification, but		
CC	XX	was obtained in electronic format from WIPO at		
CC	XX	ftp.wipo.int/pub/published_pct_sequences		
CC	XX			
SEQ	XX	Sequence 13 BP; 2 A; 9 C; 0 G; 2 T; 0 U; 0 Other;		
Query Match	16.0%;	Score 10.4;	DB 1;	Length 13;
Best Local Similarity	91.7%;	Pred. No. 2e+02;		
Matches	11;	Conservative	0;	Mismatches 1;
				Indels 0;
				Gaps 0;
Qy	49	GGGGTGGAGGT	60	
	11			
Db	13	GGGGTGGAGGT	2	
RESULT 166				
ID	ABC75859/C	standard; DNA; 13 BP.		

```
XX AC ABC75859;
XX XX
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 75876 for detecting SNP TSC0019443.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 75876; 29bp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 50 GGGTTGAGGTT 61
Db 13 GGGTTGAGGTT 2
RESULT 167
ABC11944
ID ABC11944 standard; DNA; 13 BP.
XX AC ABC11944;
XX XX
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 11951 for detecting SNP TSC0002866.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
```

```
PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 11951; 29bp + Sequence Listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TGGAAATGGAATT 16
Db 2 TGGAAATGGAATT 13
RESULT 168
ABC87801/C
ID ABC87801 standard; DNA; 13 BP.
XX AC ABC87801;
XX XX
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 87818 for detecting SNP TSC0022071.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX FN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 87818; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTGAGGCTT 62
DB 12 GGGTGAGGCTT 1
XX
RESULT 169
ABF60883/C
ID ABF60883 standard; DNA; 13 BP.
XX
AC ABF60883;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 160880 for detecting SNP TSC0040514.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
OS
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001MO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 160880; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 1 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 5 TGGATGGAATT 16
DB 13 TGGATGGAATT 2
XX
RESULT 170
ABC99009/C
ID ABC99009 standard; DNA; 13 BP.
XX
AC ABC99009;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 99026 for detecting SNP TSC0024596.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
OS
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001MO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 99026; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 9 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX

```

OY      46 GCTGGAGTTGA 57
      |||||||
Db      12 GCGGAGGTTGA 1
      |||||||

RESULT 171
ABC89701/C
ID      ABC89701 standard; DNA; 13 BP.
AC      ABC89701;
XX
XX
XX      21-FEB-2002 (first entry)
DE
XX      Oligonucleotide SEQ ID NO 89718 for detecting SNP TSC0022492.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 89718; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      16.0%; Score 10.4; DB 1; Length 13;
XX      Best Local Similarity 91.7%; Pred. No. 2e+02;
XX      Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      51 GGTGGAGGTTT 62
      |||||||
Db      13 GGTGGAGGATT 2
      |||||||

RESULT 172
ABF67787/C
ID      ABF67787 standard; DNA; 13 BP.
AC      ABF67787;
XX
XX
XX      22-FEB-2002 (first entry)
DT
XX

```

```

DE      Oligonucleotide SEQ ID NO 167784 for detecting SNP TSC0010654.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 167784; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      16.0%; Score 10.4; DB 1; Length 13;
XX      Best Local Similarity 91.7%; Pred. No. 2e+02;
XX      Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      51 GGTGGAGGTTT 62
      |||||||
Db      12 GGTGGAGGTTT 1
      |||||||

RESULT 173
ABF51528
ID      ABF51528 standard; DNA; 13 BP.
AC      ABF51528;
XX
XX
XX      21-FEB-2002 (first entry)
DT
XX
XX      Oligonucleotide SEQ ID NO 151525 for detecting SNP TSC0038276.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX

```



```

XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 151525; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1;
XX
QY 8 AATGGAATTGGA 19
XX |||||
XX 1 AATGGAATTGGA 12
XX
Db
XX
RESULT 174
ABC69963/c
ID ABC69963 standard; DNA; 13 BP.
XX
XX ABC69963;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 69980 for detecting SNP TSC0018209.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

```

```

PS Claim 1; SEQ ID NO 69980; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1;
XX
QY 2 TTCTGGAATGGA 13
XX |||||
XX 13 TTTTGAATGGA 2
XX
Db
XX
RESULT 175
ABC22673/c
ID ABC22673 standard; DNA; 13 BP.
XX
XX ABC22673;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 22690 for detecting SNP TSC0004469.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 22690; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX

```

```
CC      ftp.wipo.int/pub/published_pct_sequences
XX      SQ      Sequence 13 BP; 1 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      29      AGAACGAGAAAGA 40
          ||||| ||||| |||||
          13      AGAAAGAGAAAGA 2

RESULT 176
ABC99008
ID      ABC99008 standard; DNA; 13 BP.
XX
AC      ABC99008;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 99025 for detecting SNP TSC0024596.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PS      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
PS      Claim 1; SEQ ID NO 99025; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 1 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      46      GGTGGGGTTGGA 57
          ||||| ||||| |||||
          2      GCGGGGGTTGGA 13

DB
```

```
RESULT 177
ABC87800
ID      ABC87800 standard; DNA; 13 BP.
XX
AC      ABC87800;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 87817 for detecting SNP TSC0022071.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PS      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
PS      Claim 1; SEQ ID NO 87817; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 1 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      51      GGTGGAGGTTT 62
          ||||| ||||| |||||
          2      GGTGGAGGTTT 13

DB

RESULT 178
ABC89083/c
ID      ABC89083 standard; DNA; 13 BP.
XX
AC      ABC89083;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 89100 for detecting SNP TSC0022367.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```

XX Homo sapiens.
OS
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 89100; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1 TTTCTGGAATGG 12
XX 12 TTTTGGAAATGC 1
XX
XX RESULT 179
XX ABF67786
XX ID ABF67786 standard; DNA; 13 BP.
XX
XX AC ABF67786;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 167783 for detecting SNP TSC0010654.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX
XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 167783; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 51 GGTGGAGGTTT 62
XX 2 GGTGGAGTTT 13
XX
XX RESULT 180
XX ABH08615/C
XX ID ABH08615 standard; DNA; 13 BP.
XX
XX AC ABH08615;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 208592 for detecting SNP TSC0050963.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 208592; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP, 5 A, 3 C, 1 G, 4 T, 0 U, 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATCGAATT 16
DB 12 TGGATCGAATT 1

RESULT 181
ABC18621/c
ID ABC18621 standard; DNA; 13 BP.
XX
AC ABC18621;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 18628 for detecting SNP TSC0003928.
XX
XX

SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX

MO200177384-A2.
XX
XX

18-OCT-2001.
XX

06-APR-2001; 2001WO-1B000713.
XX

07-APR-2000; 2000DE-01019173.
XX

(EPIC-) EPICENOMICS AG.
XX

Olek A, Piepenbrock C, Berlin K;
XX

WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

Claim 1; SEQ ID NO 18628; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 13 BP, 6 A, 7 C, 0 G, 0 T, 0 U, 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 44 TTGCTGGGCTTG 55
DB 12 TTGCTGGGCTTG 1

RESULT 182
ABF12721/c
ID ABF12721 standard; DNA; 13 BP.
XX
AC ABF12721;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112718 for detecting SNP TSC0028167.
XX
XX

SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX

MO200177384-A2.
XX
XX

18-OCT-2001.
XX

06-APR-2001; 2001WO-1B000713.
XX

07-APR-2000; 2000DE-01019173.
XX

(EPIC-) EPICENOMICS AG.
XX

Olek A, Piepenbrock C, Berlin K;
XX

WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

Claim 1; SEQ ID NO 112718; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 13 BP, 0 A, 3 C, 0 G, 10 T, 0 U, 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
DB 13 GAACAGAAAGAA 2

RESULT 183
ABC87796
ID ABC87796 standard; DNA; 13 BP.
XX
AC ABC87796;

```

XX 18-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 87813 for detecting SNP TSC0022071.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 87813; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTTCGAGGTTT 62
DB 2 GGGTCGAGGTTT 13

```

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 135270; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTCGAGGTT 61
DB 13 GAGTTCGAGGTT 2

```

PT designed to detect single-nucleotide polymorphisms and cytosine methylation status.

PS Claim 1; SEQ ID NO 144595; 29pp + Sequence Listing; German.

PX

PY This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The CC
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The CC
CC oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABBH0010-ABBH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp://int/pub/publicised_pct_sequences

CC
CC
CC
SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;

Query Match Best Local Similarity 16.0%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 50 GGCTTGAGGTT 61
|||||||
Db 1 GGCTTGGAGGT 12

RESULT 186
ABC75858
ID ABC75858 standard; DNA; 13 BP.
XX
AC ABC75858;
DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 75875 for detecting SNP TSC0019443.
DM
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PM WO200177384-A2.
PD 18-OCT-2001.
PX
PE 06-APR-2001; 2001WO-IBO00713.
PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
PL WPJ; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is PT
PT designed to detect single-nucleotide polymorphisms and cytosine PT
PT methylation status. CC
CS Claim 1; SEQ ID NO 75875; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABBH0010-ABBH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp://int/pub/publicated_pct_sequences

CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
QY	Query Match 16.0%; Score 10.4; DB 1; Length 13; Best Local Similarity 91.7%; Pred. No. 2e+02; Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0
D8	50 GGATTGAGGCTT 61 1 GGATTGAGGCTT 12
RESULT 187	
ABC61689/c	
ID	ABC61689 standard; DNA; 13 BP.
XX	
AC	ABC61689;
XX	
DT	21-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 61706 for detecting SNP TSC0016408.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIC-) EPIDENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PS	Claim 1; SEQ ID NO 61706; 29pp + Sequence listing; German.
XX	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
QY	Query Match 16.0%; Score 10.4; DB 1; Length 13; Best Local Similarity 91.7%; Pred. No. 2e+02; Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
44	TTGCTGGCGTTG 55

Db 12 TTGATGGGCTTG 1

RESULT 188
ID ABF51529/c
XX ABF51529 standard; DNA; 13 BP.
XX
AC ABF51529;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 151526 for detecting SNP TSC0038276.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 151526; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 8 AATGCAATTGGA 19
||| |||||
Db 13 AATGCAATTGGA 2

RESULT 189
ID ABH08606
XX ABH08606 standard; DNA; 13 BP.
XX
AC ABH08606;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 208583 for detecting SNP TSC0050963.
XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 208583; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TCGAATGCAATT 16
||| |||||
Db 2 TCGAATGCAATT 13

RESULT 190
ID ABH45217/c
XX ABH45217 standard; DNA; 13 BP.
XX
AC ABH45217;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 245194 for detecting SNP TSC0059877.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

```

XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 245194; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 48 TGGGGTTGGAGG 59
Db 13 TGGGGTTGGGG 2
XX
RESULT 191
ABH64847/c
ID ABH64847 standard; DNA; 13 BP.
XX
AC ABH64847;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 264824 for detecting SNP TSC0064191.
XX
KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 264824; 29bp + Sequence Listing; German.
XX

```

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGT 60
Db 13 GGGGTTGGAGAT 2
XX
RESULT 192
AAQ79357
ID AAQ79357 standard; DNA; 10 BP.
XX
AC AAQ79357;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1995 (first entry)
XX
DE Sequence of lymphokine consensus sequence located at posn. 1871 in
DE hepsLH.
XX
KM Erythropoietin; erythropoiesis; red blood cell; regulatory element; ss.
XX
OS Synthetic.
XX
PN WO9423570-A1.
XX
PD 27-OCT-1994.
XX
PF 15-APR-1994; 94WO-US004141.
XX
PR 15-APR-1993; 93US-00046295.
PR 23-JUN-1993; 93US-00082850.
XX
PA (UNYNY ) UNIV NEW YORK STATE.
XX
PI Lee-Huang S;
XX
DR WPI; 1994-341353/42.
XX
PT New regulatory regions of human erythropoietin gene - used for studying
PT and treating diseases and for prodn. of transgenic animal models (Eng).
XX
PS Disclosure; Table I, p. 12; 81pp; English.
XX
CC AAQ79353 shows the nt. sequence of the entire 9.3 kb genomic clone
CC hepsLH. This nucleic acid sequence includes EPO coding sequence, a 5'
CC flanking region contg. multiple regulatory elements and a 3' flanking
CC region contg. multiple regulatory elements. AAQ79354 shows the extended
CC 5' flanking region and includes all the 5' regulatory elements. This
CC region, consisting of the first 3892 of AAQ79353, was not found in the
CC 3.6 kb EPO genomic clone from fetal liver reported by others. The
CC flanking region comprises 3892 bp and contains CAAT and TATA boxes and at
CC lease 321 potential transcriptional regulatory elements. AAQ79356-079362
CC show several of these elements and their positions. The nucleotide
CC position of these elements is measured from the BamH1 site at the 5' end
CC of AAQ79353. (Updated on 25-MAR-2003 to correct PN field.)
XX

```


SQ Sequence 10 BP; 2 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 56 GAGGTTTCAC 65
 1 GAGGTTTCAC 10
 Db
 RESULT 193
 AAV50176/c
 ID AAV50176 standard; DNA; 10 BP.
 AC AAV50176;
 XX
 DT 21-OCT-1998 (first entry)
 XX
 DE Yeast tag for additional NORF chromosome 8 tag position 107992.
 XX
 KW Yeast; Saccharomyces cerevisiae; transcriptome; cell cycle; regulation;
 KM eukaryotic cell; antifungal; SAGE tag; gene expression;
 KW serial analysis of gene expression; probe; ss.
 XX
 OS Saccharomyces cerevisiae.
 OS Synthetic.
 XX
 PN WO9832847-A2.
 XX
 PD 30-JUL-1998.
 XX
 PF 22-JUN-1998; 98WO-US001216.
 XX
 PR 23-JAN-1997; 97US-0035917P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
 XX
 PI Velculeacu VE, Vogelstein B, Kinzler KW;
 DR WPI; 1998-427943/36.
 XX
 PT Yeast transcriptome - useful for modulating eukaryotic cell, for
 screening antifungal agents, and for identifying genes in cell cycle
 PT progression.
 PS Claim 1; Page 24; 44pp; English.
 XX
 CC Yeast transcriptome is encoded by a DNA molecule comprising a yeast gene
 involved in cell cycle progression selected from the group of
 CC nonannotated ORF (NORF) genes. SAGE (serial analysis gene expression)
 CC tags for highly expressed genes and NORF genes are given in AAV50051 to
 CC AAV50345. The present invention describes: (1) a method of using yeast
 CC genes to modulate the cell cycle which comprises administering to a cell
 CC an isolated DNA molecule comprising a yeast gene which is involved in
 CC cell cycle progression selected from differentially expressed genes (SAGE
 CC tags given in AAV50051 to AAV50345); (2) a method for screening candidate
 CC antifungal drugs which comprises contacting a test substance with a yeast
 CC cell and monitoring expression of a yeast gene which is involved in cell
 CC cycle progression; (3) a method of identifying human genes which are
 CC involved in cell cycle progression which comprises hybridizing a probe
 CC comprising at least 10 contiguous nucleotides of a yeast gene which is
 CC differentially expressed between at least 2 phases selected from the log
 CC phase, the S phase and the G2/M phase; and (4) a probe for ascertaining
 CC the phase in the cell cycle, where the probe comprises at least 14
 CC contiguous nucleotides of a NORF gene (SAGE tags given in AAV50051 to
 CC AAV50345), or as an array of probes on a solid support
 CC
 SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 ATAGCCCAAG 30
 10 ATAGCCCAAG 1
 Db
 RESULT 194
 AA277894/c
 ID AA277894 standard; DNA; 10 BP.
 XX
 AC AA277894;
 XX
 DT 10-APR-2000 (first entry)
 XX
 DE Human dendritic cell SAGE tag, SEQ ID NO:322.
 XX
 KW SAGE tag; serial analysis of gene expression; antigen-presenting cell;
 KM APC; monocyte-derived dendritic cell; differential gene expression;
 KM immunostimulatory cofactor; costimulatory factor; CTL; cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.
 XX
 OS Homo sapiens.
 OS WO965924-A2.
 XX
 PN WO965924-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 18-JUN-1999; 99WO-US013800.
 XX
 PR 19-JUN-1998; 98US-0089833P.
 PR 19-JUN-1998; 98US-0089844P.
 PR 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089878P.
 PR 19-JUN-1998; 98US-0089911P.
 PR 19-JUN-1998; 98US-0089922P.
 PR 19-JUN-1998; 98US-0089933P.
 PR 19-JUN-1998; 98US-0089944P.
 PR 19-JUN-1998; 98US-0089957P.
 PR 19-JUN-1998; 98US-0089999P.
 PR 19-JUN-1998; 98US-0090000P.
 PR 19-JUN-1998; 98US-0090035P.
 PR 19-JUN-1998; 98US-0090036P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 PR 19-JUN-1998; 98US-0090042P.
 PR 19-JUN-1998; 98US-0090043P.
 PR 19-JUN-1998; 98US-0090044P.
 PR 19-JUN-1998; 98US-0090045P.
 PR 19-JUN-1998; 98US-0090047P.
 PR 19-JUN-1998; 98US-0090048P.
 PR 19-JUN-1998; 98US-0090072P.
 PR 19-JUN-1998; 98US-0090076P.
 PR 19-JUN-1998; 98US-0090077P.
 PR 19-JUN-1998; 98US-0090078P.
 PR 19-JUN-1998; 98US-0090079P.
 PR 19-JUN-1998; 98US-0090080P.
 PR 08-DEC-1998; 98US-0111715P.
 XX
 PA (GENZ) GENZYME CORP.
 PA (ROBE) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX
 PI Roberts BL, Shankara S;
 DR WPI; 2000-106077/09.
 XX
 PT Isolated polynucleotides differentially expressed in antigen-presenting
 PT cells, useful in gene vaccines against cancer.
 PS Claim 1; Page 73; 130pp; English.
 XX
 CC Sequences AA277573-279709 represent SAGE (serial analysis of gene


```

XX DR WPI; 2000-350734/30.
XX
PT Genes most frequently expressed in human monocytes and GM-macrophages and
PT M-macrophages studied and with cDNAs characterized, for study of gene
PT specificity, disease onset mechanism, drug development and diagnosis.
XX
PS Claim 49; Page 132; 138pp; Japanese.
XX
CC The present invention describes 100 human genes, which are expressed most
CC frequently in human monocytes. The cDNA of each gene has a sequence fully
CC defined in the specification, and lacking the CARG sequence located
CC adjacent to polyA region. Also described are: (1) an antibody
CC specifically for the protein encoded by any of the genes; (2)
CC oligonucleotides obtained from the cDNA sequences; (3) 380 human genes
CC which are expressed most frequently in human macrophages, differentiated
CC from human monocytes by granulocyte-macrophage colony-stimulating factor,
CC the cDNA of each gene has a fully defined sequence, given in the
CC specification, lacking the base sequence CARG located most closely to the
CC poly A region; (4) an antibody specifically for the protein encoded by
CC any of the genes of (3); and (5) oligonucleotides obtained from the cDNA
CC sequences of (3). The genes and cDNAs, are used for the study of gene
CC specificity and disease onset mechanism e.g. oncogenesis, genetic
CC diseases, drug development and diagnosis. AAF56107 to AAF56586 represent
CC specifically claimed oligonucleotide tag sequences for human genes
CC expressed in monocytes and macrophages
XX
SQ Sequence 10 BP; 5 A; 3 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 26 CCAAGAACAG 35
    |||||
    1 CCAAGAACAG 10
Db
RESULT 197
AAH64133/C
ID AAH64133 standard; cDNA; 10 BP.
XX
AC AAH64133;
XX
DT 20-SEP-2001 (first entry)
XX
DE Human ubiquitously expressed transcriptome sequence SEQ ID NO: 973.
XX
KM Human: transcriptome; gene expression pattern; cancer; drug screening;
KM cancer diagnosis; cell specific gene expression; ss.
XX
OS Homo sapiens.
XX
PN WO200138577-A2.
XX
PD 31-MAY-2001.
XX
PF 21-NOV-2000; 2000MO-US031922.
XX
PR 24-NOV-1999; 99US-00448480.
XX
PA (UYJO ) UNIV JOHNS HOPKINS.
XX
PI Velculescu VE, Vogelstein B, Kinzler KW;
XX
DR WPI; 2001-367706/38.
XX
PT New isolated polynucleotides, useful for identifying specific cell type,
PT such as cancer cell, comprises transcriptomes expressed in particular
PT cell types.
XX
PS Claim 13; Page 61; 94pp; English.
XX

```

```

CC The present invention describes a method of identifying the type of cell
CC in a sample, involving determining which of the sequences AAH63161-
CC AAH64724 is expressed by the cell. The transcriptomes described in the
CC invention are cell-type specific, cancer specific or ubiquitously
CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of the
CC transcriptomes described in the exemplification of the invention
XX
SQ Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 56 GAGGTTTCAC 65
    |||||
    10 GAGGTTTCAC 1
Db
RESULT 198
AAF41485
ID AAF41485 standard; DNA; 10 BP.
XX
AC AAF41485;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:8224.
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KM nor previously assigned open reading frame; nonannotated ORF; SAGE;
KM serial analysis of gene expression; antifungal; tag; identification;
KM linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000MO-US016223.
XX
PR 16-JUN-1999; 99US-00335032.
XX
PA (UYJO ) UNIV JOHNS HOPKINS.
XX
PI Velculescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
XX Example; Page 293; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
XX

```

CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC method may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

XX Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 U; 0 Other;

XX Query Match 15.4%; Score 10; DB 1; Length 10;
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGGAAATGCA 13
 Db 1 CTGGAAATGCA 10

RESULT 199
 AAF36810/c
 ID AAF36810 standard; DNA; 10 BP.
 XX AAF36810;
 AC
 XX 23-MAR-2001 (first entry)
 DT
 XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3549.
 DE
 XX Yeast; Saccharomyces cerevisiae; characterisation: cell cycle; NORF;
 KM nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KM serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 PN MO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 XX Example; Page 126; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression

CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC method may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

XX Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

XX Query Match 15.4%; Score 10; DB 1; Length 10;
 XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 12 GAATTGACA 21
 Db 10 GAATTGACA 1

RESULT 200
 AAF35563/c
 ID AAF35563 standard; DNA; 10 BP.
 XX AAF35563;
 AC
 XX 23-MAR-2001 (first entry)
 DT
 XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2302.
 DE
 XX Yeast; Saccharomyces cerevisiae; characterisation: cell cycle; NORF;
 KM nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KM serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 PN MO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 XX Example; Page 82; 419pp; English.

XX The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression

CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 ATAGCCCAAG 30
 Db 10 ATAGCCCAAG 1

RESULT 201
 AAF33393/c
 ID AAF33393 standard; DNA; 10 BP.
 AC AAF33393;
 DT 23-MAR-2001 (first entry)
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:132.
 XX
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 PS Claim 1; Page 24; 419pp; English.
 XX
 CC The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log

CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 ATAGCCCAAG 30
 Db 10 ATAGCCCAAG 1

RESULT 202
 AAD26008
 ID AAD26008 standard; DNA; 10 BP.
 AC AAD26008;
 DT 26-MAR-2002 (first entry)
 XX
 DE Primer #10 to detect human P14 gene polymorphisms.
 XX
 KW Human; protease inhibitor; P14; kallistatin; therapy; polymorphic site;
 KW P5; haplotyping; genotyping; acute pancreatitis; drug screening;
 KW antiinflammatory; chromosome 14q31-q32.1; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179227-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 13-APR-2001; 2001WO-US012255.
 XX
 PR 13-APR-2000; 2000US-0196990P.
 XX
 PA (GENA-) GENMAISSANCE PHARM INC.
 XX
 PI Choi JY, Koshy B, Sanchis A;
 XX
 DR WPI; 2002-075060/10.
 XX
 PT Genotyping protease inhibitor 4 gene of individual for determining
 PT haplotype of individual, involves determining identity of nucleotide pair
 PT at specific polymorphic sites for two copies of gene.
 XX
 PS Claim 18; Page 14; 79pp; English.
 XX
 CC The present invention relates to genotyping protease inhibitor (PI) 4
 CC (kallistatin) gene of an individual, involves determining for the two
 CC copies of the P14 gene present in the individual, the identity of the
 CC nucleotide pair at one or more polymorphic sites. P14 gene is located on
 CC chromosome 14q31-q32.1. Genotyping is useful for determining if an

```
CC individual has a haplotype or haplotype pairs defined in the
CC specification. Haplotyping is useful for improving the efficacy and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with P14 activity, e.g. acute
CC pancreatitis, to validate P14 as a candidate agent for treating a
CC specific condition or disease predicted to be associated with P14
CC activity, and in the design of clinical trials of candidate drugs for
CC treating a specific condition or disease predicted to be associated with
CC P14 activity. The P14 gene is useful in studying the expression and
CC function of P14, and in expressing P14 protein for use in screening for
CC candidate drugs to treat diseases related to P14 activity. The present
CC sequence is a primer to detect human P14 gene polymorphisms
XX
SQ Sequence 10 BP; 1 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

Query Match      15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GGGTTGAGG 59
   |||||
Db 1 GGGTTGAGG 10

RESULT 203
ABV84279
ID ABV84279 standard; cDNA; 10 BP.
XX
XX ABV84279;
XX
XX 12-DEC-2002 (first entry)
XX
XX Human ceruloplasmin SAGE tag #89.
DE
XX
XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
KW expression pattern; differential expression; ss.
XX
XX Homo sapiens.
OS
XX
XX JP2002209591-A.
PN
XX
XX 30-JUL-2002.
PD
XX
XX 19-JAN-2001; 2001JP-00012328.
PF
XX
XX 19-JAN-2001; 2001JP-00012328.
PR
XX
XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
PA
XX
XX WPI; 2002-631294/68.
DR
XX
XX Human chronic hepatitis C tissue expression exaoperating gene group
PT comprises 100 high-ranking genes.
XX
XX Claim 1; Page 12; 139pp; Japanese.
XX
XX The invention relates to SAGE (serial analysis of gene expression) tags
CC representing groups of genes which are differentially expressed in human
CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
CC polyA region of cDNAs derived from a variety of genes. These tags serve
CC to uniquely identify each transcript and can thus be used to analyse the
CC pattern of gene expression in particular cell types. The invention also
CC relates to proteins encoded by the genes expressed in chronic hepatitis C
CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
CC the expression of groups of genes that are overexpressed in chronic
CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
CC treatment of these diseases. Such genes, inhibitors of their expression
CC or activity, and antibodies against the gene products may be used in the
CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
CC expressed genes out of those genes which are overexpressed in
CC hepatocellular carcinoma compared with normal liver tissue
XX
SQ Sequence 10 BP; 1 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

Query Match      15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
CC ABV84191-ABV84290 are SAGE tags representing the 100 most highly
CC expressed genes out of those genes which are overexpressed in chronic
CC hepatitis C liver tissue compared with normal liver tissue
XX
SQ Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 U; 0 Other;

Query Match      15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGGAATGGA 13
   |||||
Db 1 CTGGAATGGA 10

RESULT 204
ABV84417
ID ABV84417 standard; cDNA; 10 BP.
XX
XX ABV84417;
XX
XX 12-DEC-2002 (first entry)
XX
XX Human ceruloplasmin (ferroxidase) SAGE tag #227.
DE
XX
XX SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
KW expression pattern; differential expression; ss.
XX
XX Homo sapiens.
OS
XX
XX JP2002209591-A.
PN
XX
XX 30-JUL-2002.
PD
XX
XX 19-JAN-2001; 2001JP-00012328.
PF
XX
XX 19-JAN-2001; 2001JP-00012328.
PR
XX
XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
PA
XX
XX WPI; 2002-631294/68.
DR
XX
XX Human chronic hepatitis C tissue expression exaoperating gene group
PT comprises 100 high-ranking genes.
XX
XX Claim 19; Page 16; 139pp; Japanese.
XX
XX The invention relates to SAGE (serial analysis of gene expression) tags
CC representing groups of genes which are differentially expressed in human
CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
CC polyA region of cDNAs derived from a variety of genes. These tags serve
CC to uniquely identify each transcript and can thus be used to analyse the
CC pattern of gene expression in particular cell types. The invention also
CC relates to proteins encoded by the genes expressed in chronic hepatitis C
CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
CC the expression of groups of genes that are overexpressed in chronic
CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
CC treatment of these diseases. Such genes, inhibitors of their expression
CC or activity, and antibodies against the gene products may be used in the
CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
CC ABV84391-ABV84490 are SAGE tags representing the 100 most highly
CC expressed genes out of those genes which are overexpressed in
CC hepatocellular carcinoma compared with normal liver tissue
XX
SQ Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 U; 0 Other;

Query Match      15.4%; Score 10; DB 1; Length 10;
```



```

XX PR 03-JAN-2001; 2001DE-01000127.
XX XX
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PS Claim 24; Page 304; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
XX SQ Sequence 11 BP; 3 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

Query Match      15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred.No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
   |||||
   |||||
Db 10 GAGGTTTCAC 1

RESULT 208
ABV64236/c
ID ABV64236 standard; cDNA; 11 BP.
XX AC
XX AC ABV64236;
XX DT 21-OCT-2002 (first entry)
XX DT
XX DE Human skin EST 2022.
XX DE
XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX KW immunosuppressive; antiinflammatory; cytosatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PN
XX PD 11-JUL-2002.
XX PD
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PF
XX PR 03-JAN-2001; 2001DE-01000127.
XX PR
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PT
XX XX

```

```

PS Disclosure; Page 81; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
XX SQ Sequence 11 BP; 3 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

Query Match      15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred.No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
   |||||
   |||||
Db 10 GAGGTTTCAC 1

RESULT 209
ABV70859/c
ID ABV70859 standard; cDNA; 11 BP.
XX AC
XX AC ABV70859;
XX DT 21-OCT-2002 (first entry)
XX DT
XX DE Human skin EST 8645.
XX DE
XX KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX KW immunosuppressive; antiinflammatory; cytosatic; SAGE; neurodermatitis;
XX KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX OS Homo sapiens.
XX PN WO200253774-A2.
XX PN
XX PD 11-JUL-2002.
XX PD
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PF
XX PR 03-JAN-2001; 2001DE-01000127.
XX PR
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX DR
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PT
XX PS Claim 24; Page 277; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag

```


CC (EST) of the invention
XX Sequence 11 BP; 4 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
DB 10 GAGGTTTCAC 1

RESULT 210
ABV63438/c
ID ABV63438 standard; cDNA; 11 BP.

AC ABV63438;

DT 21-OCT-2002 (first entry)

XX Human skin EST 1224.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KM immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KM psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253774-A2.

XX 11-JUL-2002.

PF 20-DEC-2001; 2001WO-EP015179.

PR 03-JAN-2001; 2001DE-01000127.

XX (HENK) HENKEL KGAA.

PI Petersohn D, Conradt M, Hofmann K;

DR WPI; 2002-590638/63.

PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.

PS Disclosure; Page 58; 1345pp; German.

CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention

XX Sequence 11 BP; 4 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
DB 10 GAGGTTTCAC 1

RESULT 211
ABV6020/c
ID ABV6020 standard; cDNA; 11 BP.

AC ABV6020;

DT 21-OCT-2002 (first entry)

XX Human skin EST 3806.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KM immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KM psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253774-A2.

XX 11-JUL-2002.

PF 20-DEC-2001; 2001WO-EP015179.

PR 03-JAN-2001; 2001DE-01000127.

XX (HENK) HENKEL KGAA.

PI Petersohn D, Conradt M, Hofmann K;

DR WPI; 2002-590638/63.

PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.

PS Disclosure; Page 130; 1345pp; German.

CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention

XX Sequence 11 BP; 4 A; 6 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 TTGCTGGGCT 53
DB 10 TTGCTGGGCT 1

RESULT 212
ABV65667
ID ABV65667 standard; cDNA; 11 BP.

AC ABV65667;

DT 21-OCT-2002 (first entry)

XX Human skin EST 3453.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KM immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KM psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

```

XX OS Homo sapiens.
XX XX WO200253774-A2.
XX PN 11-JUL-2002.
XX PD
XX PF 20-DEC-2001; 2001WO-EP015179.
XX XX
XX PR 03-JAN-2001; 2001DE-01000127.
XX XX
XX PA (HENK ) HENKEL KGAA.
XX XX
XX PI Petersohn D, Conradt M, Hofmann K;
XX XX
XX DR WPI; 2002-590638/63.
XX XX
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PS
XX PS Disclosure; Page 121; 1345pp; German.
XX CC
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
SQ Sequence 11 BP; 2 A; 3 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AACCTTGCTG 49
Db 2 AACCTTGCTG 11

RESULT 213
ABK99462/c
ID ABK99462 standard; DNA; 11 BP.
XX AC
XX AC ABK99462;
XX DT
XX DT 21-OCT-2002 (first entry)
XX XX
DE Human CYP3A5 gene polymorphic reference DNA sequence #44.
XX XX
XX KM Human; CYP3A5; polymorphism; cancer; cardiovascular disease; diabetes;
XX KM AIDS; African American; forensic marker; pharmacological; cyclostatic;
XX KM antidiabetic; anti-HIV; gene therapy; ds.
XX OS
XX OS Homo sapiens.
XX XX
XX PN WO200253775-A2.
XX PD
XX PD 11-JUL-2002.
XX XX
XX PF 21-DEC-2001; 2001WO-EP015290.
XX XX
XX PR 28-DEC-2000; 2000EP-00128627.
XX PR 28-DEC-2000; 2000US-0258684P.
XX PR 29-DEC-2000; 2000US-0258952P.
XX PR 16-JAN-2001; 2001EP-00100172.

```

```

PR 18-JAN-2001; 2001US-0262859P.
PR 16-AUG-2001; 2001EP-00118884.
PR 16-AUG-2001; 2001US-0312825P.
XX XX
XX PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX XX
XX PI Wojnowski L, Haberl M, Hueter E;
XX XX
XX DR WPI; 2002-583628/62.
XX XX
XX PT Novel CYP3A5 polynucleotide useful for diagnosis and treatment of cancer,
XX PT cardiovascular diseases, diabetes and AIDS, and for identifying
XX PT polymorphisms.
XX PS
XX PS Example 2; Page 51; 138pp; English.
XX CC
XX CC The present invention relates to a new CYP3A5 polynucleotide encoding a
XX CC polypeptide, where the polynucleotide is capable of hybridizing to a
XX CC CYP3A5 gene. The invention is useful in an in vitro method for
XX CC identifying a polymorphism. The invention is also useful for useful for
XX CC diagnosing a disorder related to the presence of a molecular variant of a
XX CC CYP3A5 or susceptibility to such a disorder, where the disorder is
XX CC cancer, or diseases including cardiovascular diseases, diabetes and AIDS.
XX CC The invention can further be used for the preparation of a diagnostic
XX CC composition for diagnosing a disease in a subject having a genome
XX CC comprising a variant allele of the CYP3A5 gene, where the subject is an
XX CC African American. The molecules of the invention are as forensic markers
XX CC and in pharmacological studies. The present nucleic acid sequence
XX CC represents a human CYP3A5 gene polymorphism reference DNA sequence, as
XX CC described in the invention
SQ Sequence 11 BP; 3 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 AATGGATTG 17
Db 10 AATGGATTG 1

RESULT 214
AAV06858
ID AAV06858 standard; DNA; 12 BP.
XX AC
XX AC AAV06858;
XX DT
XX DT 01-JUN-1998 (first entry)
XX XX
DE One from an array of 56 cystic fibrosis oligonucleotides.
XX XX
XX KM H-ras; wild-type; immobilising; diagnosis; ethylene acrylic acid;
XX KM ethylene methacrylic acid; polypropylene; biotin; cystic fibrosis; array;
XX KM ss.
XX OS
XX OS Synthetic.
XX XX
XX PN WO9746597-A1.
XX PD
XX PD 11-DEC-1997.
XX XX
XX PF 22-MAY-1997; 97WO-US008880.
XX XX
XX PR 05-JUN-1996; 96US-00658664.
XX XX
XX PA (BECT ) BECKMAN INSTR INC.
XX XX
XX PI Milton RC;
XX XX
XX DR WPI; 1998-051910/05.
XX XX
XX PT Polymeric reagents for immobilising biopolymers - are stable under

```

PT synthesis conditions.
XX
PS Example 7; Fig 19; 66pp; English.
XX
CC The present sequence represents one of an array of 58 cystic fibrosis
CC oligonucleotides. The invention relates to a new reagent for immobilising
CC a biopolymer. It comprises a solid support fabricated from a polymeric
CC material having at least one surface comprising pendant acyl fluoride
CC functionalities. The reagent is stable under conditions for synthesising
CC and immobilising biopolymers and is stable under conditions used to
CC analyse the biopolymers. The reagents can be formed into devices which
CC are physically rugged and inexpensive which can be used in analytical and
CC diagnostic procedures
XX
SQ Sequence 12 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTT 61
Db 2 GTTGAGGTT 11
XX
RESULT 215
AAC68048/c
ID AAC68048 standard; DNA; 12 BP.
XX
AC AAC68048;
XX
XX
DT 20-FEB-2001 (first entry)
XX
DE Oligonucleotide G11 used in a method for preparing biochips.
XX
XX Hydrogel biochip; biological activity screening; gene characterisation;
KM gene function study; gene discovery;
KM isocyanate-functional hydrogel prepolymer; ss.
XX
OS Unidentified.
XX
XX WO200065097-A1.
XX
XX PD 02-NOV-2000.
XX
XX PF 26-APR-2000; 2000WO-US011282.
XX
XX PR 26-APR-1999; 99US-00299831.
XX
XX PA (BIOC-) BIOCEPT INC.
XX
PI Hahn S, Fagnani R, Tsienberg P;
XX
DR WPI; 2001-007095/01.
XX
XX Preparing hydrogel biochip with biomolecules immobilized on it, useful
PT for gene discovery; comprises covalently binding hydrogel prepolymers and
PT biomolecules, and initiating polymerization of the hydrogel prepolymer.
XX
PS Disclosure; Page 27; 58pp; English.
XX
XX The present invention relates to a method for preparing a hydrogel
CC biochip, which has a biomolecule e.g. an oligonucleotide immobilised on
CC it. The method comprises providing an organic solvent solution of
CC isocyanate-functional hydrogel prepolymer (HP) and a solution of a
CC biomolecule, covalently binding the biomolecule to HP, and initiating
CC polymerisation of HP. The present sequence is an oligonucleotide which
CC was used as a biomolecule in the present invention. This oligonucleotide
CC is useful for making biochips which are useful for gene discovery, gene
CC characterisation, functional gene studies, screening for biological
XX activity and related studies

SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGAGGTTT 62
Db 12 TTGAGGTTT 3
XX
RESULT 216
ABI06792
ID ABI06792 standard; DNA; 12 BP.
XX
AC ABI06792;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306765 for detecting SNP TSC0022165.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 306765; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP). The
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABCG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTT 61
Db 1 GTTGAGGTT 10
XX
RESULT 217
ABH04270/c

```
ID ABH84270 standard; DNA; 12 BP.
XX
AC ABH84270;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 284263 for detecting SNP TSC0011746.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 284263; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGGAGGTTT 62
DB 10 TTGGAGGTTT 1
RESULT 218
AB142194/C
ID AB142194 standard; DNA; 12 BP.
XX
AC AB142194;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 342167 for detecting SNP TSC0042414.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
```

```
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 342167; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTTT 61
DB 10 GTTGAGGTTT 1
RESULT 219
AB146629
ID AB146629 standard; DNA; 12 BP.
XX
AC AB146629;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 346602 for detecting SNP TSC0044669.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
```

DR	WPI, 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 346602; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SEQ	Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match	15.4%; Score 10; DB 1; Length 12;
Best Local Similarity	100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	53 TTGAGGTTT 62
Db	2 TTGAGGTTT 11
RESULT 220	
AB170669/C	
ID	AB170669 standard; DNA; 12 BP.
XX	
AC	AB170669;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide primer SEQ ID NO 370642 for detecting SNP TSC0058289.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI, 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 370642; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SEQ	Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match	15.4%; Score 10; DB 1; Length 12;
Best Local Similarity	100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	53 TTGAGGTTT 62
Db	2 TTGAGGTTT 11
RESULT 220	
AB170669/C	
ID	AB170669 standard; DNA; 12 BP.
XX	
AC	AB170669;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide primer SEQ ID NO 370642 for detecting SNP TSC0058289.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI, 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 370642; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SEQ	Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match	15.4%; Score 10; DB 1; Length 12;
Best Local Similarity	100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	53 TTGAGGTTT 62
Db	2 TTGAGGTTT 11
RESULT 220	
AB170669/C	
ID	AB170669 standard; DNA; 12 BP.
XX	
AC	AB170669;
XX	
DT	22-FEB-2002 (first entry)
XX	

CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
XX	
XX	Query Match 15.4%; Score 10; DB 1; Length 12;
XX	Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX	Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	49 GGGGTTGGAG 58
DB	12 GGGGTTGGAG 3
DB	
DB	RESULT 221
DB	AB134548/C
XX	AB134548 standard; DNA; 12 BP.
XX	
XX	AB134548;
XX	
XX	22-FEB-2002 (first entry)
DE	Oligonucleotide primer SEQ ID NO 334521 for detecting SNP TSC0038211.
XX	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB000713.
XX	
XX	07-APR-2000; 2000DE-01019173.
PR	
XX	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
XX	WPI; 2001-657177/75.
DR	
XX	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
XX	Claim 1; SEQ ID NO 334521; 29pp + Sequence Listing; German.
XX	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX	
XX	Query Match 15.4%; Score 10; DB 1; Length 12;
XX	Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX	Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0

```

QY      53 TTGAGGTTT 62
      |||||
      11 TTGAGGTTT 2
Db
RESULT 222
AB169406/C
ID      AB169406 standard; DNA; 12 BP.
XX
AC      AB169406;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 369379 for detecting SNP TSC0000520.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 369379; 29bp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      52 GTTGAGGTT 61
      |||||
      12 GTTGAGGTT 3
Db
RESULT 223
AB164587/C
ID      AB164587 standard; DNA; 12 BP.
XX
AC      AB164587;
XX
DT      22-FEB-2002 (first entry)
XX

```

```

XX      Oligonucleotide primer SEQ ID NO 364560 for detecting SNP TSC0054570.
DE
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 364560; 29bp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      7 GAATGGAATT 16
      |||||
      12 GAATGGAATT 3
Db
RESULT 224
AB142193/C
ID      AB142193 standard; DNA; 12 BP.
XX
AC      AB142193;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 342166 for detecting SNP TSC0042414.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 342166; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGAGGTT 61
Db 10 GTTGAGGTT 1
XX
RESULT 225
ABIS5467
ID ABIS5467 standard; DNA; 12 BP.
XX
XX ABIS5467;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 355440 for detecting SNP TSC0049640.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
XX Claim 1; SEQ ID NO 355440; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAAT 15
Db 2 GGAATGGAAT 11
XX
RESULT 226
AB107646
ID AB107646 standard; DNA; 12 BP.
XX
XX AB107646;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide primer SEQ ID NO 307619 for detecting SNP TSC0022594.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 307619; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGGAGGTTT 62
DB 1 TTGGAGGTTT 10

RESULT 227
ABH84274/c
ID ABH84274 standard; DNA; 12 BP.

XX ABH84274;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 284267 for detecting SNP TSC0011747.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 284267; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGGAGGTTT 62
DB 11 TTGGAGGTTT 2

RESULT 228
ABI66699/c
ID ABI66699 standard; DNA; 12 BP.

XX ABI66699;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 366672 for detecting SNP TSC0055912.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 366672; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGGAGGTTT 62
DB 12 TTGGAGGTTT 3

RESULT 229
ABI09673
ID ABI09673 standard; DNA; 12 BP.

XX ABI09673;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 309646 for detecting SNP TSC0023602.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 309646; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTT 61
Db 1 GTTGAGGTT 10
RESULT 230
ABI30165
ID ABI30165 standard; DNA; 12 BP.
XX
XX ABI30165;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide primer SEQ ID NO 330138 for detecting SNP TSC0035356.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX

XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330138; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 12 BP; 2 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GGGTTGAGG 59
Db 2 GGGTTGAGG 11
RESULT 231
ABI07667/c
ID ABI07667 standard; DNA; 12 BP.
XX
XX ABI07667;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide primer SEQ ID NO 307640 for detecting SNP TSC0022603.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 307640; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGGAGGTTT 62
   |||||
   |||||
Db 11 TTGGAGGTTT 2

RESULT 232
AB152354/C
ID AB152354 standard; DNA; 12 BP.
XX
XX AB152354;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 352327 for detecting SNP TSC0047816.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 352327; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
```

```
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGGAGGTTT 62
   |||||
   |||||
Db 11 TTGGAGGTTT 2

RESULT 233
AB15302/C
ID AB15302 standard; DNA; 12 BP.
XX
XX AB15302;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 365275 for detecting SNP TSC0055021.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 365275; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GGGTTGAGG 59
   |||||
   |||||
Db 12 GGGTTGAGG 3

RESULT 234
AB123654
ID AB123654 standard; DNA; 12 BP.
XX
```

```

AC  ABI23654;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 323627 for detecting SNP TSC0031504.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 323627; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 15.4%; Score 10; DB 1; Length 12;
XX  Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX  Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX  7 GAATGGAATT 16
XX  |||||
XX  1 GAATGGAATT 10
XX
XX  RESULT 235
XX  ID ABI00156 standard; DNA; 12 BP.
XX
XX  ABI00156;
XX
XX  22-FEB-2002 (first entry)
XX
XX  Oligonucleotide primer SEQ ID NO 300129 for detecting SNP TSC0018874.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX  WO200177384-A2.
XX

```

```

XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 300129; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 12 BP; 1 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 15.4%; Score 10; DB 1; Length 12;
XX  Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX  Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX  49 GGGGTTGGAG 58
XX  |||||
XX  1 GGGGTTGGAG 10
XX
XX  RESULT 236
XX  ID ABI25871/C
XX
XX  ABI25871;
XX
XX  22-FEB-2002 (first entry)
XX
XX  Oligonucleotide primer SEQ ID NO 325844 for detecting SNP TSC0032754.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 325844; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGGAGGTTT 62
12 TTGGAGGTTT 3
Db 12 TTGGAGGTTT 3
RESULT 237
AB130164
ID AB130164 standard; DNA; 12 BP.
XX
XX AB130164;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 330137 for detecting SNP TSC0035356.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 330137; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GGCTTGAGG 59
2 GGCTTGAGG 11
Db 2 GGCTTGAGG 11
RESULT 238
AB146947/C
ID AB146947 standard; DNA; 12 BP.
XX
XX AB146947;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 346920 for detecting SNP TSC0044834.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 346920; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGGAGGTTT 62

```

Db      10 TTGAGGTTT 1
|||||
RESULT 239
ID      ABH67422/c
XX      ABH67422 standard; DNA; 12 BP.
AC      ABH67422;
XX
XX      22-FEB-2002 (first entry)
DE      Oligonucleotide primer SEQ ID NO 267399 for detecting SNP TSC0000164.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIDENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 267399; 29bp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX      Query Match      15.4%; Score 10; DB 1; Length 12;
XX      Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      5 TGGAATCGAA 14
      |||||
      10 TGGAATCGAA 1
Db

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIDENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 291960; 29bp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX      Query Match      15.4%; Score 10; DB 1; Length 12;
XX      Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      54 TTGAGGTTTC 63
      |||||
      3 TTGAGGTTTC 12
Db

```

```

XX PN MO200190418-A1.
XX PD 29-NOV-2001.
XX PF 22-MAY-2001; 2001WO-US016394.
XX PR 22-MAY-2000; 2000US-0206512P.
XX RA (REGC ) UNIV CALIFORNIA.
XX PI Cai H, Goodwin PM, Keller RA, Werner JH;
XX DR WPI; 2002-083123/11.
XX PT Rapid haplotyping of DNA or RNA segments, comprises labeling at least 2
XX target sites on a segment of DNA or RNA with separate distinguishable
XX fluorescent hybridization probes.
XX PS Example 1; Page 22; 49pp; English.
XX CC The invention relates to rapid haplotyping a DNA or RNA segment by single
XX molecule detection. The method involves labelling at least 2 target sites
XX on a DNA or RNA segment with separate distinguishable luminescent marker
XX hybridisation probes, where the targets are selected genetic markers and
XX detecting the presence or absence of each luminescent hybridisation probe
XX on each DNA segment to determine the haplotype of each DNA or RNA
XX segment. The method is useful for rapid haplotyping of DNA or RNA
XX for haplotyping ML-AF4/98(+) chimeric gene
SQ Sequence 12 BP; 0 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 23 AGCCCAAGAA 32
DB 11 AGCCCAAGAA 2
RESULT 242
AADD5617/c
ID AAD25617 standard; DNA; 12 BP.
XX
AC AAD25617;
XX
DT 26-MAR-2002 (first entry)
XX
DE ML-Cy5P PNA probe used for haplotyping ML-AF4/98(+) chimeric gene.
XX
KM Haplotyping; single molecule detection; luminescent marker;
XX genetic marker; ML-AF4/98(+); peptide nucleic acid; PNA; probe; ss.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
XX modified_base 1
XX /*tag= a
XX /mod_base= OTHER
XX /note= "N,N'-biscarboxypentyl-5, 5'-
XX disulfoetoinidiscarboxyanine (Cy5) fluorophore labelled
XX thymine; This base is linked to the label via linker"
XX 12
XX /*tag= b
XX /note= "This base is attached to a linker sequence"
XX
PN MO200190418-A1.
XX PD 29-NOV-2001.
XX PF 22-MAY-2001; 2001WO-US016394.

```

```

XX PR 22-MAY-2000; 2000US-0206512P.
XX RA (REGC ) UNIV CALIFORNIA.
XX PI Cai H, Goodwin PM, Keller RA, Werner JH;
XX DR WPI; 2002-083123/11.
XX PT Rapid haplotyping of DNA or RNA segments, comprises labeling at least 2
XX target sites on a segment of DNA or RNA with separate distinguishable
XX fluorescent hybridization probes.
XX PS Example 1; Page 22; 49pp; English.
XX CC The invention relates to rapid haplotyping a DNA or RNA segment by single
XX molecule detection. The method involves labelling at least 2 target sites
XX on a DNA or RNA segment with separate distinguishable luminescent marker
XX hybridisation probes, where the targets are selected genetic markers and
XX detecting the presence or absence of each luminescent hybridisation probe
XX on each DNA segment to determine the haplotype of each DNA or RNA
XX segment. The method is useful for rapid haplotyping of DNA or RNA
XX for haplotyping ML-AF4/98(+) chimeric gene
SQ Sequence 12 BP; 0 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 23 AGCCCAAGAA 32
DB 11 AGCCCAAGAA 2
RESULT 243
ADE13956/c
ID ADE13956 standard; DNA; 12 BP.
XX
AC ADE13956;
XX
DT 29-JAN-2004 (first entry)
XX
DE Optineurin promoter motif, repeat element or regulatory region #65.
XX
KM Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
XX SNP; glaucoma; progressive ocular hypertensive disorder;
XX glaucoma related disorder; motif; repeat element; regulatory region.
XX
OS Homo sapiens.
XX
PN US2003190617-A1.
XX
PD 09-OCT-2003.
XX
PF 06-MAR-2002; 2002US-00091281.
XX
PR 06-MAR-2002; 2002US-00091281.
XX
XX (SIEE/) SI E.
XX (RAYM/) RAYMOND V.
XX (MORI/) MORISSETTE J.
XX
XX Raymond V, Morissette J, Si E;
XX
XX WPI; 2003-864168/80.
XX
XX New nucleic acid sequences of the optineurin gene are useful to detect
XX polymorphisms particularly single nucleotide polymorphisms in the
XX optineurin promoter to diagnose, prognosis and treat glaucoma and related
XX disorders.

```


Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
| | | | | | | |
Db 4 TGGGGTTGGA 13

RESULT 246

ABC72461/c
ID ABC72461 standard; DNA; 13 BP.

AC ABC72461;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 72478 for detecting SNP TSC0018723.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 72478; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
| | | | | | | |
Db 10 TGGGGTTGGA 1

RESULT 247

ABF96459/c

ID ABF96459 standard; DNA; 13 BP.

XX ABF96459;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 196456 for detecting SNP TSC0008585.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 196456; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
| | | | | | | |
Db 10 TGGGGTTGGA 1

RESULT 248

ABC98944

ID ABC98944 standard; DNA; 13 BP.

AC ABC98944;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 98961 for detecting SNP TSC0024580.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.


```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 98961; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGG 59
XX |||||
XX 4 GGGTTGAGG 13
XX
XX RESULT 249
XX ABC98945/C
XX ID ABC98945 standard; DNA; 13 BP.
XX
XX AC ABC98945;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 98962 for detecting SNP TSC0024580.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 98962; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGG 59
XX |||||
XX 10 GGGTTGAGG 1
XX
XX Db
XX
XX RESULT 250
XX ABC08152
XX ID ABC08152 standard; DNA; 13 BP.
XX
XX AC ABC08152;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 8143 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 8143; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX

```

CC	represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_sequences
XX	
SQ	Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
QY	Query Match 15.4%; Score 10; DB 1; Length 13; Best Local Similarity 100.0%; Pred. No. 2.3e+02; Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db	52 GTTGAGAGTT 61 3 GTTGAGAGTT 12
RESULT 251	
ABC38818	
ID	ABC38818 standard; DNA; 13 BP.
XX	
AC	ABC38818;
XX	
DT	20-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 38835 for detecting SNP TSC0011952.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PMA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piegenbrock C, Berlin K;
XX	
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 38835; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_sequences
SQ	Sequence 13 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 1 Other;
QY	Query Match 15.4%; Score 10; DB 1; Length 13; Best Local Similarity 83.3%; Pred. No. 2.3e+02; Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
31	AACGAGAGAAC 42

```

Db      2  AAAAGAAAGAAAY 13

RESULT 252
ABF14181/c
ID  ABF14181 standard; DNA; 13 BP.
XX
AC  ABF14181;
XX
DT  21-FEB-2002 (first entry)
DE  Oligonucleotide SEQ ID NO 114178 for detecting SNP TSC0028568.
XX
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX  PF
XX  07-APR-2000; 2000DE-01019173.
XX  PR
XX  (EPIC-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
PI
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 114178; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX  Sequence 13 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 1 Other;
SQ

Query Match      15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      53 TTGAGGTTT 62
      |||||
      |||||
      |||||
      |||||
      |||||
      12 TTGGAGGTTT 3

RESULT 253
ABF78290
ID  ABF78290 standard; DNA; 13 BP.
XX
XX  ABF78290;
XX
XX  22-FEB-2002 (first entry)
DT
DE  Oligonucleotide SEQ ID NO 178287 for detecting SNP TSC0044161.
XX

```

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 178287; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 52 GTTGAGGTTTC 63
 Db 2 GTTGAGGTTT 13
 RESULT 254
 ABH09786
 ID ABH09786 standard; DNA; 13 BP.
 XX
 AC ABH09786;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 209763 for detecting SNP TSC0051216.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 PF
 XX 06-APR-2001; 2001WO-IB000713.
 PR
 XX 07-APR-2000; 2000DE-01019173.
 PR

XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 209763; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGAGGTTT 61
 Db 4 GTTGAGGTTT 13
 RESULT 255
 ABH14635/C
 ID ABH14635 standard; DNA; 13 BP.
 XX
 AC ABH14635;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 214612 for detecting SNP TSC0052224.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 PF
 XX 06-APR-2001; 2001WO-IB000713.
 PR
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 214612; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 GGGGTTGGAG 58
|||||||
Db 10 GGGGTTGGAG 1

RESULT 256

ABF35131/c
ID ABF35131 standard; DNA; 13 BP.

AC ABF35131;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 135128 for detecting SNP TSC0033685.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 135128; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGATTGGA 57
|||||||
Db 10 TGGGATTGGA 1

RESULT 257

ABF68180
ID ABF68180 standard; DNA; 13 BP.

AC ABF68180;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 168177 for detecting SNP TSC0042062.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 168177; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 1 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TGGATTGGA 19
|||||||
Db 1 TGGATTGGA 10

RESULT 258

ABF72180

```

ID  ABF72180 standard; DNA; 13 BP.
XX
XX  ABF72180;
AC
XX  22-FEB-2002 (first entry)
DT
XX  Oligonucleotide SEQ ID NO 172177 for detecting SNP TSC0042932.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
XX  WO200177384-A2.
PN
XX  18-OCT-2001.
PD
XX  06-APR-2001; 2001WO-IB000713.
PF
XX  07-APR-2000; 2000DE-01019173.
PR
XX  (EPIC-) EPIDENOMICS AG.
PA
XX  Olek A, Piepenbrock C, Berlin K;
PI
XX  WPI; 2001-657177/75.
DR
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 172177; 29bp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGAGGTTT 62
    |||||
    |||||
Db 2 GGTGGAAGTTT 13
XX
RESULT 259
ID  ABF78291/c
XX  ABF78291 standard; DNA; 13 BP.
AC
XX  ABF78291;
AC
XX  22-FEB-2002 (first entry)
DT
XX  Oligonucleotide SEQ ID NO 178288 for detecting SNP TSC0044161.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX

```

```

XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 178288; 29bp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 52 GGTGAGGTTTC 63
    |||||
    |||||
Db 12 GTTGAGTGTTTY 1
XX
RESULT 260
ID  ABF78294
XX  ABF78294 standard; DNA; 13 BP.
AC
XX  ABF78294;
AC
XX  22-FEB-2002 (first entry)
DT
XX  Oligonucleotide SEQ ID NO 178291 for detecting SNP TSC0044161.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 178291; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
OY 52 GTTGAGGTTTC 63
Db 2 GTTGACGTTT 13
XX
RESULT 261
ABH12398
ID ABH12398 standard; DNA; 13 BP.
XX
AC ABH12398;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 212375 for detecting SNP TSC0051732.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 212375; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 51 GGTGAGAGT 60
Db 1 GGTGAGAGT 10
XX
RESULT 262
ABC18902
ID ABC18902 standard; DNA; 13 BP.
XX
AC ABC18902;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 18919 for detecting SNP TSC0003970.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 18919; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 7 G; 2 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGT 60
 DB 2 GAGGTTGGAGGY 13

RESULT 263
 ABC18903/C
 ID ABC18903 standard; DNA; 13 BP.
 XX
 AC ABC18903;
 XX
 DT 20-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 18920 for detecting SNP TSC0003970.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIC-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR MPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 18920; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 2 A; 7 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGT 60
 DB 12 GAGGTTGGAGGY 1

RESULT 264
 ABC69993/C
 ID ABC69993 standard; DNA; 13 BP.
 XX
 AC ABC69993;
 XX
 DT 21-FEB-2002 (first entry)
 XX

XX
 DE Oligonucleotide SEQ ID NO 70010 for detecting SNP TSC0018219.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIC-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR MPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 70010; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGGAGGTTT 62
 DB 13 TTGGAGGTTT 4

RESULT 265
 ABC53076
 ID ABC53076 standard; DNA; 13 BP.
 XX
 AC ABC53076;
 XX
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 53093 for detecting SNP TSC0014670.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 53093; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGAGAGTTT 62
XX |||||||
DB 2 TTGAGAGTTT 11
XX
RESULT 266
ABF14904
ID ABF14904 standard; DNA; 13 BP.
XX
XX ABF14904;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 114901 for detecting SNP TSC0028776.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX

XX
XX Claim 1; SEQ ID NO 114901; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 51 GGTTGAGAGT 60
XX |||||||
DB 3 GGTTGAGAGT 12
XX
RESULT 267
ABCI6841/C
ID ABCI6841 standard; DNA; 13 BP.
XX
XX ABCI6841;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 16848 for detecting SNP TSC0003657.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 16848; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGAGTTT 62
|||||

Db 13 TTGAGAGTTT 4

RESULT 268

ABF29456
ID ABF29456 standard; DNA; 13 BP.

XX
AC ABF29456;

XX
DT 21-FEB-2002 (first entry)

XX
DE Oligonucleotide SEQ ID NO 129453 for detecting SNP TSC0032391.

XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

XX
PA (EPIC-) EPIDENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;

XX
DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 129453; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 2 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 50 GGGTTGAGG 59
|||||

Db 2 GGGTTGAGG 11

RESULT 269
ABF78235/C
ID ABF78235 standard; DNA; 13 BP.

XX
AC ABF78235;

XX
DT 22-FEB-2002 (first entry)

XX
DE Oligonucleotide SEQ ID NO 178292 for detecting SNP TSC0044161.

XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

XX
PA (EPIC-) EPIDENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;

XX
DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 178292; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 6 A; 4 C; 1 G; 1 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;

Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 52 GTTGAGAGTTTC 63
|||||

Db 12 GTTGAGAGTTT 1

RESULT 270

ABH28568
ID ABH28568 standard; DNA; 13 BP.

XX
AC ABH28568;

XX
DT 22-FEB-2002 (first entry)

XX
DE Oligonucleotide SEQ ID NO 228545 for detecting SNP TSC0009540.

XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 228545; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 1 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 50 GGCTTGACGCTT 61
 DB 2 GGCTTGACGCTT 13
 XX
 RESULT 271
 ABH09787/C
 ID ABH09787 standard; DNA; 13 BP.
 AC
 XX ABH09787;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 209764 for detecting SNP TSC0051216.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX

XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 209764; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGACGCTT 61
 DB 10 GTTGACGCTT 1
 XX
 RESULT 272
 ABH1477/C
 ID ABH1477 standard; DNA; 13 BP.
 AC
 XX ABH1477;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 241454 for detecting SNP TSC0001145.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 241454; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 10 TGGATTGGA 19
DB 13 TGGATTGGA 4
RESULT 273
ABC38819/c
ID ABC38819 standard; DNA; 13 BP.
XX
AC ABC38819;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 38836 for detecting SNP TSC0011952.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 38836; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 31 AACGAAAGAAC 42
DB 12 AAAAGAAAGAA 1
RESULT 274
ABF35130
ID ABF35130 standard; DNA; 13 BP.
XX
AC ABF35130;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 135127 for detecting SNP TSC0033685.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 135127; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGGTTGGA 57
DB 4 TGGGGTTGGA 13
RESULT 275
ABF68181/c
ID ABF68181 standard; DNA; 13 BP.
XX

AC ABF68181;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 168178 for detecting SNP TSC0042062.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 168178; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 10 TGGAAATTGGA 19
DB 13 TGGAAATTGGA 4
XX
RESULT 276
ABF72181/C
ID ABF72181 standard; DNA; 13 BP.
XX
AC ABF72181;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172178 for detecting SNP TSC0042932.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 172178; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 51 GCTTGAGAGTTT 62
DB 12 GCTTGAGAGTTT 1
XX
RESULT 277
ABH28569/C
ID ABH28569 standard; DNA; 13 BP.
XX
AC ABH28569;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 228546 for detecting SNP TSC0009540.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 228546; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTTGAGGTT 61
DB 12 GGGTTGAGCTT 1
RESULT 278
ABH66664
ID ABH66664 standard; DNA; 13 BP.
XX
XX ABH66664;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 266641 for detecting SNP TSC0064607.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 266641; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 2 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGTTGAGGTT 60
DB 2 GAGTTGAGAGT 13
RESULT 279
ABC08153/c
ID ABC08153 standard; DNA; 13 BP.
XX
XX ABC08153;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 8144 for detecting SNP TSC002280.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 8144; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTT 61

```
Db          11 |||||
              GTTGGAGGTT 2

RESULT 280
ABC08156
ID ABC08156 standard; DNA; 13 BP.
XX
XX ABC08156;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 8147 for detecting SNP TSC0002280.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX MO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 8147; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match          15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY          52 GTTGGAGGTT 61
              |||||
              GTTGGAGGTT 12
Db          3 GTTGGAGGTT 12

RESULT 281
ABC88551/c
ID ABC88551 standard; DNA; 13 BP.
XX
XX ABC88551;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 88568 for detecting SNP TSC0022253.
DE
```

```
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX MO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 88568; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match          15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY          7 GAATGGAATT 16
              |||||
              GAATGGAATT 4
Db          13 GAATGGAATT 4

RESULT 282
ABF14836
ID ABF14836 standard; DNA; 13 BP.
XX
XX ABF14836;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 114833 for detecting SNP TSC0028759.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX MO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
```

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR WPI; 2001-657177/75.
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 114833; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 GGTTGAGGTT 60
 |||||
 2 GGTTGGAGGT 11
 DB
 RESULT 283
 ABF39155/c
 ID ABF39155 standard; DNA; 13 BP.
 XX
 AC ABF39155;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 139152 for detecting SNP TSC0034855.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 139152; 29pp + Sequence Listing; German.

XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 51 GGTTGAGGTTT 62
 |||||
 12 GGTTGGGGGTTT 1
 DB
 RESULT 284
 ABH36930
 ID ABH36930 standard; DNA; 13 BP.
 XX
 AC ABH36930;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 236907 for detecting SNP TSC0000091.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 236907; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGAGGTT 61
 DB 4 GTTGAGGTT 13
 RESULT 285
 ABH59464
 ID ABH59464 standard; DNA; 13 BP.
 AC ABH59464;
 DT 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 259441 for detecting SNP TSC0063013.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 259441; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 5 TGGATGGAAT 16
 DB 2 TGGATGGAAT 13
 RESULT 286

ABF21342
 ID ABF21342 standard; DNA; 13 BP.
 AC ABF21342;
 DT 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 121339 for detecting SNP TSC0030310.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPIC-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 121339; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 52 GTTGAGGTTTC 63
 DB 2 GTTGAGGTTGTY 13
 RESULT 287
 ABH27163/C
 ID ABH27163 standard; DNA; 13 BP.
 AC ABH27163;
 DT 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 227140 for detecting SNP TSC0053396.
 DE
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS


```

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 227140; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 5 C; 1 G; 0 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTTC 63
XX |||||
XX |||||
XX |||||
XX
XX DB 12 GTTGCGGTTT 1
XX
XX RESULT 288
XX ABE52228
XX ID ABE52228 standard; DNA; 13 BP.
XX
XX AC ABE52228;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 152225 for detecting SNP TSC0038463.
XX
XX SNF, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;

```

```

XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 152225; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTTC 63
XX |||||
XX |||||
XX |||||
XX
XX DB 2 GTGAGGTTT 13
XX
XX RESULT 289
XX ABE60990
XX ID ABE60990 standard; DNA; 13 BP.
XX
XX AC ABE60990;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 160987 for detecting SNP TSC0040537.
XX
XX SNF, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 160987; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

```

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
 DB 1 TTGAGGTTT 10

RESULT 290
 ABC68982
 ID ABC68982 standard; DNA; 13 BP.

AC ABC68982;
 DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 68999 for detecting SNP TSC0017967.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
 OS
 WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 68999; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX

SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 10 TGGATTGGA 19
 DB 3 TGGATTGGA 12

RESULT 291
 ABF02807/C
 ID ABF02807 standard; DNA; 13 BP.

AC ABF02807;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 102804 for detecting SNP TSC0025690.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
 OS

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PI (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 102804; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX

SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
 DB 12 TTGAGGTTT 3

RESULT 292
 ABC6872
 ID ABC6872 standard; DNA; 13 BP.

AC ABC6872;

DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 66889 for detecting SNP TSC0017525.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 66889; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 51 GGTGGAGCT 60
DB 2 GGTGGAGCT 11
XX
XX
RESULT 293
ABF18949/C
ID ABF18949 standard; DNA; 13 BP.
XX
XX ABF18949;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 118946 for detecting SNP TSC0029695.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.

XX
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
PS Claim 1; SEQ ID NO 118946; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGCTT 62
DB 11 TTGGAGCTT 2
XX
XX
RESULT 294
ABF24945/C
ID ABF24945 standard; DNA; 13 BP.
XX
XX
XX ABF24945;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 124942 for detecting SNP TSC0031231.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 124942; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC000010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 49 GGCGTTGGAG 58
|||||
Db 10 GGCGTTGGAG 1

RESULT 295
ABF73195/C
ID ABF73195 standard; DNA; 13 BP.
XX
AC ABF73195;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173192 for detecting SNP TSCC043135.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; gastric ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K,
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX

Claim 1; SEQ ID NO 173192; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC000010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC

CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SX	
XX	Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
QY	
Db	Query Match 15.4%; Score 10; DB 1; Length 13; Best Local Similarity 100.0%; Pred. No. 2.3e+02; Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0 48 TTGGGTTTGA 57 11 TTGGGTTTGA 2
RESULT 296	
ABC69992	
ID	ABC69992 standard; DNA; 13 BP.
XX	
AC	ABC69992;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 70009 for detecting SNP TSC0018219.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
PX	
PN	WO200177384-A2.
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WIPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PS	Claim 1; SEQ ID NO 70009; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SX	
SEQ	Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
Query Match	15.4%; Score 10; DB 1; Length 13;
Best Local Similarity	100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative	0; Mismatches 0; Indels 0; Gaps 0
53 TTGGAGGTTT 62	
1 TTGGAGGTTT 10	

```
RESULT 297
ABH18948
ID ABH18948 standard; DNA; 13 BP.
XX
AC ABH18948;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 118945 for detecting SNP TSC0029695.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 118945; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGAGGTTT 62
|||||
|11111111|
Db 3 TTGAGGTTT 12
RESULT 298
ABH16777/C
ID ABH16777 standard; DNA; 13 BP.
XX
AC ABH16777;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216754 for detecting SNP TSC0052685.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 216754; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 10 TGGATTGCA 19
|||||
|111111111|
Db 10 TGGATTGCA 1
RESULT 299
ABH42921/C
ID ABH42921 standard; DNA; 13 BP.
XX
AC ABH42921;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 242898 for detecting SNP TSC0000705.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
```

PA (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1, SEQ ID NO 242898; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP, 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGGAGGTT 61
DB 13 GTTGGAGGTT 4
XX
XX
XX RESULT 300
ABF14837/C
ID ABF14837 standard; DNA; 13 BP.
XX
XX ABF14837;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 114834 for detecting SNP TSC0028759.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPiG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1; SEQ ID NO 114834; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 1 Other;
SQ
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 GGTGGAGGT 60
DB 12 GGTGGAGGT 3
XX
XX
XX RESULT 301
ABF21338
ID ABF21338 standard; DNA; 13 BP.
XX
XX ABF21338;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 121335 for detecting SNP TSC0030310.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPiG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1; SEQ ID NO 121335; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 1 Other;
SQ

```

Query Match          15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches      10; Conservative      1; Mismatches      1; Indels      0; Gaps      0;

OY           52 GTTGAGGTTTC 63
   |||||
DB            2 GTTGAAGGTCT 13

RESULT 302
ABF21339/C
ID ABF21339 standard; DNA; 13 BP.
AC ABF21339;
DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 121336 for detecting SNP TSC0030310.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KI central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
PD 18-OCT-2001.
PF 06-APR-2001; 2001WO-IB000713.
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
BS Claim 1; SEQ ID NO 121336; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcc_sequences
CX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 1 Other;

Query Match          15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches      10; Conservative      1; Mismatches      1; Indels      0; Gaps      0;

OY           52 GTTGAGGTTTC 63
   |||||
DB            12 GTTGAAGGTCT 1

RESULT 303
ABF93539/C
ID ABF93539 standard; DNA; 13 BP.
```

XX	ABP93539;
AC	22-FEB-2002 (first entry)
XX	
DT	
XX	
DE	Oligonucleotide SEQ ID NO 193536 for detecting SNP TSC0047609.
XX	
XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
FN	
XX	18-OCT-2001.
PD	
XX	06-APR-2001; 2001WO-IB000713.
PF	
XX	07-APR-2000; 2000DE-01019173.
PR	
XX	(EPIG-) EPIGENOMICS AG.
PA	
PI	Olek A, Piepenbrock C, Berlin K,
XX	WPI, 2001-657177/75.
DR	
XX	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 193536; 29pp + Sequence Listing; German.
XX	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG9989, ABH00010-ABP9989, ABH00010-ABH9989 and AH00010-ABH82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	
SQ	Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
	Query Match 15.4%; Score 10; DB 1; Length 13;
	Best Local Similarity 100.0%; Pred. No. 2.3e+02;
	Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	10 TGGAAATTGGA 19
DB	11 TGGAAATTGGA 2
	RESULT 304
	ABH36931/C
ID	ABH36931 standard; DNA; 13 BP.
XX	
AC	ABH36931;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 236508 for detecting SNP TSC00000091.
XX	
XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 236908; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGGAGGTT 61
XX |||||
DB 10 GTTGGAGGTT 1
XX
RESULT 305
ABH42920
ID ABH42920 standard; DNA; 13 BP.
XX
AC ABH42920;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 242897 for detecting SNP TSC0000705.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 242897; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGGAGGTT 61
XX |||||
DB 1 GTTGGAGGTT 10
XX
RESULT 306
ABH6665/C
ID ABH6665 standard; DNA; 13 BP.
XX
AC ABH6665;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 266642 for detecting SNP TSC0064607.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 266642; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 1 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 49 GGGGTGAGGT 60
 12 GAGGTGAGGT 1

RESULT 307
 ABC08157/c
 ID ABC08157 standard; DNA; 13 BP.
 AC ABC08157;
 XX
 XX
 DT 20-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide SEQ ID NO 8148 for detecting SNP TSC0002280.
 XX
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PD 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 8148; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 6 C; 1 G; 2 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 52 GTTGAGGTT 61
 11 GTTGAGGTT 2

RESULT 308
 ABF21343/c
 ID ABF21343 standard; DNA; 13 BP.
 AC ABF21343;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide SEQ ID NO 121340 for detecting SNP TSC0030310.
 XX
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PD 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 121340; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH99989
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 1 Other;

QY 52 GTTGAGGTTTC 63
 12 GTTGAGGTTCT 1

RESULT 309
 ABF24944
 ID ABF24944 standard; DNA; 13 BP.
 AC ABF24944;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 XX

```
DE Oligonucleotide SEQ ID NO 124941 for detecting SNP TSC0031231.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 124941; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 49 GGGGTTGGAG 58
XX 4 GGGGTTGGAG 13
XX
XX
XX RESULT 310
XX ABF52229/c
XX ID ABF52229 standard; DNA; 13 BP.
XX
XX AC ABF52229;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 152226 for detecting SNP TSC0038463.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
```

```
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 152226; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;
SQ
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX
XX 52 GTTGAGGTTTC 63
XX 12 GTTGGAGGTTT 1
XX
XX
XX RESULT 311
XX ABH10859/c
XX ID ABH10859 standard; DNA; 13 BP.
XX
XX AC ABH10859;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 210836 for detecting SNP TSC0051461.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

PS Claim 1; SEQ ID NO 210836; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 53 TTGGAGCTTT 62
 |||||
 12 TTGGAGCTTT 3
 Db
 RESULT 312
 ABH12399/C
 ID ABH12399 standard; DNA; 13 BP.
 XX
 AC ABH12399;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 212376 for detecting SNP TSC0051732.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 212376; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 GGTTCGAGCT 60
 |||||
 13 GGTTCGAGCT 4
 Db
 RESULT 313
 ABH41476
 ID ABH41476 standard; DNA; 13 BP.
 XX
 AC ABH41476;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 241453 for detecting SNP TSC001145.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 241453; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB:00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 10 TCGAATTGGA 19
 |||||
 1 TCGAATTGGA 10
 Db

```
RESULT 314
ABF14180
ID ABF14180 standard; DNA; 13 BP.
XX
XX
AC ABF14180;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 114177 for detecting SNP TSC0028568.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPiG-) EPIGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 114177; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;
XX
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGGTTT 62
XX |||||||
XX 2 TTGGAGGTTT 11
XX
XX
RESULT 315
ABC66873/c
ID ABC66873 standard; DNA; 13 BP.
XX
XX
AC ABC66873;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 66890 for detecting SNP TSC0017525.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPiG-) EPIGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 66890; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 51 GGTGGAGGT 60
XX |||||||
XX 12 GGTGGAGGT 3
XX
XX
RESULT 316
ABF39154
ID ABF39154 standard; DNA; 13 BP.
XX
XX
AC ABF39154;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 139151 for detecting SNP TSC0034855.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPiG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 139151; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGGAGGTTT 62
||| ||| |||
Db 2 GGTGGGGGTTT 13
XX
RESULT 317
ID ABF93015/c
XX ABF93015 standard; DNA; 13 BP.
XX
XX ABF93015;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 193012 for detecting SNP TSC0047481.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WPI; 2001-657177/75.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 193012; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGGTTT 62
||| ||| |||
Db 13 TTGGAGGTTT 4
XX
RESULT 318
ID ABF52057/c
XX ABF52057 standard; DNA; 13 BP.
XX
XX ABF52057;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 152054 for detecting SNP TSC0038422.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WPI; 2001-657177/75.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 152054; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;

```

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGAGGTTT 62
   |||||
   |||||
Db 12 TTGGAGTTT 3

RESULT 319
ABH14634
ID ABH14634 standard; DNA; 13 BP.
AC ABH14634;
XX
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 214611 for detecting SNP TSC0052224.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 214611, 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 GGGGTTGGAG 58
   |||||
   |||||
Db 4 GGGGTTGGAG 13

RESULT 320
ABH59465/C
ID ABH59465 standard; DNA; 13 BP.
XX
XX ABH59465;
AC

```

```

XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 259442 for detecting SNP TSC0063013.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 259442; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGAATGGAATT 16
   |||||
   |||||
Db 12 TGGATGGAATT 1

RESULT 321
ABC68983/C
ID ABC68983 standard; DNA; 13 BP.
AC ABC68983;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 69000 for detecting SNP TSC0017967.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

```

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 69000; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 10 TGGAAATTGCA 19
XX |||||
XX 11 TGGAAATTGCA 2
XX
XX
XX RESULT 322
XX ABF29457/C
XX ID ABF29457 standard; DNA; 13 BP.
XX
XX AC ABF29457;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 129454 for detecting SNP TSC0032391.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

```

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 129454; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 50 GGGTTGGAGG 59
XX |||||
XX 12 GGGTTGGAGG 3
XX
XX
XX RESULT 323
XX ABF96458
XX ID ABF96458 standard; DNA; 13 BP.
XX
XX AC ABF96458;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 196455 for detecting SNP TSC0008585.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 196455; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX

```

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
|||||
DB 4 TGGGGTTGGA 13

RESULT 324
ABH27160
ID ABH27160 standard; DNA; 13 BP.

AC ABH27160;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 227137 for detecting SNP TSC0055396.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPig-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 227137; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTC 63
|||||

DB 2 GTTGAGGTTT 13

RESULT 325

ID ABC74005/C

AC ABC74005;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 74022 for detecting SNP TSC0019042.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPig-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 74022; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 10 C; 0 G; 1 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGT 60
|||||
DB 12 GGGGTTGAGGY 1

RESULT 326

ID ABC53077/C

AC ABC53077;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 53094 for detecting SNP TSC0014670.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPig-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 53094; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 53 TTGGAGCTTT 62
 Db 12 TTGGAGCTTT 3
 XX
 RESULT 327
 ABC08543/C
 ID ABC08543 standard; DNA; 13 BP.
 XX
 AC ABC08543;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 8534 for detecting SNP TSC0002341.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

XX
 PA (EPig-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 8534; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GGGTTGGAGG 59
 Db 11 GGGTTGGAGG 2
 XX
 RESULT 328
 ABF93014
 ID ABF93014 standard; DNA; 13 BP.
 XX
 AC ABF93014;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 193011 for detecting SNP TSC0047481.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPig-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 193011; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGAGGCTT 62
|||||||
1 TTGAGGCTT 10

RESULT 329

ID ABH16776 standard; DNA; 13 BP.

XX ABH16776;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 216753 for detecting SNP TSC0052685.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

CC Claim 1; SEQ ID NO 216753; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TCGAATTGGA 19
|||||||
4 TCGAATTGGA 13

RESULT 330

ID ABC08542 standard; DNA; 13 BP.

XX ABC08542;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 8533 for detecting SNP TSC0002341.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

CC Claim 1; SEQ ID NO 8533; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GGGTTGAGG 59
|||||||
3 GGGTTGAGG 12

RESULT 331

ABC08550

```

ID ABC88550 standard; DNA; 13 BP.
XX
AC ABC88550;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 88567 for detecting SNP TSC0022253.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 88567; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 7 GAATGAATT 16
| | | | | | |
| | | | | | |
Db 1 GAATGAATT 10
XX
RESULT 332
ABF93538
ID ABF93538 standard; DNA; 13 BP.
XX
AC ABF93538;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 193535 for detecting SNP TSC0047609.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX

```

```

XX
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 193535; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 10 TCGAATTGCA 19
| | | | | | |
| | | | | | |
Db 3 TCGAATTGCA 12
XX
RESULT 333
ABF73194
ID ABF73194 standard; DNA; 13 BP.
XX
AC ABF73194;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173191 for detecting SNP TSC0043135.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 173191; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 48 TTGGGTTTGA 57
DB 3 TTGGGTTTGA 12
XX
RESULT 334
ABH10858
ID ABH10858 standard; DNA; 13 BP.
XX
AC ABH10858;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 210835 for detecting SNP TSC0051461.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 210835; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGTTT 62
DB 2 TTGGAGTTT 11
XX
RESULT 335
ABF60991/C
ID ABF60991 standard; DNA; 13 BP.
XX
XX ABF60991;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 160988 for detecting SNP TSC0040537.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 160988; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY	53	TTGGAGGTTT	62
DB	13	TTGGAGGTTT	4
RESULT 336			
ID	ABC74004	standard; DNA; 13 BP.	
XX	ABC74004;		
XX	21-FEB-2002	(first entry)	
DE	Oligonucleotide SEQ ID NO 74021 for detecting SNP TSC0019042.		
XX			
XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;		
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;		
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic;		
XX			
OS	Homo sapiens.		
XX			
PN	WO200177384-A2.		
PD	18-OCT-2001.		
XX			
PE	06-APR-2001; 2001WO-1B000713.		
PR	07-APR-2000; 2000DE-01019173.		
XX			
PA	(EPIG-) EPIGENOMICS AG.		
PI	Olek A. Piepenbrock C, Berlin K;		
DR	WPI; 2001-657177/75.		
XX			
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is		
PT	designed to detect single-nucleotide polymorphisms and cytosine		
PT	methylation status.		
XX			
XX			
XX	Claim 1; SEQ ID NO 74021; 29bp + Sequence Listing; German.		
XX			
CC	This invention describes novel oligonucleotide primers or peptide nucleic		
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)		
CC	and cytosine methylation status in chemically pretreated genomic DNA. The		
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a		
CC	range of diseases including immune system, gastrointestinal, respiratory,		
CC	central nervous system, cardiovascular and metabolic disorders. The		
CC	oligonucleotides are also used for detecting cell type differentiation. ABC00010		
CC	-ABC09989, ABF00010-ABF09989, ABH00010-ABH09989 and ABI00010-ABI02073		
CC	represent the oligomers described in the invention. NOTE: The sequence		
CC	data for this patent did not form part of the printed specification, but		
CC	was obtained in electronic format from WIPO at		
CC	ftp.wipo.int/pub/published_pct_sequences		
XX			
XX	Sequence 13 BP; 1 A; 0 C; 10 G; 1 T; 0 U; 1 Other;		
QY			
Query Match	15.4%;	Score 10;	DB 1; Length 13;
Best Local Similarity	83.3%;	Pred. No. 2.3e+02;	
Matches 10;	Conservative 1;	Mismatches 1;	Indels 0; Gaps 0
OY	49	GGGGTTGGAGCT	60
DB	2	GGGGGTGGAGCT	13
RESULT 337			
ID	ABF02806	standard; DNA; 13 BP.	
XX	ABF02806;		
XX	21-FEB-2002	(first entry)	
XX			

XX	Oligonucleotide SEQ ID NO 102803 for detecting SNP TSC0025690.
DE	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	(EPIG-) EPIDEMIOLOGY AG.
PA	
PI	Olek A, Piepenbrock C, Berlin K;
DR	WI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PS	
PS	Claim 1; SEQ ID NO 102803; 29pp + Sequence Listing; German.
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AH000010-AH182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
	Query Match 15.4%; Score 10; DB 1; Length 13;
	Best Local Similarity 100.0%; Pred. No. 2.3e+02;
	Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	53 TTGGAGGTTT 62
DB	2 TTGGAGGTTT 11
RESULT 338	
ABF14905/c	
ID	ABF14905 standard; DNA, 13 BP.
XX	
AC	ABF14905;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 114902 for detecting SNP TSC0028776.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
XX	

PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 114902; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 51 GGTTCGAGGT 60
DB 11 GGTTCGAGGT 2
XX
RESULT 339
ABCI6840
ID ABCI6840 standard; DNA; 13 BP.
XX
AC ABCI6840;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16847 for detecting SNP TSC0003657.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 16847; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGAGGTTT 62
DB 1 TTGAGGTTT 10
XX
RESULT 340
ABH27161/C
ID ABH27161 standard; DNA; 13 BP.
XX
AC ABH27161;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 227138 for detecting SNP TSC0055396.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 227138; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

Sequence 13 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTC 63
 |||||
 DB 12 GTTGGGTTT 1

RESULT 341

ABH27162
 ID ABH27162 standard; DNA; 13 BP.

AC ABH27162;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 227139 for detecting SNP TSC0055396.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 227139; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTC 63
 |||||
 DB 2 GTTGGGTTT 13

RESULT 342
 ABF52056
 ID ABF52056 standard; DNA; 13 BP.

AC ABF52056;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 152053 for detecting SNP TSC0038422.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 152053; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGAGGTTT 62
 |||||
 DB 2 TTGAGGTTT 11

RESULT 343

ABZ58187
 ID ABZ58187 standard; DNA; 13 BP.

AC ABZ58187;

XX 22-APR-2003 (first entry)

DE Thrombin binding aptamer.

XX Thrombin; blood clotting; thrombosis; thrombolytic; anticoagulant;
 KM cerebroprotective; cardiant; antiinflammatory; gene therapy; aptamer; ss.

```

XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT misc_difference 7
XX FT /*tag= a
XX FT /note= "N represents a sequence of 2-5 nucleotides"
XX PN WO2003002592-A1.
XX PD 09-JAN-2003.
XX PF 28-JUN-2002; 2002WO-AU000853.
XX PR 29-JUN-2001; 2001AU-00006041.
XX PA (UNIX ) UNISEARCH LTD.
XX PI King GC;
XX PS WPI; 2003-210238/20.
XX DR
XX PT New aptamer for treating and/or preventing thrombosis, stroke, myocardial
XX PT infarction, respiratory failure, inflammation, cancer or neural disease,
XX PT comprises a circular oligonucleotide defining one to four target binding
XX PT regions.
XX PS Disclosure; Page 3; 55pp; English.
XX CC The present sequence is an example of a known thrombin binding aptamer
XX CC used as an antithrombotic agent. The invention relates to novel cyclic
XX CC thrombin inhibitor aptamers (see AB258178-85) that include thrombin
XX CC binding quadruplex regions (see AB258177). These aptamers are generally
XX CC better inhibitors of thrombin in serum than their linear counterparts,
XX CC show improved stability in serum and are more stable to nuclease. They
XX CC are used in claimed methods of treating thrombosis, of preventing or
XX CC reducing coagulation of blood or blood-derived products, and of capturing
XX CC leucocytes from a physiological fluid. They can also be used to prevent
XX CC thrombosis, to prevent and/or treat stroke, myocardial infarction,
XX CC respiratory failure, inflammatory disorders, cancer or its metastasis and
XX CC neural disease, and in conjunction with tissue and/or organ transplants
XX CC and/or xenotransplants, particularly in relation to vascular grafts
XX CC
XX SQ Sequence 13 BP; 0 A; 0 C; 8 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No.2.3e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 51 GGTGGAGGTT 61
XX ||||| |||||
XX 1 GGTGGAGGTT 11
XX
XX Db
XX
XX RESULT 344
XX AAD19397
XX ID AAD19397 standard; DNA; 13 BP.
XX AC AAD19397;
XX XX
XX DT 18-DEC-2001 (first entry)
XX XX
XX DE Partial pRSETC-NFIL6 vector #2 to construct mutated C/EBPbeta-1 vector.
XX XX
XX CC CCAAT/enhancer binding protein; C/EBPbeta; transcription factor;
XX KW interleukin; IL; p20; inflammation; adult respiratory distress syndrome;
XX KW allergic rhinitis; arthritis; bronchitis; bronchopulmonary dysplasia;
XX KW cystic fibrosis; extensive allergic alveolitis; anti-inflammatory;
XX KW idiopathic pulmonary fibrosis; interstitial lung disease; anti-allergic;
XX KW inflammatory bowel disease; respiratory viral infection; anti-arthritis;
XX KW anti-asthma; intestinal; antiviral; ds.
XX XX
XX OS Unidentified.

```

```

XX PN WO200160320-A2.
XX PD 23-AUG-2001.
XX PF 20-FEB-2001; 2001WO-US005578.
XX PR 18-FEB-2000; 2000US-0183584P.
XX PA (UYVA-) UNIT VANDERBILT.
XX PI Brigham KU, Stecenko AA, Sealy L;
XX DR WPI; 2001-581897/65.
XX PT Treating inflammation, particularly of the lung, by increasing activity
XX PT of p20, the beta3-isoform of CCAAT/enhancer binding protein.
XX PS Example 6; Fig 11D; 20pp; English.
XX CC The present sequence is a partial pRSETC-NFIL6 vector which is used for
XX CC constructing epitope tagged CCAAT/Enhancer Binding Protein (C/EBP)beta-1
XX CC retroviral vector with a mutation in the C/EBPbeta-2 translation
XX CC initiation site. The C/EBPbeta is a transcription factor which is
XX CC identified as being critical for maximal interleukin (IL)-6 and IL-8
XX CC expression. The isoforms of C/EBPbeta are C/EBPbeta-1, C/EBPbeta-2 and
XX CC C/EBPbeta-3 (referred as p20). The p20 isoform of C/EBPbeta is useful for
XX CC treating inflammation, adult respiratory distress syndrome, allergic
XX CC rhinitis, arthritis, bronchitis, bronchopulmonary dysplasia, cystic
XX CC fibrosis, extensive allergic alveolitis, idiopathic pulmonary fibrosis,
XX CC inflammatory bowel disease, interstitial lung disease and respiratory
XX CC viral infection
XX
XX SQ Sequence 13 BP; 4 A; 2 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No.2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 9 ATGGAATTGACG 21
XX ||||| |||||
XX 1 ATGGAATTGCGCA 13
XX
XX Db
XX
XX RESULT 345
XX ABR05600
XX ID ABR05600 standard; DNA; 13 BP.
XX AC ABR05600;
XX XX
XX DT 21-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide SEQ ID NO 105597 for detecting SNP TSC0026469.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.

```


XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 105597; 29bp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 49 GGGGTTGGAGTT 61
 DB 1 GGAGTTGAGGTT 13
 RESULT 346
 ABC06574
 ID ABC06574 standard; DNA; 13 BP.
 XX
 AC ABC06574;
 XX
 DT 20-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 6565 for detecting SNP TSC002008.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 6565; 29bp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 29 AGAAGGAAAGAA 41
 DB 1 AAAAAGAAAGAA 13
 RESULT 347
 ABC63815
 ID ABC63815 standard; DNA; 13 BP.
 XX
 AC ABC63815;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 63832 for detecting SNP TSC0016855.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 63832; 29bp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 10 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY      26 CCAAGACGAGAA 38
DB      1 CCAAAAACAAAA 13

RESULT 348
ABF16688
ID      ABF16688 standard; DNA; 13 BP.
AC      ABF16688;
XX
XX
XX      21-FEB-2002 (first entry)
DE      Oligonucleotide SEQ ID NO 116685 for detecting SNP TSC0029195.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 116685; 29bp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 0 A; 1 C; 6 G; 6 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      15.1%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX      Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      44 TTGCTGGGTTGG 56
DB      1 TTGTTGGGTTGG 13

RESULT 349
ABF69512
ID      ABF69512 standard; DNA; 13 BP.
AC      ABF69512;
XX
XX
XX      22-FEB-2002 (first entry)
XX

```

```

DE      Oligonucleotide SEQ ID NO 169509 for detecting SNP TSC0042344.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 169509; 29bp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      15.1%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX      Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      49 GGGGTTGGAGGTT 61
DB      1 GGAGTTAGAGGTT 13

RESULT 350
ABF69513/C
ID      ABF69513 standard; DNA; 13 BP.
AC      ABF69513;
XX
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 169510 for detecting SNP TSC0042344.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX

```

```
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 169510; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
Db 13 GGAGTTAGAGGTT 1
XX
RESULT 351
ABH00238
ID ABH00238 standard; DNA; 13 BP.
XX
AC ABH00238;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200215 for detecting SNP TSC0049265.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

```
PS Claim 1; SEQ ID NO 200215; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 1 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 50 GGGTTGGAGGTTT 62
Db 1 GGGTTGGAGGTTT 13
XX
RESULT 352
ABC54295/c
ID ABC54295 standard; DNA; 13 BP.
XX
AC ABC54295;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 54312 for detecting SNP TSC0014910.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 54312; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
```

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 49 GGGGTTGAGGTT 61
 DB 13 GAGGTCGAGGTT 1

RESULT 353
 ABF05602
 ID ABF05602 standard; DNA; 13 BP.
 AC ABF05602;
 XX
 DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 105599 for detecting SNP TSC0026469.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PI WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PS (EPIG-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 105599; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 1 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 49 GGGGTTGAGGTT 61
 DB 1 GGAGTCGAGGTT 13

RESULT 354
 ABC31788
 ID ABC31788 standard; DNA; 13 BP.
 XX
 AC ABC31788;
 XX
 DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 31805 for detecting SNP TSC0009913.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PI WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PS (EPIG-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 31805; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 45 TGCTGGGCTTGA 57
 DB 1 TGTTGGGCTTGA 13

RESULT 355
 ABC11500
 ID ABC11500 standard; DNA; 13 BP.
 XX
 AC ABC11500;
 XX
 DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 11499 for detecting SNP TSC0002800.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 11499; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 1 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 44 TTGCTGGGGTTGG 56
XX | | | | | | | |
XX 1 TGCGCGGGGTTGG 13
XX
RESULT 356
ABC1501/c
ID ABC1501 standard; DNA; 13 BP.
XX
XX ABC1501;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 11500 for detecting SNP TSC0002800.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 11500; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 44 TTGCTGGGGTTGG 56
XX | | | | | | | |
XX 13 TGCGCGGGGTTGG 1
XX
RESULT 357
ABC37879/c
ID ABC37879 standard; DNA; 13 BP.
XX
XX ABC37879;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 37896 for detecting SNP TSC0011764.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 37896; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SO Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTTT 62
DB 13 GGGTTGAGGTTT 1

RESULT 358
ABH00234
ID ABH00234 standard; DNA; 13 BP.
XX
AC ABH00234;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200211 for detecting SNP TSC0049265.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 200211; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

SO Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTTT 62
DB 1 GGGTTGAGGTTT 13

RESULT 359
ABF65172
ID ABF65172 standard; DNA; 13 BP.
XX
AC ABF65172;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 165169 for detecting SNP TSC0041424.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 165169; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

SO Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGTTGAGGTTT 61
DB 1 GGGTTGAGGTTT 13

RESULT 360
ABH62562/C
ID ABH62562 standard; DNA; 13 BP.
XX
AC ABH62562;
XX

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 75172; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 21 ATAGCCCAAGAAC 33
Db 1 ATACCAATATAC 13
|||||
|

RESULT 363
ABC8518
ID ABC8518 standard; DNA; 13 BP.
XX
XX ABC8518;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 58535 for detecting SNP TSC0015706.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 58535; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TTTCGAGTGA 13
Db 1 TTTCGAGTGA 13
|||||
|

RESULT 364
ABC11401/C
ID ABC11401 standard; DNA; 13 BP.
XX
XX ABC11401;
XX
XX 20-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 11400 for detecting SNP TSC002788.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11400; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GCGTTGAGCTTT 62
|||||


```

Db      13 GGGTAGGAGGTGT 1
RESULT 365
ID      ABF35262
XX      ABF35262 standard; DNA; 13 BP.
XX      ABF35262;
AC      ABF35262;
XX      21-FEB-2002 (first entry)
XX      21-FEB-2002 (first entry)
DE      Oligonucleotide SEQ ID NO 135259 for detecting SNP TSC0033738.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WPI; 2001-657177/75.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIC-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX      Claim 1; SEQ ID NO 135259; 29bp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
SQ      Query Match      15.1%; Score 9.8; DB 1; Length 13;
        Best Local Similarity 84.6%; Pred. No. 2.4e+02;
        Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      52 GTTGAGGTTTCA 64
        |||||
        1 GTTAGGAGTTTTA 13

```

```

KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WPI; 2001-657177/75.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIC-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX      Claim 1; SEQ ID NO 139899; 29bp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
SQ      Query Match      15.1%; Score 9.8; DB 1; Length 13;
        Best Local Similarity 84.6%; Pred. No. 2.4e+02;
        Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      48 TTGGGTTGAGGT 60
        |||||
        1 TTGGGTTGAGGT 13

```

```

RESULT 366
ID      ABF39902
XX      ABF39902 standard; DNA; 13 BP.
XX      ABF39902;
AC      ABF39902;
XX      21-FEB-2002 (first entry)
XX      21-FEB-2002 (first entry)
DE      Oligonucleotide SEQ ID NO 139899 for detecting SNP TSC0035033.
XX

```

```

RESULT 367
ID      ABH33027/C
XX      ABH33027 standard; DNA; 13 BP.
XX      ABH33027;
AC      ABH33027;
XX      22-FEB-2002 (first entry)
XX      22-FEB-2002 (first entry)
DE      Oligonucleotide SEQ ID NO 233004 for detecting SNP TSC0056853.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WPI; 2001-657177/75.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX

```

```
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 233004; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 46 GCTGGGGTTTGAG 58
Db 13 GTTGGGGTTTGAG 1
XX
RESULT 368
ABH10963/c
ID ABH10963 standard; DNA; 13 BP.
XX
XX ABH10963;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 210940 for detecting SNP TSC0051481.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 210940; 29pp + Sequence Listing; German.
XX
```

```
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 46 GCTGGGGTTTGAG 58
Db 13 GTTGGGGTTTGAG 1
XX
RESULT 369
ABH38624
ID ABH38624 standard; DNA; 13 BP.
XX
XX ABH38624;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 238601 for detecting SNP TSC0001527.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 238601; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
```

SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 5 TGGATGGAATTG 17
 DB 1 TGGAGGGGAATTG 13
 RESULT 370
 ABH15566
 ID ABH15566 standard; DNA; 13 BP.
 AC ABH15566;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 215543 for detecting SNP TSC0052427.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 215543; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABCG9989, ABP00010-ABP99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 6 GGAATGGAATTG 18
 DB 1 GGAATGCTTTGG 13
 RESULT 371
 ABH41660/c

ID ABH41660 standard; DNA; 13 BP.
 XX
 AC ABH41660;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 241637 for detecting SNP TSC058921.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 241637; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABCG9989, ABP00010-ABP99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 32 ACAGAAAGAACT 44
 DB 13 ACATATAATCACT 1
 RESULT 372
 ABH42926
 ID ABH42926 standard; DNA; 13 BP.
 XX
 AC ABH42926;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 242903 for detecting SNP TSC0000706.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

```
XX WO200177384-A2.
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 242903; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGCTT 61
Db 1 GGGGATGGAGCTT 13
XX
RESULT 373
ID ABH62128/c
XX ABH62128 standard; DNA; 13 BP.
XX
AC ABH62128;
XX
AT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 262105 for detecting SNP TSC0063595.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
```

```
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 262105; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 0 C; 5 G; 8 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 26 CCAGACACGAAA 38
Db 13 CCAGACACGAAA 1
XX
RESULT 374
ID ABC71135
XX ABC71135 standard; DNA; 13 BP.
XX
AC ABC71135;
XX
AT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 71152 for detecting SNP TSC0018445.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 71152; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
```

```

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      36 AAAGAACTTGCT 48
      ||| ||| ||| |||
      1 AAAAACCCTTACT 13

RESULT 375
ABC52081
ID ABC52081 standard; DNA; 13 BP.
XX
AC ABC52081;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 52098 for detecting SNP TSC0014495.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 52098; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      20 CATAGCCCAAGAA 32
      ||| ||| ||| |||
      1 CATAGCCCAATTA 13

RESULT 376
ABF05603/c
ID ABF05603 standard; DNA; 13 BP.
XX
AC ABF05603;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 105600 for detecting SNP TSC0026469.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 105600; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 1 G; 2 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      49 GGGGTTGAGGTT 61
      ||| ||| ||| |||
      13 GGAGTTCGAGGTT 1

RESULT 377
ABC06244/c
ID ABC06244 standard; DNA; 13 BP.
XX
AC ABC06244;
XX
DT 20-FEB-2002 (first entry)

```

```

XX  Oligonucleotide SEQ ID NO 6235 for detecting SNP TSC0001951.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K,
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 6235; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 0 A; 0 C; 4 G; 9 T; 0 U; 0 Other:
SQ
XX
XX  Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX  Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX  QY 25 CCCAAGAACAGAA 37
XX  13 CCCAAAAACAAA 1
XX
XX  RESULT 378
XX  ABF07731/c
XX  ID ABF07731 standard; DNA; 13 BP.
XX
XX  ABF07731;
XX
XX  21-FEB-2002 (first entry)
XX
XX  Oligonucleotide SEQ ID NO 107728 for detecting SNP TSC0026974.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX
XX

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K,
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 107728; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other:
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 49 GGGGTTGAGGTT 61
XX 13 GGGTTTCGAGGTT 1
XX
XX RESULT 379
XX ABC10826
XX ID ABC10826 standard; DNA; 13 BP.
XX
XX ABC10826;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 10817 for detecting SNP TSC0002699.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K,
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```

XX Claim 1; SEQ ID NO 10817; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGGTTGG 56
Db 1 TTGTTAGGGGTTGG 13
RESULT 380
ABC11400
ID ABC11400 standard; DNA; 13 BP.
XX
AC ABC11400;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 11399 for detecting SNP TSC0002788.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 11399; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GGGTTGAGGTTT 62
Db 1 GGGTTAGGAGGTTT 13
RESULT 381
ABF16686
ID ABF16686 standard; DNA; 13 BP.
XX
AC ABF16686;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116683 for detecting SNP TSC0029195.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 116683; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGGTTGG 56
Db 1 TTGTTAGGGGTTGG 13

RESULT 382
ABF20476
ID ABF20476 standard; DNA; 13 BP.
XX
AC ABF20476;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 120473 for detecting SNP TSC0030069.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 120473; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 7 GAATGGAATTGA 19
Db 1 GAATGTAATGGA 13
XX
RESULT 383
ABF39903/c
ID ABF39903 standard; DNA; 13 BP.
XX
AC ABF39903;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 139900 for detecting SNP TSC0030033.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 139900; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 48 TGGGCTTGGAGCT 60
Db 13 TTGGCTTGTAGCT 1
XX
RESULT 384
ABF67880
ID ABF67880 standard; DNA; 13 BP.
XX
AC ABF67880;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 167877 for detecting SNP TSC0006909.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX

XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 167877; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 44 TTGCTGGGGTTGG 56
Db 1 TTGCTGGGGTTGG 13
XX
RESULT 385
ABF98316
ID ABF98316 standard; DNA; 13 BP.
XX
AC ABF98316;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 198313 for detecting SNP TSC0048804.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 198313; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 5 TGGATGCAATTG 17
Db 1 TGGATGCAATTG 13
XX
RESULT 386
ABF98317/C
ID ABF98317 standard; DNA; 13 BP.
XX
AC ABF98317;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 198314 for detecting SNP TSC0048804.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 198314; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TGGATGGAATTG 17
Db 13 TGGATGGAATTG 1

RESULT 387
ABH29613/c
ID ABH29613 standard; DNA; 13 BP.
XX
AC ABH29613;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 229590 for detecting SNP TSC0055987.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 229590; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TGGATGGAATTG 17
Db 13 TGGATGGAATTG 1

RESULT 388
ABH57829/c
ID ABH57829 standard; DNA; 13 BP.
XX

AC ABH57829;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 257806 for detecting SNP TSC0062709.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 257806; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 GGGTTGGAAGTTT 62
Db 13 GGGTTGGAAGTTT 1

RESULT 389
ABH62563
ID ABH62563 standard; DNA; 13 BP.
XX
AC ABH62563;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 262540 for detecting SNP TSC0007733.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX

CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 36 AAGAGACCTGCT 48
DB 13 AAAAAACCTTACT 1

RESULT 392

ABG52080/C
ID ABC52080 standard; DNA; 13 BP.

AC ABC52080;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 52097 for detecting SNP TSC001495.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-1B000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 52097; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 20 CATAGCCCAAGAA 32

DB 13 CATAGCCCAATAA 1

RESULT 393

ABF04649/C
ID ABF04649 standard; DNA; 13 BP.

AC ABF04649;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 104646 for detecting SNP TSC0026161.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001WO-1B000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 104646; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 6 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTTT 62
DB 13 GGGTTGCTGTTT 1

RESULT 394

ABF07729/C
ID ABF07729 standard; DNA; 13 BP.

AC ABF07729;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 107726 for detecting SNP TSC0026974.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 107726; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 49 GGGGTTGGAGGTT 61
Db 13 GGGTTTGGAGTT 1
XX
RESULT 395
ABCI0827/c
ID ABCI0827 standard; DNA; 13 BP.
XX
AC ABCI0827;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 10818 for detecting SNP TSC0002699.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 10818; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 44 TTGCTGGGGTTGG 56
Db 13 TTGCTGGGGTTGG 1
XX
RESULT 396
ABCI6849/c
ID ABCI6849 standard; DNA; 13 BP.
XX
AC ABCI6849;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16856 for detecting SNP TSC0003661.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 16856; 29pp + Sequence Listing; German.
XX

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 28 AAGAACAGAAAGA 40
|||
13 AAAAAAGAAAGA 1

RESULT 397
ABF32796/C
ID ABF32796 standard; DNA; 13 BP.
XX
AC ABF32796;
XX
DT 21-FEB-2002 (first entry)
XX

Oligonucleotide SEQ ID NO 132793 for detecting SNP TSC0033116.
XX

SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX

WO200177384-A2.
XX

18-OCT-2001.
XX

06-APR-2001; 2001WO-IB000713.
XX

07-APR-2000; 2000DE-01019173.
XX

(EPIG-) EPIGENOMICS AG.
XX

Olek A, Piepenbrock C, Berlin K;
XX

WPI; 2001-657177/75.
XX

Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

Claim 1; SEQ ID NO 132793; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 33 CAGAAAGAACCTT 45
|||
13 CAAAAAAACCTT 1

RESULT 398
ABF32797
ID ABF32797 standard; DNA; 13 BP.
XX
AC ABF32797;
XX
DT 21-FEB-2002 (first entry)
XX

Oligonucleotide SEQ ID NO 132794 for detecting SNP TSC0033116.
XX

SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX

WO200177384-A2.
XX

18-OCT-2001.
XX

06-APR-2001; 2001WO-IB000713.
XX

07-APR-2000; 2000DE-01019173.
XX

(EPIG-) EPIGENOMICS AG.
XX

Olek A, Piepenbrock C, Berlin K;
XX

WPI; 2001-657177/75.
XX

Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

Claim 1; SEQ ID NO 132794; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 33 CAGAAAGAACCTT 45
|||
13 CAAAAAAACCTT 13

RESULT 399

```

ABF47357/c
ID ABF47357 standard; DNA; 13 BP.
XX
AC ABF47357;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 147354 for detecting SNP TSC0037222.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 147354; 29pp + Sequence Listing; German.
XX
PS This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 52 GTTGAGGTTTCA 64
Db 13 GTTGAGGTTTCA 1
XX
RESULT 400
ABF73692
ID ABF73692 standard; DNA; 13 BP.
XX
AC ABF73692;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173689 for detecting SNP TSC0043258.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 173689; 29pp + Sequence Listing; German.
XX
PS This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAATTGG 18
Db 1 GGAAGGAGTTGG 13
XX
RESULT 401
ABH33542
ID ABH33542 standard; DNA; 13 BP.
XX
AC ABH33542;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 233519 for detecting SNP TSC0010037.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 233519; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
SQ Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 10 TGAATTGCACAT 22
DB 1 TGTAAATTCGAAT 13
RESULT 402
ABF58451/C
XX ID ABF58451 standard; DNA; 13 BP.
XX
XX ABF58451;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 158448 for detecting SNP TSC0039892.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 158448; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 50 GGGTTGAGGTTT 62
DB 13 GGGTTGAAAGTTT 1
RESULT 403
ABH34278
XX ID ABH34278 standard; DNA; 13 BP.
XX
XX ABH34278;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 234255 for detecting SNP TSC0057164.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 234255; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
SQ Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGTTGGAGTT 61
 | | | | | | | | | |
 Db 1 GAGTTGGGGTT 13

RESULT 404
 ABF6466
 ID ABF6466 standard; DNA; 13 BP.
 XX
 AC ABF6466;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 186463 for detecting SNP TSC0045930.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 186463; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 0 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACGAAAGA 40
 | | | | | | | | | |
 Db 1 AAGAAAGAGAAGA 13

RESULT 405
 ABH16219/C
 ID ABH16219 standard; DNA; 13 BP.
 XX
 AC ABH16219;
 XX

DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 216196 for detecting SNP TSC0052577.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 216196; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 AAGAACGAAAGA 41
 | | | | | | | | | |
 Db 13 AAAATGAAAGAA 1

RESULT 406
 ABH62129
 ID ABH62129 standard; DNA; 13 BP.
 XX
 AC ABH62129;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 262106 for detecting SNP TSC0063595.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

```
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
PR (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 262106; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 8 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 26 CCAAGAACAGAAA 38
Db 1 CCAACACACACAAA 13
RESULT 407
ABC31789/c
ID ABC31789 standard; DNA; 13 BP.
XX ABC31789;
AC 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 31806 for detecting SNP TSC0009913.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
```

```
PT methylation status.
XX Claim 1; SEQ ID NO 31806; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 45 TGCTGGCGTTGGA 57
Db 13 TGTTGGGTTTGA 1
RESULT 408
ABF33180
ID ABF33180 standard; DNA; 13 BP.
XX ABF33180;
AC 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 133177 for detecting SNP TSC0033237.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 133177; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
```

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 48 TTGGGTTGAGGT 60
Db 1 TTGGGTTGCGGCT 13
RESULT 409
ID ABE67881/c
XX ABE67881 standard; DNA; 13 BP.
XX
AC ABE67881;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 167878 for detecting SNP TSC0006309.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 167878; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGCTTG 56
Db 13 TTGCTGGGCTTG 1

RESULT 410
ID ABH04581/c
XX ABH04581 standard; DNA; 13 BP.
XX
AC ABH04581;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 204558 for detecting SNP TSC0050176.
XX
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 204558; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 TTCTGGAATGAA 14
Db 13 TTTTGAATGTGA 1
RESULT 411
ID ABH05560
XX ABH05560 standard; DNA; 13 BP.
XX
AC ABH05560;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 205537 for detecting SNP TSC0050381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 205537; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 34 AGAAGAACCCTTG 46
|||
1 AGAAGAATTG 13
XX
Db 1 AGAAGAATTG 13
XX
RESULT 412
ABCT4671/C
ID ABC74671 standard; DNA; 13 BP.
XX
AC ABC74671;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 74688 for detecting SNP TSC0019191.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 74688; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 50 GGGTGGAGGTTT 62
|||
13 GGTGTGAGGTTT 1
XX
Db 13 GGTGTGAGGTTT 1
XX
RESULT 413
ABF04647/C
ID ABF04647 standard; DNA; 13 BP.
XX
AC ABF04647;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 104644 for detecting SNP TSC0026161.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 104644; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic


```
XX AC ABC60968;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 60985 for detecting SNP TSC0016246.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WP1; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 60985; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGTT 61
   ||| ||| ||| |||
Db 1 GGAGGTGAGGTT 13

RESULT 417
ABF20477/c
ID ABF20477 standard; DNA; 13 BP.
XX AC ABF20477;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 120474 for detecting SNP TSC0030069.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
```

```
EN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WP1; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 120474; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 7 GAATGGAATTGCA 19
   ||| ||| ||| |||
Db 13 GAATGTAATGCA 1

RESULT 418
ABF22178
ID ABF22178 standard; DNA; 13 BP.
XX AC ABF22178;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 122175 for detecting SNP TSC0030537.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WP1; 2001-657177/75.
XX DR
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 122175; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 5 TGGATGGAATTG 17
 Db 1 TTGATTGGAATTG 13
 DB
 RESULT 419
 ID ABF32116 standard; DNA; 13 BP.
 AC ABF32116;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 132113 for detecting SNP TSC0032971.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPig-) EPiGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 DR
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 132113; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 5 TGGATGGAATTG 17
 Db 1 TTGATTGGAATTG 13
 DB
 RESULT 420
 ID ABF39905 standard; DNA; 13 BP.
 AC ABF39905;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 139902 for detecting SNP TSC0035033.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPig-) EPiGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 DR
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 139902; 29bp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 TCGGGTGGAGT 60
 |||||
 DB 13 TCGGTTGTAGT 1

RESULT 421
 ABF73693/C
 ID ABF73693 standard; DNA; 13 BP.
 XX
 AC ABF73693;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 173690 for detecting SNP TSC0043258.
 XX
 DE

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 173690; 29bp + Sequence listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGAAATGGAATTGG 18
 |||||
 DB 13 GGAAAGGAGTTGG 1

RESULT 422
 ABH33543/C
 ID ABH33543 standard; DNA; 13 BP.
 XX
 AC ABH33543;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 233520 for detecting SNP TSC0010037.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 233520; 29bp + Sequence listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 10 TGAATTGGACAT 22
 |||||
 DB 13 TGTAAATGGAAAT 1

RESULT 423
 ABH10962
 ID ABH10962 standard; DNA; 13 BP.
 XX
 AC ABH10962;
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 210939 for detecting SNP TSC0051481.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX


```

XX 07-APR-2000; 2000DE-01019173.
PR (EPiG-) EPiGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 210939; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
SQ
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 46 GCTGGGGTTGAG 58
Db 1 GTTGGGGTTGAG 13
XX
RESULT 424
ABF62973/c
ID ABF62973 standard; DNA; 13 BP.
XX
AC ABF62973;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 162970 for detecting SNP TSC0040972.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```

```

PS Claim 1; SEQ ID NO 162970; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
SQ
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 5 TGGAAATGGAATTG 17
Db 13 TGAATGGAATTG 1
XX
RESULT 425
ABH15571/c
ID ABH15571 standard; DNA; 13 BP.
XX
AC ABH15571;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 215548 for detecting SNP TSC0052427.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 215548; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX

```

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 6 GGAATGGAATTGG 18

DB 13 GGAATGCGCTTGG 1

RESULT 426

ABH44502

ID ABH44502 standard; DNA; 13 BP.

AC ABH44502;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 244479 for detecting SNP TSC0059689.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 244479; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 9 A; 0 C; 4 G; 0 T; 0 U; 0 Other;

XX Query Match

XX Best Local Similarity 15.1%; Score 9.8; DB 1; Length 13;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 28 AAGAACAGAAACA 40

DB 1 AAGAAAGGAAAGA 13

RESULT 427

ABH62561

ID ABH62561 standard; DNA; 13 BP.

AC ABH62561;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 262538 for detecting SNP TSC0007733.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 262538; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

XX Query Match

XX Best Local Similarity 15.1%; Score 9.8; DB 1; Length 13;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 33 CAGAAAGACCTT 45

DB 1 CATTAATPACCTT 13

RESULT 428

ABC73212

ID ABC73212 standard; DNA; 13 BP.

AC ABC73212;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 73229 for detecting SNP TSC0018874.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 73229; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 49 GGGGTGAGGTT 61
Db 1 GGAGTTGAGTT 13
RESULT 429
ABC01962
ID ABC01962 standard; DNA; 13 BP.
XX
XX ABC01962;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 1953 for detecting SNP TSC0000769.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 1953; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 50 GGGGTGAGGTT 62
Db 1 GGAGTTGAGTT 13
RESULT 430
ABC60969/c
ID ABC60969 standard; DNA; 13 BP.
XX
XX ABC60969;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 60986 for detecting SNP TSC0016246.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 60986; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 13 GGAGGTGGAGGTT 1

RESULT 431

ABC61676
ID ABC61676 standard; DNA; 13 BP.

XX ABC61676;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 61693 for detecting SNP TSC0016406.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 61693; 29bp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 50 GGGTGGAGGTT 62
Db 1 GGGTGGAGGTT 13

RESULT 432

ABF31799/c
ID ABF31799 standard; DNA; 13 BP.

XX ABF31799;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 131796 for detecting SNP TSC0032899.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 131796; 29bp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 13 BP; 1 A; 3 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 29 AGAAGAGAAAGAA 41
Db 13 AGAATGAGAAAGAA 1

RESULT 433

ABF32795
ID ABF32795 standard; DNA; 13 BP.

XX ABF32795;

```
XX 21-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 132792 for detecting SNP TSC0033116.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 132792; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 33 CAGAAAGAACCTT 45
XX |||||
XX 1 CAAMAAACAACCTT 13
XX
RESULT 434
XX ABH22410
XX ID ABH22410 standard; DNA; 13 BP.
XX
XX ABH22410;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 222387 for detecting SNP TSC0054107.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WPI; 2001-657177/75.
XX
XX WO200177384-A2.
XX
```

```
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 222387; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 7 GAATGGAATTGGA 19
XX |||||
XX 1 GAATGGAATTGGA 13
XX
RESULT 435
XX ABH05561/C
XX ID ABH05561 standard; DNA; 13 BP.
XX
XX ABH05561;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 205538 for detecting SNP TSC0050381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX
```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 205538, 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP). The
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 34 AGAAGACCTTG 46
13 AGAAGACTTTTG 1
XX
Db 13 AGAAGACTTTTG 1
XX
RESULT 436
ABH34279/c
ID ABH34279 standard; DNA; 13 BP.
XX
AC ABH34279;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 234256 for detecting SNP TSC0057164.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 234256; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
13 GAGGTTGGGGGTT 1
XX
Db 13 GAGGTTGGGGGTT 1
XX
RESULT 437
ABH16293/c
ID ABH16293 standard; DNA; 13 BP.
XX
AC ABH16293;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216270 for detecting SNP TSC0052602.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 216270; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
13 GGGGTTGGAGGTT 1

```

DB      13 GGGCTTGGTGCTT 1

RESULT 438
ABH44503/C
ID      ABH44503 standard; DNA; 13 BP.
XX
AC      ABH44503;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 244480 for detecting SNP TSC0059689.
XX
XX      SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
FN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PE      06-APR-2001; 2001WO-1B000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI, 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
PS      Claim 1; SEQ ID NO 244480; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABE00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI62073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 0 A; 4 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0
XX
OY      28 AAGAACAGAAACA 40
XX      ||||| |||||
XX      13 AAGAAAGCAAGA 1
XX
RESULT 439
ABCT73213/C
ID      ABCT73213 standard; DNA; 13 BP.
XX
AC      ABCT73213;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 73230 for detecting SNP TSC0018874.
XX

```

KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200177384-A2.	
PD	18-OCT-2001.	
XX		
PF	06-APR-2001; 2001WO-IB000713.	
XX		
PR	07-APR-2000; 2000DE-01019173.	
XX		
PA	(EPIG-) EPIGENOMICS AG.	
PI	Olek A, Piepenbrock C, Berlin K;	
XX		
XX	WPI, 2001-657177/75.	
DR		
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX		
PS	Claim 1; SEQ ID NO 73230; 29pp + Sequence Listing; German.	
XX		
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC00010	
CC	-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX		
SO	Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;	
XX		
Query Match	15.1%; Score 9.8; DB 1; Length 13;	
Best Local Similarity	84.6%; Pred. No. 2.4e+02;	
Matches 11; Conservative	0; Mismatches 2; Indels 0; Gaps 0;	
OY	49 GGGGTTGGAGGTT 61	
Db	13 GGAGTTGGAGGTT 1	
RESULT 440		
ABC99215/C		
ID	ABC99215 standard; DNA; 13 BP.	
XX		
AC	ABC99215;	
XX		
DT	21-FEB-2002 (first entry)	
DE	Oligonucleotide SEQ ID NO 99232 for detecting SNP TSC0024650.	
XX		
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200177384-A2.	
XX		
PD	18-OCT-2001.	
XX		
PF	06-APR-2001; 2001WO-IB000713.	
XX		
PR	07-APR-2000; 2000DE-01019173.	

```

XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 99232; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGCTTGGAGTT 61
XX ||| ||| ||| |||
Db 13 GGGATTGGTGGTT 1
XX
XX RESULT 441
XX ID ABF04646 standard; DNA; 13 BP.
XX AC ABF04646;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 104643 for detecting SNP TSC0026161.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 104643; 29pp + Sequence Listing; German.
XX

```

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 0 C; 6 G; 7 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 50 GGGCTTGGAGTT 62
XX ||| ||| ||| |||
Db 1 GGGTTTGGTGGTT 13
XX
XX RESULT 442
XX ID ABC55719 standard; DNA; 13 BP.
XX AC ABC55719;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 55736 for detecting SNP TSC0015187.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 55736; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

```


SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 22 TAGCCCAAGACA 34
 1 TAAACCAAAACA 13
 Db
 RESULT 443
 ABF09481/c
 ID ABF09481 standard; DNA; 13 BP.
 AC ABF09481;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 109478 for detecting SNP TSC0027391.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 109478; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 48 TGGGGTTGAGGT 60
 13 TGAGGTGTGAGT 1
 Db
 RESULT 444
 ABC16848

ID ABC16848 standard; DNA; 13 BP.
 XX
 AC ABC16848;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 16855 for detecting SNP TSC0003661.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 16855; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 28 AAGAACGAAAGA 40
 1 AAAAAAGAAACA 13
 Db
 RESULT 445
 ABF17417
 ID ABF17417 standard; DNA; 13 BP.
 XX
 AC ABF17417;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 117414 for detecting SNP TSC0029372.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX WO200177384-A2.
 PN 18-OCT-2001.
 XX
 PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 117414; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 21 ATAGCCCAAGAC 33
 DB 1 ATATCCCAAAAC 13
 XX
 RESULT 446
 ABF32117/C
 ID ABF32117 standard; DNA; 13 BP.
 XX
 AC ABF32117;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 132114 for detecting SNP TSC0032971.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PI (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 132114; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 5 TGGAAATGGAATTG 17
 DB 13 TTGAATGAGATTG 1
 XX
 RESULT 447
 ABH21397/C
 ID ABH21397 standard; DNA; 13 BP.
 XX
 AC ABH21397;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 221374 for detecting SNP TSC0053878.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PI (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 221374; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

```
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 6 GGAAATGGAATTGG 18
DB 13 GGAAAGGGAATTGG 1
RESULT 448
ABF75985/C
ID ABF75985 standard; DNA; 13 BP.
XX
AC ABF75985;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 175982 for detecting SNP TSC0005690.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 175982; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 50 GGGTTGAGGCTTT 62
DB 13 GGGTTGGTGGTTT 1
RESULT 449
ABH38625/C
ID ABH38625 standard; DNA; 13 BP.
XX
AC ABH38625;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 238602 for detecting SNP TSC0001527.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 238602; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TGGAAATGGAATTG 17
DB 13 TGGAGGGAATTG 1
RESULT 450
ABG68819/C
ID ABG68819 standard; DNA; 13 BP.
XX
AC ABG68819;
XX
DT 21-FEB-2002 (first entry)
```

XX Oligonucleotide SEQ ID NO 68836 for detecting SNP TSC0017929.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPiGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 68836; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABR00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 3 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 48 TGGGGTTGGAGGT 60
DB 13 TGGGGGTGGGGGT 1
XX
XX
XX RESULT 451
XX ABC44906
XX ID ABC44906 standard; DNA; 13 BP.
XX
XX ABC44906;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 44923 for detecting SNP TSC0013136.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPiGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 44923; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABR00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
XX
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 29 AGAACGAAAGAA 41
DB 1 AGAAAGAAAGAAA 13
XX
XX
XX RESULT 452
XX ABC74670
XX ID ABC74670 standard; DNA; 13 BP.
XX
XX ABC74670;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 74687 for detecting SNP TSC0019191.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPiGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

XX PS Claim 1; SEQ ID NO 74687; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GGGTTGAGGTTT 62
Db 1 GGTGTGAGGTTT 13
XX
XX RESULT 453
XX ABF04648
ID ABF04648 standard; DNA; 13 BP.
XX
XX ABF04648;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 104645 for detecting SNP TSC0026161.
XX
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 104645; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 0 A; 1 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GGGTTGAGGTTT 62
Db 1 GGGTTGAGGTTT 13
XX
XX RESULT 454
XX ABC05436
ID ABC05436 standard; DNA; 13 BP.
XX
XX AC ABC05436;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 5427 for detecting SNP TSC0001821.
XX
XX DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 5427; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 49 GGGTTGAGGTTT 61
Db 1 GAGTTGAGGATT 13

```

RESULT 455
ABC05437/C
ID ABC05437 standard; DNA; 13 BP.
XX
AC ABC05437;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5428 for detecting SNP TSC0001821.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1, SEQ ID NO 5428; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 49 GGGGTTGAGGTT 61
XX | |||||
XX 13 GAGTTGAGAGAT 1
XX
XX RESULT 456
ABC06575/C
ID ABC06575 standard; DNA; 13 BP.
XX
XX ABC06575;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 6566 for detecting SNP TSC0002008.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX
XX

```

```

XX
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1, SEQ ID NO 6566; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 29 AGACAGAAAGAA 41
XX | || |||||
XX 13 AAAAAGAAAGAA 1
XX
XX RESULT 457
ABC58519/C
ID ABC58519 standard; DNA; 13 BP.
XX
XX ABC58519;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 58536 for detecting SNP TSC0015706.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX

```

XX Olek A, Piepenbrock C, Berlin K;
 XX MPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 58536; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 1 TTTCTGGAATGGA 13
 Db 13 TTTTGGAGTGA 1
 RESULT 458
 ABF09480
 ID ABF09480 standard; DNA; 13 BP.
 AC ABF09480;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 109477 for detecting SNP TSC0027391.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX MPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 109477; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 48 TGGGCTTGGAGCT 60
 Db 1 TGGAGTTTGAAGCT 13
 RESULT 459
 ABF16689/c
 ID ABF16689 standard; DNA; 13 BP.
 AC ABF16689;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 116686 for detecting SNP TSC029195.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX MPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 116686; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 6 C; 1 G; 0 T; 0 U; 0 Other;


```
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 173725; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 TTCTGGAATGGA 14
DB 1 TTATGTAAATGGA 13
XX
XX RESULT 463
XX ABC92814
XX ID ABC92814 standard; DNA; 13 BP.
XX
XX ABC92814;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 92831 for detecting SNP TSC0023215.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
```

```
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 92831; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GCGTTGAGGTTT 62
DB 1 GGGTAGGAGGTTT 13
XX
XX RESULT 464
XX ABC20850
XX ID ABC20850 standard; DNA; 13 BP.
XX
XX ABC20850;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 20867 for detecting SNP TSC0004238.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status..
XX
XX Claim 1; SEQ ID NO 20867; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 48 TGCGGTTGGAGT 60
DB 1 TAGGTTGGATGT 13

RESULT 465
ABCT3225/C
ID ABC73225 standard; DNA; 13 BP.

XX ABC73225;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 73242 for detecting SNP TSC0018875.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1, SEQ ID NO 73242; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 46 GCTGGGTTGGAG 58

DB 13 GCTGGGTTGGAG 1

RESULT 466
ABF31798
ID ABF31798 standard; DNA; 13 BP.

XX ABF31798;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 131795 for detecting SNP TSC0032899.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1, SEQ ID NO 131795; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 1 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 29 AGAACAGAAAGAA 41
DB 1 AGAATCGAAGAGA 13

RESULT 467
ABF32794/C
ID ABF32794 standard; DNA; 13 BP.

XX ABF32794;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 132791 for detecting SNP TSC0033116.

```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 132791; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 33 CAGAAAGAACCTT 45
Db 13 CAAAAACAACTT 1
RESULT 468
ABF33181/c
ID ABF33181 standard; DNA; 13 BP.
XX
XX ABF33181;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 133178 for detecting SNP TSC003237.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
```

```
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 133178; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 8 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 48 TGGCGTTGAGGT 60
Db 13 TTGCGTTGCGGCT 1
RESULT 469
ABF75984
ID ABF75984 standard; DNA; 13 BP.
XX
XX ABF75984;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 175981 for detecting SNP TSC0005690.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 175981; 29pp + Sequence Listing; German.
XX
```



```

ABF66699/c
ID ABF66699 standard; DNA; 13 BP.
XX
XX ABF66699;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 166696 for detecting SNP TSC0041746.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 166696; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX
XX 29 AGAATGACATTA 41
OY |||||
DB 13 AGAATGAAAAA 1
XX
XX
XX RESULT 473
XX ABH57530
XX ID ABH57530 standard; DNA; 13 BP.
XX
XX ABH57530;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 257507 for detecting SNP TSC0005086.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 257507; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX
XX 11 GGAATTGACATTA 23
OY |||||
DB 1 GGAATTGATATTA 13
XX
XX
XX RESULT 474
XX ABC75154/c
XX ID ABC75154 standard; DNA; 13 BP.
XX
XX ABC75154;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 75171 for detecting SNP TSC019290.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI

```

XX WPI, 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX

PS Claim 1; SEQ ID NO 75171, 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP, 2 A, 0 C, 4 G, 7 T, 0 U, 0 Other;

XX

XX

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

XX Matches 11, Conservative 0; Mismatches 2; Indels 0; Gaps 0.

XX

XX 21 ATAGCCCAAGAAC 33

XX ||| ||||| |||

XX 13 ATMACCAATAC 1

XX

XX

XX RESULT 475

XX ABF05601/C

XX ID ABF05601 standard; DNA; 13 BP.

XX

XX AC ABF05601;

XX

XX 21-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 105598 for detecting SNP TSC0026469.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIC-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

XX WPI, 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 105598; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP, 2 A, 0 C, 4 G, 7 T, 0 U, 0 Other;

XX

XX

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

XX Matches 11, Conservative 0; Mismatches 2; Indels 0; Gaps 0.

XX

XX 21 ATAGCCCAAGAAC 33

XX ||| ||||| |||

XX 13 ATMACCAATAC 1

XX

XX

XX RESULT 475

XX ABF05601/C

XX ID ABF05601 standard; DNA; 13 BP.

XX

XX AC ABF05601;

XX

XX 21-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 105598 for detecting SNP TSC0026469.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIC-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

XX WPI, 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 105598; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP, 2 A, 0 C, 4 G, 7 T, 0 U, 0 Other;

XX

XX

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

XX Matches 11, Conservative 0; Mismatches 2; Indels 0; Gaps 0.

XX

XX 21 ATAGCCCAAGAAC 33

XX ||| ||||| |||

XX 13 ATMACCAATAC 1

XX

XX

XX RESULT 475

XX ABF05601/C

XX ID ABF05601 standard; DNA; 13 BP.

XX

XX AC ABF05601;

XX

XX 21-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 105598 for detecting SNP TSC0026469.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIC-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

XX WPI, 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 105598; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 13 BP, 2 A, 0 C, 4 G, 7 T, 0 U, 0 Other;

XX

XX

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

XX Matches 11, Conservative 0; Mismatches 2; Indels 0; Gaps 0.

XX

XX 21 ATAGCCCAAGAAC 33

XX ||| ||||| |||

XX 13 ATMACCAATAC 1

XX

XX

XX RESULT 475

XX ABF05601/C

XX ID ABF05601 standard; DNA; 13 BP.

XX

XX AC ABF05601;

XX

XX 21-FEB-2002 (first entry)

XX

XX Oligonucleotide SEQ ID NO 105598 for detecting SNP TSC0026469.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIC-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

XX WPI, 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 105598; 29pp + Sequence Listing; German.

XX

XX This invention describes novel oligonucleotide primers or peptide nucle

CC	range of diseases including immune system, gastrointestinal, respiratory
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010-ABG9989, ABH00010-ABH9989, ABH00010-ABH9989 and ABH00010-ABH82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
Query Match	15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative	0; Mismatches 2; Indels 0; Gaps 0
OY	49 GGGTTGGAGTTC 61 13 GGAGTTTGAGGTT 1
Dn	
RESULT 76	
ABC55718/C	
ID	ABC55718 standard; DNA; 13 BP.
XX	
AC	ABC55718;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 55735 for detecting SNP TSC0015187.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
XX	
Pf	06-APR-2001; 2001MO-IB000713.
PR	07-APR-2000; 2000DB-01019173.
PA	(EPIG-) EPIDENOMICS AG.
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
XX	Claim 1; SEQ ID NO 55735; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010-
CC	ABG9989, ABH00010-ABH9989, ABH00010-ABH9989 and ABH00010-ABH82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
Query Match	15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 2.4e+02;

```

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 22 TAGCCCAAGACA 34
   |||||
Db 13 TAACCCAAAAACA 1

RESULT 477
ABF17416/C
ID ABF17416 standard; DNA; 13 BP.
XX
XX ABF17416;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 117413 for detecting SNP TSC0029372.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 117413; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 21 ATAGCCCAAGAC 33
   |||||
Db 13 ATATCCCAAAACA 1

RESULT 478
ABF31794
ID ABF31794 standard; DNA; 13 BP.
XX
XX ABF31794;
XX

```

```

DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 131791 for detecting SNP TSC0032899.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 131791; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 0 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 29 AGAACGAAAGAA 41
   |||||
Db 1 AGAATTCGAAAGAA 13

RESULT 479
ABF1795/C
ID ABF1795 standard; DNA; 13 BP.
XX
XX ABF1795;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 131792 for detecting SNP TSC0032899.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX

```

```

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 131792; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 29 AGAACAGAAAGAA 41
XX 13 AGAATTGAAAGAA 1
XX
XX RESULT 480
XX ID ABR39904 standard; DNA; 13 BP.
XX
XX ABR39904;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 139901 for detecting SNP TSC0035033.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine

```

```

PT methylation status.
XX
XX Claim 1; SEQ ID NO 139901; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 48 TGGGCTTGGAGGT 60
XX 1 TGGGTTTGGGT 13
XX
XX RESULT 481
XX ID ABH00239/C
XX ABH00239 standard; DNA; 13 BP.
XX
XX ABH00239;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 200216 for detecting SNP TSC0049265.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 200216; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence

```


CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 7 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTTT 62
DB 13 GGGTTGAGGTTT 1

RESULT 482

ABF50558
ID ABF50558 standard; DNA; 13 BP.

AC ABF50558;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 150555 for detecting SNP TSC0037990.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 150555; 29pp + Sequence listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TTTTGGAAATGA 13
DB 1 TTTTGGAAATGA 13

RESULT 483

ABH12784/c
ID ABH12784 standard; DNA; 13 BP.

AC ABH12784;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 212761 for detecting SNP TSC0051837.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 212761; 29pp + Sequence listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 20 CATAGCCCAAGA 32
DB 13 CATATCCCAAAA 1

RESULT 484

ABF88569/c
ID ABF88569 standard; DNA; 13 BP.

AC ABF88569;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 188566 for detecting SNP TSC0010549.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 188566; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 28 AGAGACGAGAAAGA 40
||| |||||
13 AATTAAGAAAGA 1
XX
Db
XX
RESULT 485
ABF65173/C
ID ABF65173 standard; DNA; 13 BP.
XX
AC ABF65173;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 165170 for detecting SNP TSC0041424.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 165170; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGAGGTT 61
||| |||||
13 GAGGTTGAGGTT 1
XX
Db
XX
RESULT 486
ABH15570
ID ABH15570 standard; DNA; 13 BP.
XX
AC ABH15570;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 215547 for detecting SNP TSC0052427.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 215547; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 6 GGAAATGGAAATTGG 18
1 GGAAATGGCGTTGG 13
Db
RESULT 487
ABH16218
ID ABH16218 standard; DNA; 13 BP.
XX
AC ABH16218;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216195 for detecting SNP TSC0052577.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001MO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 216195; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 29 AGAACAGAAAGAA 41
1 AAAATGAAAAGAA 13
Db
RESULT 488
ABH16292
ID ABH16292 standard; DNA; 13 BP.
XX
AC ABH16292;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216269 for detecting SNP TSC0052602.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001MO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 216269; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 49 GGGTTGGAGGTT 61
1 GGGTTGGGCGTT 13
Db
RESULT 489
ABH42927/C
ID ABH42927 standard; DNA; 13 BP.

```
XX AC ABH42927;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 242904 for detecting SNP TSC0000706.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 242904; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 49 GGGGTTGAGGTT 61
XX |||||
XX 13 GGGGATGAGGTT 1
XX
XX RESULT 490
XX ABH62560/c
XX ID ABH62560 standard; DNA; 13 BP.
XX AC ABH62560;
XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 262537 for detecting SNP TSC0007733.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX DR
```

```
PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 262537; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 33 CAGAAAGAACCTT 45
XX |||||
XX 13 CATAAATAACCTT 1
XX
XX RESULT 491
XX ABC68818
XX ID ABC68818 standard; DNA; 13 BP.
XX AC ABC68818;
XX
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 68835 for detecting SNP TSC0017929.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
```

```
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1, SEQ ID NO 68835; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 10 G; 3 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAGCT 60
   |||||
Db 1 TGGGGGTGGGGCT 13

RESULT 492
ABC34456
ID ABC34456 standard; DNA; 13 BP.
XX
AC ABC34456;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 34473 for detecting SNP TSC0010991.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1, SEQ ID NO 34473; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
```

```
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 AGACGAGAAAGAA 41
   |||||
Db 1 AAAAGGAAAGAA 13

RESULT 493
ABH21396
ID ABH21396 standard; DNA; 13 BP.
XX
AC ABH21396;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 221373 for detecting SNP TSC0053878.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1, SEQ ID NO 221373; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 6 GGATGGAATTGG 18
 DB 1 GGAAGGGAATTG 13

RESULT 494

ID ABH22411/C
 ID ABH22411 standard; DNA; 13 BP.

AC ABH22411;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 222388 for detecting SNP TSC0054107.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 222388; 29pp + Sequence listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 7 GAATGGAATTGGA 19

DB 13 GAATGGAATTGGA 1

RESULT 495

ID ABF75610
 ID ABF75610 standard; DNA; 13 BP.

AC ABF75610;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 175607 for detecting SNP TSC0043628.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 175607; 29pp + Sequence listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

XX Query Match 15.1%; Score 9.8; DB 1; Length 13;

XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;

XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 TTCTGGAATGGA 13

DB 1 TGCTGGAATGGA 13

RESULT 496

ID ABF75611/C
 ID ABF75611 standard; DNA; 13 BP.

AC ABF75611;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 175608 for detecting SNP TSC0043628.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 175608; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1 TTCTGGATGGA 13
XX | | | | | | | | | | | | | | |
XX 13 TGCTGGATGGA 1
XX
Db 13 TGCTGGATGGA 1
XX
RESULT 497
ABH04580
ID ABH04580 standard; DNA; 13 BP.
XX
AC ABH04580;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 204557 for detecting SNP TSC0050176.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

PS Claim 1; SEQ ID NO 204557; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 2 TTCTGGATGGA 14
XX | | | | | | | | | | | | | | |
XX 1 TTCTGGATGGA 13
XX
Db 1 TTCTGGATGGA 13
XX
RESULT 498
ABH12785
ID ABH12785 standard; DNA; 13 BP.
XX
AC ABH12785;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 212762 for detecting SNP TSC0051837.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 212762; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 20 CATAGCCCAAGAA 32
 DB 1 CATATCCCAAAA 13

RESULT 499
 ABC68985/C
 ID ABC68985 standard; DNA; 13 BP.
 XX
 AC ABC68985;

DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 69002 for detecting SNP TSC0017967.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 69002; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 GCTGGCGTTTGAG 58
 DB 13 GGTGGAGTTTGAG 1

RESULT 500

ABC73224
 ID ABC73224 standard; DNA; 13 BP.

XX ABC73224;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 73241 for detecting SNP TSC0018875.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 73241; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 GCTGGCGTTTGAG 58
 DB 1 GGTGGAGTTTGAG 13

RESULT 501

ABC54294
 ID ABC54294 standard; DNA; 13 BP.

XX ABC54294;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 54311 for detecting SNP TSC0014910.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.


```

XX OS Homo sapiens.
XX XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX CC Claim 1; SEQ ID NO 54311; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 49 GGGGTTGAGGTT 61
Db 1 GAGGCTGAGGTT 13
XX
RESULT 502
XX ABF67883/c
XX ID ABF67883 standard; DNA; 13 BP.
XX AC ABF67883;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 167880 for detecting SNP TSC0006909.
XX XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX CC Claim 1; SEQ ID NO 167880; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 7 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 44 TTGCTGGGCTTG 56
Db 13 TTGCTGGGCTTG 1
XX
RESULT 503
XX ABF73729/c
XX ID ABF73729 standard; DNA; 13 BP.
XX AC ABF73729;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 173726 for detecting SNP TSC0043265.
XX XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX CC Claim 1; SEQ ID NO 173726; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at [ftp.wipo.int/pub/published_pat_sequences](http://wipo.int/pub/published_pat_sequences)

```

Query Match      15.1%;   Score 9.8;   DB 1;   Length 13;
Best Local Similarity 84.6%;   Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0

```

QY	2	TTCTGAATGAA	14
Db	13	TTATGTAATGAA	1

RESULT	504
ID	ABH00235/c
vv	ABH00235 standard; DNA; 13 BP.

Query Match 15.1%; Score 9.8; DB 1; Length 13.

Oy	50	GGGTTGCAGCTTT	62
Db	13	GGGTTTGGCGTTT	1

RESULT 505
ABF50559/C
ID ABF50559 standard; DNA; 13 BP.
vv

Query Match	15.1%	Score 9.8;	DB 1;	Length 13;
Best Local Similarity	84.6%	Pred. No. 2.4e+02;		
Matches 11; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY	1	TTTCTGGAATGGA	13
Db	13	TTTTTGGAAATAGA	1

RESULT	506
ABH29612	
ABH29612	standard; DNA; 13 BP
ABH29612;	
ABH29612;	

```

XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 229589 for detecting SNP TSC0055987.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 229589; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TCGAATGGAATTG 17
DB 1 TCGAATGGAATTG 13
XX
XX RESULT 507
XX ABF86467/C
XX ID ABF86467 standard; DNA; 13 BP.
XX
XX ABF86467;
XX
XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 186464 for detecting SNP TSC0045930.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

```

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 186464; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 5 C; 0 G; 8 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 AAGAACGAAAGA 40
DB 13 AAGAACGAAAGA 1
XX
XX RESULT 508
XX ABF62972
XX ID ABF62972 standard; DNA; 13 BP.
XX
XX ABF62972;
XX
XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 162969 for detecting SNP TSC0040972.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 162969; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TGGATGGAATTG 17
1 TGAATGGAATTG 13
Db
RESULT 509
ABC68984
ID ABC68984 standard; DNA; 13 BP.
AC ABC68984;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 69001 for detecting SNP TSC0017967.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPiGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX
PS Claim 1; SEQ ID NO 69001; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 46 GCTGGGCTTGAG 58
1 GGTGGAGTTGAG 13
Db
RESULT 510
ABC99662
ID ABC99662 standard; DNA; 13 BP.
AC ABC99662;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 99679 for detecting SNP TSC0024759.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPiGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX
PS Claim 1; SEQ ID NO 99679; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 6 GGAATGGAATTG 18
1 TGGATGGAATTG 13

Db 1 GGTATGGAGTTGG 13

RESULT 511

ABC06245

ID ABC06245 standard; DNA; 13 BP.

XX

AC ABC06245;

XX

DT 20-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 6236 for detecting SNP TSC0001951.

XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIC-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 6236; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 9 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 25 CCCAAGACAGAA 37

DB 1 CCCAAAAACAAA 13

RESULT 512

ABF07728

ID ABF07728 standard; DNA; 13 BP.

XX

AC ABF07728;

XX

DT 21-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 107725 for detecting SNP TSC0026974.

XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIC-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 107725; 29pp + Sequence Listing; German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGTTTGAAGTT 61

DB 1 GGGTTTGAAGTT 13

RESULT 513

ABC61677/c

ID ABC61677 standard; DNA; 13 BP.

XX

AC ABC61677;

XX

DT 21-FEB-2002 (first entry)

XX

DE Oligonucleotide SEQ ID NO 61694 for detecting SNP TSC0016406.

XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

```

XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 61694; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTTT 62
DB 13 GGGGTAGAGGTTT 1

```

RESULT 514
ABF35263/c
ID ABR35263 standard; DNA; 13 BP.

AC ABR35263;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 135260 for detecting SNP TSC0033738.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 135260; 29pp + Sequence Listing; German.

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
CC Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
CC
CC Query Match 15.1%; Score 9.8; DB 1; Length 13;
CC Best Local Similarity 84.6%; Pred. No. 2.4e+02;
CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CC
QY 52 GTTGAAGGTTTCA 64
DB 13 GTAGGAGGTTTCA 1

```

RESULT 515
ABF47356
ID ABF47356 standard; DNA; 13 BP.

AC ABF47356;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 147353 for detecting SNP TSC0037222.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 147353; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTCA 64
|||||
1 GTTGCGTTTCA 13

RESULT 516

ABH33026
ID ABH33026 standard; DNA; 13 BP.

AC ABH33026;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 233003 for detecting SNP TSC0056853.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 233003; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 GCTGGGTTTGAG 58
|||||
1 GTTGCGTTTCA 13

RESULT 517
ABF88568

ID ABF88568 standard; DNA; 13 BP.

AC ABF88568;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 188565 for detecting SNP TSC0010549.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 188565; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAGA 40
|||||
1 AATTAAGAAAGA 13

RESULT 518
ABC20851/C

ID ABC20851 standard; DNA; 13 BP.

AC ABC20851;

DT 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 20868 for detecting SNP TSC0004238.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.

XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB000713.
XX	
XX	07-APR-2000; 2000DE-01019173.
XX	
XX	(EPIG-) EPIGENOMICS AG.
XX	
XX	Olek A, Piepenbrock C, Berlin K;
XX	
XX	WPI, 2001-657177/75.
XX	
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is
XX	designed to detect single-nucleotide polymorphisms and cytosine
XX	methylation status.
XX	
XX	Claim 1, SEQ ID NO 20868; 29pp + Sequence Listing; German.
XX	
XX	This invention describes novel oligonucleotide primers or peptide nucleic
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX	and cytosine methylation status in chemically pretreated genomic DNA. The
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX	range of diseases including immune system, gastrointestinal, respiratory,
XX	central nervous system, cardiovascular and metabolic disorders. The
XX	oligomers are also used for detecting cell type differentiation. ABC00010
XX	-AB93989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX	represent the oligomers described in the invention. NOTE: The sequence
XX	data for this patent did not form part of the printed specification, but
XX	was obtained in electronic format from WIPO at
XX	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX	
XX	Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX	Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX	Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0
QY	48 TGGGTTGAGCT 60
DB	13 TAGGTTGAGT 1
XX	
XX	RESULT 519
XX	ABC99214
XX	ID ABC99214 standard; DNA; 13 BP.
XX	
XX	ABC99214;
XX	
XX	21-FEB-2002 (first entry)
XX	
XX	OLIGONUCLEOTIDE SEQ ID NO 99231 for detecting SNP TSC0024650.
XX	
XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
XX	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
XX	
XX	06-APR-2001; 2001WO-IB000713.
XX	
XX	07-APR-2000; 2000DE-01019173.
XX	
XX	(EPIG-) EPIGENOMICS AG.
XX	
XX	Olek A, Piepenbrock C, Berlin K;
XX	
XX	

DR WP1, 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 99231, 29pp + Sequence Listing, German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

CC

SQ Sequence 13 BP, 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

XX

QY 49 GGGGTTGAGGCTT 61

Db 1 GGGATTGTGCTT 13

XX

RESULT 520

ABC99663/c

ID ABC99663 standard; DNA; 13 BP.

XX ABC99663;

XX 21-FEB-2002 (first entry)

XX

DE Oligonucleotide seq ID NO 99680 for detecting SNP TSC0024759.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

XX W0200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001, 2001WO-IB000713.

XX

XX 07-APR-2000, 2000DE-01019173.

XX

XX (EPig-) EPiGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

DR WP1, 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 99680, 29pp + Sequence Listing, German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

CC

SQ Sequence 13 BP, 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

XX

QY 49 GGGGTTGAGGCTT 61

Db 1 GGGATTGTGCTT 13

XX

RESULT 520

ABC99663/c

ID ABC99663 standard; DNA; 13 BP.

XX ABC99663;

XX 21-FEB-2002 (first entry)

XX

DE Oligonucleotide seq ID NO 99680 for detecting SNP TSC0024759.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

XX W0200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001, 2001WO-IB000713.

XX

XX 07-APR-2000, 2000DE-01019173.

XX

XX (EPig-) EPiGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

DR WP1, 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 99680, 29pp + Sequence Listing, German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

CC

SQ Sequence 13 BP, 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

XX

QY 49 GGGGTTGAGGCTT 61

Db 1 GGGATTGTGCTT 13

XX

RESULT 520

ABC99663/c

ID ABC99663 standard; DNA; 13 BP.

XX ABC99663;

XX 21-FEB-2002 (first entry)

XX

DE Oligonucleotide seq ID NO 99680 for detecting SNP TSC0024759.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

XX W0200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001, 2001WO-IB000713.

XX

XX 07-APR-2000, 2000DE-01019173.

XX

XX (EPig-) EPiGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

DR WP1, 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 99680, 29pp + Sequence Listing, German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

CC

SQ Sequence 13 BP, 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

XX

QY 49 GGGGTTGAGGCTT 61

Db 1 GGGATTGTGCTT 13

XX

RESULT 520

ABC99663/c

ID ABC99663 standard; DNA; 13 BP.

XX ABC99663;

XX 21-FEB-2002 (first entry)

XX

DE Oligonucleotide seq ID NO 99680 for detecting SNP TSC0024759.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

XX W0200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001, 2001WO-IB000713.

XX

XX 07-APR-2000, 2000DE-01019173.

XX

XX (EPig-) EPiGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K,

XX

DR WP1, 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1, SEQ ID NO 99680, 29pp + Sequence Listing, German.

XX

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

CC

SQ Sequence 13 BP, 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

XX

QY 49 GGGGTTGAGGCTT 61

Db 1 GGGATTGTGCTT 13

XX

RESULT 520

ABC99663/c

ID ABC99663 standard; DNA; 13 BP.

XX ABC99663;

XX 21-FEB-2002 (first entry)

XX

DE Oligonucleotide seq ID NO 99680 for detecting SNP TSC0024759.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGATGGAATTCG 18
DB 13 GGATGGAATTCG 1

RESULT 521
ABC01963/c
ID ABC01963 standard; DNA; 13 BP.
XX
AC ABC01963;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 1954 for detecting SNP TSC000769.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001MO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 1954; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGTTGGAGGTTT 62
DB 13 GGTTGGAGGTTT 1

RESULT 522
ABC37878
ID ABC37878 standard; DNA; 13 BP.
XX
AC ABC37878;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 37895 for detecting SNP TSC0011764.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001MO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 37895; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGTTGGAGGTTT 62
DB 1 GGTTGGAGGTTT 13

RESULT 523
ABC63814/c
ID ABC63814 standard; DNA; 13 BP.
XX
AC ABC63814;
XX
DT 21-FEB-2002 (first entry)

```
XX Oligonucleotide SEQ ID NO 63831 for detecting SNP TSC0016855.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DB-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 63831; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 0 C; 3 G; 10 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 26 CCAGACAGAGAAA 38
Db 13 CCAAAAACAAAA 1
RESULT 524
ABF16687/C
ID ABF16687 standard; DNA; 13 BP.
XX
XX ABF16687;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 116684 for detecting SNP TSC0029195.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
```

```
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DB-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 116684; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGGTTGG 56
Db 13 TTGTTGGGTTGG 1
RESULT 525
ABF2179/C
ID ABF2179 standard; DNA; 13 BP.
XX
XX ABF2179;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 122176 for detecting SNP TSC0030537.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DB-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

XX Claim 1; SEQ ID NO 122176; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 5 TGGATGGAATTG 17
Db 13 TTGATTGGAATTG 1
XX
RESULT 526
ABF72760
ID ABF72760 standard; DNA; 13 BP.
XX
AC ABF72760;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172757 for detecting SNP TSC0009140.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX OS
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIDENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PT
PS Claim 1; SEQ ID NO 172757; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAATTG 18
Db 1 GGAATGGGTTTG 13
XX
RESULT 527
ABF72761/C
ID ABF72761 standard; DNA; 13 BP.
XX
AC ABF72761;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172758 for detecting SNP TSC0009140.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX OS
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIDENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PT
PS Claim 1; SEQ ID NO 172758; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAATTG 18
Db 13 GGAATGGGTTTG 1

```
RESULT 528
ABF98632
ID ABF98632 standard; DNA; 13 BP.
XX
XX
AC ABF98632;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 198629 for detecting SNP TSC0008196.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 198629; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 29 AGACAGAGAAAGA 41
XX |||||
XX 1 ATAAAGAAAGAA 13
XX
RESULT 529
ABF90375/C
ID ABF90375 standard; DNA; 13 BP.
XX
XX
AC ABF90375;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 190372 for detecting SNP TSC0046824.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX
```

```
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 190372; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 5 TCGAATGGAATTG 17
XX |||||
XX 13 TCGAATGGAATTG 1
XX
RESULT 530
ABH15567/C
ID ABH15567 standard; DNA; 13 BP.
XX
XX
AC ABH15567;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 215544 for detecting SNP TSC0052427.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX
```

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 215544; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGATTGG 18
Db 13 GGAATGGTTGG 1
XX
RESULT 531
ABH41661
ID ABH41661 standard; DNA; 13 BP.
XX
AC ABH41661;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 241638 for detecting SNP TSC0058921.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 241638; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 32 ACAGAAAGAACT 44
Db 1 ACATAAATTAACCT 13
XX
RESULT 532
ABF66698
ID ABF66698 standard; DNA; 13 BP.
XX
AC ABF66698;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166695 for detecting SNP TSC0041746.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 166695; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 29 AGAACAGAGAGAA 41
|||||
Db 1 AGAATGAGAAAAA 13

RESULT 533

ABH57531/c
ID ABH57531 standard; DNA; 13 BP.

XX ABH57531;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 257508 for detecting SNP TSC0005086.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

PS Claim 1; SEQ ID NO 257508; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 11 GGAATGACATA 23
|||||
Db 13 GGAATTGAATATA 1

RESULT 534

ABH57828
ID ABH57828 standard; DNA; 13 BP.

AC ABH57828;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 257805 for detecting SNP TSC0062709.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

PS Claim 1; SEQ ID NO 257805; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 50 GGGTTGAGGTTT 62
|||||
Db 1 GGGTTGAGGATTT 13

Search completed: August 12, 2004, 15:28:58
Job time : 5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:32:42 ; Search time 1 Seconds
(without alignments)
0.227 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65
Sequence: 1 ttcttcgacgtgacgtgac.....gtcgggttgaggatttcac 65

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 134 seqs, 1745 residues

Total number of hits satisfying chosen parameters: 268

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Listing first 134 summaries

Database : rgcdh:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	19.8	30.5	23	1	ACCESSION:AB3656
C 2	19.8	30.5	23	1	ACCESSION:AR300570
C 3	19.8	30.5	23	1	ACCESSION:BD106469
C 4	15.8	24.3	21	1	ACCESSION:AX084313
C 5	14.4	22.2	18	1	ACCESSION:BD107600
C 6	14.4	21.5	18	1	ACCESSION:AR000413
C 7	13.8	21.2	17	1	ACCESSION:BD183671
C 8	13.4	20.6	17	1	ACCESSION:AX217386
C 9	13.4	20.6	17	1	ACCESSION:AX217387
C 10	13.4	20.0	17	1	ACCESSION:AX217388
C 11	13.4	20.0	17	1	ACCESSION:AX217388
C 12	13.4	20.0	17	1	ACCESSION:AX217388
C 13	13.4	20.0	17	1	ACCESSION:AX217388
C 14	12.8	19.7	17	1	ACCESSION:AR053059
C 15	12.8	19.7	17	1	ACCESSION:AR053059
C 16	12.8	19.7	17	1	ACCESSION:AR053059
C 17	12.8	19.7	17	1	ACCESSION:BD254337
C 18	12.8	19.7	17	1	ACCESSION:BD254337
C 19	12.8	19.7	17	1	ACCESSION:BD254337
C 20	12.8	19.7	17	1	ACCESSION:BD254337
C 21	12.4	19.1	15	1	ACCESSION:BD233078
C 22	12.4	19.1	15	1	ACCESSION:BD233078
C 23	12.4	19.1	15	1	ACCESSION:BD233078
C 24	12.4	19.1	15	1	ACCESSION:BD233078
C 25	11.4	17.5	13	1	ACCESSION:AX547657
C 26	11.4	17.5	13	1	ACCESSION:AX547657
C 27	11.4	17.5	13	1	ACCESSION:AX547657
C 28	11.4	17.5	13	1	ACCESSION:AX547657
C 29	11.4	17.5	13	1	ACCESSION:AX547657
C 30	11.4	17.5	13	1	ACCESSION:AX547657
C 31	11.4	17.5	13	1	ACCESSION:AX547657
C 32	11.4	17.5	13	1	ACCESSION:AX547657
C 33	11.4	17.5	13	1	ACCESSION:AX547657

C 34	11	16.9	13	1	BD086508	ACCESSION:BD086508
C 35	11	16.9	13	1	BD086527	ACCESSION:BD086527
C 36	10.8	16.6	14	1	AR178312	ACCESSION:AR178312
C 37	10.8	16.6	14	1	AR178313	ACCESSION:AR178313
C 38	10.8	16.6	14	1	128572	ACCESSION:128572
C 39	10.8	16.6	14	1	158734	ACCESSION:158734
C 40	10.8	16.6	14	1	AX016242	ACCESSION:AX016242
C 41	10.8	16.6	14	1	AX287231	ACCESSION:AX287231
C 42	10.8	16.6	14	1	AX323394	ACCESSION:AX323394
C 43	10.8	16.6	14	1	AX323395	ACCESSION:AX323395
C 44	10.8	16.6	14	1	BD135020	ACCESSION:BD135020
C 45	10.4	16.0	12	1	AR036346	ACCESSION:AR036346
C 46	10.4	16.0	12	1	AR036347	ACCESSION:AR036347
C 47	10.4	16.0	12	1	AR036365	ACCESSION:AR036365
C 48	10.4	16.0	12	1	AR036366	ACCESSION:AR036366
C 49	10.4	16.0	12	1	AR036368	ACCESSION:AR036368
C 50	10.4	16.0	12	1	AR036368	ACCESSION:AR036368
C 51	10.4	16.0	12	1	112563	ACCESSION:112563
C 52	10.4	16.0	12	1	112564	ACCESSION:112564
C 53	10.4	16.0	12	1	112565	ACCESSION:112565
C 54	10.4	16.0	12	1	120199	ACCESSION:120199
C 55	10.4	16.0	12	1	120200	ACCESSION:120200
C 56	10.4	16.0	12	1	120202	ACCESSION:120202
C 57	10.4	16.0	12	1	172094	ACCESSION:172094
C 58	10.4	16.0	12	1	172095	ACCESSION:172095
C 59	10.4	16.0	12	1	172113	ACCESSION:172113
C 60	10.4	16.0	12	1	172114	ACCESSION:172114
C 61	10.4	16.0	12	1	172116	ACCESSION:172116
C 62	10.4	16.0	12	1	BD080369	ACCESSION:BD080369
C 63	10.4	16.0	12	1	121837	ACCESSION:121837
C 64	10.4	16.0	13	1	AR275240	ACCESSION:AR275240
C 65	10.4	16.0	13	1	AR339891	ACCESSION:AR339891
C 66	10.4	16.0	13	1	AX711144	ACCESSION:AX711144
C 67	10.4	16.0	13	1	BD238904	ACCESSION:BD238904
C 68	10.4	16.0	10	1	AX153058	ACCESSION:AX153058
C 69	10.4	16.0	10	1	BD065196	ACCESSION:BD065196
C 70	10.4	16.0	10	1	BD166544	ACCESSION:BD166544
C 71	10.4	16.0	10	1	BD166682	ACCESSION:BD166682
C 72	10.4	16.0	11	1	AX471270	ACCESSION:AX471270
C 73	10.4	16.0	11	1	AX472179	ACCESSION:AX472179
C 74	10.4	16.0	11	1	AX624183	ACCESSION:AX624183
C 75	10.4	16.0	11	1	AX624981	ACCESSION:AX624981
C 76	10.4	16.0	11	1	AX625481	ACCESSION:AX625481
C 77	10.4	16.0	11	1	AX626412	ACCESSION:AX626412
C 78	10.4	16.0	11	1	AX626765	ACCESSION:AX626765
C 79	10.4	16.0	11	1	AX631604	ACCESSION:AX631604
C 80	10.4	16.0	11	1	AX632402	ACCESSION:AX632402
C 81	10.4	16.0	12	1	105995	ACCESSION:105995
C 82	10.4	16.0	12	1	108795	ACCESSION:108795
C 83	10.4	16.0	12	1	AR349259	ACCESSION:AR349259
C 84	10.4	16.0	12	1	AR349261	ACCESSION:AR349261
C 85	10.4	16.0	13	1	AR01985	ACCESSION:AR01985
C 86	9.8	15.1	13	1	A06431	ACCESSION:A06431
C 87	9.8	15.1	13	1	BD062265	ACCESSION:BD062265
C 88	9.4	14.5	11	1	116094	ACCESSION:116094
C 89	9.4	14.5	11	1	AX393078	ACCESSION:AX393078
C 90	9.4	14.5	11	1	AX470597	ACCESSION:AX470597
C 91	9.4	14.5	11	1	AX470878	ACCESSION:AX470878
C 92	9.4	14.5	11	1	AX471365	ACCESSION:AX471365
C 93	9.4	14.5	11	1	AX623489	ACCESSION:AX623489
C 94	9.4	14.5	11	1	AX624179	ACCESSION:AX624179
C 95	9.4	14.5	11	1	AX624329	ACCESSION:AX624329
C 96	9.4	14.5	11	1	AX624484	ACCESSION:AX624484
C 97	9.4	14.5	11	1	AX625720	ACCESSION:AX625720
C 98	9.4	14.5	11	1	AX625789	ACCESSION:AX625789
C 99	9.4	14.5	11	1	AX626474	ACCESSION:AX626474
C 100	9.4	14.5	11	1	AX627570	ACCESSION:AX627570
C 101	9.4	14.5	11	1	AX628639	ACCESSION:AX628639
C 102	9.4	14.5	11	1	AX628640	ACCESSION:AX628640
C 103	9.4	14.5	11	1	AX628771	ACCESSION:AX628771
C 104	9.4	14.5	11	1	AX629905	ACCESSION:AX629905
C 105	9.4	14.5	11	1	AX630278	ACCESSION:AX630278
C 106	9.4	14.5	11	1	AX630910	ACCESSION:AX630910

```
C 107 9.4 14.5 11 1 AX631600 ACCESSION:AX631600
C 108 9.4 14.5 11 1 AX631750 ACCESSION:AX631750
C 109 9.4 14.5 11 1 AX631905 ACCESSION:AX631905
C 110 9.4 14.5 12 1 A03728 ACCESSION:A03728
C 111 9.4 14.5 12 1 A03729 ACCESSION:A03729
C 112 9.4 14.5 12 1 A03738 ACCESSION:A03738
C 113 9.4 14.5 12 1 A03921 ACCESSION:A03921
C 114 9.4 14.5 12 1 A31783 ACCESSION:A31783
C 115 9.4 14.5 12 1 A47652 ACCESSION:A47652
C 116 9.4 14.5 12 1 AR027870 ACCESSION:AR027870
C 117 9.4 14.5 12 1 AR036375 ACCESSION:AR036375
C 118 9.4 14.5 12 1 AR036376 ACCESSION:AR036376
C 119 9.4 14.5 12 1 AR074233 ACCESSION:AR074233
C 120 9.4 14.5 12 1 AR074249 ACCESSION:AR074249
C 121 9.4 14.5 12 1 AR074305 ACCESSION:AR074305
C 122 9.4 14.5 12 1 AR172240 ACCESSION:AR172240
C 123 9.4 14.5 12 1 I20197 ACCESSION:I20197
C 124 9.4 14.5 12 1 I20198 ACCESSION:I20198
C 125 9.4 14.5 12 1 I20474 ACCESSION:I20474
C 126 9.4 14.5 12 1 I72123 ACCESSION:I72123
C 127 9.4 14.5 12 1 I72124 ACCESSION:I72124
C 128 9.4 14.5 12 1 AR307251 ACCESSION:AR307251
C 129 9.4 14.5 12 1 AR307276 ACCESSION:AR307276
C 130 9.4 14.5 12 1 AR307278 ACCESSION:AR307278
C 131 9.4 14.5 12 1 AX032595 ACCESSION:AX032595
C 132 9.4 14.5 12 1 AX032611 ACCESSION:AX032611
C 133 9.4 14.5 12 1 AX032667 ACCESSION:AX032667
C 134 9.4 14.5 12 1 BD080370 ACCESSION:BD080370
```

ALIGNMENTS

```
RESULT 1
LOCUS A83656 23 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 12 from Patent WO9849309.
ACCESSION A83656
VERSION A83656.1 GI:6732906
KEYWORDS
```

SOURCE

ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 23)

AUTHORS Utrans-Schneitz,U. and Lesslauer,W.

TITLE RAT ST38.2 CHEMOKINE

JOURNAL Patent: WO 9849309-A 12 05-NOV-1998;

HOFFMANN LA ROCHE (CH)

FEATURES

source Location/Qualifiers

1..23 /organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 30.5%; Score 19.8; DB 1; Length 23;

Best Local Similarity 91.3%; Pred. No. 1.6;

Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGACATAGCC 26

Db 23 CTGGATGGAATTGACACAGCC 1

```
RESULT 2
LOCUS AR300570/c 23 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 12 from patent US 6537794.
ACCESSION AR300570
VERSION AR300570.1 GI:31688075
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
FEATURES
Unclassified.
```

```
REFERENCE 1 (bases 1 to 23)
AUTHORS Lesslauer,W. and Utrans-Schneitz,U.
TITLE Chemokine
JOURNAL Patent: US 6537794-A 12 25-MAR-2003;
FEATURES
source Location/Qualifiers
1..23 /organism="unknown"
/mol_type="unassigned DNA"
```

Query Match 30.5%; Score 19.8; DB 1; Length 23;

Best Local Similarity 91.3%; Pred. No. 1.6;

Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGACATAGCC 26

Db 23 CTGGATGGAATTGACACAGCC 1

RESULT 3

```
BD106469/c 23 bp DNA linear PAT 18-SEP-2002
LOCUS BD106469
DEFINITION Rat ST38.2 chemokine.
ACCESSION BD106469
VERSION BD106469.1 GI:23201287
KEYWORDS JP 2002500509-A/10.
```

SOURCE Chlamydia sp.

ORGANISM Chlamydia sp.

REFERENCE Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.

AUTHORS Lesslauer,W. and Schneitz,U.U.

TITLE Rat ST38.2 chemokine

JOURNAL Patent: JP 2002500509-A 10 08-JAN-2002;

F HOFFMANN LA ROCHE AG

COMMENT PN JP 2002500509-A/10

PD 08-JAN-2002

PF 23-APR-1998 JP 1998546575

PR 30-APR-1997 EP 97107135.2

PI WERNER LESSLAUER, UTRIKE UTRANS SCHNEITZ

PC C12N15/19,C07K14/52,C12N5/08,C12N5/10,C12Q1/68,C07K19/00, PC

C07K16/24

PC A61K38/19,G01N33/50,G01N33/53

CC Strandedness: Single;

CC Topology: Linear;

CC /desc = 'primer';

FH Key

FEATURES Location/Qualifiers

source 1..23 /organism="Chlamydia sp."

/mol_type="genomic DNA"

/db_xref="taxon:35827"

Query Match 30.5%; Score 19.8; DB 1; Length 23;

Best Local Similarity 91.3%; Pred. No. 1.6;

Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGACATAGCC 26

Db 23 CTGGATGGAATTGACACAGCC 1

RESULT 4

```
AX084313/c 21 bp DNA linear PAT 28-FEB-2001
LOCUS AX084313
DEFINITION Sequence 107 from Patent WO0110902.
ACCESSION AX084313
VERSION AX084313.1 GI:13185815
KEYWORDS
```

SOURCE Synthetic construct

ORGANISM Synthetic construct

REFERENCE 1

AUTHORS Shimkete,R.A. and Fernandes,B.

TITLE Nucleic acids and secreted polypeptides encoded thereby

JOURNAL Patent: WO 0110902-A 107 15-FEB-2001;
 FEATURES Curagen Corporation (US)
 source Location/Qualifiers
 1. .21
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="PCR PRIMER"

Query Match 24.3%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 7.8;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 42 CCTTGGTGGGTGGAGT 60
 Db 21 CCTTCTGGGTGTAGT 3

RESULT 5
 BD107600
 LOCUS Novel microsatellite DNA derived from pear plants and method for
 DEFINITION discriminating pear plants using the same.
 ACCESSION BD107600.1 GI:23202418
 VERSION JP 2002034597-A/9.
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Yamamoto,T., Sawamura,Y., Imai,T., Matsuda,N., Saito,T., Shoda,M.,
 Kotohuki,K., Hayaishi,K., Ba,Y., Kozono,M. and Kimura,T.
 TITLE Novel microsatellite DNA derived from pear plants and method for
 JOURNAL discriminating pear plants using the same
 COMMENT Patent: JP 2002034597-A 9 05-FEB-2002;
 FRUIT TREE RES STATION
 OS Artificial Sequence
 PN JP 2002034597-A/9
 PD 05-FEB-2002 JP 2002220339
 PF 21-JUL-2000 JP 2002220339
 PI TOSHIYA YAMAMOTO, YUTAKA SAWAMURA, TSUYOSHI IMAI, NAGAO MATSUDA,
 TOSHIHIRO SAITO, MORIYUKI SHODA, KAZUO KOTOBUKI, KENKI HAYASHI,
 YOSHIYUKI BAN,
 PI MASANORI KOZONO, TETSUYA KIMURA
 PC C12Q1/68,A01H1/00,C12N15/09,C12N15/00
 CC Description of Artificial Sequence:Primer
 FH Key Location/Qualifiers
 FT source 1. .18
 /organism="Artificial Sequence".
 FEATURES Location/Qualifiers
 source 1. .18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 22.2%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 12;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACGAGAAAGACC 43
 Db 2 AAGACGACGAAAGACC 17

RESULT 6
 AR000413
 LOCUS Sequence 138 from patent US 5736356.
 DEFINITION 18 bp DNA linear PAT 04:DEC-1998
 ACCESSION AR000413
 VERSION AR000413.1 GI:3962944
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

Unclassified.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Sano,K., Kumazawa,Y., Yasueda,H., Seguro,K. and Moroki,M.
 TITLE Transglutaminase originating from *Craesostrea gigas*
 JOURNAL Patent: US 5736356-A 138 07-APR-1998;
 FEATURES Location/Qualifiers
 source 1. .18
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 21.5%; Score 14; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 14;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 30 GAACAGAAAGACC 43
 Db 16 GAACAGAAAGACC 3

RESULT 7
 BD183671/c
 LOCUS 17 bp DNA linear PAT 17-JUN-2003
 DEFINITION Method for classifying genotype of hepatitis B viruses, and primers
 ACCESSION BD183671
 VERSION BD183671.1 GI:31875871
 KEYWORDS JP 2002355098-A/8.
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Tanihara,A., Osaka,T., Mizoue,M., Kato,H., Orito,E. and Ueda,R.
 TITLE Method for classifying genotype of hepatitis B viruses, and primers
 JOURNAL and probes for the same
 COMMENT Patent: JP 2002355098-A 8 10-DEC-2002;
 GENOME SCIENCE LABORATORIES CO LTD
 OS Hepatitis virus (hepatitis B virus)
 PN JP 2002355098-A/8
 PD 10-DEC-2002 JP 2001246141
 PF 14-AUG-2001 JP 2001246141
 PI AKIKO TANIHARA, TAKUYA OSAKA, MASASHI MIZOUE, HIDEAKI KATO, ETSURO
 Orito,
 PI RYUZO UEDA
 PC C12Q1/68,C12N15/09,C12N15/09,C12Q1/70,G01N33/50,G01N33/53, PC
 G01N33/56,
 PC G01N33/569//C12Q1/68,C12R1:93),(C12Q1/70,C12R1:93),C12N15/00,
 PC C12N15/00
 CC Probe employing the naturally occurred sequence of Hepatitis B
 CC virus type
 CC C. Location/Qualifiers
 FH Key 1. .17
 FT source /organism="Hepatitis virus (hepatitis B FT
 virus)".
 FEATURES Location/Qualifiers
 source 1. .17
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 21.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 14;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 GAACCTTGGTGGGTTG 55
 Db 17 GATCCTTGTGGGGTTG 1

RESULT 8
 AX217386/c

LOCUS AX217386 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2828 from Patent WO0159103.
 ACCSSION AX217386
 VERSION AX217386.1 GI:15527447
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 JOURNAL nogo gene expression
 Patent: WO 0159103-A 2828 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
 |||||
 Db 16 GCCCAAGAACAGAGA 2

RESULT 9
 LOCUS AX217387 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2829 from Patent WO0159103.
 ACCSSION AX217387
 VERSION AX217387.1 GI:15527448
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 JOURNAL nogo gene expression
 Patent: WO 0159103-A 2829 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
 |||||
 Db 15 GCCCAAGAACAGAGA 1

RESULT 10
 LOCUS AX217388 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2830 from Patent WO0159103.
 ACCSSION AX217388
 VERSION AX217388.1 GI:15527449
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 JOURNAL nogo gene expression
 Patent: WO 0159103-A 2830 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 JOURNAL nogo gene expression
 Patent: WO 0159103-A 2830 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGA 36
 |||||
 Db 14 GCCCAAGAACAGA 2

RESULT 11
 LOCUS AX217756 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 3198 from Patent WO0159103.
 ACCSSION AX217756
 VERSION AX217756.1 GI:15527817
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 JOURNAL nogo gene expression
 Patent: WO 0159103-A 3198 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGA 36
 |||||
 Db 14 GCCCAAGAACAGA 2

RESULT 12
 LOCUS AX733882 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 5516 from Patent WO03025175.
 ACCSSION AX733882
 VERSION AX733882.1 GI:30513225
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1 Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversal, apoptosis and/or virus resistance and their use as
 medicines

JOURNAL Patent: WO 03025175-A 5516 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
source

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 20.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 TCGAATTGACAT 22
|||||
Db 5 TCGAATTGACAT 17

RESULT 13

AX757493 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 814 from Patent WO03040369.
DEFINITION AX757493
ACCESSION AX757493.1 GI:32252109
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 814 15-MAY-2003;
Molecular Engines Laboratories (FR)

FEATURES

1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 20.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 TCGAATTGACAT 22
|||||
Db 5 TCGAATTGACAT 17

RESULT 14

AR053059 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 29 from patent US 5834181.
DEFINITION AR053059
ACCESSION AR053059
VERSION AR053059.1 GI:5977921
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Shuber,A.P.
TITLE High throughput screening method for sequences or genetic alterations in nucleic acids
JOURNAL Patent: US 5834181-A 29 10-NOV-1998;
FEATURES Location/Qualifiers
1. .17
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 22;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CCAAGAACAGAAAGAA 41
|||||
Db 2 CTAAGAACAGAAATGAA 17

RESULT 15

AR065020 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 29 from patent US 5849483.
DEFINITION AR065020
ACCESSION AR065020
VERSION AR065020.1 GI:5995236
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Shuber,A.P.
TITLE High throughput screening method for sequences or genetic alterations in nucleic acids
JOURNAL Patent: US 5849483-A 29 15-DEC-1998;
FEATURES Location/Qualifiers
1. .17
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 22;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CCAAGAACAGAAAGAA 41
|||||
Db 2 CTAAGAACAGAAATGAA 17

RESULT 16

BD254337 17 bp DNA linear PAT 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
DEFINITION BD254337
ACCESSION BD254337
VERSION BD254337.1 GI:33064107
KEYWORDS JP 2002541795-A/2130.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Meswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2130 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC

COMMENT

OS Eukaryote
PN JP 2002541795-A/2130
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN
PC C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
1. .17
FT source /organism="Eukaryote".

FEATURES
source

1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTGGGGTTGGAGGTTT 62
 |||||
 17 CTGGGGTTGAGGCTT 2

RESULT 17
 BD258370/c 17 bp DNA linear PAT 17-JUL-2003
 LOCUS Regulation of repressor genes using nucleic acid molecules.
 DEFINITION BD258370
 ACCESSION BD258370.1 GI:33068140
 VERSION JP 2002541795-A/6163.
 KEYWORDS unidentifed
 SOURCE unclassified
 ORGANISM unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 6163 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC
 COMMENT OS Eukaryote
 PN JP 2002541795-A/6163
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key Location/Qualifiers
 FT source 1..17
 /organism='Eukaryote',
 /location/Qualifiers
 1..17
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 10 TGGAAATTGGACATAGC 25
 |||||
 17 TGGAGTTGGACACAGC 2

RESULT 18
 I32565 17 bp DNA linear PAT 06-FEB-1997
 LOCUS Sequence 29 from patent US 5589330.
 DEFINITION I32565
 ACCESSION I32565
 VERSION I32565.1 GI:1823356
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE Unclassified.
 1 (bases 1 to 17)
 AUTHORS Shuber, A.P.
 TITLE High-throughput screening method for sequence or genetic
 alterations in nucleic acids using elution and sequencing of
 complementary oligonucleotides

JOURNAL Patent: US 5589330-A 29 31-DEC-1996;
 FEATURES Location/Qualifiers
 source 1..17
 /organism='unassigned DNA'
 /mol_type='unassigned DNA'

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGAACGAGAAAGA 41
 |||||
 2 CTAAGAACGAGATGAA 17

RESULT 19
 AX218301 17 bp RNA linear PAT 07-SEP-2001
 LOCUS Sequence 3743 from Patent WO0159103.
 DEFINITION AX218301
 ACCESSION AX218301
 VERSION AX218301.1 GI:15528362
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Blatt, L., Mcswigen, J. and Chowitra, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 nogo gene expression
 JOURNAL Patent: WO 0159103-A 3743 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
 Mcswigen, James (US); Chowitra, Bharat M. (US)
 Location/Qualifiers
 1..17
 /organism='synthetic construct'
 /mol_type='unassigned RNA'
 /db_xref='taxon:32630'
 /note='Nucleic Acid'

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGAACGAGAAAGA 41
 |||||
 2 CCAAGAACGAGAAAGA 17

RESULT 20
 BD233057 15 bp DNA linear PAT 17-JUL-2003
 LOCUS Method of detecting mutation selected by drug in HIV protease gene.
 DEFINITION BD233057
 ACCESSION BD233057
 VERSION BD233057.1 GI:33042827
 KEYWORDS JP 2002518065-A/153.
 SOURCE Aids-associated retrovirus
 ORGANISM Aids-associated retrovirus
 Viruses; Retroid viruses; Retroviridae.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Stuyver, L.
 TITLE Method of detecting mutation selected by drug in HIV protease gene
 JOURNAL Patent: JP 2002518065-A 153 25-JUN-2002;
 INNOGENETICS NV
 COMMENT OS Aids-associated retrovirus
 PN JP 2002518065-A/153
 PD 25-JUN-2002
 PF 22-JUN-1999 JP 2000556068
 PR 24-JUN-1998 EP 96870143.9
 PI LIEVEN STUYVER
 PC C12N15/09, C12Q1/68, C12Q1/70, C12N15/00
 CC Method of detecting mutation selected by drug in HIV protease
 FH Key gene Location/Qualifiers

	FT	source	1. .15	/organism='Aids-associated retrovirus'.
FEATURES	FT	Location/Qualifiers		
Source		1. .15		
		/organism="Aids-associated retrovirus"		
		/mol_type="genomic DNA"		
		/db_xref="taxon:11966"		
Query Match		19.1%; Score 12.4; DB 1; Length 15;		
Best Local Similarity		92.9%; Pred. No. 22;		
Matches	13; Conservative	0; Mismatches	1; Indels	0; Gaps
OY	49	GCGGTTGGAGGTTT	62	
Db	1	GAAGTTGGAGGTTT	14	
RESULT 21				
BD233078				
LOCUS	BD233078	15 bp	DNA	linear PAT 17-JUL-2003
DEFINITION	Method of detecting mutation selected by drug in HIV protease gene.			
ACCESSION	BD233078			
VERSION	BD233078.1 GI:33042848			
KEYWORDS	JP 2002518065-A/174.			
SOURCE	Aids-associated retrovirus			
ORGANISM	Aids-associated retrovirus			
REFERENCE	Viruses; Retroid viruses; Retroviridae.			
AUTHORS	1 (bases 1 to 15)			
TITLE	Stuyver,L.			
JOURNAL	Method of detecting mutation selected by drug in HIV protease gene			
COMMENT	Patent: JP 2002518065-A 174 25-JUN-2002;			
	INNOGENETICS NV			
OS	Aids-associated retrovirus			
PN	JP 2002518065-A/174			
PD	25-JUN-2002			
PF	22-JUN-1999 JP 2000556068			
PR	24-JUN-1998 EP 98870143.9			
PI	LIEVEN STUYVER			
PC	C12N15/09,C12Q1/68,C12Q1/70,C12N15/00			
CC	Method of detecting mutation selected by drug in HIV protease			
GC	gene			
FH	key	Location/Qualifiers		
FT	source	1. .15		
		/organism='Aids-associated retrovirus'.		
FEATURES		Location/Qualifiers		
source		1. .15		
		/organism="Aids-associated retrovirus"		
		/mol_type="genomic DNA"		
		/db_xref="taxon:11966"		
Query Match		19.1%; Score 12.4; DB 1; Length 15;		
Best Local Similarity		92.9%; Pred. No. 22;		
Matches	13; Conservative	0; Mismatches	1; Indels	0; Gaps
OY	49	GCGGTTGGAGGTTT	62	
Db	1	GAAGTTGGAGGTTT	14	
RESULT 22				
AX007611				
LOCUS	AX007611	15 bp	DNA	linear PAT 06-SEP-2000
DEFINITION	Sequence 153 from Patent WO9967428.			
ACCESSION	AX007611			
VERSION	AX007611.1 GI:9995308			
KEYWORDS	.			
SOURCE	Aids-associated retrovirus			
ORGANISM	Aids-associated retrovirus			
REFERENCE	Viruses; Retroid viruses; Retroviridae.			
AUTHORS	1			
TITLE	Stuyver,L.			
	Method for detection of drug-selected mutations in the hiv protease			
gene				

```

JOURNAL      Patent: WO 9667428-A 153 29-DEC-1999;
              INNOCENTICS NV (BE); STUYVER LIEVEN (BE)
FEATURES
  source
    1..15
      /organism="Aids-associated retrovirus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:11966"

Query Match      19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 22;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTTT 62
      ||| ||||| |||||
Db      1 GGAGTTGGAGGTTT 14

RESULT 23
AX007632      15 bp      DNA      linear      PAT 06-SEP-2000
LOCUS
DEFINITION      Sequence 174 from Patent WO967428.
ACCESSION      AX007632
VERSION      AX007632.1 GI:9995329
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  AUTHORS
  TITLE
JOURNAL
  source
    1..15
      /organism="Aids-associated retrovirus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:11966"

Query Match      19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 22;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTTT 62
      ||| ||||| |||||
Db      1 GGAGTTGGAGGTTT 14

RESULT 24
AX104604      13 bp      DNA      linear      PAT 30-APR-2001
LOCUS
DEFINITION      Sequence 796 from Patent WO0122972.
ACCESSION      AX104604
VERSION      AX104604.1 GI:13920801
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1
  AUTHORS      Krieg,A.M., Schetter,C. and Voljmer,J.C.
  TITLE      Immunostimulatory nucleic acids
  JOURNAL      Patent: WO 0122972-A 796 05-APR-2001;
              UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
              GmbH (DE)
FEATURES
  source
    1..13
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"

Query Match      17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 29;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy 49 GGGGTGGAGGTT 61
Db 1 GGGGTGGAGGTT 13

RESULT 25
LOCUS AX355422 13 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 450 from Patent WO0197843.
ACCESSION AX355422
VERSION AX355422.1 GI:18620090
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Weiner, G. and Hartmann, G.
TITLE Methods for enhancing antibody-induced cell lysis and treating cancer
JOURNAL Patent: WO 0197843-A 450 27-DEC-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES
source Location/Qualifiers
1..13
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide-phosphorothioate backbone"

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 29;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 1 GGGGTGGAGGTT 13

RESULT 26
LOCUS AX547657 13 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 796 from Patent WO02053141.
ACCESSION AX547657
VERSION AX547657.1 GI:25812801
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Bratzler, R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 796 11-JUL-2002;
Coley Pharmaceutical Group, Inc. (US)
FEATURES
source Location/Qualifiers
1..13
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Sequence"

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 29;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 1 GGGGTGGAGGTT 13

RESULT 27
LOCUS BD233079 14 bp DNA linear PAT 17-JUL-2003

DEFINITION Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION BD233079
VERSION BD233079.1 GI:33042849
KEYWORDS JP 2002518065-A/175.
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1
AUTHORS Stuyver, L.
TITLE Method of detecting mutation selected by drug in HIV protease gene
JOURNAL Patent: JP 2002518065-A 175 25-JUN-2002;
INNOGENETICS NV
COMMENT OS Aids-associated retrovirus
PN JP 2002518065-A/175
PD 25-JUN-2002
PF 22-JUN-1999 JP 2000556068
PR 24-JUN-1998 EP 98870143.9
PI LIEVEN STUYVER
PC C12N15/09, C12Q1/68, C12Q1/70, C12N15/00
CC Method of detecting mutation selected by drug in HIV protease
C12N15/09, C12Q1/68, C12Q1/70, C12N15/00
CC Method of detecting mutation selected by drug in HIV protease
FH Key gene
FT source Location/Qualifiers
1..14
/organism="Aids-associated retrovirus".
/mol_type="genomic DNA"
/db_xref="taxon:11966"

Query Match 17.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 50 GGGTGGAGGTT 62
Db 1 GAGTTGGAGGTT 13

RESULT 28
LOCUS AX007633 14 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 175 from Patent WO9967428.
ACCESSION AX007633
VERSION AX007633.1 GI:9995330
KEYWORDS
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1
AUTHORS Stuyver, L.
TITLE Method for detection of drug-selected mutations in the hiv protease gene
JOURNAL Patent: WO 9967428-A 175 29-DEC-1999;
INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES
source Location/Qualifiers
1..14
/organism="Aids-associated retrovirus"
/mol_type="unassigned DNA"
/db_xref="taxon:11966"

Query Match 17.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 50 GGGTGGAGGTT 62
Db 1 GAGTTGGAGGTT 13

RESULT 29
LOCUS I45950 15 bp DNA linear PAT 07-OCT-1997

DEFINITION Sequence 22 from patent US 5639603.
ACCESSION 145950
VERSION 145950.1 GI:2469915
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Dower, W.J., Barrett, R.W., Gallop, M.A. and Needeles, M.C.
TITLE Synthesizing and screening molecular diversity
JOURNAL Patent: US 5639603-A 22 17-JUN-1997;
FEATURES
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAATG 17
|||||
2 TGGATGGAAGTG 14

Db

RESULT 30
AR278927/c 15 bp DNA linear PAT 10-APR-2003
LOCUS AR278927
DEFINITION Sequence 5 from patent US 6514693.
ACCESSION AR278927
VERSION AR278927.1 GI:29713570
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lansdorf, P.
TITLE Method for detecting multiple copies of a repeat sequence in a
JOURNAL nucleic acid molecule
FEATURES Patent: US 6514693-A 5 04-FEB-2003;
source 1. .15
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAATG 17
|||||
13 TGGATGGAATGG 1

Db

RESULT 31
AR278931 15 bp DNA linear PAT 10-APR-2003
LOCUS AR278931
DEFINITION Sequence 9 from patent US 6514693.
ACCESSION AR278931
VERSION AR278931.1 GI:29713574
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lansdorf, P.
TITLE Method for detecting multiple copies of a repeat sequence in a
JOURNAL nucleic acid molecule
FEATURES Patent: US 6514693-A 9 04-FEB-2003;
source 1. .15
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAATG 17
|||||
3 TGGATGGAATCG 15

Db

RESULT 32
AX587070 15 bp DNA linear PAT 10-JAN-2003
LOCUS AX587070
DEFINITION Sequence 92 from Patent WO02072883.
ACCESSION AX587070
VERSION AX587070.1 GI:27655945
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Roetger, A.
TITLE Nucleotide carrier for diagnosing and treating oral diseases
JOURNAL Patent: WO 02072883-A 92 19-SEP-2002;
FEATURES Roetger, Antje (DB)
source 1. .15
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Bacteria"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 TCTGGAATGGAAT 15
|||||
2 TCTGGAATGGAAT 14

Db

RESULT 33
BD086489 13 bp DNA linear PAT 27-AUG-2002
LOCUS BD086489
DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
ACCESSION BD086489
VERSION BD086489.1 GI:22632099
KEYWORDS JP 2001523451-A/20.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 13)
AUTHORS Anuschiwan, P., Uhlmann, E. and Weiser, C.
TITLE Tenascin antisense oligonucleotide for treating leukemia
JOURNAL Patent: JP 2001523451-A 20 27-NOV-2001;
COMMENT AVENTIS PHARMA DEUTSCHLAND GMBH
OS Unidentified
FN JP 2001523451-A/20
PD 27-NOV-2001
PF 29-OCT-1998 JP 2000521185
PR 15-NOV-1997 DE 197 50 702.6
PI PEYMAN ANUSCHIRWAN EUGEN UHLMANN CAROLINE WEISER PC
CI2N15/09,A61K31/711,A61K48/00,A61P17/00,C12Q1/68,C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
CC Tenascin antisense oligonucleotide for treating leukemia PH
Key Location/Qualifiers
FT exon 1. .13.
Location/Qualifiers
1. .13
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
 |||||
 3 ACAGAAAGAAC 13

RESULT 34

LOCUS BD086508 13 bp DNA linear PAT 27-AUG-2002
 DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
 ACCESSION BD086508
 VERSION BD086508.1 GI:22632118
 KEYWORDS JP 2001523451-A/39.
 SOURCE unidentified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 13)
 AUTHORS Anuschirwan, P., Uhlmann, E. and Weiser, C.
 TITLE Tenascin antisense oligonucleotide for treating leukemia
 JOURNAL Patent: JP 2001523451-A 39 27-NOV-2001;
 AVENTIS PHARMA DEUTSCHLAND GMBH
 COMMENT OS Unidentified
 PN JP 2001523451-A/39
 PD 27-NOV-2001
 PF 29-OCT-1998 JP 2000521185
 PR 15-NOV-1997 DE 197 50 702.6
 PI PEYMAN ANUSCHIRWAN, EUGEN UHLMANN, CAROLINE WEISER PC
 C12N15/09, A61K31/711, A61K48/00, A61P17/00, C12Q1/68, C12N15/00 CC
 Strandness: Single;
 CC Topology: Linear;
 CC Tenascin antisense oligonucleotide for treating leukemia FH
 Key FT exon Location/Qualifiers
 1. 13.
 1. 13
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

FEATURES

source 1. 13
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
 |||||
 3 ACAGAAAGAAC 13

RESULT 35

LOCUS BD086527 13 bp DNA linear PAT 27-AUG-2002
 DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
 ACCESSION BD086527
 VERSION BD086527.1 GI:22632137
 KEYWORDS JP 2001523451-A/58.
 SOURCE unidentified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 13)
 AUTHORS Anuschirwan, P., Uhlmann, E. and Weiser, C.
 TITLE Tenascin antisense oligonucleotide for treating leukemia
 JOURNAL Patent: JP 2001523451-A 58 27-NOV-2001;
 AVENTIS PHARMA DEUTSCHLAND GMBH
 COMMENT OS Unidentified
 PN JP 2001523451-A/58
 PD 27-NOV-2001
 PF 29-OCT-1998 JP 2000521185
 PR 15-NOV-1997 DE 197 50 702.6
 PI PEYMAN ANUSCHIRWAN, EUGEN UHLMANN, CAROLINE WEISER PC

C12N15/09, A61K31/711, A61K48/00, A61P17/00, C12Q1/68, C12N15/00 CC
 Strandedness: Single;
 CC Topology: Linear;
 CC Tenascin antisense oligonucleotide for treating leukemia FH
 Key FT exon Location/Qualifiers
 1. 13.
 1. 13
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

FEATURES

source 1. 13
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
 |||||
 3 ACAGAAAGAAC 13

RESULT 36

LOCUS AR178312 14 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 29 from patent US 6319672.
 ACCESSION AR178312
 VERSION AR178312.1 GI:20219450
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)
 AUTHORS Crouzet, J., Scherman, D., Wils, P., Blanche, F. and Cameron, B.
 TITLE Purification of a triple helix formation with an immobilized oligonucleotide
 JOURNAL Patent: US 6319672-A 29 20-NOV-2001;
 Location/Qualifiers
 1. 14
 1. 14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACGAAAGAA 41
 |||||
 1 AAGAAAAAAAAAGAA 14

RESULT 37

LOCUS AR178313 14 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 30 from patent US 6319672.
 ACCESSION AR178313
 VERSION AR178313.1 GI:20219451
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)
 AUTHORS Crouzet, J., Scherman, D., Wils, P., Blanche, F. and Cameron, B.
 TITLE Purification of a triple helix formation with an immobilized oligonucleotide
 JOURNAL Patent: US 6319672-A 30 20-NOV-2001;
 Location/Qualifiers
 1. 14
 1. 14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAGAA 41
|||||
Db 14 AAGAAAAAAGAA 1

RESULT 38
LOCUS 128572 14 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 25 from patent US 5571937.
ACCESSION 128572
VERSION 128572.1 GI:1819348
KEYWORDS
SOURCE Unknown.
ORGANISM Unassigned.
REFERENCE 1 (bases 1 to 14)
AUTHORS Watanabe,K.A., Ren,W.-Y. and Weil,R.
TITLE Complementary DNA and toxins
JOURNAL Patent: US 5571937-A 25 05-NOV-1996;
FEATURES Location/Qualifiers
source 1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAGAA 41
|||||
Db 14 AAGAAAAAAGATGAA 14

RESULT 39
LOCUS 158734 14 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 25 from patent US 5652350.
ACCESSION 158734
VERSION 158734.1 GI:2477972
KEYWORDS
SOURCE Unknown.
ORGANISM Unassigned.
REFERENCE 1 (bases 1 to 14)
AUTHORS Watanabe,K.A., Ren,W.-Y. and Weil,R.
TITLE Complementary DNA and toxins
JOURNAL Patent: US 5652350-A 25 29-JUL-1997;
FEATURES Location/Qualifiers
source 1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAGAA 41
|||||
Db 14 AAGAAAAAAGATGAA 14

RESULT 40
LOCUS AX016242 14 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 9 from Patent WO949067.
ACCESSION AX016242
VERSION AX016242.1 GI:10041819
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
artificial sequences.

AUTHORS Wils,P., Ciolina,C. and Scherman,D.
TITLE Nucleic acid transfer vectors, compositions containing same and
JOURNAL uses
Patent: WO 9949067-A 9 30-SEP-1999;
WILS PIERRE (FR); CIOLINA CAROLE (FR); SCHERMAN DANIEL (FR); RHONE
POULENC RORER SA (FR)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="misc_binding"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAGAA 41
|||||
Db 14 AAGAAAAAAGAA 14

RESULT 41
LOCUS AX287231 14 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 31 from Patent WO0168122.
ACCESSION AX287231
VERSION AX287231.1 GI:17049164
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Schlingensiepen,K.H., Schlingensiepen,R., Apfel,R., Brysch,W.,
Jachimczak,P. and Bogdahn,U.
TITLE A method for reversing the immunosuppressive effects of the
JOURNAL melanoma inhibitory activity mla
Patent: WO 0168122-A 31 20-SEP-2001;
Biagnostik Gesellschaft fuer Biomedizinare Diagnostik mbH (DE)
FEATURES Location/Qualifiers
source 1..14
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 17 GGAATAGCCACAG 30
|||||
Db 14 GGAATAGCCACAG 14

RESULT 42
LOCUS AX323394 14 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 29 from Patent WO0192511.
ACCESSION AX323394
VERSION AX323394.1 GI:18094156
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
TITLE Purification of a triple helix formation with an immobilized
JOURNAL oligonucleotide
Patent: WO 0192511-A 29 06-DEC-2001;
Aventis Pharma (FR)
FEATURES Location/Qualifiers
source 1..14

```

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/Note="synthetic oligonucleotide"

Query Match      16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGAGAAAGAA 41
        |||||
        1 AAGAAAAAAGAA 14

Db

RESULT 43
LOCUS      AX323395/c      14 bp      DNA      linear      PAT 07-JAN-2002
DEFINITION Sequence 30 from Patent WO0192511.
ACCESSION  AX323395
VERSION     AX323395.1 GI:18094157
KEYWORDS
SOURCE      synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Crouzet,J., Sherman,D., Wils,P., Blanche,F. and Cameron,B.
TITLE       Purification of a triple helix formation with an immobilized
            oligonucleotide
JOURNAL     Patent: WO 0192511-A 30 06-DEC-2001;
            Aventis Pharma (FR)
FEATURES
            location/Qualifiers
            1..14
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /Note="synthetic oligonucleotide"

Query Match      16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGAGAAAGAA 41
        |||||
        14 AAGAAAAAAGAA 1

Db

RESULT 44
LOCUS      BD135020      14 bp      DNA      linear      PAT 18-SEP-2002
DEFINITION Vector having nucleic acid transferred thereinto, compositions
ACCESSION  BD135020
VERSION     BD135020.1 GI:23229655
KEYWORDS   JP 2002507429-A/9.
SOURCE      unidentified
            unidentified
            unclassified.
            1 (bases 1 to 14)
            Stolina,C., Sherman,D. and Wills,P.
            Vector having nucleic acid transferred thereinto, compositions
            containing the vector and utilization thereof
            Patent: JP 2002507429-A 9 12-MAR-2002;
            AVENTIS PHARMA SA
            OS      Unidentified
            PN      JP 2002507429-A/9
            PD      12-MAR-2002
            PF      19-MAR-1999 JP 2000538027
            PR      24-MAR-1998 FR 98/03573,18-MAY-1998 US 60/085 848 PI
            CAROL STOLINA,DANIEL SHERMAN,PIERRE WILLS
            PC      C12N15/09,A61K39/39,A61K48/00,C12N1/15,C12N1/19,C12N5/10, PC
            C12N15/00,
            CC      C12N5/00
            Strandedness: Single;

```

```

CC      CC      Topology: linear;
CC      CC      Vector having nucleic acid transferred thereinto, compositions
            containing
            CC      the vector and utilization thereof
            PH      Key      Location/Qualifiers
            FT      source      1..14
            FT      /organism='unidentified'.
            location/Qualifiers
            1..14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 40;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGAGAAAGAA 41
        |||||
        1 AAGAAAAAAGAA 14

Db

RESULT 45
LOCUS      A14857/c      12 bp      DNA      linear      PAT 16-MAY-1994
DEFINITION Nucleotide sequence 1 from patent number EP0334694.
ACCESSION  A14857
VERSION     A14857.1 GI:512100
KEYWORDS
SOURCE      unidentified
            unidentified
            unclassified.
            1 (bases 1 to 12)
            Cravador,A., De Vos-Pierreux,M.J. and Bollen,A.
            Nucleic acid probes with non-radioactive labels, and preparation
            processes
            Patent: EP 0334694-A 1 27-SEP-1989;
            IIR-CEMILITARG S.A.; LA REGION WALLONNE
            location/Qualifiers
            1..12
            /organism="unidentified"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32644"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      17 GGACATAGCCCA 28
        |||||
        12 GGACGAGCCCA 1

Db

RESULT 46
LOCUS      AR036346      12 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5872105.
ACCESSION  AR036346
VERSION     AR036346.1 GI:5953014
KEYWORDS
SOURCE      Unknown.
            Unclassified.
            1 (bases 1 to 12)
            Kool,E.T.
            Single-stranded circular oligonucleotides useful for drug delivery
            Patent: US 5872105-A 9 16-FEB-1999;
            location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

```

Query Match	16.0%	Score 10.4	DB 1	Length 12
Best Local Similarity	91.7%	Pred. No. 40		
Matches	11	Conservative	0	Mismatches 1
				Indels 0
				Gaps 0
QY	28	AAGAACGAGAAG	39	
Db	1	AAGAAAGAAG	12	

RESULT	47				
AR036347/c					
LOCUS	AR036347	12 bp	DNA	linear	PAT 29-SEP-1999
DEFINITION	Sequence	10	from patent US 5872105.		
ACCESSION	AR036347				
VERSION	AR036347.1	GI:5953015			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 12)				
TITLE	Kooli,E.T.				
JOURNAL	Single-stranded circular oligonucleotides useful for drug delivery				
FEATURES	Patent: US 5872105-A 10 16-FEB-1999;				
source	location/Qualifiers				
	1..12				

Query Match	16.0%	Score 10.4	DB 1	Length 12
Best Local Similarity	91.7%	Pred. No. 40		
Matches 11; Conservative	0	Mismatches 1	Indels 0	Gaps 0
QY	28	AAGAACGGAAG	39	
db	12	AAGAAAAGAAG	1	

RESULT	48			
LOCUS	AR036365			
DEFINITION	AR036365	12 bp	DNA	linear
ACCESSION	Sequence 28	from patent US 5872105.		PAT 29-SEP-1999
VERSION	AR036365			
KEYWORDS	AR036365..1	GI:5953033		
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	Unclassified.			
AUTHORS	1 (bases 1 to 12)			
TITLE	Kool,E.T.			
JOURNAL	Single-stranded circular oligonucleotides useful for drug delivery			
FEATURES	Patent: US 5872105-A 29 16-FEB-1999;			
SOURCE	Location/Qualifiers			
	1..12			
	/organism="unknown"			
	/mol_type="unassigned DNA"			

Query Match	16.0%	Score 10.4	DB 1	Length 12
Best Local Similarity	91.7%	Pred. No. 40		
Matches 11	Conservative 0	Mismatches 1	Indels 0	Gaps 0
QY	30	GAACGAGAAAGAA	41	
Db	1	GAAGAGAAAGAA	12	
RESULT 49				
AR036366				
LOCUS	AR036366	12 bp	DNA	linear
DEFINITION	Sequence 29 from parent US 5872105.			PAT 29-SEP-1999
ACCESSION	AR036366			
VERSION	AR036366.1	GI:5953034		
KEYWORDS				
SOURCE	Unknown.			

ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 12)
TITLE	Kool, E.T.
JOURNAL	Single-stranded circular oligonucleotides useful for drug delivery
FEATURES	Patent: US 5872105-A 29 16-FEB-1999;
SOURCE	Location/Qualifiers
	1..12

```

Query Match          15.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 GAACGAAGACA 41
      ||| |||||
Db       1 GAAAGAAAGACA 12

```

RESULT 50				
AR036368/c	AR036368	12 bp	DNA	linear
LOCUS	Sequence	31	from patent	US 5872105.
DEFINITION	AR036368			
ACCESSION	AR036368.1	GI:5953036		
VERSION				
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	Unclassified.			
AUTHORS	1 (bases 1 to 12)			
TITLE	Kool B.T.			
JOURNAL	Single-stranded circular oligonucleotides useful for drug delivery			
FEATURES	Patent: US 5872105-A 31 16-FEB-1999;			
Location/Qualifiers	1..12			
source	/organism="unknown"			
	/mol_type="unassigned DNA"			

Query Match	16.0%	Score 10.4	DB 1	Length 12;
Best Local Similarity	Pred. No. 40;			
Matches 11; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;
Oy	30 GAACAGAAAGAA	41		
Dd	12 GAAAAGAAAAGA	1		

LOCUS	112563	12 bp	DNA	linear	PAT 26-JUL-1995
DEFINITION	Sequence 9 from patent US 5426180.				
ACCESSION	112563				
VERSION	112563.1				
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 12)				
AUTHORS	Kool E.T.				
TITLE	Methods of making single-stranded circular oligonucleotides				
JOURNAL	Patent: US 5426180 A 9 20-JUN-1995;				
FEATURES	Location/Qualifiers				
SOURCE	1..12				
	/organism="unknown"				
	/mol_type="unassigned DNA"				

Query Match	16.0%	Score 10.4	DB 1	Length 12
Best Local Similarity	91.7%	Pred. No. 40		
Matches 11	Conservative	0	Mismatches 1	Indels 0
Gaps	0			

```
Db      1 AAGAAAGAAAG 12

RESULT 52
LOCUS   112564
DEFINITION Sequence 10 from patent US 5426180.
ACCESSION 112564
VERSION  112564.1 GI:909948
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS  Kool,E.T.
TITLE     Methods of making single-stranded circular oligonucleotides
JOURNAL   Patent: US 5426180-A 10 20-JUN-1995;
FEATURES  Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
Db      12 AAGAAAGAAAG 1

RESULT 53
LOCUS   112565
DEFINITION Sequence 11 from patent US 5426180.
ACCESSION 112565
VERSION  112565.1 GI:909949
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS  Kool,E.T.
TITLE     Methods of making single-stranded circular oligonucleotides
JOURNAL   Patent: US 5426180-A 11 20-JUN-1995;
FEATURES  Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
Db      1 AAGAAATAGAAAG 12

RESULT 54
LOCUS   120199
DEFINITION Sequence 14 from patent US 5514546.
ACCESSION 120199
VERSION  120199.1 GI:1600554
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS  Kool,E.T.
TITLE     Stem-loop oligonucleotides containing parallel and antiparallel
JOURNAL   binding domains
FEATURES  Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
Db      1 AAGAAATAGAAAG 12

JOURNAL Patent: US 5514546-A 14 07-MAY-1996;
FEATURES Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
Db      1 AAGAAATAGAAAG 12

JOURNAL Patent: US 5514546-A 15 07-MAY-1996;
FEATURES Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
Db      1 AAGAAATAGAAAG 12

JOURNAL Patent: US 5514546-A 17 07-MAY-1996;
FEATURES Location/Qualifiers
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
Db      12 AAGAAATAGAAAG 1
```

RESULT 57
LOCUS 172094 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 9 from patent US 5683874.
ACCESSION 172094
VERSION 172094.1 GI:3008233
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 9 04-NOV-1997;
FEATURES
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 12 AAGAAAGAAAG 12

RESULT 58
LOCUS 172095 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 10 from patent US 5683874.
ACCESSION 172095
VERSION 172095.1 GI:3008234
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 10 04-NOV-1997;
FEATURES
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 12 AAGAAAGAAAG 12

RESULT 59
LOCUS 172113 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 28 from patent US 5683874.
ACCESSION 172113
VERSION 172113.1 GI:3008252
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 28 04-NOV-1997;

FEATURES
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 12 GAAGAGAAAGAA 12

RESULT 60
LOCUS 172114 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 29 from patent US 5683874.
ACCESSION 172114
VERSION 172114.1 GI:3008253
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 29 04-NOV-1997;
FEATURES
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 12 GAAGAGAAAGAA 12

RESULT 61
LOCUS 172116 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 31 from patent US 5683874.
ACCESSION 172116
VERSION 172116.1 GI:3008255
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 31 04-NOV-1997;
FEATURES
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 12 GAAGAGAAAGAA 12

RESULT 62

BD080369/c
LOCUS BD080369 12 bp DNA linear PAT 27-AUG-2002
DEFINITION Methods of synthesizing oligonucleotides with random codons.
ACCESSION BD080369
VERSION BD080369.1 GI:22625972
KEYWORDS JP 2001299342-A/35.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 12)
AUTHORS Huse, W.D.
JOURNAL Methods of synthesizing oligonucleotides with random codons
TITLE Patent: JP 2001299342-A 35 30-OCT-2001;
JOURNAL IXSYS INC
COMMENT OS Artificial Sequence
PN JP 2001299342-A/35
PD 30-OCT-2001
PF 15-MAR-2001 JP 2001075101
PR 24-AUG-1990 US 573648
PI WILLIAM D HUSE
PC C12N15/00, C07H21/04, C12Q1/68, C12N15/00
CC synthetic construct
FH Key
FT source 1.12 Location/Qualifiers
FEATURES
source 1.12 Location/Qualifiers
1.12 /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGAATGGAATT 16
DB 12 TGAATGGAATT 1

RESULT 63
LOCUS 121837 13 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 14 from patent US 5525468.
ACCESSION 121837
VERSION 121837.1 GI:1602191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 13)
AUTHORS McSwigen, J.A.
TITLE Assay for ribozyme target site
JOURNAL Patent: US 5525468-A 14 11-JUN-1996;
FEATURES
source 1.13 Location/Qualifiers
1.13 /organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 10 TGAATTGACA 21
DB 13 TGAATCGACA 2

RESULT 64
LOCUS AR275240 13 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 45 from patent US 6506893.
ACCESSION AR275240

VERSION AR275240.1 GI:29708241
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS El Solh, N. and Allignet, J.
TITLE Polynucleotides and their use for detecting resistance to
JOURNAL streptogramin A or to streptogramin B and related compounds
FEATURES
source 1.13 Location/Qualifiers
1.13 /organism="unknown"
/mol_type="genomic DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 7 GAATGGAATTGG 18
DB 13 GAATGGAATTGG 2

RESULT 65
LOCUS AR339891 13 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 36 from patent US 6570001.
ACCESSION AR339891
VERSION AR339891.1 GI:33731110
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS Solh, N.E. and Allignet, J.
TITLE Polynucleotides and their use for detecting resistance to
JOURNAL streptogramin A or to streptogramin B and related compounds
FEATURES
source 1.13 Location/Qualifiers
1.13 /organism="unknown"
/mol_type="genomic DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 7 GAATGGAATTGG 18
DB 13 GAATGGAATTGG 2

RESULT 66
LOCUS AX711144 13 bp DNA linear PAT 11-APR-2003
DEFINITION Sequence 444 from Patent EP1288296.
ACCESSION AX711144
VERSION AX711144.1 GI:29787525
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Draper, K.G., McSwigen, J.A., Holecsek, J.J., Dudycz, L.W.,
Macejak, D.G. and Mamone, J.A.
TITLE Method and reagent for inhibiting HBV viral replication
JOURNAL Patent: EP 1288296-A 444 05-MAR-2003;
FEATURES
source 1.13 Location/Qualifiers
1.13 /organism="synthetic construct"
/mol_type="unassigned DNA"


```

BD166544
LOCUS      BD166544                10 bp      DNA
DEFINITION Human liver disease-expressing genes.
ACCESSION  BD166544
VERSION    BD166544.1 GI:27872356
KEYWORDS   JP 2002209591-A/89.
SOURCE     unidentified
ORGANISM   unidentified
            unclassified.
            1 (bases 1 to 10)
REFERENCE  Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
AUTHORS   Human liver disease-expressing genes
TITLE      Patent: JP 2002209591-A 89 30-JUL-2002;
JOURNAL    JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT    OS Homo sapiens (human)
           PN JP 2002209591-A/89
           PD 30-JUL-2002
           PE 19-JAN-2001 JP 2001012328
           PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
           YAMASHITA
PC         C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC         C12P21/08,
PC         C12N15/00
CC         Human liver disease-expressing genes
FH         Key
FT         source
            Location/Qualifiers
            1..10
            /organism="Homo sapiens (human)".
FEATURES
source
            Location/Qualifiers
            1..10
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 10;
Matches 10; Conservative 100.0%; Pred. No. 39;
Mismatches 0; Indels 0; Gaps 0;

QY      4 CTGGAGATGA 13
        |||||
        1 CTGGAGATGA 10

Db

RESULT 71
LOCUS      BD166682                10 bp      DNA
DEFINITION Human liver disease-expressing genes.
ACCESSION  BD166682
VERSION    BD166682.1 GI:27872494
KEYWORDS   JP 2002209591-A/227.
SOURCE     unidentified
ORGANISM   unidentified
            unclassified.
            1 (bases 1 to 10)
REFERENCE  Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
AUTHORS   Human liver disease-expressing genes
TITLE      Patent: JP 2002209591-A 227 30-JUL-2002;
JOURNAL    JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT    OS Homo sapiens (human)
           PN JP 2002209591-A/227
           PD 30-JUL-2002
           PE 19-JAN-2001 JP 2001012328
           PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
           YAMASHITA
PC         C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC         C12P21/08,
PC         C12N15/00
CC         Human liver disease-expressing genes
FH         Key
FT         source
            Location/Qualifiers
            1..10
            /organism="Homo sapiens (human)".
FEATURES
source
            Location/Qualifiers
            1..10
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 10;
Matches 10; Conservative 100.0%; Pred. No. 39;
Mismatches 0; Indels 0; Gaps 0;

QY      4 CTGGAGATGA 13
        |||||
        1 CTGGAGATGA 10

Db

RESULT 72
LOCUS      AX471270/c              11 bp      DNA
DEFINITION Sequence 847 from Patent WO2053773.
ACCESSION  AX471270
VERSION    AX471270.1 GI:22206395
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  Hofmann,K., Conradt,M. and Petersohn,D.
AUTHORS   Method for determining skin stress or skin ageing in vitro
TITLE      Patent: WO 02053773-A 847 11-JUL-2002;
JOURNAL    HENKEL KGAA (DE)
COMMENT    Location/Qualifiers
           1..11
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

FEATURES
source
            Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 100.0%; Pred. No. 43;
Mismatches 0; Indels 0; Gaps 0;

QY      8 AATGGAGATTG 17
        |||||
        10 AATGGAGATTG 1

Db

RESULT 73
LOCUS      AX472179/c              11 bp      DNA
DEFINITION Sequence 170 from Patent WO02053775.
ACCESSION  AX472179
VERSION    AX472179.1 GI:22207216
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  Husterl,E., Haberl,M. and Wojnowski,L.
AUTHORS   Identification of the genetic determinants of the polymorphic
TITLE      Cyp3a5 expression
JOURNAL    Patent: WO 02053775-A 170 11-JUL-2002;
JOURNAL    EPIDAUROS BIOTECHNOLOGIE AG (DE)
COMMENT    Location/Qualifiers
           1..11
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

FEATURES
source
            Location/Qualifiers
            1..11
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 100.0%; Pred. No. 43;
Mismatches 0; Indels 0; Gaps 0;

QY      8 AATGGAGATTG 17
        |||||
        10 AATGGAGATTG 1

Db

```



```

RESULT 74
AX624183/c      11 bp      DNA      linear      PAT 21-FEB-2003
LOCUS           Sequence 1224 from Patent WO02053774.
ACCESSION       AX624183
VERSION         AX624183.1 GI:28452124
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS         Petersohn,D., Conradt,M. and Hofmann,K.
TITLE           Method for determining homeostasis of the skin
JOURNAL         Patent: WO 02053774-A 1224 11-JUL-2002;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source          1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match     15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
Db 10 GAGGTTTCAC 1

RESULT 75
AX624981/c      11 bp      DNA      linear      PAT 21-FEB-2003
LOCUS           Sequence 2022 from Patent WO02053774.
ACCESSION       AX624981
VERSION         AX624981.1 GI:28452922
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS         Petersohn,D., Conradt,M. and Hofmann,K.
TITLE           Method for determining homeostasis of the skin
JOURNAL         Patent: WO 02053774-A 2022 11-JUL-2002;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source          1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match     15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
Db 10 GAGGTTTCAC 1

RESULT 76
AX625481/c      11 bp      DNA      linear      PAT 21-FEB-2003
LOCUS           Sequence 2322 from Patent WO02053774.
ACCESSION       AX625481
VERSION         AX625481.1 GI:28453422
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS         Petersohn,D., Conradt,M. and Hofmann,K.
TITLE           Method for determining homeostasis of the skin
JOURNAL         Patent: WO 02053774-A 2522 11-JUL-2002;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source          1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match     15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 AATTGACAT 22
Db 10 AATTGACAT 1

RESULT 77
AX626412        11 bp      DNA      linear      PAT 21-FEB-2003
LOCUS           Sequence 3453 from Patent WO02053774.
ACCESSION       AX626412
VERSION         AX626412.1 GI:28454450
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS         Petersohn,D., Conradt,M. and Hofmann,K.
TITLE           Method for determining homeostasis of the skin
JOURNAL         Patent: WO 02053774-A 3453 11-JUL-2002;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source          1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match     15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AACCTGCTG 49
Db 2 AACCTGCTG 11

RESULT 78
AX626765/c      11 bp      DNA      linear      PAT 21-FEB-2003
LOCUS           Sequence 3806 from Patent WO02053774.
ACCESSION       AX626765
VERSION         AX626765.1 GI:28454803
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS         Petersohn,D., Conradt,M. and Hofmann,K.
TITLE           Method for determining homeostasis of the skin
JOURNAL         Patent: WO 02053774-A 3806 11-JUL-2002;
                Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source          1. .11
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 44 TTGCTGGGGT 53
DB 10 TTGCTGGGGT 1

RESULT 79

LOCUS AX631604/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 8646 from Patent WO02053774.
ACCESSION AX631604
VERSION AX631604.1 GI:28459680
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS 1
TITLE Petersohn, D., Conradt, M. and Hofmann, K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 8646 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers

FEATURES

1. 11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 56 GAGGTTTCAC 65
DB 10 GAGGTTTCAC 1

RESULT 80

LOCUS AX632402/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 9444 from Patent WO02053774.
ACCESSION AX632402
VERSION AX632402.1 GI:28468017
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS 1
TITLE Petersohn, D., Conradt, M. and Hofmann, K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 9444 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers

FEATURES

1. 11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 56 GAGGTTTCAC 65
DB 10 GAGGTTTCAC 1

RESULT 81

LOCUS 105995 12 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 12 from Patent EP 0275856.
ACCESSION 105995
VERSION 105995.1 GI:590815
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

1 (bases 1 to 12)
AUTHORS Bollen, A.J., Gheysen, D., Jacobs, P., Pierard, L. and Collen, D.J.
TITLE New plasmidogen activators
JOURNAL Patent: EP 0275856-A1 12 27-JUL-1988;
LOCATION/Qualifiers

FEATURES

1. 12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 42 CCTTGCTGGG 51
DB 2 CCTTGCTGGG 11

RESULT 82

LOCUS 108795 12 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 16 from Patent WO 8804690.
ACCESSION 108795
VERSION 108795.1 GI:588500
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

1 (bases 1 to 12)
AUTHORS Bollen, A.J., Gheysen, D., Jacobs, P., Pierard, L. and Collen, D.J.
JOURNAL Patent: WO 8804690-A 16 30-JUN-1988;
LOCATION/Qualifiers

FEATURES

1. 12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 12;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 42 CCTTGCTGGG 51
DB 2 CCTTGCTGGG 11

RESULT 83

LOCUS AR349259/c 12 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 6 from patent US 6583986.
ACCESSION AR349259
VERSION AR349259.1 GI:33749984
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

1 (bases 1 to 12)
AUTHORS Storti, W.J., Sibley, K., Ovadia, S., Kimball, S. and Falvo, B.
TITLE Method and apparatus for managing thermal energy emissions
JOURNAL Patent: US 6583986-A 6 24-JUN-2003;
LOCATION/Qualifiers

1. 12
/organism="unknown"
/mol_type="genomic DNA"

Query Match	15.4%;	Score 10;	DB 1;	Length 12;
Best Local Similarity	100.0%;	Pred. No. 47;		
Matches	10;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
QY	23 AGCCCAAGAA 32			
Db	11 AGCCCAAGAA 2			
RESULT 84				
AR349261/c	AR349261	12 bp	DNA	linear
LOCUS	Sequence 8 from patent US 6583986.			PAT 17-AUG-2003
DEFINITION	AR349261			
ACCESSION	AR349261.1	GI:33749986		
VERSION				
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	Unclassified.			
AUTHORS	1 (bases 1 to 12)			
TITLE	Scotti,W.J., Sibley,K., Ovadia,S., Kimball,S. and Falvo,B.			
JOURNAL	Method and apparatus for managing thermal energy emissions.			
FEATURES	Patent: US 6583986-A 8 24-JUN-2003;			
source	Location/Qualifiers			
	1..12			
	/organism="unknown"			
	/mol_type="genomic DNA"			
Query Match	15.4%;	Score 10;	DB 1;	Length 12;
Best Local Similarity	100.0%;	Pred. No. 47;		
Matches	10;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
QY	23 AGCCCAAGAA 32			
Db	11 AGCCCAAGAA 2			
RESULT 85				
A01985/c	A01985	13 bp	DNA	linear
LOCUS	Artificial sequence for promoter fragment for			PAT 23-MAR-1993
DEFINITION	glyceraldehyde-3-phosphate dehydrogenase operon.			
ACCESSION	A01985.1	GI:344517		
VERSION				
KEYWORDS				
SOURCE				
ORGANISM	synthetic construct			
REFERENCE	synthetic construct			
AUTHORS	artificial sequences.			
JOURNAL	1 (bases 1 to 13)			
FEATURES	Patent: WO 8404538-A 13 22-NOV-1984;			
source	Location/Qualifiers			
	1..13			
	/organism="synthetic construct"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:32630"			
Query Match	15.1%;	Score 9.8;	DB 1;	Length 13;
Best Local Similarity	84.6%;	Pred. No. 55;		
Matches	11;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
QY	30 GAACAGAAAGAAC 42			
Db	13 GAAGAGAAACAC 1			
RESULT 86				
A06431/c	A06431	13 bp	DNA	linear
LOCUS	Artificial sequence for promoter fragment for			PAT 21-MAY-1993
DEFINITION	glyceraldehyde-3-phosphate dehydrogenase operon, duplicate.			
ACCESSION	A06431			

VERSION	A06431.1	GI:411257
KEYWORDS	.	
SOURCE	synthetic construct	
ORGANISM	synthetic construct	
	artificial sequences.	
REFERENCE	1 (bases 1 to 13)	
AUTHORS	Edens,L., Russell,S.W., Visser,C. and Verrips,C.T.,	
TITLE	Improvements in the expression of newly introduced genes in yeast cells	
JOURNAL	Patent: EP 0129268-A 14 27-DEC-1984;	
UNILEVER NV; UNILEVER PLC		
FEATURES	location/Qualifiers	
source	1..13	
	/organism="synthetic construct"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:32630"	
Query Match	15.1%; Score 9.8; DB 1; Length 13;	
Best Local Similarity	84.6%; Pred.No.55;	
Matches	11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
OY	30 GACAGAAAGAAC 42	
DB	13 GAAGAACAAC 1	
RESULT 87	BD062265	13 bp DNA linear PAT 27-AUG-2002
LOCUS	Nucleic acid for detecting Mycobacterium bacteria.	
DEFINITION	BD062265	
ACCESSION	BD062265.1 GI:22607870	
VERSION	JP 2001299354-A/37.	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	artificial sequences.	
REFERENCE	1 (bases 1 to 13)	
AUTHORS	Fukushima,M., Kakinuma,K., Kawaguchi,R. and Kasai,H.	
TITLE	Nucleic acid for detecting Mycobacterium bacteria	
JOURNAL	Patent: JP 2001299354-A 37 30-OCT-2001;	
	SRL INC,MARINE BIOTECHNOLOGY INST CO LTD,NIPPON GENE CO LTD	
COMMENT	OS Artificial Sequence	
	PN JP 2001299354-A/37	
	PD 30-OCT-2001	
	PF 21-APR-2000 JP 2000121604	
	PI MASO FUKUSHIMA,KENICHI KAKINUMA,RYUJI KAWAGUCHI,HIROAKI KASAI	
	PC C12N15/09,C12Q1/68,G01N33/569//C12Q1/68,C12R1:325),(C12Q1/68,	
	PC C12R1:33),	
	PC C12N15/00	
	CC Nucleic Acid for detecting Mycobacterium tuberculosis FH	
FEATURES	location/Qualifiers	Key
source	1..13	
	/organism="synthetic construct"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32630"	
Query Match	15.1%; Score 9.8; DB 1; Length 13;	
Best Local Similarity	84.6%; Pred.No.55;	
Matches	11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
OY	44 TTGCTGGGGTTTG 56	
DB	13 TCGGTGGGGTTTG 1	
RESULT 88	I16094	11 bp DNA linear PAT 03-APR-1996
LOCUS	Sequence 3 from patent US 5474897.	
DEFINITION	I16094	
ACCESSION	I16094.1 GI:1251002	
VERSION		
KEYWORDS	.	

```

SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 11)
TITLE        Weiss, A. and Fraser, J.
JOURNAL      Screening assay for the identification of novel immunosuppressives
FEATURES     using cultured T cells
source       Patent: US 5474897-A 3 12-DRC-1995;
             Location/Qualifiers
             1..11
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TGGAGGTTTCA 64
Db 1 TGGAGGTTTCA 11

RESULT 89
AX393078/c      11 bp      DNA      linear      PAT 23-MAR-2002
LOCUS           Sequence 8 from Patent WO0210217.
DEFINITION      AX393078
ACCESSION       AX393078
VERSION         AX393078.1 GI:19701128
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS      St Croix, B., Kinzler, K.W. and Vogelstein, B.
TITLE        Endothelial cell expression patterns
JOURNAL      Patent: WO 0210217-A 8 07-FEB-2002;
             The Johns Hopkins University (US)
FEATURES     Location/Qualifiers
source       1..11
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 27 CAAGACAGAA 37
Db 11 CAAGACAGAA 1

RESULT 90
AX470597/c      11 bp      DNA      linear      PAT 09-AUG-2002
LOCUS           Sequence 174 from Patent WO02053773.
DEFINITION      AX470597
ACCESSION       AX470597
VERSION         AX470597.1 GI:22205722
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS      Hofmann, K., Conradt, M. and Petersohn, D.
TITLE        Method for determining skin stress or skin ageing in vitro
JOURNAL      Patent: WO 02053773-A 174 11-JUL-2002;
             HENKEL KGAA (DE)
FEATURES     Location/Qualifiers
source       1..11
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGAACTT 44
Db 1 AGAAGAACTT 11

RESULT 91
AX470878/c      11 bp      DNA      linear      PAT 09-AUG-2002
LOCUS           Sequence 455 from Patent WO02053773.
DEFINITION      AX470878
ACCESSION       AX470878
VERSION         AX470878.1 GI:22206003
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS      Hofmann, K., Conradt, M. and Petersohn, D.
TITLE        Method for determining skin stress or skin ageing in vitro
JOURNAL      Patent: WO 02053773-A 455 11-JUL-2002;
             HENKEL KGAA (DE)
FEATURES     Location/Qualifiers
source       1..11
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
Db 11 GGACATAGCCC 1

RESULT 92
AX471365/c      11 bp      DNA      linear      PAT 09-AUG-2002
LOCUS           Sequence 942 from Patent WO02053773.
DEFINITION      AX471365
ACCESSION       AX471365
VERSION         AX471365.1 GI:22206490
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS      Hofmann, K., Conradt, M. and Petersohn, D.
TITLE        Method for determining skin stress or skin ageing in vitro
JOURNAL      Patent: WO 02053773-A 942 11-JUL-2002;
             HENKEL KGAA (DE)
FEATURES     Location/Qualifiers
source       1..11
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGAACTT 44
Db 1 AGAAGAACTT 11

```

RESULT 93
AX623489/c
LOCUS AX623489 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 530 from Patent WO02053774.
ACCESSION AX623489
VERSION AX623489.1 GI:28451430
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 530 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 15 TTGGACTATGC 25
|||||
11 TTGGATATATGC 1

Db 11 TTGGATATATGC 1

RESULT 94
AX624179/c
LOCUS AX624179 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1220 from Patent WO02053774.
ACCESSION AX624179
VERSION AX624179.1 GI:28452120
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 1220 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
|||||
11 GGACGTAGCCC 1

Db 11 GGACGTAGCCC 1

RESULT 95
AX624329/c
LOCUS AX624329 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1370 from Patent WO02053774.
ACCESSION AX624329
VERSION AX624329.1 GI:28452270
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 1370 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 55 GGAGGTTTCAC 65
|||||
11 GGAGGTTTCAC 1

Db 11 GGAGGTTTCAC 1

RESULT 96
AX624484
LOCUS AX624484 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1525 from Patent WO02053774.
ACCESSION AX624484
VERSION AX624484.1 GI:28452425
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 1525 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGACTCT 44
|||||
1 AGAAGACTCT 11

Db 1 AGAAGACTCT 11

RESULT 97
AX625720
LOCUS AX625720 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2761 from Patent WO02053774.
ACCESSION AX625720
VERSION AX625720.1 GI:28453661
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2761 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
FEATURES
source 1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 55;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGG 59
 |||||
 1 GGGGCTGGAGG 11

Db

RESULT 98
 AX625789/c
 LOCUS AX625789 11 bp DNA linear PAT 21-FEB-2003
 DEFINITION Sequence 2830 from Patent WO02053774.
 ACCESSION AX625789
 VERSION AX625789.1 GI:28453730
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A/2830 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
 source
 1. .11
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 55;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 29 AGACAGAAAG 39
 |||||
 11 ATACAGAAAG 1

Db

RESULT 99
 AX626474/c
 LOCUS AX626474 11 bp DNA linear PAT 21-FEB-2003
 DEFINITION Sequence 3515 from Patent WO02053774.
 ACCESSION AX626474
 VERSION AX626474.1 GI:28454512
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A/3515 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
 source
 1. .11
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 55;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 27 CAAGAACAGAA 37
 |||||
 11 CAAGACAGAA 1

Db

RESULT 100
 AX627570/c

LOCUS AX627570 11 bp DNA linear PAT 21-FEB-2003
 DEFINITION Sequence 4611 from Patent WO02053774.
 ACCESSION AX627570
 VERSION AX627570.1 GI:28455608
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A/4611 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
 source
 1. .11
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 55;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 50 GGGTTGGAGCT 60
 |||||
 11 GGGTGGAGCT 1

Db

RESULT 101
 AX628639/c
 LOCUS AX628639 11 bp DNA linear PAT 21-FEB-2003
 DEFINITION Sequence 5680 from Patent WO02053774.
 ACCESSION AX628639
 VERSION AX628639.1 GI:28456677
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A/5680 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
 source
 1. .11
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 55;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGG 59
 |||||
 11 GGGGCTGGAGG 1

Db

RESULT 102
 AX628640/c
 LOCUS AX628640 11 bp DNA linear PAT 21-FEB-2003
 DEFINITION Sequence 5681 from Patent WO02053774.
 ACCESSION AX628640
 VERSION AX628640.1 GI:28456678
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
 TITLE Method for determining homeostasis of the skin
 JOURNAL Patent: WO 02053774-A/5681 11-JUL-2002;
 Henkel Kommanditgesellschaft auf Aktien (DE)

TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 5681 11-JUL-2002; (DE)
FEATURES Henkel Kommanditgesellschaft auf Aktien (DE)
source Location/Qualifiers

1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 AGAAGAGAAAG 39
|||||
Db 11 AGAAGAGACAG 1

RESULT 103
AX628771/c 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX628771
DEFINITION Sequence 5812 from Patent WO02053774.
ACCESSION AX628771
VERSION AX628771.1 GI:28456809

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 5812 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
source Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 CCAAGAACACA 36
|||||
Db 11 CCAATAACACA 1

RESULT 104
AX629905 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX629905
DEFINITION Sequence 6946 from Patent WO02053774.
ACCESSION AX629905
VERSION AX629905.1 GI:28457943

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6946 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
source Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 46 GCTGGGGTTGG 56
|||||
Db 1 GCTGGGGTTGG 11

RESULT 105
AX630278/c 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX630278
DEFINITION Sequence 7319 from Patent WO02053774.
ACCESSION AX630278
VERSION AX630278.1 GI:28458316

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7319 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
source Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 31 AACAGAAAGA 41
|||||
Db 11 AACAGAGAGA 1

RESULT 106
AX630910/c 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX630910
DEFINITION Sequence 7951 from Patent WO02053774.
ACCESSION AX630910
VERSION AX630910.1 GI:28458950

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7951 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)

FEATURES
source Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 15 TTGGACATAGC 25
|||||
Db 11 TTGGATATAGC 1

RESULT 107
AX631600/c 11 bp DNA linear PAT 21-FEB-2003
LOCUS AX631600
DEFINITION Sequence 8642 from Patent WO02053774.

```

ACCESSION  AX631600.1  GI:28459676
VERSION
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE   1
AUTHORS     Petersohn, D., Conrad, M. and Hofmann, K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8642 11-JUL-2002;
             Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1..11
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
    |||||
    11 GGACGTAGCCC 1

RESULT 108
LOCUS      AX631750
DEFINITION Sequence 8792 from Patent WO02053774.
ACCESSION  AX631750
VERSION    AX631750.1  GI:28459857
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE   1
AUTHORS     Petersohn, D., Conrad, M. and Hofmann, K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8792 11-JUL-2002;
             Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
  source
    1..11
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 55 GGAGCTTTTAC 65
    |||||
    11 GGAGCTTTTAC 1

RESULT 109
LOCUS      AX631905
DEFINITION Sequence 8947 from Patent WO02053774.
ACCESSION  AX631905
VERSION    AX631905.1  GI:28460043
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE   1
AUTHORS     Petersohn, D., Conrad, M. and Hofmann, K.
TITLE       Method for determining homeostasis of the skin
JOURNAL     Patent: WO 02053774-A 8947 11-JUL-2002;

```

```

FEATURES
  source
    1..11
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGACCT 44
    |||||
    1 AGAAGACCT 11

RESULT 110
LOCUS      A03728
DEFINITION synthetic linker.
ACCESSION  A03728
VERSION    A03728.1  GI:410914
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified

REFERENCE   1 (bases 1 to 12)
AUTHORS     Grundmann, U., Amann, E. and Zettlmeissl, G.
TITLE       Production of factor XIIIa by gene technology
JOURNAL     Patent: EP 0236978-A 2 16-SEP-1987;
             BEHRINGWERKE Aktiengesellschaft
FEATURES
  source
    1..12
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGGA 19
    |||||
    2 ATGGAATTGGA 12

RESULT 111
LOCUS      A03729
DEFINITION synthetic linker.
ACCESSION  A03729
VERSION    A03729.1  GI:410915
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified

REFERENCE   1 (bases 1 to 12)
AUTHORS     Grundmann, U., Amann, E. and Zettlmeissl, G.
TITLE       Production of factor XIIIa by gene technology
JOURNAL     Patent: EP 0236978-A 3 16-SEP-1987;
             BEHRINGWERKE Aktiengesellschaft
FEATURES
  source
    1..12
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGGA 19
    |||||

```


Db 11 ATGGAATTGCA 1

RESULT 112

LOCUS A03738

DEFINITION Nucleotide sequence 12 from patent number EP0236978.

ACCESSION A03738

VERSION A03738.1 GI:410920

KEYWORDS

SOURCE

ORGANISM

REFERENCE

1 (bases 1 to 12)

1 Grundmann, U., Amann, E. and Zettlmeis, G.
Production of factor XIIIa by gene technology
Patent: EP 0236978-A 12 16-SEP-1987;
BEHRINGWERKE Aktiengesellschaft
Location/Qualifiers

FEATURES

source

1. .12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGCA 19
|||||
2 ATGGAATTGCA 12

Db

RESULT 113

LOCUS A03921

DEFINITION Nucleotide sequence 3 from patent number EP0238329.

ACCESSION A03921

VERSION A03921.1 GI:410932

KEYWORDS

SOURCE

ORGANISM

REFERENCE

1 (bases 1 to 12)

1 Jeffreys, A.J.
Improvements in genetic probes
Patent: EP 0238329-A 3 23-SEP-1987;
IMPERIAL CHEMICAL INDUSTRIES PLC
Location/Qualifiers

FEATURES

source

1. .12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGG 59
|||||
2 GGGGCTGGAGG 12

Db

RESULT 114

LOCUS A31783

DEFINITION synthetic linker DNA from patent EP0494702.

ACCESSION A31783

VERSION A31783.1 GI:1247277

KEYWORDS

SOURCE

ORGANISM

artificial sequences.

REFERENCE

1 (bases 1 to 12)

1 Grundmann, U., Amann, E. and Zettlmeis, G.
Production of factor XIIIa by gene technology
Patent: EP 0494702-A 1 15-JUL-1992;
BEHRINGWERKE Aktiengesellschaft
Location/Qualifiers

FEATURES

source

1. .12
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGCA 19
|||||
2 ATGGAATTGCA 12

Db

RESULT 115

LOCUS A47652/c

DEFINITION Sequence 12 from Patent EP0692535.

ACCESSION A47652

VERSION A47652.1 GI:2301593

KEYWORDS

SOURCE

ORGANISM

REFERENCE

1 (bases 1 to 12)

1 Colore, S. and Pirozky, E.
Oligonucleotides to inhibit the role of isoprenyl protein
transferases
Patent: EP 0692535-A 12 17-JAN-1996;
SOD CONSEILS RECH APPLIC (FR)
Other publication CN 1124142 960612
Other publication CZ 9501688 960515
Other publication BR 9503015 960604
Other publication NZ 272398 960426
Other publication HU 72133 960328
Other publication JP 8051985 960227
Other publication FR 2721930 960105
Other publication FR 2721827 960105
Other publication FI 953170 951230
Other publication SE 9502259 951230
Other publication PL 309384 960108
Other publication NO 952601 960102
Other publication AU 2329995 960111
Other publication CA 2152233 951230
Other publication GB 2290791 960110.
Other publication

FEATURES

source

1. .12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 AGCCCAAGAAC 33
|||||
11 AGCCCAAAAC 1

Db

RESULT 116

LOCUS AR027870/c

DEFINITION Sequence 12 from patent US 5856461.

ACCESSION AR027870

VERSION AR027870.1 GI:5938690

KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Colote, S. and Pirozky, E.
Oligonucleotides to inhibit the expression of isoprenyl protein transferases
JOURNAL Patent: US 5856461-A 12 05-JAN-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 23 ACCCCAGAAC 33
Db 11 AGCCCAAAAC 1

RESULT 117
LOCUS AR036375 12 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 38 from patent US 5872105.
ACCESSION AR036375
VERSION AR036375.1 GI:5953043
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Kool, E.T.
TITLE Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL Patent: US 5872105-A 38 16-FEB-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAG 39
Db 1 AAGAAAGAAAG 12

RESULT 118
LOCUS AR036376 12 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 39 from patent US 5872105.
ACCESSION AR036376
VERSION AR036376.1 GI:5953044
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Kool, E.T.
TITLE Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL Patent: US 5872105-A 39 16-FEB-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAG 39
Db 1 AAGAAAGAAAG 12

RESULT 119
LOCUS AR074233 12 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 41 from patent US 5952490.
ACCESSION AR074233
VERSION AR074233.1 GI:10000988
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)
AUTHORS Hanecak, R.C., Anderson, K.P., Bennett, C.Frank, Chiang, M.-Y.,
Brown-Driver, V.L., Ecker, D.J., Vickers, T.A., Wyatt, J.R. and
Imbach, J. Louis.
TITLE Oligonucleotides having a conserved G4 core sequence
JOURNAL Patent: US 5952490-A 41 14-SEP-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 120
LOCUS AR074249 12 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 57 from patent US 5952490.
ACCESSION AR074249
VERSION AR074249.1 GI:10001004
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Hanecak, R.C., Anderson, K.P., Bennett, C.Frank, Chiang, M.-Y.,
Brown-Driver, V.L., Ecker, D.J., Vickers, T.A., Wyatt, J.R. and
Imbach, J. Louis.
TITLE Oligonucleotides having a conserved G4 core sequence
JOURNAL Patent: US 5952490-A 57 14-SEP-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 121
LOCUS AR074305 12 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 113 from patent US 5952490.
ACCESSION AR074305
VERSION AR074305.1 GI:10001060
KEYWORDS
SOURCE Unknown.

```

ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 12)
AUTHORS        Hanecak,R.C., Anderson,K.P., Bennett,C.Frank., Chiang,M.-Y.,
                Brown-Driver,V.L., Ecker,D.J., Vickers,T.A., Wyatt,V.R. and
                Imbach,J.Louis.
TITLE          Oligonucleotides having a conserved G4 core sequence
JOURNAL        Patent: US 5952490-A 113 14-SEP-1999;
FEATURES       Location/Qualifiers
                source
                1..12
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY              48 TGGGGTTGGAG 58
                |||||
                2 TGGGGTTGGAG 12
Db

RESULT 122
LOCUS      ARI72240 12 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 64 from patent US 6303295.
ACCESSION  ARI72240
VERSION     ARI72240.1 GI:17911731
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 12)
AUTHORS      Taylor,E.Will., Nadimpalli,R.Gopal. and Ramanathan,C.Sekar.
TITLE        Selenoproteins, coding sequences and methods
JOURNAL      Patent: US 6303295-A 64 16-OCT-2001;
FEATURES     Location/Qualifiers
                source
                1..12
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY              3 TCTGAATGGA 13
                |||||
                Db          12 TCTGAATGGA 2

RESULT 123
LOCUS      I20197 12 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 12 from patent US 5514546.
ACCESSION  I20197
VERSION     I20197.1 GI:1600552
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 12)
AUTHORS      Koal,E.T.
TITLE        Stem-loop oligonucleotides containing parallel and antiparallel
                binding domains
JOURNAL      Patent: US 5514546-A 12 07-MAY-1996;
FEATURES     Location/Qualifiers
                source
                1..12
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY              28 AAGACGAAAG 39
                |||||
                Db          1 AAGAAAGAAAG 12

RESULT 124
LOCUS      I20198 12 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 13 from patent US 5514546.
ACCESSION  I20198
VERSION     I20198.1 GI:1600553
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 12)
AUTHORS      Koal,E.T.
TITLE        Stem-loop oligonucleotides containing parallel and antiparallel
                binding domains
JOURNAL      Patent: US 5514546-A 13 07-MAY-1996;
FEATURES     Location/Qualifiers
                source
                1..12
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY              28 AAGACGAAAG 39
                |||||
                Db          1 AAGAAAGAAAG 12

RESULT 125
LOCUS      I20474 12 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 53 from patent US 5514577.
ACCESSION  I20474
VERSION     I20474.1 GI:1600829
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 12)
AUTHORS      Draper,K.G., Crooke,S.T., Mirabelli,C.K., Ecker,D.J., Hanecak,R.C.,
                Anderson,K.P., Brown-Driver,V.L. and Wyatt,V.R.
TITLE        Oligonucleotide therapies for modulating the effects of herpes
                viruses
JOURNAL      Patent: US 5514577-A 53 07-MAY-1996;
FEATURES     Location/Qualifiers
                source
                1..12
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY              48 TGGGGTTGGAG 58
                |||||
                Db          2 TGGGGTTGGAG 12

RESULT 126
LOCUS      I72123 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 38 from patent US 5683874.
ACCESSION  I72123
VERSION     I72123.1 GI:3008262
KEYWORDS
SOURCE      Unknown.

```

```

ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 5683874-A 38 04-NOV-1997;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 1 AAGANAGAAAG 12

RESULT 127
172124
LOCUS 172124 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 39 from patent US 5683874.
ACCESSION 172124
VERSION 172124.1 GI:3008263
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 5683874-A 39 04-NOV-1997;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 1 AAGAAAAAAG 12

RESULT 128
AR307251
LOCUS AR307251 12 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5 from patent US 6551774.
ACCESSION AR307251
VERSION AR307251.1 GI:31697778
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 6551774-A 5 22-APR-2003;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 131
AX032595
LOCUS AX032595 12 bp DNA linear PAT 20-SEP-2000
DEFINITION Sequence 41 from Patent EP1016715.
ACCESSION AX032595
VERSION AX032595.1 GI:10279533

```

```

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 129
AR307276
LOCUS AR307276 12 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 33 from patent US 6551774.
ACCESSION AR307276
VERSION AR307276.1 GI:31697803
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 6551774-A 33 22-APR-2003;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 130
AR307278
LOCUS AR307278 12 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 35 from patent US 6551774.
ACCESSION AR307278
VERSION AR307278.1 GI:31697805
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 6551774-A 35 22-APR-2003;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 131
AX032595
LOCUS AX032595 12 bp DNA linear PAT 20-SEP-2000
DEFINITION Sequence 41 from Patent EP1016715.
ACCESSION AX032595
VERSION AX032595.1 GI:10279533

```

KEYWORDS
SOURCE unidentified
ORGANISM unclassified

REFERENCE
AUTHORS 1
Imbach,J.L., Brown-Driver,V.L., Vickers,T.A., Ecker,D.J.,
Bennett,C.F., Chiang,M.Y., Anderson,K.P., Hanecak,R.C. and
Wyatt,J.R.

TITLE
JOURNAL Oligonucleotides having a conserved g4 core sequence
Patent: EP 1016715-A 41 05-JUL-2000;
ISIS PHARMACEUTICALS INC (US)

FEATURES
source 1..12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGAG 12

RESULT 132
AX032611 12 bp DNA linear PAT 20-SEP-2000

LOCUS
DEFINITION Sequence 57 from Patent EP1016715.
ACCESSION AX032611
VERSION AX032611.1 GI:10279549

KEYWORDS
SOURCE unidentified
ORGANISM unclassified

REFERENCE
AUTHORS 1
Imbach,J.L., Brown-Driver,V.L., Vickers,T.A., Ecker,D.J.,
Bennett,C.F., Chiang,M.Y., Anderson,K.P., Hanecak,R.C. and
Wyatt,J.R.

TITLE
JOURNAL Oligonucleotides having a conserved g4 core sequence
Patent: EP 1016715-A 57 05-JUL-2000;
ISIS PHARMACEUTICALS INC (US)

FEATURES
source 1..12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGAG 12

RESULT 133
AX032667 12 bp DNA linear PAT 20-SEP-2000

LOCUS
DEFINITION Sequence 113 from Patent EP1016715.
ACCESSION AX032667
VERSION AX032667.1 GI:10279605

KEYWORDS
SOURCE unidentified
ORGANISM unclassified

REFERENCE
AUTHORS 1
Imbach,J.L., Brown-Driver,V.L., Vickers,T.A., Ecker,D.J.,
Bennett,C.F., Chiang,M.Y., Anderson,K.P., Hanecak,R.C. and
Wyatt,J.R.

TITLE
JOURNAL Oligonucleotides having a conserved g4 core sequence

JOURNAL Patent: EP 1016715-A 113 05-JUL-2000;
ISIS PHARMACEUTICALS INC (US)

FEATURES
source 1..12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGAG 12

RESULT 134
BD080370/c 12 bp DNA linear PAT 27-AUG-2002

LOCUS
DEFINITION Methods of synthesizing oligonucleotides with random codons.
ACCESSION BD080370
VERSION BD080370.1 GI:22625973

KEYWORDS
SOURCE JP 2001299342-A/36.
synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
AUTHORS 1 (bases 1 to 12)
Huse,W.D.

TITLE
JOURNAL Methods of synthesizing oligonucleotides with random codons
Patent: JP 2001299342-A 36 30-OCT-2001;
IXSYS INC

COMMENT
OS Artificial Sequence
PN JP 2001299342-A/36
PD 30-OCT-2001
PR 15-MAR-2001 JP 2001075101
PR 24-AUG-1990 US 573648
PI WILLIAM D HUSE
PC C12N15/00,C07H21/04,C12Q1/68,C12N15/00
CC synthetic construct
FH Key
FT source 1..12
/organism='Artificial Sequence'.
Location/Qualifiers

FEATURES
source 1..12
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 6 GGAATGGAATT 16
|||||
Db 11 GGATGGAATT 1

Search completed: August 12, 2004, 15:32:44
Job time : 2 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:30:40 ; Search time 1 seconds
(without alignments)
0.117 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65
Sequence: 1 tttctcgatgcgattgcgac.....gtctggggttcgaggttcac 65

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 0.5

Searched: 61 seqs, 898 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 61 summaries

Database : pub:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	25	38.5	25	1	US-10-717-597-3888
2	25	38.5	25	1	US-10-717-597-3888
3	20	30.8	20	1	US-10-033-742-20
4	20	30.8	20	1	US-10-033-742-21
5	20	30.8	20	1	US-10-033-742-22
6	20	30.8	20	1	US-10-033-742-23
7	19.8	30.5	23	1	US-10-345-859-12
8	15.8	24.3	21	1	US-10-004-551-107
9	13.8	21.2	17	1	US-09-848-754A-2614
10	13.4	20.6	16	1	US-10-377-216-367
11	13.4	20.6	16	1	US-10-126-022-367
12	13.4	20.6	16	1	US-09-780-164-127
13	13.4	20.6	17	1	US-09-780-164-128
14	13.4	20.6	17	1	US-09-780-164-129
15	13.4	20.6	17	1	US-09-780-164-129
16	13.4	20.6	17	1	US-09-780-164-129
17	12.8	19.7	16	1	US-09-969-373-2913
18	12.8	19.7	17	1	US-09-866-108-2464
19	12.8	19.7	17	1	US-09-866-108-2465
20	12.8	19.7	17	1	US-09-780-164-1042
21	12.8	19.7	17	1	US-10-156-306-3729
22	12.8	19.7	17	1	US-10-723-361-2464
23	12.8	19.7	17	1	US-10-723-361-2465
24	11.4	17.5	13	1	US-09-888-326-450
25	11.4	17.5	13	1	US-09-776-479-796
26	11.4	17.5	13	1	US-09-776-479-796
27	11.4	17.5	13	1	US-10-314-578-796
28	11.4	17.5	13	1	US-10-112-653-769
29	11.4	17.5	13	1	US-10-017-995-796
30	11.4	17.5	15	1	US-10-132-002-5
31	10.8	16.6	14	1	US-10-132-002-9
32	10.8	16.6	14	1	US-09-981-803-32
33	10.8	16.6	14	1	US-09-981-803-32
33	10.8	16.6	14	1	US-10-275-071-29

Published - Applications - NA

C 34	10.8	16.6	14	1	US-10-275-071-30	Sequence 30, Appl
C 35	10.8	16.6	14	1	US-10-684-830-35	Sequence 35, Appl
C 36	10.8	16.6	14	1	US-10-684-830-36	Sequence 36, Appl
C 37	10.8	16.6	14	1	US-10-684-830-38	Sequence 38, Appl
C 38	10.4	16.0	13	1	US-10-253-904-45	Sequence 45, Appl
C 39	10.4	16.0	13	1	US-10-392-970-36	Sequence 36, Appl
C 40	10.4	16.0	13	1	US-10-033-145-322	Sequence 322, App
C 41	10.4	15.4	10	1	US-10-330-627-973	Sequence 973, App
C 42	10.4	15.4	11	1	US-10-450-797-847	Sequence 847, App
C 43	10.4	15.4	12	1	US-10-091-281-67	Sequence 67, Appl
C 44	9.8	15.1	13	1	US-09-789-836-31	Sequence 31, Appl
C 45	9.8	15.1	13	1	US-09-789-831-29	Sequence 29, Appl
C 46	9.4	14.5	11	1	US-09-918-715-8	Sequence 8, Appl
C 47	9.4	14.5	11	1	US-10-450-797-174	Sequence 174, App
C 48	9.4	14.5	11	1	US-10-450-797-455	Sequence 455, App
C 49	9.4	14.5	11	1	US-10-450-797-942	Sequence 942, App
C 50	9.4	14.5	12	1	US-09-263-959-425	Sequence 425, App
C 51	9.4	14.5	12	1	US-09-263-959-587	Sequence 587, App
C 52	9.4	14.5	12	1	US-09-263-959-660	Sequence 660, App
C 53	9.4	14.5	12	1	US-10-140-896-4	Sequence 4, Appl
C 54	9.4	14.5	12	1	US-10-232-927A-5	Sequence 5, Appl
C 55	9.4	14.5	12	1	US-10-232-927A-33	Sequence 33, Appl
C 56	9.4	14.5	12	1	US-10-232-927A-35	Sequence 35, Appl
C 57	9.4	14.5	12	1	US-10-422-262-18	Sequence 18, Appl
C 58	9.4	14.5	12	1	US-10-422-262-19	Sequence 19, Appl
C 59	9.4	14.5	12	1	US-10-422-262-20	Sequence 20, Appl
C 60	9.4	14.5	12	1	US-10-422-262-21	Sequence 21, Appl
C 61	9.4	14.5	12	1	US-10-422-262-22	Sequence 22, Appl

ALIGNMENTS

```

RESULT 1
US-10-717-597-3888
; Sequence 3888, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dornier, Andrew J.
; APPLICANT: Trepcichio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AML01080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3888
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-3888

Query Match      38.5% Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.62;
Matches 25; Conservative 0; Mismatches 0; Incels 0; Gaps 0;

QY      11 GGATTGACATAGCCCAAGAACAG 35
Db      1 GGATTGACATAGCCCAAGAACAG 25

RESULT 2
US-10-717-597-3889
; Sequence 3889, Application US/10717597

```

```
/ Publication No. US20040110221A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Burezynski, Michael E.
/ APPLICANT: Twine, Natalie C.
/ APPLICANT: Dornier, Andrew J.
/ APPLICANT: Trepicchio, William L.
/ APPLICANT: Slonim, Donna K.
/ APPLICANT: Stover, Jennifer A.
/ TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
/ FILE REFERENCE: AM1010801
/ CURRENT APPLICATION NUMBER: US/10/717,597
/ PRIOR FILING DATE: 2003-11-21
/ PRIOR APPLICATION NUMBER: US 60/459,782
/ PRIOR FILING DATE: 2003-04-03
/ PRIOR APPLICATION NUMBER: US 60/427,982
/ NUMBER OF SEQ ID NOS: 4904
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 3889
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-717-597-3889
```

```
Query Match
Best Local Similarity 38.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 16 TGGACATAGCCCAAGACGAAAGA 40
DB 1 TGGACATAGCCCAAGACGAAAGA 25
```

```
RESULT 3
US-10-033-742-20/c
/ Sequence 20, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA E
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 20
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-20
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TTTCTGGAATGGAAATGGAC 20
DB 20 TTTCTGGAATGGAAATGGAC 1
```

```
RESULT 4
US-10-033-742-21/c
/ Sequence 21, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA E
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
```

```
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-21
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 11 GGAATTGACATAGCCCAAG 30
DB 20 GGAATTGACATAGCCCAAG 1
```

```
RESULT 5
US-10-033-742-22/c
/ Sequence 22, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA E
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 22
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-22
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 27 CAAGACAGAAAGACCTTG 46
DB 20 CAAGACAGAAAGACCTTG 1
```

```
RESULT 6
US-10-033-742-23/c
/ Sequence 23, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA E
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 23
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-23
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 46 GCTGGGGTTGAGGTTTCAC 65
```


Db 20 GCTGGGCTTGAGTTTCAC 1

```
RESULT 7
US-10-345-859-12/c
; Sequence 12, Application US/10345859
; Publication No. US20030175895A1
; GENERAL INFORMATION:
; APPLICANT: Leselauer, Werner
; Utans-Schneitz, Ulrike
; TITLE OF INVENTION: NEW CHEMOKINE
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: N.J.
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/345,859
; FILING DATE: 16-Jan-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,353
; FILING DATE: <Unknown>
; APPLICATION NUMBER: EP 97107135.2
; FILING DATE: 30-APR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kreisler, Lewis J
; REGISTRATION NUMBER: 38522
; REFERENCE/DOCKET NUMBER: 13235
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (973) 235-4387
; TELEFAX: (973) 235-2363
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-345-859-12

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 3;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGGATGGAATTCGACATRACC 26
Db 23 CTGGATGGAATTCGACACAGCC 1

RESULT 8
US-10-004-551-107/c
; Sequence 107, Application US/10004551
; Publication No. US20030004310A1
; GENERAL INFORMATION:
; APPLICANT: SHIMKETS, RICHARD A
; APPLICANT: FERNANDES, RIMA
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY
; FILE REFERENCE: 15966-559
; CURRENT APPLICATION NUMBER: US/10/004,551
; CURRENT FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: 09/535,949
```

```
; PRIOR FILING DATE: 2000-08-10
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 107
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-10-004-551-107
```

Query Match 24.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 9.6;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 42 CCTTGCTGGGCTTGAGGT 60
Db 21 CCTTCTGGGCTTGAGGT 3

```
RESULT 9
US-09-848-754A-2614
; Sequence 2614, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
; FILE REFERENCE: MBH800-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2614
```

Query Match 21.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 14;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 34 AGAAGAACCTTGCTGC 50
Db 1 AGAAGAACCTTGCTGC 17

```
RESULT 10
US-10-277-216-367
; Sequence 367, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 367
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
```

US-10-277-216-367

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGGTTGGAGGT 60
DB 2 GCTGGGGTTGGAGGT 16

RESULT 11

US-10-126-022-367
; Sequence 367, Application US/10126022
; Publication No. US2004002215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 367
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-367

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGGTTGGAGGT 60
DB 2 GCTGGGGTTGGAGGT 16

RESULT 12

US-09-780-164-127/C
; Sequence 127, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 127
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-127

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
|||||

DB 16 GCCCAAGAACAGAA 2

RESULT 13

US-09-780-164-128/C
; Sequence 128, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 128
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-128

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
DB 15 GCCCAAGAACAGAA 1

RESULT 14

US-09-780-164-129/C
; Sequence 129, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 129
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-129

Query Match

Best Local Similarity 20.0%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 36
DB 13 GCCCAAGAACAGAA 1

RESULT 15

US-09-780-164-497/C
; Sequence 497, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim

```

; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 497
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-164-497

Query Match          20.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      24  |G|C|C|C|A|G|A|C|A|G|A| 36
Db      14  |G|C|C|C|A|G|A|C|A|G|A| 2

RESULT 16
; US-09-969-373-2913/c
; Sequence 2913, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Efectz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2913
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Glycine max
; US-09-969-373-2913

Query Match          19.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      44  |T|T|G|C|T|G|G|G|T|T|G|A|G|C| 59
Db      16  |T|T|G|C|T|G|G|T|T|G|T|G|G| 1

RESULT 17
; US-09-866-108-2464
; Sequence 2464, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-2464

Query Match          19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      4  |C|T|G|A|T|G|A|A|T|T|G|A| 19
Db      2  |C|T|G|A|T|T|G|A|C|T|T|G|A| 17

RESULT 18
; US-09-866-108-2465
; Sequence 2465, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2465
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2465
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      4 CTGGAATGGAATTGGA 19
         |||||
Db       1 CTGATGTGACTTGA 16
```

```
RESULT 19
US-09-780-164-1042
; Sequence 1042, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1042
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-1042
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      26 CCAAGAACGAAAGAA 41
         |||||
Db       2 CCAAGAAAGAAAGAA 17
```

```
RESULT 20
US-10-156-306-3729
; Sequence 3729, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
; FILE REFERENCE: MEH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; PRIOR FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3729
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3729
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 18;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      5 TCGAATGGAATTGAC 20
         :|||:
Db       2 UGGAAGAAAGUCGAC 17
```

```
RESULT 21
US-10-723-361-2464
; Sequence 2464, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2464
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      4 CTGGAATGGAATTGGA 19
```

Db 2 CTGATTGACTTGA 17

```
RESULT 22
US-10-723-361-2465
; Sequence 2465, Application US/10723361
; Publication No. US20040137588A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; FILE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2465
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2465

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 4 CTGAATGGAATGGA 19
Db 1 CTGATTGACTTGA 16

```
RESULT 23
US-09-888-326-450
; Sequence 450, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE OF INVENTION: Cell Lysis and Treating Cancer
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
```

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 450
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-450

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGTT 61
Db 1 GGGGTTGGAGGTT 13

```
RESULT 24
US-09-776-479-796
; Sequence 796, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouton, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-796
```

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGTT 61
Db 1 GGGGTTGGAGGTT 13

```
RESULT 25
US-09-776-479-796
; Sequence 796, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouton, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
```

```
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-796

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 26
US-10-314-578-796
; Sequence 796, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jörg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; PRIOR FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-796

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 27
US-10-112-653-769
; Sequence 769, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Berg, Daniel J.
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; FILE REFERENCE: C01039/70060 (AMS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; PRIOR FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 769
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-769

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 28
US-10-017-995-796
; Sequence 796, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; PRIOR FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-796

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 29
US-10-132-002-5/C
; Sequence 5, Application US/10132002
; Publication No. US2003002204A1
; GENERAL INFORMATION:
; APPLICANT: Lansdorp, Peter
; TITLE OF INVENTION: Method for Detecting Multiple Copies of
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSER: HOWSON & HOWSON
; STREET: 321 NO. US2003002204A1ristown Road
; CITY: Spring House
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/132,002
; FILING DATE: 25-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/730,635
; FILING DATE: 11-OCT-1996
; ATTORNEY/AGENT INFORMATION:
```

NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-132-002-5

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 24;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGATGGATTG 17
DB 13 TGGATGGATTG 1

RESULT 30
US-10-132-002-9
Sequence 9, Application US/10132002
Publication No. US20030022204A1
GENERAL INFORMATION:
APPLICANT: lamsdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
a Repeat Sequence in a Nucleic Acid Molecule
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: HOWSON & HOWSON
STREET: 321 No. US20030022204A1ristown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/132,002
FILING DATE: 25-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-132-002-9

Query Match 17.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 24;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGATGGATTG 17
DB 3 TGGATGGATTG 15

RESULT 31
US-09-981-803-32
Sequence 32, Application US/09981803
Publication No. US20030032092A1
GENERAL INFORMATION:
APPLICANT: Joel CROUZET
APPLICANT: Daniel SCHERMAN
APPLICANT: Beatrice CAMERON
APPLICANT: Pierre WILS
APPLICANT: Anne-Marie DARQUET
TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
FILE REFERENCE: MINICIRCLE
CURRENT APPLICATION NUMBER: US/09/981,803
CURRENT FILING DATE: 2001-10-19
NUMBER OF SEQ ID NOS: 50
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 32
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Description of the artificial sequence:
US-09-981-803-32

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACGAAAGAA 41
DB 1 AAGAAAAAAGAA 14

RESULT 32
US-09-981-803-48/C
Sequence 48, Application US/09981803
Publication No. US20030032092A1
GENERAL INFORMATION:
APPLICANT: Joel CROUZET
APPLICANT: Daniel SCHERMAN
APPLICANT: Beatrice CAMERON
APPLICANT: Pierre WILS
APPLICANT: Anne-Marie DARQUET
TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
FILE REFERENCE: MINICIRCLE
CURRENT APPLICATION NUMBER: US/09/981,803
CURRENT FILING DATE: 2001-10-19
NUMBER OF SEQ ID NOS: 50
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 48
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Description of the artificial sequence:
US-09-981-803-48

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 AAGAACGAAAGAA 41

Db 14 AAGAAAAAAGAA 1

RESULT 33

```
US-10-275-071-29
; Sequence 29, Application US/10275071
; Publication No. US20030186268A1
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 08888.0138-02
; CURRENT APPLICATION NUMBER: US/10/275.071
; PRIOR FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: 09/580,923
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-10-275-071-29
```

```
Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 34

```
US-10-275-071-30/c
; Sequence 30, Application US/10275071
; Publication No. US20030186268A1
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 08888.0138-02
; CURRENT APPLICATION NUMBER: US/10/275.071
; PRIOR FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: 09/580,923
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; PRIOR FILING DATE: 1995-11-08
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
```

; OTHER INFORMATION: oligonucleotide
US-10-275-071-30

```
Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 28 AAGAACAGAAAGAA 41
Db 14 AAGAAAAAAGAA 1

RESULT 35

```
US-10-684-830-35
; Sequence 35, Application US/10684830
; Publication No. US20040142452A1
; GENERAL INFORMATION:
; APPLICANT: Gencell S.A.; Aventis Pharmaceuticals, Inc.
; APPLICANT: Soubrier, Fabienne
; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Me
; FILE REFERENCE: 8888.0132-02
; CURRENT APPLICATION NUMBER: US/10/684,830
; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: US 10/268,948
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US 09/043,193
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Escherichia coli
US-10-684-830-35
```

```
Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 36

```
US-10-684-830-36/c
; Sequence 36, Application US/10684830
; Publication No. US20040142452A1
; GENERAL INFORMATION:
; APPLICANT: Gencell S.A.; Aventis Pharmaceuticals, Inc.
; APPLICANT: Soubrier, Fabienne
; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Me
; FILE REFERENCE: 8888.0132-02
; CURRENT APPLICATION NUMBER: US/10/684,830
; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: US 10/268,948
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US 09/043,193
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414
; PRIOR FILING DATE: 1996-09-13
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Escherichia coli
US-10-684-830-36
```


Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAGAGAA 41
|||||
14 AAGAAAAAAAAAGAA 1

RESULT 37
US-10-684-830-38/c

; Sequence 38, Application US/10684830
; Publication No. US20040142452A1
; GENERAL INFORMATION:

; APPLICANT: Genecell S.A.; Aventis Pharmaceuticals, Inc.

; APPLICANT: Soubrier, Fabienne

; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Met

; FILE REFERENCE: 888.0132-02
; CURRENT APPLICATION NUMBER: US/10/684,830

; PRIOR FILING DATE: 2003-10-15

; PRIOR APPLICATION NUMBER: US 10/268,948

; PRIOR FILING DATE: 2002-10-11

; PRIOR APPLICATION NUMBER: US 09/043,193

; PRIOR FILING DATE: 1998-03-13

; PRIOR APPLICATION NUMBER: PCT/FR96/01414

; PRIOR FILING DATE: 1996-09-13

; NUMBER OF SEQ ID NOS: 39

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 38

; LENGTH: 14

; TYPE: DNA

; ORGANISM: Escherichia coli

US-10-684-830-38

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAGAGAA 41
|||||
14 AAGAAAAAAAAAGAA 1

RESULT 38
US-10-253-904-45/c

; Sequence 45, Application US/10253904
; Publication No. US2003015813A1
; GENERAL INFORMATION:

; APPLICANT: EL SOLH, NEVINE

; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE

; TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED

; FILE REFERENCE: 03715-0059
; CURRENT APPLICATION NUMBER: US/10/253,904

; PRIOR FILING DATE: 2002-09-25

; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 45

; LENGTH: 13

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Primer

US-10-253-904-45

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 27;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GAATGAGATTGG 18
|||||
7 GAATGAGATTGG 18

Db 13 GAATGAGATTGG 2

RESULT 39
US-10-392-970-36/c

; Sequence 36, Application US/10392970
; Publication No. US20030176679A1
; GENERAL INFORMATION:

; APPLICANT: El Solh, Nevine

; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE

; TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED

; FILE REFERENCE: 03495.0173-00000

; CURRENT APPLICATION NUMBER: US/10/392,970

; PRIOR FILING DATE: 2003-03-21

; PRIOR APPLICATION NUMBER: US/09/099,932

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/050,380

; PRIOR FILING DATE: EARLIER FILING DATE: 1997-06-20

; NUMBER OF SEQ ID NOS: 50

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 36

; LENGTH: 13

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer

US-10-392-970-36

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 27;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GAATGAGATTGG 18
|||||
13 GAATGAGATTGG 2

RESULT 40
US-10-033-145-322/c

; Sequence 322, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:

; APPLICANT: GENZYME CORPORATION

; APPLICANT: ROBERTS, BRUCE

; TITLE OF INVENTION: SHANKARA, SRINIVAS

; FILE REFERENCE: GA0201C

; CURRENT APPLICATION NUMBER: US/10/033,145

; PRIOR FILING DATE: 2001-11-05

; PRIOR APPLICATION NUMBER: PCT/US99/13800

; PRIOR FILING DATE: 1999-06-18

; NUMBER OF SEQ ID NOS: 2137

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 322

; LENGTH: 10

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-033-145-322

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 TTGCTGGGGT 53
|||||
10 TTGCTGGGGT 1

RESULT 41
US-10-330-627-973/c

; Sequence 973, Application US/10330627

```

; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcriptomes
; FILE REFERENCE: 001107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 973
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-973

```

```

Query Match      15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      56 GAGGTTTCAC 65
Db      10 GAGGTTTCAC 1

```

```

RESULT 42
US-10-450-797-847/c
; Sequence 847, Application US/10450797
; Publication No. US20040142355A1
; GENERAL INFORMATION:
; APPLICANT: Peterson, Dirk
; APPLICANT: Conrad, Marcus
; APPLICANT: Hofmann, Kay
; TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
; FILE REFERENCE: HEK-0041
; CURRENT APPLICATION NUMBER: US/10/450,797
; CURRENT FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: PCT/EP01/15178
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: DE 101 00 121.5
; PRIOR FILING DATE: 2001-01-03
; NUMBER OF SEQ ID NOS: 1435
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 847
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-450-797-847

```

```

Query Match      15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      13 AATTGGACAT 22
Db      10 AATTGGACAT 1

```

```

RESULT 43
US-10-091-281-67/c
; Sequence 67, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEORIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06

```

```

; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 67
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative PCAT/CAAT.01 motif
US-10-091-281-67

```

```

Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      14 ATTGACATA 23
Db      10 ATTGACATA 1

```

```

RESULT 44
US-09-789-836-31
; Sequence 31, Application US/09789836
; Patent No. US20020082204A1
; GENERAL INFORMATION:
; APPLICANT: BRIGHAM, KENNETH L.
; APPLICANT: STECENKO, ARLINE A.
; APPLICANT: SEALY, LINDA
; TITLE OF INVENTION: TREATMENT OF INFLAMMATION WITH P20
; FILE REFERENCE: N-6977
; CURRENT APPLICATION NUMBER: US/09/789,836
; CURRENT FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/183,584
; PRIOR FILING DATE: 2000-02-18
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 31
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-09-789-836-31

```

```

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 33;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      9 ATGGAATTGACA 21
Db      1 ATGGAAGTGCCA 13

```

```

RESULT 45
US-09-789-831-29
; Sequence 29, Application US/09789831
; Publication No. US2003016586A1
; GENERAL INFORMATION:
; APPLICANT: SEALY, LINDA
; TITLE OF INVENTION: C/EBP-BETA ISOFORMS AND METHODS OF USE IN CELL REGULATION
; FILE REFERENCE: N-6978
; CURRENT APPLICATION NUMBER: US/09/789,831
; CURRENT FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/183,532
; PRIOR FILING DATE: 2000-02-18
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```

OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide
US-09-789-831-29

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 33;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 9 ATGGAATTGACA 21
|||||
Db 1 ATGGAAGTGCCA 13

RESULT 46
US-09-918-715-8/c

Sequence 8, Application US/09918715
Publication No. US20030017157A1
GENERAL INFORMATION:
APPLICANT: Brad St. Croix
APPLICANT: Bert Vogelstein
APPLICANT: Kenneth Kinzler
TITLE OF INVENTION: ENDOTHELIAL CELL EXPRESSION PATTERNS
FILE REFERENCE: 1107.00134
CURRENT APPLICATION NUMBER: US/09/918,715
CURRENT FILING DATE: 2001-08-01
PRIOR APPLICATION NUMBER: 60/222,599
PRIOR FILING DATE: 2000-08-02
PRIOR APPLICATION NUMBER: 60/224,360
PRIOR FILING DATE: 2000-08-11
PRIOR APPLICATION NUMBER: 60/282,850
PRIOR FILING DATE: 2000-04-11
NUMBER OF SEQ ID NOS: 358
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-09-918-715-8

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 27 CAAGACAGAA 37
|||||
Db 11 CAAGACAGAA 1

RESULT 47
US-10-450-797-174/c

Sequence 174, Application US/10450797
Publication No. US20040142335A1
GENERAL INFORMATION:
APPLICANT: Petersohn, Dirk
APPLICANT: Conradt, Marcus
APPLICANT: Hofmann, Kay
TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
FILE REFERENCE: HENK-0041
CURRENT APPLICATION NUMBER: US/10/450,797
CURRENT FILING DATE: 2003-12-04
PRIOR APPLICATION NUMBER: PCT/EP01/15178
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: DE 101 00 121.5
PRIOR FILING DATE: 2001-01-03
NUMBER OF SEQ ID NOS: 1435
SOFTWARE: PatentIn version 3.2
SEQ ID NO 174
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-10-450-797-174

Query Match 14.5%; Score 9.4; DB 1; Length 11;

Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 27 CAAGACAGAA 37
|||||
Db 11 CAAGACAGAA 1

RESULT 48
US-10-450-797-455/c

Sequence 455, Application US/10450797
Publication No. US20040142335A1
GENERAL INFORMATION:
APPLICANT: Petersohn, Dirk
APPLICANT: Conradt, Marcus
APPLICANT: Hofmann, Kay
TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
FILE REFERENCE: HENK-0041
CURRENT APPLICATION NUMBER: US/10/450,797
CURRENT FILING DATE: 2003-12-04
PRIOR APPLICATION NUMBER: PCT/EP01/15178
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: DE 101 00 121.5
PRIOR FILING DATE: 2001-01-03
NUMBER OF SEQ ID NOS: 1435
SOFTWARE: PatentIn version 3.2
SEQ ID NO 455
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-10-450-797-455

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
|||||
Db 11 GGACATAGCCC 1

RESULT 49
US-10-450-797-942

Sequence 942, Application US/10450797
Publication No. US20040142335A1
GENERAL INFORMATION:
APPLICANT: Petersohn, Dirk
APPLICANT: Conradt, Marcus
APPLICANT: Hofmann, Kay
TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
FILE REFERENCE: HENK-0041
CURRENT APPLICATION NUMBER: US/10/450,797
CURRENT FILING DATE: 2003-12-04
PRIOR APPLICATION NUMBER: PCT/EP01/15178
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: DE 101 00 121.5
PRIOR FILING DATE: 2001-01-03
NUMBER OF SEQ ID NOS: 1435
SOFTWARE: PatentIn version 3.2
SEQ ID NO 942
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-10-450-797-942

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGAACTT 44
|||||
Db 1 AGAAGAACTT 11

```
RESULT 50
US-09-263-959-425
; Sequence 425, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 425:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-425
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAA 38
DB 2 AAGAAAAGAAA 12

RESULT 51
US-09-263-959-587/C
; Sequence 587, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 660:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-660
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 587:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-587
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 28 AAGAACAGAAA 38
DB 11 AAGAAAAGAAA 1

RESULT 52
US-09-263-959-660
; Sequence 660, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 660:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-660
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 28 AAGAACGAAA 38
|||||
Db 2 AAGAAAAGAAA 12

RESULT 53
US-10-140-896-4
; Sequence 4, Application US/10140896
; Publication No. US20030167518A1
; GENERAL INFORMATION:
; APPLICANT: Yeh, Kai-Wun
; APPLICANT: Wang, Shu-Jen
; TITLE OF INVENTION: SPORAMIN PROMOTER AND USES THEREOF
; FILE REFERENCE: 12139-002001
; CURRENT APPLICATION NUMBER: US/10/140,896
; PRIOR FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 60/289,630
; NUMBER OF SEQ. ID NOS: 5
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ. ID NO 4
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Ipomoea batatas
US-10-140-896-4

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 35 GAAAGAACCTT 45
|||||
Db 2 GAAAGCACCTT 12

RESULT 54
US-10-232-927A-5
; Sequence 5, Application US/10232927A
; Publication No. US20030190638A1
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Calvin B. Harley
; Scott L. Weinrich
; Catherine M. Strahl
; Michael J. Mceachern
; Jerry Shay
; Woodring E. Wright
; Elizabeth H. Blackburn
; Nam Woo Kim
; Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; CONDITIONS RELATED TO
; TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; STORAGE
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/232,927A
; FILING DATE: 29-Aug-2002
; CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,535
; FILING DATE: 20-Aug-1999
; APPLICATION NUMBER: 08/819,867
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Chambers, Daniel M.
; REGISTRATION NUMBER: 34,561
; REFERENCE/DOCKET NUMBER: 224/232
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ. ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-232-927A-5

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGCTTGAG 58
|||||
Db 2 TGGGCTTGAG 12

RESULT 55
US-10-232-927A-33
; Sequence 33, Application US/10232927A
; Publication No. US20030190638A1
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Calvin B. Harley
; Scott L. Weinrich
; Catherine M. Strahl
; Michael J. Mceachern
; Jerry Shay
; Woodring E. Wright
; Elizabeth H. Blackburn
; Nam Woo Kim
; Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; CONDITIONS RELATED TO
; TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; STORAGE
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/232,927A
; FILING DATE: 29-Aug-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,535
; FILING DATE: 20-Aug-1999
; APPLICATION NUMBER: 08/819,867

FILED DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-232-927A-33

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||
Db 2 TGGGGTTGGAG 12

RESULT 56
US-10-232-927A-35
Sequence 35, Application US/10232927A
Publication No. US20030190638A1
GENERAL INFORMATION:
APPLICANT: Michael D. West
Calvin B. Hatley
Scott L. Weinrich
Catherine M. Strahl
Michael J. McEachern
Jerry Shay
Woodring E. Wright
Elizabeth H. Blackburn
Nam Woo Kim
Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
CONDITIONS RELATED TO
TELOMERE LENGTH AND/OR
TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
Street: 633 West Fifth Street
Suite 4700
City: Los Angeles
State: California
Country: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/232,927A
FILING DATE: 29-Aug-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561

REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-10-232-927A-35

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||
Db 2 TGGGGTTGGAG 12

RESULT 57
US-10-422-262-18/c
Sequence 18, Application US/10422262
Publication No. US20030219848A1
GENERAL INFORMATION:
APPLICANT: NAOVI, TABASSUM
APPLICANT: ROUHANI, RIAZ
APPLICANT: SINGH, RAJENDRA
TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
FILE REFERENCE: 3817.11-1
CURRENT APPLICATION NUMBER: US/10/422,262
PRIOR FILING DATE: 2003-04-24
PRIOR APPLICATION NUMBER: 60/376,935
PRIOR FILING DATE: 2002-05-02
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 18
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-422-262-18

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGA 40
|||
Db 12 GAGCAGAAAGA 2

RESULT 58
US-10-422-262-19/c
Sequence 19, Application US/10422262
Publication No. US20030219848A1
GENERAL INFORMATION:
APPLICANT: NAOVI, TABASSUM
APPLICANT: ROUHANI, RIAZ
APPLICANT: SINGH, RAJENDRA
TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
FILE REFERENCE: 3817.11-1
CURRENT APPLICATION NUMBER: US/10/422,262
PRIOR FILING DATE: 2003-04-24
PRIOR APPLICATION NUMBER: 60/376,935
PRIOR FILING DATE: 2002-05-02
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1

```
; SEQ ID NO 19
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-422-262-19

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 GAACAGAAAGA 40
Db      12 GAGCAGAAAGA 2

RESULT 59
US-10-422-262-20/c
; Sequence 20, Application US/10422262
; Publication No. US20030219848A1
; GENERAL INFORMATION:
; APPLICANT: NAQVI, TABASSUM
; APPLICANT: ROUHANI, RIAZ
; APPLICANT: SINGH, RAJENDRA
; TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
; FILE REFERENCE: 3817.11-1
; CURRENT APPLICATION NUMBER: US/10/422,262
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: 60/376,935
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-422-262-20

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 GAACAGAAAGA 40
Db      12 GAGCAGAAAGA 2

RESULT 60
US-10-422-262-21/c
; Sequence 21, Application US/10422262
; Publication No. US20030219848A1
; GENERAL INFORMATION:
; APPLICANT: NAQVI, TABASSUM
; APPLICANT: ROUHANI, RIAZ
; APPLICANT: SINGH, RAJENDRA
; TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
; FILE REFERENCE: 3817.11-1
; CURRENT APPLICATION NUMBER: US/10/422,262
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: 60/376,935
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide from PNA sequence
US-10-422-262-21

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 GAACAGAAAGA 40
Db      12 GAGCAGAAAGA 2

RESULT 61
US-10-422-262-22/c
; Sequence 22, Application US/10422262
; Publication No. US20030219848A1
; GENERAL INFORMATION:
; APPLICANT: NAQVI, TABASSUM
; APPLICANT: ROUHANI, RIAZ
; APPLICANT: SINGH, RAJENDRA
; TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
; FILE REFERENCE: 3817.11-1
; CURRENT APPLICATION NUMBER: US/10/422,262
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: 60/376,935
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-422-262-22

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 GAACAGAAAGA 40
Db      12 GAGCAGAAAGA 2
```

Search completed: August 12, 2004, 15:30:41
Job time : 1 secs

THIS PAGE BLANK (USPTO)